Abstracts from the
34th Annual Meeting of the
Consortium of Multiple Sclerosis Centers

May – June 2020

Visit www.mscare.org to view archived meeting content.
2020 Virtual Annual Meeting of the CMSC

The editorial team is pleased to present this supplement to the International Journal of MS Care (IJMSC) containing the abstracts from the 2020 Virtual Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC). These abstracts include platform, poster, and Whitaker Research Track presentations, as well as a few late-breaking abstracts. In these unusual times, we all have had to modify many of our activities due to the COVID-19 pandemic, including the introduction of virtual scientific meetings. While the CMSC generously offers free registration to this meeting, many health care providers may not have the time to attend the live online sessions. The print version of this supplement is being distributed to members of the CMSC. The electronic version will be available to all on the IJMSC website at ijmsc.org.

We would like to thank Sanofi Genzyme for their support, which made this publication possible.

While reading abstracts does not completely replace in-person networking, our team hopes that this supplement will attest to the fact that the desire to share innovation and research has not been extinguished by the pandemic. We hope that you and your loved ones are keeping safe in these challenging times.

—Francois Bethoux, MD
Editor in Chief
CMSC Abstract Review Committee

CO-CHAIRS

Amy Perrin Ross, APN, MSN, CNRN, MSCN
Loyola University of Chicago MS Clinic
Chicago, IL
aperrinros@aol.com

Carrie Hersh, DO, MSc
Mellen Program for Multiple Sclerosis
Lou Ruvo Center for Brain Health
Cleveland Clinic Nevada
Las Vegas, NV
hershe@ecf.org

REVIEWERS

Farren Briggs, PhD, ScM
Case Western Reserve University
Cleveland, OH
farren.briggs@case.edu

Dorothea Cassidy-Pfohl, RN, BS, MSCN
Bala Cynwyd, PA
dcpfohl@verizon.net

Kathleen Czuba, SLP
Loyola University Medical Center
Oak Brook Terrace, IL
kateczuba@gmail.com

Robert Fallis, MD, MSCS
Ohio State University
Columbus, OH
robert.fallis@osumc.edu

Mary Kay Fink, RN, MSN, ACNS-BC, MSCN
John L. Trotter Multiple Sclerosis Center
St. Louis, MO
marykayfink@wustl.edu

Cindy Gackle, OTR/L, MSCS
Minneapolis, MN
cgackle@cptelem.com

Ajay Gupta, MD, MSCS
Fort Wayne Neurological Center
Fort Wayne, IN
agupta@fwncc.com

Colleen Harris, MN, NP, MSCN, MSCS
University of Calgary MS Clinic
Calgary, AB, Canada
collen.harris@albertahealthservices.ca

Rock Heyman, MD
University of Pittsburgh Medical Center
Pittsburgh, PA
heymra@upmc.edu

Gloria Hou, MD
University of Washington
Seattle, WA
ghou1@u.washington.edu

Sue Kushner, MS, PT
Slippery Rock University
Valencia, VA
susan.kushner@sruc.edu

Beverly Layton, RN, BSN, CCRC, MSCN
Birmingham VA Medical Center
Birmingham, AL
blayton55@bellsouth.net

Deborah Miller, PhD, LISW-S
Mellen Center for MS Treatment and Research
Cleveland, OH
millerd@ccf.org

Kelly Morton, PharmD
Loyola University of Chicago MS Clinic
Chicago, IL
Kelly.Morton@lubs.org

Nancy Navarro, APN
Suburban Physicians
Aurora, IL
N.Navarro1@comcast.net

Cynthia Sullivan, PhD
Neuropsychology Associates of Fairfax, LLC
Fairfax, VA
csullivan@neuropsychologyfairfax.com

Gloria von Geldern, MD
University of Washington Medical Center
Seattle, WA
vgeldern@uw.edu

Jeff Wilken, PhD
Neuropsychology Associates of Fairfax, LLC
Fairfax, VA
jwilken@neuropsychologyfairfax.com

Annette Wundes, MD
Western MS Center at UWMC / MSRTC
Seattle, WA
awundes@u.washington.edu

STAFF

Rachelle U. Ramirez
Multimedia Manager
Consortium of MS Centers
Hackensack, NJ
rramirez@mscare.org

Jennifer Pichardo
Project Coordinator
Consortium of MS Centers
Hackensack, NJ
jpichardo@mscare.org
Abstract Titles

PLATFORMS

DISEASE ASSESSMENT AND MANAGEMENT

(DAM01) International Registry Tracking Pregnancy Outcomes in Women Treated with Dimethyl Fumarate

(DAM02) Menarche and Relapses in Girls with Pediatric Multiple Sclerosis

(DAM03) Complexity of Aging with Multiple Sclerosis: Graceful Concessions or Kicking and Screaming?

(DAM04) Serum Glial Fibrillary Acidic Protein Is Elevated in a Subset of Neuromyelitis Optica Patients and Associated with Increased Risk of Attacks

(DAM05) Machine Learning Algorithms Applied to Visual Metrics to Classify Demyelinating Disease Diagnosis in Children

(DAM06) Updated Recommendations for a Standardized Magnetic Resonance Imaging Protocol for Multiple Sclerosis

DISEASE-MODIFYING THERAPY

(DMT01) Comparative Effectiveness of Switching from Natalizumab to a Moderate-Versus High-Efficacy Disease-Modifying Therapy in Clinical Practice

(DMT02) Yearly Efficacy and Safety Outcomes Over 4 Years After Last Alemtuzumab Course in Pooled CARE-MS I and II Patients by Number of Additional Courses Received Through Year 9

(DMT03) Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials

(DMT04) Treatment Emergent Adverse Events Occurring Early in the Treatment Course of Cladribine Tablets in Two Phase 3 Trials in Multiple Sclerosis

PSYCHOSOCIAL: COGNITION

(PSY01) A Mindfulness Group Intervention in Newly Diagnosed Persons with Multiple Sclerosis: A Pilot Study

(PSY02) Effects of Weekly Participation in a Wellness Program on Self-Reported Measures for People Living with Multiple Sclerosis: A 3-Year Analysis

(PSY03) Examining Multilevel Environmental Correlates of Physical Activity Among Older Adults with Multiple Sclerosis

(PSY04) Effect of Nabiximols Cannabinoid Oromucosal Spray on Depressive Symptoms, Suicidality, and Cognition in Patients with Multiple Sclerosis

(PSY06) Multiple Sclerosis Management: Predicting Disease Trajectory of Multiple Sclerosis on Multidimensional Data Including Digital Cognitive Assessment and Patient-Reported Outcomes Using Machine Learning Techniques

REHABILITATION

(RHI01) Significant Structural Neuroplasticity Changes Can Follow Physical Behavioral Change Therapy for Multiple Sclerosis

(RHI02) A New Look at the Symbol Digit Modalities Test in Multiple Sclerosis and Disabilities

(RHI03) Creating a Yoga Program as Part of a Comprehensive Multiple Sclerosis Care Model

(RHI04) Feasibility of “Sit Less, Move More”: An Intervention for Reducing Sedentary Behavior Among African Americans with Multiple Sclerosis

(RHI05) The Effect of Aerobic Fitness on Physical and Cognitive Function and Brain Volume in Older Adults with Multiple Sclerosis

(RHI06) Functional Electrical Stimulation Cycling Exercise Reduces Lower Limb Strength Asymmetry in Persons with Multiple Sclerosis

POSTERS

COMPLEMENTARY AND ALTERNATIVE THERAPIES

(CAM01) Multiple Sclerosis Imbalance: Visual Rehabilitation

(CAM02) Acupuncture and Electromagnetotherapy for Chronic Pain Relief in Multiple Sclerosis

(CAM03) The Effects of Reflexology in People with Multiple Sclerosis

(CAM04) The Effects of CBD-THC Tincture Oil in Reducing Symptoms and Overall Symptom Management Medication Dosages, in Persons with Multiple Sclerosis

(CAM05) Challenges and Opportunities in Progressive Multiple Sclerosis Trials: Lessons from Lipoic Acid

(CAM06) Exercise in Medicine: A Complementary Exercise Promotion Approach Within Comprehensive Multiple Sclerosis Care

(CAM07) Changes in Dietary Habits of Individuals Living with Multiple Sclerosis Enrolled in a Day Wellness Program

CASE REPORTS/CASE SERIES

(CRS01) Seasonal Variation and Other Observations in Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease

(CRS02) Multiple Surgeries and Misdiagnosis Before Multiple Sclerosis Diagnosis: A Case Report

(CRS03) Head Trauma as Onset for Multiple Sclerosis Diagnosis: A Case Report

(CRS04) Team Approach Yields Surprising Functional Progress and Quality-of-Life Changes in a Challenging Case of Neuromyelitis Optica

(CRS05) Differential Diagnosis and Treatment of Tumefactive Demyelination in a Teenaged Girl

(CRS06) A Long-Standing Case of Recurrent Transverse Myelitis Due to Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Antibody Mimicking Multiple Sclerosis

(CRS07) Case Report of Severe Multiple Sclerosis Relapse Due to B-Cell Reconstitution Post Alemtuzumab

(CRS08) Demographics, Clinical Characteristics, and Outcomes of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease Followed Up at Washington University in St. Louis

(CRS09) A Fatal Case of Alemtuzumab-Induced Immune Thrombocytopenic Purpura in a Patient with Relapsing Multiple Sclerosis

(CRS10) Colitis Associated with Teriflunomide

(CRS11) Remarkable Recovery of Fulminant Multiple Sclerosis After Treatment Induction with Cyclophosphamide

(CRS12) Neurofibromatosis Type 1 and Multiple Sclerosis in the Same Patient

(CRS13) Successful Use of Immunotherapy for Osmotic Demyelination Syndrome

DISEASE-MODIFYING THERAPY

(DXT01) Maintenance of Working Status and Work Productivity in Persons with Multiple Sclerosis Treated with Dimethyl Fumarate: A 5-Year Analysis of the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry

(DXT02) Early Effect of Ofatumumab on B-Cell Counts and Magnetic Resonance Imaging Activity in Relapsing Multiple Sclerosis Patients: Results from the APLIOS Study

(DXT03) Analyses of the Effect of Disease Duration on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the EXPAND Study

(DXT04) Siponimod First-Dose Effects in Patients with Secondary Progressive Multiple Sclerosis Receiving Concomitant Selective Serotonin Reuptake Inhibitor Therapy

(DXT05) Efficacy of Droxidimel Fumarate in Highly Active Relapsing-Remitting Multiple Sclerosis: Interim Results from the Phase 3 EVOVE-MS-1 Study

(DXT06) Real-World Effectiveness of Peginterferon Beta-1a Versus Interferon Beta-1a and Glatiramer Acetate in US Multiple Sclerosis Patients

(DXT07) Injection Site Reactions and Risk of Discontinuation Among New and Experienced Peginterferon Beta-1a Users in the Péginterferon-1a Observational Program

(DXT08) Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Diagnosed Within 3 or 4 Years Prior to the CLARITY Study

(DXT09) Exploration of Factors Which Influence Treatment Decisions of Patients with Multiple Sclerosis

(DXT10) Siponimod Affects Disability Progression in Patients with Secondary Progressive Multiple Sclerosis Independent of Relapse Activity: Results from the Phase 3 EXPAND Study

(DXT11) The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis

(DXT12) Real-World Effectiveness of Peginterferon Beta-1a Versus Teriflunomide in US Multiple Sclerosis Patients

(DXT13) Disease-Modifying Therapies: How Confident Are We That We Understand Their Risk?

(DXT14) Long-Term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder

(DXT15) Inabilizumab Reduces Neuromyelitis Optica Spectrum Disorder Disability Worsening: Outcomes and Long-Term Follow-up Data from the NMOmentum Trial

(DXT16) Effectiveness of Delayed-Release Dimethyl Fumarate Relative to Duration of Prior Glatiramer Acetate in Patients Enrolled in the RESPOND Study

(DXT17) Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (JTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis

(DXT18) Adherence and Compliance with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis
Abstract Titles

(DXT20) Glatiramer Acetate [GA] Produced by Magpi Pharma Is Equivalent to Commercially Available GA Preparations

(DXT22) Characterization of Incidence and Time-to-Recovery from Grade 3/4 Lymphopenia Lasting ≥6 Months in Patients with Multiple Sclerosis Treated with Cladribine Tablets

(DXT23) Disease-Modifying Therapy Landscape: An Evaluation of Cost and Care

(DXT24) Two Expanded Disability Status Scale Subscales Evaluated in Patients with Relapsing-Remitting or Secondary Progressive Multiple Sclerosis

(DXT26) Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies

(DXT27) Integrated Lymphopenia Analysis in Younger and Older Patients with Multiple Sclerosis Treated with Cladribine Tablets

(DXT28) Effectiveness of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis with Baseline Expanded Disability Status Scale Score ≥3.5 or ≤3.0 in CLARITY

(DXT29) ACAPELLA: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive Multiple Sclerosis, Year 2 Data

(DXT30) ACAPELLA: Hypogammaglobulinemia and JC Virus Status in Ocrelizumab-Treated Patients, Year 2 Data

(DXT31) Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Neuromyelitis Optica Spectrum Disorder: Phase 3 PREVENT Study

(DXT33) ACAPELLA: B-Cell Reconstitution in Ocrelizumab-Treated Patients

(DXT34) Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine-Treated Patients at the 96-Week Timepoint (CLARITY) Using Deconvolution Algorithms

(DXT35) Real-World Experience with Ocrelizumab: A Safety Analysis

(DXT36) Effect of Efavirenz, a Brunt's Tyrosine Kinase Inhibitor, on Immune Cell and Immunoglobulin Levels over 48 Weeks in a Phase 2 Study in Relapsing Multiple Sclerosis

(DXT37) Effect of Teriflunomide on Brain Volume Loss in Patients with Relapsing Multiple Sclerosis of Differing Ages in TEMSO

(DXT38) Effects of Ozanimod on Information Processing Speed: Findings from the Phase 3 SUNBEAM and DAYBREAK Extension Trials

(DXT39) Effect of the S1P1/5 Receptor Modulator Ozanimod on Cognitive Processing Speed in Subjects with Relapsing Multiple Sclerosis: Design of the ENLIGHTEN Study

(DXT41) Eculizumab Benefits a Broad Range of Patients with Aquaporin-4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder: The Phase 3 PREVENT Study

(DXT42) Rational and Design of CLASSICMS Study Evaluating Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets

(DXT43) Analyses of the Effect of Baseline Age on the Efficacy and Safety of Siponimod in Patients with Active Secondary Progressive Multiple Sclerosis from the EXPAND Study

(DXT44) Real-World Patterns of Disease Progression in Patients with Multiple Sclerosis Who Are Adherent Versus Nonadherent to Disease-Modifying Treatments over 6 Years

(DXT45) Pharmacist-Based Intervention for Improving Baseline Laboratory Monitoring for Patients on Multiple Sclerosis Disease-Modifying Therapies

(DXT46) Cognitive Performance and Disability Across Age Groups in Teriflunomide-Treated Patients in the TeriPRO Study

(DXT48) Efficacy of Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event: REFLEX Study – Outcomes in Patients Stratified by 2017 McDonald Criteria

(DXT49) Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Aged Over and Under 30 Years in the CLARITY Study

(DXT50) Prevalence of Serious Adverse Pregnancy Outcomes After Exposure to Interferon Beta Before or During Pregnancy: Stratification by Characteristics of Pregnant Women with Multiple Sclerosis in a Register-Based Cohort Study in Finland and Sweden

(DXT51) High Rates of Adherence to Oral Diroximel Fumarate and Dimethyl Fumarate Are Observed and Sustained in Relapsing Multiple Sclerosis Patients

(DXT52) Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: The Phase 3 PREVENT Study

(DXT53) Multiple Sclerosis Clinical Phenotypes: Using Technology to Educate Patients and Optimize Treatment

(DXT54) Assessment of the Discontinuation Rates of Disease-Modifying Therapy in Veterans with Multiple Sclerosis

(DXT55) Herpes Zoster Virus (HZV) Infections Among Multiple Sclerosis Patients Treated with Various Disease-Modifying Therapies

(DXT56) Potential Weight Changes Among Patients with Multiple Sclerosis Undergoing Treatment with Ocrevus (Ocrelizumab)

(DXT57) FAST: Faster and Safe Administration of Tysabri

(DXT58) Reduction of Risk of Secondary Progressive Multiple Sclerosis within 2 Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study

(DXT59) The CLARITY Study: Efficacy Outcomes Among Patients Who Received Disease-Modifying Drugs Prior to Treatment with Cladribine Tablets

(DXT60) Correlations Between Four Common Measures of Cognition in Patients with Secondary Progressive Multiple Sclerosis

(DXT61) Injection-Related Reactions with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Pooled Analysis of the Phase 3 ASCLEPIOS I and II Trials

(DXT62) Real-World Treatment Patterns in Patients with Multiple Sclerosis Using Disease-Modifying Therapies

(DXT63) Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis Among Adult Saudis: A Tertiary Care Center Experience

(DXT64) Evaluation of Rituximab Regimens and Outcomes in Neuromyelitis Optica Patients from a Single Academic Medical Center: A Retrospective Chart Review

(DXT65) Longitudinal Disability Follow-up in Patients with 6-Month Confirmed Disability Improvement or Worsening in the CAREMS and Extension Studies

(DXT66) Clinical Benefits of Eculizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study

(DXT67) Cognitive Functions over the Course of 5 Years in Multiple Sclerosis Patients Treated with Disease-Modifying Therapies

(DXT69) One-Year Interim Analysis of Real-World Patient-Reported Outcomes in Relapsing-Remitting Multiple Sclerosis Patients Transferring to Alemtuzumab (PRO-ACT Study)

(DXT70) Clinical Characteristics and Outcomes of Pregletriferon Beta-1a Treatment by Age: A Subgroup Analysis of the Pregletriferon Observational Program

(DXT71) Efficacy and Safety of Teriflunomide in Patients with Relapsing-Remitting Multiple Sclerosis of Varying Disease Duration: Analysis of Pooled Clinical Trials

(DXT73) Updated Safety of Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis: Integrated Safety Analysis and Postapproval Data

(DXT74) An Analysis of the Relationship Between Cladribine Dose and Risk of Malignancies in Patients with Multiple Sclerosis

(DXT75) Switches to Established and Recently Approved Oral Disease-Modifying Therapies: Comparison of Patient Clinical Profiles and Therapy Selection Drivers

(DXT76) First-Line Ocrelizumab Use for Relapsing-Remitting Multiple Sclerosis in the United States: Trend and Comparison to Glatiramer Acetate and Dimethyl Fumarate

(DXT77) Alemtuzumab Maintains Efficacy on Clinical and Magnetic Resonance Imaging Lesion Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in Relapsing-Remitting Multiple Sclerosis Patients: CARE-MS II Follow-up (TOPAZ Study)

(DXT78) The FLUENT Study: Changes in Immune Cell Profile, and in Clinical and Safety Outcomes, in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis

(DXT79) Efficacy of Ocrelizumab Treatment on Cognitive Functions in Persons with Multiple Sclerosis

EPIDEMIOLOGY AND GENETICS

(EPI01) Determining the Effect of Early Versus Later Diagnosis of Multiple Sclerosis on Long-Term Prognosis in a Real-World Setting

(EPI02) Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

(EPI03) Increase in Family Recurrence in Patients Diagnosed with Multiple Sclerosis in the Years 2017-2019 in Hispanic Population of Puerto Rico

(EPI04) Diet Quality and Nutritional Adequacy of Micronutrients Among People with Relapsing-Remitting Multiple Sclerosis: An Analysis of Weighted Food Records
Background: To date, delayed-release dimethyl fumarate (DMF) exposure during pregnancy has not shown any safety signals in clinical trial and postmarketing data, however the DMF label recommends use during pregnancy only if potential benefit justifies the potential risk to the fetus. In the general population, 62% of pregnancies end in live birth, 22% end in induced abortion, and 16% end in fetal loss. Similar rates have been observed in patients with multiple sclerosis (MS).

Objectives: An international registry trial registration: NCT01911767 was started to prospectively evaluate pregnancy outcomes in women with MS exposed to DMF since 1 day before the first day of their last menstrual period before conception or during pregnancy; results are reported for the United States as well as the overall population.

Methods: In this ongoing registry, data were collected at enrollment, 6-7 months of gestation, 4 weeks after estimated delivery date, and at 4, 12, and 52 weeks after birth. Infant and maternal outcomes included ectopic and molar pregnancies, birth defects, spontaneous abortions or infant death occurring at ≤52 weeks of age, and maternal death at ≤12 weeks postdelivery. Potential birth defects were adjudicated by an external expert. Gestational size was classified as small (<10th percentile), appropriate (10th-90th), or large (>90th) based on standardized growth charts.

Results: As of April 2019, 263 patients were enrolled; 57 in the United States. Median gestational week at first DMF exposure was 1 (range, 1-13); median fetal DMF exposure duration was 5 (range, 0.1-40) weeks. Of the 214 pregnancy outcomes reported to date, 197 (92%) were live births and 17 (8%) fetal losses. In the United States, 38 pregnancy outcomes have been reported to date, 34 (89%) live births and 4 (11%) fetal losses. Of infants with known gestational age (n = 194), 176 (91%) births were full-term and 18 (9%) premature (<37 weeks). In the United States, 30 (97%) births were full-term and 1 (3%) premature. There were 16 spontaneous abortions (4 in US; 1 ectopic pregnancy outside of US), and 1 fetal death at ≥28 weeks' gestation. No perinatal, infant, or maternal deaths were reported. Infants (163 with postmenarche, 52 weeks of age, and 11 (7%). Seven (4%) infants had confirmed birth defects.

Conclusions: The adverse pregnancy outcome frequencies from the interim analysis did not exceed those observed in the MS and general populations. No safety signal has been observed to date.

Supported by: Biogen

Disclosure: Maria Houck: Nothing to disclose. Kerstin Hellwig: Bayer, Biogen, Genzyme, Sanofi, Teva, Roche, Novartis, Merck (consulting fee); Bayer, Biogen, Merck, Novartis, Sanofi Genzyme, Teva (contracted research, speakers’ bureau). David Rog: Actelion, Biogen, Merck Serono, Novartis, Sanofi, Tava Neurosciences, TG Therapeutics (contracted research); Biogen, MedDay, Merck Serono, Novartis, Roche, Sanofi, Tava Neurosciences (consulting fee); Biogen, Merck Serono, Novartis, Roche, Sanofi, Tava Neurosciences (speakers’ bureau). Christopher McGuigan: Actelion, Biogen, Merck, Novartis, Roche, Sanofi, Sanofi Genzyme (contracting fee, consulting, speaking, travel support). Kun Chen, Xiaomei Peng, Cynthia C. Jones: Biogen (ownership interest, salary). Keywords: Disease-modifying treatments in MS, Pregnancy

(DAM02) Menarche and Relapses in Girls with Pediatric Multiple Sclerosis

Kristen M. Krysko,1 Michael Waltz,1 Tanuja Chitnis,1 Bianca Weinstock-Gutman,2 Greg Aaen,3 Leslie Benson,3 John Rose,4 Yolanda Harris,5 Jennifer S. Graves,1

1University of California San Francisco, San Francisco, CA; 2Pediatrics, University of Utah, Salt Lake City, UT; 3Pediatric Neurology, Massachusetts General Hospital, Boston, MA; 4Neurology, State University of New York at Buffalo, Buffalo, NY; 5Pediatrics, Loma Linda University, San Bernardino, CA; 6Neurology, Boston Children’s Hospital, Boston, MA; 7Nursing, University of Alabama at Birmingham, Birmingham, AL; 8Neurology, NYU Langone Medical Center, New York, NY; 9Neurology, Texas Children’s Hospital, Houston, TX; 10Neurology, Washington University in Saint Louis, St. Louis, MO; 11Pediatrics and Neurology, Dell Children’s Hospital, Austin, TX; 12Pediatrics, University of Alabama at Birmingham, Birmingham, AL; 13Neurology, Cleveland Clinic, Cleveland, OH; 14Neurology, University of Utah, Salt Lake City, UT; 15Neurology and Pediatrics, University of Colorado, Aurora, CO; 16Neurosciences, University of California San Diego, San Diego, CA; 17Neurology, University of California San Diego, La Jolla, CA

Background: Sex steroid hormones have a clinical impact on the immune system. Puberty may trigger multiple sclerosis (MS) disease activity, with mean age of pediatric MS onset occurring near age 13 years. Objectives: To evaluate the association between menarche and disease course in pediatric MS through comparison of relapse rates across the premenarche, perimenarche, and postmenarche periods. Methods: This is a retrospective analysis of a prospectively followed cohort of girls meeting MS criteria within the US Network of Pediatric MS Centers database. Only individuals with known menarche dates were included in the analysis. Relapses were collected prospectively. Both negative binomial and repeated Cox regression models were used to assess the association of pubertal development stage with relapse rate, adjusted for tier of disease-modifying therapy and body mass index. Results: Of the 503 girls included, onset was during premenarche in 53, perimenarche in 84 (within ±1 year of menarche), and postmenarche in 366. The median age of MS onset was 2.5 years after menarche. In adjusted negative binomial analysis, annual relapse rate during the premenarche period was 0.63, perimenarche period was 0.50, and postmenarche period was 0.43 (P = .16). In adjusted repeated-events Cox regression analysis, there was increased hazard for relapses with onset of menarche in premenarche through menarche [premenarche HR 0.60 [95% CI, 0.45-0.79] and perimenarche HR 0.79 [95% CI, 0.62-1.02] compared to the reference of postmenarche, P = 0006]. Conclusions: Before menarche girls have lower relapse rates. Onset of puberty may be a time of increased in disease activity and may require consideration of a change in therapeutic approach.

Supported by: None

Disclosure: Kristen M. Krysko: Biogen (fellowship funding). Michael Waltz, Sue Mar, Manikum Nanduri, Moses Rodriguez, T. Charles Casper: Nothing to disclose. Tanuja Chitnis: Biogen, Novartis, Octave, Sanofi, Mallinckrodt, Verily (research support); Biogen, Novartis, Sanofi Genzyme, Bayer, Celgene, Genentech (consulting fee); Sanofi Genzyme, Novartis (contracted research). Bianca Weinstock-Gutman: Biogen, Novartis, Genentech, EMD Serono (research support); Biogen, Novartis, Genentech, Celgene, Mallinckrodt, EMD Serono (consulting fee). Greg Aaen, Leslie Benson: Biogen (contracted research). Mark Gorman: Novartis, Biogen (contracted research), Pfizer (research support). Yolanda Harris: Celgene (consulting fee); Laurens B. Krupp: Biogen, Novartis (research support); Biogen, Novartis, Red Hill Pharmaceutical, Genzyme, Gerson Lehman, Sanofi, Celgene (consulting fee); biotechnology and pharmaceutical companies for the fatigue severity scale (royalty); Timothy Latz: Biogen (consulting fee). Janey Nie: Novartis, Chugai, Roche (contracted research). Mary Benck: EMD Serono, Biogen, Merck, Novartis, Sanofi Genzyme, Genzyme (outsourcing). Adam Magill: MedImmune, Novartis, Biogen (MS Path), Genentech (research support); Novartis, Genzyme, Biogen, Multiple Sclerosis Association of America (speakers’ bureau). John Rose: Biogen, Teva Neuroscience, Vida Bio, Accredo, Genentech, Novartis (unrestricted educational grants); Teva Neuroscience, Biogen (research support). Alice Ruizatungap: Biogen (fellowship grant). Teri Schreiner: Biogen, Adamas, MSDX (contracted research). Emmanuelle Wandzura: Genentech, Biogen (contracted research); Jennifer S. Graves: Biogen, Octave, Genentech (research support); Mary Rensel, Gerson Lehman, Sanofi, Biogen (contracted research). John Rose: Biogen, Teva Neuroscience, Vida Bio, Accredo, Genentech, Novartis (unrestricted educational grants); Teva Neuroscience, Biogen (research support).

Key Words: Epidemiology of MS, Hormonal factors in MS, Natural history of MS

(DAM03) Complexity of Ageing with Multiple Sclerosis: Graceful Concessions or Kicking and Screaming?

Emma V. Richardson, Robert W. Motl

Department of Physical Therapy, University of Alabama at Birmingham, Birmingham, AL

Background: Over the past 3 decades there have been significant advances in the development of pharmaceutical and rehabilitative treatments for persons with multiple sclerosis (MS), such that life expectancy is continuing to increase. As a result of these advancements, there is a “seamless” phenomenon within the global MS population and a demographic shift of the aging landscape. While these advancements are exciting, there also exists concerns and unknowns regarding what it is like to age with MS.

Objectives: The objectives of this research were to explore the experiences of ageing in conjunction with having MS, and the different ways persons older than 60 with MS interpreted this phenomenon.

Methods: Semistructured interviews with 40 persons with MS aged 60 or older and clinical experts in MS and aging were conducted. Participants were recruiting from research databases across the United States. The interviews were audio recorded, transcribed and coded using open coding. A thematic analysis was conducted and key themes were explored. A mixed-methods design was used with quantitative data on perceived general health, functional status, and quality of life scores. Descriptive statistics were used to summarize the data. Results: The results showed that there was a variability in the interpretation of aging with MS. Some participants reported the perception of MS experiences including physical and functional impairments, and the impact of aging on health, life satisfaction, and quality of life. While others felt the impact of aging did not significantly impact their MS. The results suggested that there is a need for more research to understand the experiences of aging with MS and the interpretation of aging with MS.
Results: This research highlighted the complexity of aging with MS and the various ways persons older than 60 with MS experience and interpret the phenomenon. Most participants experienced a continued progression of physical and cognitive deficits, however aging narratives and what is culturally aligned with aging narratives. Fears about the future do remain as participants were concerned about living too long for being able to thrive. More research must be done that focuses on maintaining quality of life among older person with MS as quantity of life continues to increase.

Supported by: None

Disclosure: None

Key words: Aging and MS, Management of activities of daily living in MS

(DAM04) Serum Glial Fibrillary Acidic Protein Is Elevated in a Subset of Neuromyelitis Optica Patients and Associated with Increased Risk of Attacks

Hans-Peter Hartung,1 Orhan Aktas,2 Michael A. Smith,3 William Rees,3 Kazuo Hanyu,2,4 Hans-Peter Hartung,1 Orhan Aktas,2 Michael A. Smith,3 William Rees,3 Kazuo Hanyu,2,4

Participants who were diagnosed in middle age, however, noted a sharp enhancing behaviors from an earlier age, while others believed they had “aged out” of MS and were experiencing a peak of health and wellness. Participants who were diagnosed in middle age, however, noted a sharp progression of age-related and MS symptoms, but stated “everyone has something” and perceived the diagnosis of MS was less impactful in older age with regards to what is expected at this life stage. Concerns remained, however, regarding whether a new physical or cognitive experience was aging or MS, what the future holds regarding losing independence, losing spouses and caregivers, and growing “too old” such that quality of life is completely diminished. Conclusions: This qualitative research has highlighted the complexity of aging with MS. All participants noted a continuum of behaviors from an earlier age, while others believed they had “aged out” of MS and were experiencing a peak of health and wellness. Participants who were diagnosed in middle age, however, noted a sharp progression of age-related and MS symptoms, but stated “everyone has something” and perceived the diagnosis of MS was less impactful in older age with regards to what is expected at this life stage. Concerns remained, however, regarding whether a new physical or cognitive experience was aging or MS, what the future holds regarding losing independence, losing spouses and caregivers, and growing “too old” such that quality of life is completely diminished. Conclusions: This qualitative research has highlighted the complexity of aging with MS. All participants noted a continuum of behaviors from an earlier age, while others believed they had “aged out” of MS and were experiencing a peak of health and wellness. Participants who were diagnosed in middle age, however, noted a sharp progression of age-related and MS symptoms, but stated “everyone has something” and perceived the diagnosis of MS was less impactful in older age with regards to what is expected at this life stage. Concerns remained, however, regarding whether a new physical or cognitive experience was aging or MS, what the future holds regarding losing independence, losing spouses and caregivers, and growing “too old” such that quality of life is completely diminished. Conclusions: This qualitative research has highlighted the complexity of aging with MS. All participants noted a continuum of behaviors from an earlier age, while others believed they had “aged out” of MS and were experiencing a peak of health and wellness. Participants who were diagnosed in middle age, however, noted a sharp progression of age-related and MS symptoms, but stated “everyone has something” and perceived the diagnosis of MS was less impactful in older age with regards to what is expected at this life stage. Concerns remained, however, regarding whether a new physical or cognitive experience was aging or MS, what the future holds regarding losing independence, losing spouses and caregivers, and growing “too old” such that quality of life is completely diminished. Conclusions: This qualitative research has highlighted the complexity of aging with MS. All participants noted a continuum of behaviors from an earlier age, while others believed they had “aged out” of MS and were experiencing a peak of health and wellness. Participants who were diagnosed in middle age, however, noted a sharp progression of age-related and MS symptoms, but stated “everyone has something” and perceived the diagnosis of MS was less impactful in older age with regards to what is expected at this life stage. Concerns remained, however, regarding whether a new physical or cognitive experience was aging or MS, what the future holds regarding losing independence, losing spouses and caregivers, and growing “too old” such that quality of life is completely diminished. Conclusions: This qualitative research has highlighted the complexity of aging with MS. All participants noted a continuum of behaviors from an earlier age, while others believed they had “aged out” of MS and were experiencing a peak of health and wellness. Participants who were diagnosed in middle age, however, noted a sharp progression of age-related and MS symptoms, but stated “everyone has something” and perceived the diagnosis of MS was less impactful in older age with regards to what is expected at this life stage. Concerns remained, however, regarding whether a new physical or cognitive experience was aging or MS, what the future holds regarding losing independence, losing spouses and caregivers, and growing “too old” such that quality of life is completely diminished. Conclusions: This qualitative research has highlighted the complexity of aging with MS. All participants noted a continuum of behaviors from an earlier age, while others believed they had “aged out” of MS and were experiencing a peak of health and wellness. Participants who were diagnosed in middle age, however, noted a sharp progression of age-related and MS symptoms, but stated “everyone has something” and perceived the diagnosis of MS was less impactful in older age with regards to what is expected at this life stage. Concerns remained, however, regarding whether a new physical or cognitive experience was aging or MS, what the future holds regarding losing independence, losing spouses and caregivers, and growing “too old” such that quality of life is completely diminished. Conclusions: This qualitative research has highlighted the complexity of aging with MS. All participants noted a continuum of behaviors from an earlier age, while others believed they had “aged out” of MS and were experiencing a peak of health and wellness. Participants who were diagnosed in middle age, however, noted a sharp progression of age-related and MS symptoms, but stated “everyone has something” and perceived the diagnosis of MS was less impactful in older age with regards to what is expected at this life stage.
Machine Learning Algorithms Applied to Visual Metrics to Classify Demyelinating Disease in Children

Beyza Ciftci,1 Can Kavaklıoglu,2 Lauren Erdman,3 Anna Goldenberg,1,4,5,6,7,8 Tara Berenbaum,9 Tara Feltham,10 Fiona Castello,10 Jean Mah,10 Arun Reginald,10 Brenda Banwell,10 Giulia Longoni,10 E. Ann Yeh12

1Department of Pediatrics, The Hospital for Sick Children, Toronto, ON; 2Department of Mechanical and Industrial Engineering, Ryerson University, Toronto, ON, Canada; 3Genetics and Genome Biology Lab, The Hospital for Sick Children, Toronto, Canada; 4Department of Computer Science, University of Toronto, Toronto, ON, Canada; 5Vector Institute, Toronto, ON, Canada; 6CIFAR, Toronto, ON, Canada; 7Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada; 8Department of Clinical Neurosciences and Surgery, University of Calgary, Calgary, AB, Canada; 9Department of Pediatrics, University of Calgary, Calgary, AB, Canada; 10Ophthalmology and Vision Sciences, The Hospital for Sick Children, Toronto, ON, Canada; 11Neurology, The Children’s Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 12Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada

Background: Predicting disease classification in youth with a first episode of demyelination is feasible in some but not all cases. Machine learning algorithms can provide highly accurate predictions of outcomes directly from images, removing a major bottleneck in the speed with which predictions can be made. Objectives: To use visual metrics to predict demyelinating disease using both dermal and subclinical approaches. Methods: We prospectively collected clinical and visual data at disease onset from 224 pediatric subjects, classified using consensus definitions of demyelinating disorders and serum antibody testing for myelin oligodendrocyte glycoprotein (MOG) and aquaporin 4 (healthy control = 72, multiple sclerosis = 69, anti-MOG = 18, neuromyelitis optica spectrum disorder [NMO-OSD] = 10, monophasic acquired demyelinating syndromes [MonoADS] = 55) were recruited through the Demyelinating Disorders Program at The Hospital for Sick Children [Toronto, Ontario] and University of Calgary [Calgary, AB, Canada]. Results: In the analysis of the balanced data set, the random forest classifier (accuracy = 80%, recall = 50%, precision = 99%), XGBoost classifier (accuracy = 80%, recall = 70%, precision = 90%), and decision tree (accuracy = 90%, recall = 90%, precision = 90%) algorithms yielded the highest accuracy, recall, and precision levels for each disease class using the combination of RNFL, GCC, GCAV, and color vision. Analysis of the unbalanced data set showed lower overall levels of predictive accuracy (60%-90%) for each class using the same algorithms. Use of the OCT data alone yielded lower predictive accuracy in both balanced and unbalanced analyses. Conclusions: Machine learning algorithms can be combined with cutaneous and fundus-based metrics to classify young with demyelinating disorders. Implementation of artificial neural networks using raw OCT data and images as input are underway.

DISEASE-MODIFYING THERAPY

(DMT01) Comparative Effectiveness of Switching from Natalizumab to a Moderate-Versus High-Efficacy Disease-Modifying Therapy in Clinical Practice

CAROL M. HERSH,1 RALPH HARRIS,1 DEVON CONWAY,2 LE HUA3
1Lau RoVo Center for Brain Health, Cleveland Clinic, Las Vegas, NV; 2Las Vegas, NV; 3University of Nevada, Las Vegas, NV

Background: Natalizumab (NTZ) is a highly effective disease-modifying therapy (DMT) for relapsing multiple sclerosis (MS). Long-term use of NTZ is limited by potential safety risks that can be reduced by switching to an alternative therapy. However, NTZ discontinuation may trigger rebound disease, resulting in disability. The present study showed patients switching to moderate- (Mod) DMT vs high-efficacy therapy (HET) were at higher risk of early magnetic resonance imaging (MRI) disease activity by 6 months. Objectives: To assess the comparative effectiveness of switching from NTZ to a Mod DMT vs HET in patients with MS over 24 months. Methods: All Patients discontinuing NTZ at 2 MS centers (n = 556) who switched to Mod DMT (n = 270) vs HET (n = 130) were assessed using propensity score (PS) weighting. PS model covariates included demographics and baseline clinical and radiographic disease characteristics. Outcomes included annualized relapse rate and proportions with new T2 and/or gadolinium-enhancing (GdE) lesions, absence of disease activity (a composite measure of no relapses and/or MRI activity

Keywords: Disease-modifying treatments in MS, Imaging and MS

---

**Keywords:** Machine learning and MS

---

**Keywords:** Non-imaging biomarkers
ity, time-to-first relapse and GdE lesion, and 20% worsening of the Timed 25-Foot Walk Test (T25FW) ≥ 12 months of follow-up; 54.9%, breakthrough disease (15.3%), and adverse effects (17.3%). PS weighting was done to ensure adequate covariate balance. After PS adjustment, there were no differences in accumulated relapse rate (rate ratio = 1.44 [95% CI, 0.69-2.99], P = .334) or time-to-first relapse (HR = 2.12 [95% CI, 0.87-5.17], P = .090) by 24-month follow-up. However, patients switching to Mod DMT had higher proportions with new T2 lesions (OR = 3.99 [95% CI, 1.83-8.01], P = .011), new GdE lesions (OR = 2.72 [95% CI, 1.02-7.59], P = .042), and 20% worsening of the T25FW (OR = 1.83 [95% CI, 1.06-3.02], P = .043) and 9-HPT (HR = 1.81 [95% CI, 1.05-3.56], P = .044), and lower proportion with absence of disease activity (OR = 0.41 [95% CI, 0.20-0.71], P = .004). Switchers to Mod DMT were also at higher risk of earlier time-to-first GdE lesion (HR = 6.67 [95% CI, 2.06-21.6], P = .002).

Conclusions: By 24 months, NFT switchers to Mod DMT vs HET had lower cumulative probability of no disease activity by 24 months and were at higher risk of disability accumulation.

Supported by: None Disclosure: Carrie M. Hersch: Biogen, Genentech (consulting fee, contracted research); EMD Serono (consulting fee); Genzyme, Novartis (consulting fee, speakers’ bureau); PCORI (consulted research). Haleigh Harris: Nothing to disclose.

Dream Consor: National MS Society (contracted research); Novartis (consulting fee, contracted research); Encephalitis/Lupus Initiative (consulting fee). Le H. Hug: Biogen, Celgene, EMD Serono, Genentech, Novartis (consulting fee); Genzyme (consulting fee, speakers’ bureau).

Keywords: Comparative effectiveness, Disease-modifying treatments in MS

(DMT02) Yearly Efficacy and Safety Outcomes Over 4 Years After Last Alemotuzumab Course in Pooled CARE-MS I and II Patients by Number of Additional Courses Received Through Year 9

Regina Berkovitch,1 Roza Alrowaghm,2 Ann D. Bass,3 Aaron L. Boster,4 Giancarlo Comi,5 Ho Jin Kim,6 Volkmar Immrath,6 Jan Lycke,7 Richard A.L. Macdonnell,8 Sven Schippling,9 Bjarke Skarrack,10 Hans Tintero,11 Anthony Traboulsee,12 Patrick Vermersch,13 Heinz Wiendl,14 Tjalf Ziemssen,15 Nadia Daizehdad,16 Alan Jacobs,17 Elizabeth M. Poole,18 Barry A. Singer,19 on behalf of the CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ investigators

1Keck School of Medicine, University of Southern California, Los Angeles, CA; 2Regina Berkovitch, MD, PhD, West Hollywood, CA; 3Ami Hospital, Sharq, Kuwait; 4Neurology Center of San Antonio, San Antonio, TX; 5Boer MS Center, Columbus, OH; 6University Vita-Salute San Raffaele, Milan, Italy; 7National Research Foundation of Korea (research support); 8Research Institute, Department of Neurology, University of Münster, Münster, Germany; 9Center for Clinical Neuroscience, Carl Gustav Carus University Hospital, Dresden, Germany; 10Sanofi, Cambridge, MA; 11The Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO

Background: In CARE-MS I and II (trial registration: NCT00530348, NCT005348403), alemtuzumab treatment (12 mg/day; baseline: 5 days; 12 months: 18 doses; 24 months: 3 days) improved clinical and magnetic resonance imaging (MRI) outcomes vs subcutaneous interferon beta-1a over 2 years in patients with relapsing-remitting multiple sclerosis (MS). In 2 consecutive extensions (NCT00930553, NCT02255656 [TOPAZ]), patients could receive additional alemtuzumab (12 mg/day; 3 days; ≥12 months apart).

Objectives: Evaluate yearly efficacy and safety of alemtuzumab in pooled CARE-MS patients who did or did not receive additional alemtuzumab through year 9.

Methods: Pooled CARE-MS patients were stratified by the total number of courses received (exactly 2 courses, exactly 3 courses, 2 courses, 4 courses). Inclusion criteria: additional alemtuzumab (ie, courses 3 or 4) received by month 97 to allow ≥2 months of follow-up; no other disease-modifying therapy through year 9. Data were censored at 5 years (if received) in the 24-course groups. Outcome data were rebaselined after the last alemtuzumab course. Results: 742/811 (91%) alemtuzumab-treated patients entered the extension and could receive additional courses; courses 3 and 4 were given most frequently in years 3 (19%) and 4 (6%), respectively. Of 742 extension patients, 359 (48%), 142 (20%), and 121 (16%) were included in the 2-, 3-, and ≥4-courses groups, with 303, 76, and 15 remaining in study in year 4 after last course, respectively. Over 4 years after last course, annualized relapse rate was 0.007, 0.007, 0.007, and 0.007 in the 2-, 3-, and ≥4-courses groups, respectively, and change in mean Expanded Disability Status Scale score at year 4 after last course was −0.06, +0.08, and +0.56, respectively. Over 4 years, 83%, 85%, and 94% were free of 6-month confirmed disability worsening, and 23%, 11%, and 15% had 6-month confirmed disability improvement in the 2-, 3-, and ≥4-courses groups, respectively. Serious adverse events were generally similar between cohorts during years 1-3 after last treatment (5.1%-11.4% per year), but low patient numbers in the ≥4-courses group confounded analysis of serious adverse events in year 4 after last treatment.

Conclusions: Efficacy of additional alemtuzumab was maintained over 4 years after last course in CARE-MS patients, although the ≥4-courses group had higher disease activity and disability, as expected. Alemtuzumab safety was generally consistent between groups, except for the 4-courses cohort in year 4 after last course wherein interpretation was limited by few numbers of available patients.

Supported by: Sanofi, Bayer HealthCare Pharmaceuticals

Disclosure: Regina Berkovitch: Acorda, AstraZeneca, Bayer, Biogen, Novartis, Questcor, Sanofi, Texa (advisory boards, consulting fees). Roel A. Hoppenbrouwers: Bayer, Biogen, GlaxoSmithKline, Lundbeck, Merck Serono, Novartis, Roche, Sanofi (speaking honoraria, research grants, scientific advisory boards). Ann D. Bass: Actelion, Biogen, EMD Serono, Mallinckrodt, Novartis, Roche-Genentech, Sanofi, TG Therapeutics (consulting fees/fees for non-CME services from commercial interests or their agent/sponsor and research support). Aaron L. Boster: Biogen, Mallinckrodt, Medtronic, Novartis, Sanofi, Teva (consulting fees and/or fees for non-CME services). Giancarlo Comi: Almirall SpA, Biogen, Biogen Italia Srl, Celgene, EXCITE, FAB, Hoffmann-La Roche, Forward Pharma, Genzyme, Genzyme Europe, MedDev, Merck KGaA, Merck Sharp & Dohme SpA, Roche SpA (consulting fee). Bayer, Biogen, Dompe, Merck Serono, Novartis, Serono Symposia International Foundation, Teva (lecture fees); Sanofi (consulting, lecture fees). Ho Jin Kim: Alexion, Celtrion, Eisai, HanAll BioPharma, Merck, Novartis, Sanofi, Teva-Handok, Viela Bio (consulting and speaking fees); Journal of Clinical Neurology, Multiple Sclerosis Journal (co-editor/editorial associate editor); MedImmune/Viela Bio (steering committee); National Research Foundation of Korea (research support); Sanofi (consulting fee); Biogen (consulting fee); Sanofi (consultation fees). Richard A.L. Macdonnell: Bayer, Merck, Roche (compensation for advisory boards and/or speaking fees). Patrick Vermersch: Biogen, Novartis, Sanofi, Teva (compensation for advisory boards and/or speaking fees, research support). Sven Schippling: Biogen, Merck, Novartis, Roche, Sanofi, Teva (research and travel grants, honoraria for expert advice on MS, and speaking fees). Marie Timmer: Almirall, Bayer, Biogen, Genzyme, Merck Serono, Novartis, Roche, Sanofi-Aventis, Teva (speaking honoraria and travel/grants for scientific advisory boards for scientific advisory boards). Eliane L. Lottier: Genzyme, Roche, Sanofi, Teva (consulting and/or speaking fees, grant/research support). Patrick Vermersch: Almirall, Bayer, Merck, Roche (consulting and/or speaking fees); Biogen, Novartis, Sanofi, Teva (consulting and/or speaking fees, grant/research support). Barry A. Singer: AbbVie, Biogen, Novartis, Roche, Sanofi (research support and speaking/consulting); Teva (consulting and/or speaking fees, research support). Haleigh Harris: Nothing to disclose.

Keywords: Disease-modifying treatments in MS

(DMT03) Efficacy and Safety of Ofatumumab Versus Teriflunomide in Patients with Relapsing Multiple Sclerosis: Phase 3 ASCLEPIOS I and II Trials

Background: Ofatumumab is the first fully human anti-CD20 monoclonal antibody, administered with a monthly 20 mg subcutaneous dosing regimen. Objectives: To investigate the efficacy and safety of ofatumumab vs teriflunomide in patients with relapsing multiple sclerosis (MS).

Methods: ASCLEPIOS I and II were 2 identical phase 3, double-blind, double-dummy, active comparator-controlled, parallel-group, innovative, adaptive-design (with flexible duration), multicenter trials in patients aged 18-55 years with an Expanded Disability Status Scale score of 0.5-6.5 at screening. Patients were randomized (1:1) to receive subcutaneous ofatumumab (loading dose: days 1, 7, and 14; maintenance dose: every 4 weeks from week 4) or oral teriflunomide 14 mg once daily, for 1 year. The primary endpoint was annualized relapse rate. Key secondary endpoints included 3- and 6-month confirmed disability worsening, time to 3- and 6-month confirmed disability worsening, time to first MRI T2 lesion, time to first gadolinium-enhancing lesion, and time to first gadolinium-enhancing lesion or primary endpoint. A pre-specified ASCLEPIOS I/II pooled analysis, ofatumumab reduced the annualized relapse rate (ASCLEPIOS I and II: 50.5% and 58.5%), time to confirmed disability worsening (ASCLEPIOS I and II: 66.0%-54.4%), the most common TEAEs by time epoch after initiating treatment year.

Supported by: None

Disclosure: Anne H. Cross: Academic CME (CE provider) (speaking, slide preparation for CME); Biogen, Celgene, TG Therapeutics (consulting fee); Biogen, Genzyme, MedDay, Novartis, Roche, Sanofi, Serono (consulting fee, speaker’s bureau). Jorge Corredor: Biogen, Genzyme, Merck-Serono, Novartis, Roche (board member, contracted research); Patricia K. Coyte: Accordant, Alexion, Bayer, Biogen, Celgene, Sanofi Genzyme, GlaxoSmithKline, Mylan, Serono, TG Therapeutics (consulting fee, speaker’s bureau, travel reimbursement). Xavier Montalban: AbbVie, Teva Pharmaceutical (contracted research); Genentech/Roche, Novartis (consulting fee, contracted research); Ireneu de Seze: Alexion, Allergan, Almirall, Bayer, Biogen, Chugai, CSL Behring, F. Hoffmann-La Roche Ltd, Genzyme, LFB, Merck, Novartis, Takeda (consulting fee, expert on advisory board).

None

Supported by: None

Disclosure: Piow Oh: Biogen, Roche, Sanofi Genzyme (consulting fee, research funding); Brain Canada, MS Society of Canada (research funding); Celgene, Novartis, Receptos and Serono (grant support).

Keywords: Disease-modifying treatments in MS

PSYCHOSOCIAL: COGNITION

(PSY01) A Mindfulness Group Intervention in Newly Diagnosed Persons with Multiple Sclerosis: A Pilot Study
Sarah A. Morrow,1 Nancy Vording,2 Jordan Ward,3 Courtney S. Casserly,3 Heather Rosehart,4 Arlene Macdougall5
1Clinical Neurological Sciences, London Health Sciences Centre, London, ON, Canada; 2Clinical Neurological Sciences, Western University, London, ON, Canada; 3Clinical Neurological Sciences, University of Western Ontario, London Health Sciences Centre, London, ON, Canada; 4Psychiatry and Epidemiology & Biostatistics, St. Joseph's Health Care, Parkwood Institute, London, ON, Canada

Background: Relapsing multiple sclerosis (RMS) is a lifelong disease without a cure, usually diagnosed between age 20-40 years. Being newly diagnosed with RMS is a highly stressful event due to the unpredictable disease course after diagnosis. Thus, it is imperative that persons with multiple sclerosis have the skills and support to cope with the negative physical and emotional effects of the disease. Objectives: To assess whether a mindfulness-based intervention (MBI) will lessen the negative consequences of stress due to being newly diagnosed with RMS. Methods: A single-blind, randomized, prospective study of a 10-week MBI vs. usual standard of care alone in persons newly diagnosed (within 1 year) with RMS. Primary outcomes included the Brief COPE measure and the Hospital Anxiety and Depression Scale (HADS). Secondary outcomes included measures of perceived stress, cognitive function, fatigue, and quality of life. Subjects were assessed at baseline, postintervention, and 6 months later. Analysis of covariates was used to compare longitudinal changes, with baseline scores used as covariates. Results: 25 subjects were recruited (16 MBI, 9 controls); most were women (21 [84%]), with a mean age of 38.4 ± 9.5 years. The groups were well matched on baseline characteristics. All controls completed the study, while 4 MBI participants did not. The MBI group improved significantly on the COPE measure when compared to the control group (P = .024) as well as on the HADS depression subscale (P = .007) pre- and post-intervention; there was no significant difference over time on the HADS anxiety subscale (P = .179). On the secondary outcomes, there was a significant improvement on the Perceived Stress Scale (P = .015), and a trend towards improvement on the SF-36 (P = .073; quality of life) and the MSNQ (P = .066; perceived cognitive impairment) comparing pre- and postintervention assessments. Six-month data will be available at the time of this presentation. Conclusions: This pilot study demonstrates that an MBI improves coping, depression, and perceived stress in newly diagnosed persons with RMS.

Supported by: None
Disclosure: Sarah A. Morrow; Biogen (contracted research); Celgene (consulting fee); EMD Serono, Roche, Sanofi Genzyme (speakers' bureau). Nancy Vording; Jordan Ward, Courtney S. Casserly, Heather Rosehart, Arlene Macdougall: Nothing to disclose.

Keywords: Comprehensive care and MS, Psychological issues and MS, Wellness

(PSY02) Effects of Weekly Participation in a Wellness Program on Self-Reported Measures for People Living with Multiple Sclerosis: A 3-Year Analysis
Brian Hutchinson,1 John Schafer,2 Lacey Soyer,2 Tiffany Malone2
1Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA; 2Mercy MS Center, Community Health Plan of California, Sacramento, CA

Background: The Multiple Sclerosis Achievement Center (MSAC) conducts day wellness programs to address physical, cognitive and social well-being. Program activities include individualized and group exercise, cognitive stimulation, education, socialization, and community outings. Baseline, 1-year, and 2-year follow-up data were collected and presented at a previous Consortium of Multiple Sclerosis Centers annual meetings. Objectives: To determine, through the use of patient-reported outcome (PRO) measures, if members of these wellness programs improve self-reported health impact and quality of life over a 3-year period. Methods: Initial analysis, comparing data of baseline and 1-year participation in these wellness programs, was completed through paper/pencil outcome measures between December 2016 and August 2017 for 95 people with multiple sclerosis (PwMS). Of those 95, 2-year data for 70 PwMS were collected and analyzed in 2019 and 3-year data are being collected for 66 people. Outcome measures used for the analyses include the Multiple Sclerosis Impact Scale (MSIS-29), Multiple Sclerosis Self-Efficacy Scale-10 item (MSSE), Godin Leisure Time Exercise Questionnaire (GITEQ), and Neuro-Qol (questions from the Anxiety, Depression, Emotion & Behavior, Positive Affect, Cognition, Ability to Participate, and Social Roles sections were used). All outcomes were completed onsite at the MSAC as part of the members’ weekly participation in the program. Analysis will be completed to compare data from the initial analysis to the 3-year results. Results: As previously reported, a correlation between reports of Self-Efficacy, Anxiety, Ability to Participate, and Positive Affect (per MSSE and Neuro-Qol) were seen with both 1- and 2-year analyses. Analysis of baseline to 2-year data demonstrated statistically significant changes in Neuro-Qol sections Ability to Participate (P = .02) and Social Roles (P = .001). Another notable change in the 2-year analysis was an increase in physical activity, as measured by GITEQ (average change of 2.34 from baseline to 2 years). Data analysis will measure any changes in 3-year data compared to baseline, 1-year, and 2-year results. Conclusions: Complete collection and analysis of 3-year comparative data will be finalized in February 2020 for presentation at the meeting.

Supported by: None
Disclosure: Brian Hutchinson; Biogen (speakers’ bureau). John Schafer; Biogen, EMD Serono, Genentech, Sanofi Genzyme (speakers’ bureau). Lacey Soyer; Tiffany Malone; Nothing to disclose.

Keywords: Comprehensive care and MS, Psychological issues and MS, Wellness

(PSY03) Examining Multilevel Environmental Correlates of Physical Activity Among Older Adults with Multiple Sclerosis
Stephanie L. Silveira, Jessica F. Baird, Robert W. Motl
Physical Therapy, University of Alabama at Birmingham, Birmingham, AL

Background: With a growing population of older adults with multiple sclerosis (MS), appropriate strategies are needed to promote physical activity (PA) as a second-line approach for symptom management. Objectives: This cross-sectional study examined built environment, social environment, and individual social cognitive theory (SCT) variables as hierarchical correlates of PA in older adults with MS using a social ecological model (SEM) framework. Methods: 363 participants completed the online survey including demographics, the Abbreviated Neighborhood Walkability Scale (NEWS-A), Social Provisions Scale (SPS), Exercise Self-Efficacy Scale (EXSE), and Multidimensional Outcome Questionnaire (MOEES) and Godin Leisure-Time Exercise Questionnaire (GITEQ) Total and Health Contribution score (HCS). Spearman rank-order correlation analyses were used to examine associations among NEWS-A subscales, SPS, EXSE, MOEES, and GITEQ Total and HCS. Linear regression analyses were conducted hierarchically, first regressing GITEQ with NEWS-A subscales (built environment) in step 1, SPS (social environment) in step 2, then EXSE and MOEES (individual determinants) in step 3. Results: Land-use mix diversity, land-use mix access, street connectivity, and aesthetics were significantly correlated with GITEQ Total, whereas land-use mix diversity, land-use mix access, infrastructure and safety for walking, aesthetics, and crime were significantly correlated with GITEQ HCS. Hierarchical linear regression analyses were then conducted whereby we regressed GITEQ Total with NEWS-A subscales (step 1) with significant associations noted for land-use mix diversity and aesthetics (R² = 0.09), step 2 included SPS with significant associations noted for SPS, land-use mix diversity, and aesthetic (R² = 0.15), and finally EXSE and MOEES were included in step 3 and were the only significant correlates of GITEQ total (R² = 0.38). Regarding GITEQ HCS, land-use mix diversity, aesthetics, and crime were significant correlates in step 1 (R² = 0.10), SPS and land-use mix diversity were the only significant correlates in step 2 (R² = 0.14), and EXSE was the only significant correlate in step 3 (R² = 0.36). Conclusions: This study provides guidance for researchers and practitioners on relevant targets for tailoring PA interventions for older adults with MS and supports the continued emphasis on self-efficacy as a primary predictor of health behavior and maintenance.

Supported by: None
Disclosure: Nothing to disclose.

Keywords: Management of activities of daily living in MS, Older adults with MS, Psychological issues and MS, Wellness.
(PSO04) Effect of Nabiximols Cannabinoid Oramusocalspray on Depressive Symptoms, Suicidality, and Cognition in Patients with Multiple Sclerosis

John Deluca,1 Dawn Langdon,2 Joris Berwaerts,3 Joanne Wagner4
1Kessler Foundation, West Orange, NJ; 2Department of Psychology, Clinical, Health and Social Psychology, Royal Holloway, University of London, Egham, United Kingdom; 3Greenwich Biosciences, Inc, Carlsbad, CA

Background: Substantial evidence has shown nabiximols, a complex botanical mixture containing delta-9-tetrahydrocannabinol and cannabidiol as the principal cannabinoids, can reduce spasticity associated with multiple sclerosis (MS). This analysis assesses whether nabiximols affects other patient outcomes such as depressive symptoms, suicidality, and cognition. Objectives: Report the effect of nabiximols on depression, suicidality, and cognition using data from 2 placebo-controlled randomized controlled trials, GWSP0604 (12 weeks) and GWMS1137 (48 weeks), in patients with spasticity due to MS. Methods: Mood and suicidality were assessed using the Beck Depression Inventory-II (BDI-II) in both trials. In GWMS1137, suicidality was assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS) and working memory/processing speed using the Paced Auditory Serial Addition Test (PASAT). The combined PASAT total score was calculated combining both PASAT-1 and -2 tests scores (total of 120 points). Outcome differences between nabiximols and placebo are summarized. Results: 241 patients from GWSP0604 and 121 from GWMS1137 were included. The baseline and end-of-treatment mean BDI-II total scores were 8.7 vs 9.5 for nabiximols and 9.7 vs 10.4 for placebo, and 15.7 vs 13.5 and 13.5 vs 11.1 for placebo in GWMS1137. Differences between nabiximols and placebo of the BDI-II change from baseline adjusted means were −0.06 (−1.62, 1.49) in GWSP0604 (no significant difference) and −0.29 (−2.91, 2.33) in GWMS1137 (statistically noninferior). Question 9 of BDI-II (suicidal thoughts or wishes) showed no notable treatment differences in either trial, with only 1 patient treated with nabiximols reporting a score ≥2. On the C-SSRS, 5 (5.1%) patients randomized to placebo and 1 (1.6%) to nabiximols had a “flag” (ie, “yes” as a response), but further questioning revealed no emergent suicidal ideations or behavior in any of these patients. For GWMS1137, the baseline and end-of-treatment PASAT-1 total scores were 71.3 vs 72.4 for nabiximols and 74.5 vs 82.7 for placebo; increases may reflect practice effects. Treatment difference of the adjusted mean was −1.47 (−6.41, 3.48), indicating nabiximols does not adversely affect working memory/cognitive processing speed in patients with MS over a 48-week period compared with placebo. Conclusions: Nabiximols had no notable effects on depression, suicidality, or working memory/processing speed in patients with MS. Supported by: None

Disclosure: John Deluca: Biogen (consulting fee, contracted research, speakers’ bureau); Celgene, Novartis (consulting fee); EMD Serono, Genzyme, Sanofi, Teva (contracted research); Joris Berwaerts: GW Pharmaceutical (salary); Joanne Wagner: Greenah BioScience/GW Pharmaceutical (salary); GW Pharmaceuticals (ownership interest).

Keywords: Complementary/alternative therapies in MS; MS symptom management, Psychological issues and MS

(PSO06) Multiple Sclerosis Management: Predicting Disease Trajectory of Multiple Sclerosis on Multidimensional Data Including Digital Cognitive Assessments and Patient-Reported Outcomes Using Machine Learning Techniques

Mark Godesblatt,1 Iared Sirivivany,2 Olivia Koczmaz,2 Daniel Kantor,2 Daniel Golon,2 Myassar Zarif,2 Barbara Bumsted,3 Marijeh Buhse,2 Lori Fafard,2 Timothy Fratto,2 Jeffrey Wilken,1 Cynthia Sullivan,4 Glen Doniger4
1South Shore Neurologic Associates, Patchogue, NY; 2Florida Atlantic University, Boca Raton, FL; 3Raraportor Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; 4Washington Neuropsychology Research Group, Washington, DC; 5Nursing, State University of New York at Stony Brook, Stony Brook, NY; 6NeuroTrax Corp, Modin, Israel

Background: Multiple sclerosis (MS) disease impact is traditionally measured by magnetic resonance imaging changes, relapse rates, and Expanded Disability Status Scale (EDSS). Combining multidimensional patient-reported outcome (PRO) and objective disease impact information independent of EDSS might enhance clinical decision making. In this proof-of-concept study, patient-tracking sources expand beyond what is traditionally captured in an office visit, clinicians need tools to help integrate these varied streams of data. Machine learning has the potential to help clinicians predict meaningful patient outcomes from multidimensional and quantified data sources. Objectives: To demonstrate the feasibility of predicting clinical outcomes in MS using standard machine learning methods on multidimensional data including digital cognitive assessments and PROs. Methods: Machine learning models were trained on electronic health record data, cognitive domain scores, and PRO data. A prediction model was created given the patient’s record. 80% of the dataset was used in training, 20% in testing with an ensemble learning method (random forest classifiers) used to construct a multitude of training decision trees, which then outputted the mean prediction of the individual trees. Results: The model was trained on 258 persons with MS (72.5% female, average age 46.2 ± 10.2) over a 3-year period. Untuned models calculated F1 scores (2*Precision *Recall)/(Precision+Recall) for depression, Precision and Recall for accuracy. For multiple models predicting PROs and disease-modifying therapy choice. The most precise and accurate models were for the Driving (0.913, 0.904, 0.942, 0.912) and Modified Falls Efficacy Scale (0.789, 0.796, 0.792, 0.829), Depression (0.711, 0.765, 0.714, 0.718), Fatigue (0.716, 0.782, 0.699, 0.755), and Employment (0.672, 0.753, 0.668, 0.705). Conclusions: Machine learning combined with objective measures of disease impact and PROs can provide important information to predict economically important and disability-relevant outcomes, potentially enhancing treatment decisions. These results show promising predictive accuracy to be used in a variety of advisory applications and potentially reduce disease-related disability. The results of the other models demonstrate the feasibility of using machine learning in a broader network of clinical sites that will allow for greater accuracy, precision, and recall. The eventual goal is that these models can be used as an aid in the shared decision-making process, and to reduce inappropriate health care costs. Supported by: None

Disclosure: Mark Godesblatt: Acorda, Amgen, Medronics, Sool Therapeutics (speakers’ bureau); Biogen, EMD Serono, Novartis, Sanofi, Teva (contracted research); Iared Sirivivany: Olivia Koczmaz, Daniel Kantor, Danial Golon, Marijeh Buhse, Lori Fafard, Timothy Fratto: Nothing to disclose. Myassar Zarif: Acorda, Biogen, Genzyme, Teva (speakers’ bureau). Barbara Bumsted: Biogen, EMD Serono (contracted research); Jeffrey Wilken: Biogen (contracted research); EMD Serono (speakers’ bureau); Genzyme (contracted research, speakers’ bureau). Cynthia Sullivan: Roche (contracted research). Glen Doniger: NeuroTrax (salary).

Keywords: Comprehensive care and MS, Machine learning, Natural history of MS

(REH01) Significant Structural Neuropathological Changes Can Follow Physical Behavioral Change Therapy for Multiple Sclerosis

Victor W. Mark,1 Brent M. Womble,2 Gitendra Uswatte,3 David M. Morris,3 Mary H. Doniger,4 Sajida Sullivan,5 Staci McCoy6
1Physical Medicine and Rehabilitation, University of Alabama at Birmingham (UAB), Birmingham, AL; 2Psychology, UAB, Birmingham, AL; 3Physical Therapy, UAB, Birmingham, AL; 4Background: Constraint-induced movement therapy (CIMT) is a form of physical behavioral change therapy (BCT) that can significantly improve paretic limb use in the community in progressive multiple sclerosis (MS) for at least 1 year (Mark et al, 2018). Although a few forms of BCT can increase real-life physical activity in MS, none thus far has been examined for whether such treatment can change cerebral cortical grey matter structure. Objectives: To evaluate whether CIMT vs dose-matched control physical training can change cortical grey matter structure in progressive MS. Methods: Twenty adults with chronic MS matched for unilateral limb disability were randomized to 35 hours/2 weeks of either CIMT or a holistic complementary and alternative medicine (CAM) program (yoga, aquatic therapy, massage, relaxation techniques). Paretic limb use was measured with the Motor Activity Log (MAL), which has been validated against real-world upper limb accelerometry. Pre- and posttreatment 3-T structural brain magnetic resonance imaging scans were performed. Tensor-based morphometry (TBM) and voxel-based morphometry (VBM) were used to evaluate group-level changes in primary motor cortex (M1) structure contralateral to the more-affected arm. Whole-brain statistics were conducted using 1-sample t tests within Statistical Parametric Mapping software with a cluster-extent threshold of 10 voxels and false discovery rate of 0.1. Results: The 2 groups were identical in high expectation to benefit. CIMT produced a much larger effect size (d = 3.2) on the MAL than did CAM (d = 0.7). TBM detected an increase in the thickness of M1 after CIMT but not after CAM. VBM detected a change in M1 after CIMT, suggesting an increase in cortical density or volume or both. No change was detected after CAM. Conclusions: TBM and VBM suggest that CIMT increases M1 thickness and either volume or density in
MS, unlike dose-matched CAM. The findings suggest for the first time that physical BCT can significantly stimulate cortical neuroplasticity in a degenerative central nervous system disorder. The findings accord with our previous findings of post-CIMT significant white matter structural improvement in progressive MS (Barghi et al, 2018) and grey matter increases in stroke (Gauthier et al, 2008) and cerebral palsy (Sterling et al, 2013). Together, these findings suggest that a specific form of physical BCT can not only stimulate physical activity in the community over the long term but also well improve neurologic structure for progressive MS.

Supported by: None

Disclosure: Nothing to disclose

Keywords: CNS repair, Imaging and MS, Management of activities of daily living in MS

(RH02) A New Look at the Symbol Digit Modalities Test in Multiple Sclerosis and Disabilities

Yilan Liu,1 Victor W. Mark,2 Sean Bowman,3 Raazeen M. Mahmut,1 Janet Niemiere,1 Stacey S. Colford3

1University of Alabama at Birmingham (UAB), Birmingham, AL; 2Physical Medicine and Rehabilitation, UAB, Birmingham, AL; 3Biostatistics, UAB, Birmingham, AL

Background: Reduced information processing speed (IPS) is the most common cognitive impairment in multiple sclerosis (MS), related to reduced employment and physical ability. The Symbol Digit Modalities Test (SDMT) is the gold standard measure of IPS in MS (Benedict et al, 2017). Although many investigators have suggested that performance on the SDMT involves multiple cognitive processes, there has been little attempt to tease apart what specific cognitive processes may affect the IPS score on the SDMT. Improved understanding of the cognitive processes that contribute to IPS on the SDMT could support future cognitive rehabilitation trials to treat impaired IPS in MS.

Objectives: Assess specific eye movement measures during the SDMT to suggest what specific cognitive processes may underlie IPS on the SDMT in MS.

Methods: We recruited a convenience sample of 38 adults with MS, without clinical oculomotor impairment, who performed the SDMT while an infrared eye tracker recorded their eye movements. Eye positions were sampled at 10 Hz. Data were exported to a database for subsequent specific eye movement measures: 1) search organization as calculated by the “best r” metric (inferred as a measure of visual search), which is a linear correlation coefficient between the eye movement trajectories and the answer key at the top, inferred as a measure of symbol working memory. Spearman rho was performed to assess correlations between the variables and the SDMT IPS score (correct responses in 90 seconds).

Results: The mean (SD) SDMT IPS score was 38 (14). Both best r and total of upward saccades were positively correlated with the IPS score. The latter result was unexpected: the faster on the SDMT, the more often subjects checked the answer key. The results suggest that lower-scoring participants with MS, who less often checked the answer key during the test, may have become lost during their visual search, as reflected by their poorer search organization. Upward saccades may not so much represent working memory but rather as a strategy to assure successful test completion that is not effectively used by lower-scoring persons with MS. Further research will be needed to assess the criterion validity of specific SDMT eye movement measures relative to standard cognitive test assessments.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Information processing speed, Management of activities of daily living in MS

(RH03) Creating a Yoga Program as Part of a Comprehensive Multiple Sclerosis Care Model

Sandra Chapman, Ruth Almen, Carrie M. Hersh, Le H. Hua
Lou Ruvo Center for Brain Health, Las Vegas, NV

Background: Multiple sclerosis (MS) affects both physical and emotional health. Comprehensive programs addressing health and wellness are essential to improve quality of life. We offer a multidisciplinary approach to treatment, comprising a dedicated medical team, educational and social support, rehabilitation, research, and a health and wellness program. The benefits of yoga are increasingly recognized and subsequently requested by patients, yet dedicated programs aimed specifically for persons with MS are limited. MS specialty centers are challenged to explore ways to include yoga into a comprehensive care plan.

Objectives: We present our experience creating the Yoga for MS program as an integral component to comprehensive care.

Methods: Our MS program is contracted with a local yoga company to provide weekly sessions, using philanthropy funding. There are 3 instructors: 1 who leads and 2 others who assist, observe, and take notes. Because participants regularly engaged in dialogue before and after sessions, a 60-minute support/community sharing session was added prior to the yoga session. Our social worker attends each session to facilitate our goals and topics include implications for physical and mental health, as well as coping strategies and the importance of treatment adherence. An instructional video and meditation literature are available for use at home.

Results: The Yoga for MS Program started in November 2017, initially in a private setting with 1 instructor. In response to patients’ needs, we hired a yoga company with multiple instructors at a yoga studio in October 2018. Our current space can comfortably support 18 participants, including wheelchairs, scooters, and walkers.

To date, we have 12 participants who have a 75% attendance rate in a 12-week session. Average class size in the first year was 4, and now has doubled to 8, the largest being 14. Yoga staff observed over time increased ten newsletters and email communications. The participants also report reduced stress, increased use of coping strategies, and positive effects on balance, strength, self-esteem, and confidence. Participants also share resources and report feeling like they are “really in this together.”

Conclusions: A Yoga for MS Program can address the physical and psychological needs well-being of people with MS through comprehensive care. Future studies assessing the direct benefits of yoga are being explored.

Supported by: None

Disclosure: Sandra Chapman, Ruth Almen: Nothing to disclose. Carrie M. Hersh: Biogen, Genentech (consulting fee, contracted research); EMD Serono (consulting fee); Genzyme, Novartis (consulting fee, speakers’ bureau); PCORI (consulted research). Le H. Hua: Biogen, Celgene, EMD Serono, Genentech, Novartis (consulting fees); Genzyme (consulting fees, speakers’ bureau).

Keywords: Complementary/alternative therapies in MS, Comprehensive care and MS, Yoga

(RH04) Feasibility of “Sit Less, Move More”: An Intervention for Reducing Sedentary Behavior Among African Americans with Multiple Sclerosis

Jessica F. Baird,1 Jeffere E. Sasaki,2 Brian M. Sandroff,1 Gary Cutter,3 Robert W. Motl1

1Physical Therapy, University of Alabama at Birmingham, Birmingham, AL; 2Department of Sports Sciences, Universidade Federal do Triangulo Mineiro, Bairro Tutunas, Brazil; 3Department of Biostatistics, School of Public Health, University of Alabama at Birmingham, Birmingham, AL

Background: Sedentary behavior (SB) is a major concern in multiple sclerosis (MS), as it may accelerate disease progression and exacerbate physical disability. This is especially concerning in African Americans, a segment of the MS population who present with greater neurologic disability than Caucasians and for whom little MS research data are available. The current study examined the feasibility of an intervention focused on reducing SB in African Americans with MS.

Methods: We recruited 30 ambulatory and physically inactive African Americans with MS (age = 44 years) to participate in the “Sit Less, Move More” (SWM) program. SWM consisted of a 12-week behavioral intervention that used text- messaging along with Social Cognitive Theory principles to promote SB reduction. Feasibility was assessed on 4 domains: process, resource, management, and scientific outcomes. Participants were activPAL (AP) and ActiGraph (AG) activity monitors at 3 time points (prior to week 1 (T1), during week 6 (T2), and after week 12 (T3)) to measure changes in time spent sitting (AP data) and time spent in sedentary behavior (AG data). Estimates of effect size (Cohen’s d) were calculated to describe the treatment effect of SWM on SB.

Results: Process: Of the 64 persons initially contacted, 45 were assessed for eligibility, 31 were sent the informed consent document, and 30 returned a signed informed consent document and were included in the study. Resources: All participants returned T2 testing materials, and 29 (95%) returned T3 testing materials. Twenty-five (83%) participated in all behavioral coaching sessions. Total study costs were $7242.38 USD including costs for materials, postage, education, and participant remuneration. Management: Total personnel time to complete the study was 130 hours. Only 13 participants had valid AP data at all 3 time points, and 12 participants had valid AG data at all 3 time points. Scientific outcomes: No adverse events were reported. There was a small treatment effect on time spent sitting (d = −0.13) and sedentary time (d = −0.19).

Conclusions: The SWM intervention is safe and feasible for African Americans with MS, and yielded a small reduction in SB. The intervention was low-cost and well-received as an approach for reducing sedentary behavior, and, overall, our results suggest that the SWM program prog-
ress towards a phase 2 trial to determine its efficacy for reducing SB in African Americans with MS.

Supported by: None

Disclosure: Jessica F. Baird, Jeffrey E. Sands, Brian M. Sandraff, Beverly W. Matt: Nothing to disclose. Gary Catter, Avesis Pharmaceuticals, Biogen, BioLineRx, Brainstorm Cell Therapeutics, ClinTherapeutics, CSII, Behring, Galmed Pharmaceuticals, Genentech, Genzyme, Gildegam Pharmaceuticals, GW Pharmaceuticals, Haun Pharmaceuticals, Horizon Pharmaceuticals, Klein Baerdel Inc, MedDay, Medimmune, Merck, Merck/Pfizer, Neurim, National Heart, Lung, and Blood Institute (protocol review committee); National Institute of Child Health and Human Development (OPOF oversight committee); Neurotrs, Orphazyme, Opko Biologics, Omnisys Pharmaceuticals, Perception Neuroscience, Roata Pharmaceuticals, ReceptoCysc, Recursion Pharmaceuticals, Roche, Sanofi-Aventis, Somahlution, Teva Pharmaceuticals, TG Therapeutics, Vireo (fee for non-CME/CE services received directly from commercial interest or its agent); MGFA MG Registry, NARCOMS (contracted research); Pythagoras Inc (ownership interest).

Keywords: Sedentary behavior

(RHI05) The Effect of Aerobic Fitness on Physical and Cognitive Function and Brain Volume in Older Adults with Multiple Sclerosis

Jessica F. Baird,1 Marcos Bamman,2 Cynthia Brown,2 John R. Rinker,3 Robert W. Motl1

1Physical Therapy, University of Alabama at Birmingham (UAB), Birmingham, AL; 2UAB, Birmingham, AL; 3Neurology, UAB, Birmingham, AL

Background: There is evidence for the beneficial effects of aerobic exercise training on physical and cognitive function in persons with multiple sclerosis (MS). Improvements in function may be associated with the effects of aerobic fitness on deep gray matter (DGM) structures within the brain such as the hippocampus, thalamus, and basal ganglia. To date, we are unaware of research that has examined the effects of aerobic fitness in older adults with MS. Given the aging of the MS population, such an investigation is warranted. Objectives: The current study examined the effect of aerobic fitness on physical and cognitive function and DGM brain structures relevant to these outcomes in older adults with MS. Methods: We recruited ambulatory adults (age 55+ years) with MS (n = 20, age = 63 years). All participants underwent an assessment of aerobic fitness using a maximal, incremental exercise test on a recumbent stepper, assessments of walking speed (Timed 25-Foot Walk) and walking endurance (6-Minute Walk), assessments of cognitive function (Symbol Digit Modalities Test [SDMT]; Brief Visuospatial Memory Test [BVMT]; California Verbal Learning Test [CVLT]), and a 3T magnetic resonance image of the brain. We dichotomized participants into a “low fit” group (n = 10) and “high fit” group (n = 10) based on the results of the exercise test and calculated effect sizes (Cohen’s d) between the groups for all outcome measures. Results: Aerobic fitness had a large effect on both walking speed (d = −0.23) and walking endurance (d = 1.51). There was a moderate effect of aerobic fitness on cognitive function (Symbol Digit Modalities Test SDMT d = 0.57; CVLT d = 0.48; BVMT d = 0.67). The effect of aerobic fitness on DGM brain structures varied by structure. There was little to no effect on the thalamus (d = 0.19) and hippocampus (d = −0.01), whereas there was a moderate effect on the basal ganglia (d = 0.53). Conclusions: Our results provide novel evidence demonstrating a positive effect of aerobic fitness on physical and cognitive function in older adults with MS. As aerobic fitness is modifiable by aerobic exercise training, our results suggest that participation in regular physical activity may be an approach to ameliorate the consequences of aging with MS. Our results further suggest that improvements in function may be mediated by an effect of aerobic fitness on DGM brain structures; however, additional research is warranted to comprehensively investigate the neural adaptations associated with aerobic fitness in this population.

Supported by: None


Keywords: Exercise, Imaging and MS

(RHI06) Functional Electrical Stimulation Cycling Exercise Reduces Lower Limb Strength Asymmetry in Persons with Multiple Sclerosis

John W. Farrell III,1 Thomas Edwards,2 Robert W. Motl,1 Lara A. Flurtti1

1Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada; 3Physical Therapy, University of Alabama at Birmingham, Birmingham, AL

Background: Lower limb strength asymmetries (ie, difference ≥10% between contralateral muscle groups) have been associated with mobility impairment in persons with multiple sclerosis (PwMS), and may be a target for exercise training interventions aiming to improve mobility. Functional electrical stimulation (FES) cycling is an adapted exercise modality that has demonstrated preliminary benefits for mobility and fitness outcomes in PwMS with mobility impairment, but its potential effects on lower limb strength asymmetry remain unknown. Objectives: To assess the effect of FES cycling exercise on lower limb strength asymmetry in PwMS who have mobility impairment (ie, Expanded Disability Status Scale [EDSS] score 5.5-6.5), and to explore associations between change in lower limb strength asymmetry and change in mobility outcomes. Methods: Peak torque was recorded bilaterally for knee extensors (KEs) and flexors (KFs) using an isokinetic dynamometer, and was then used to generate lower limb strength asymmetry scores (1-(torque weak/torque strong) × 100). Mobility outcomes included the Timed 25-Foot Walk (T25FW) and the 2-Minute Walk (2MW). Participants received 24 weeks (3x/week) of either FES cycling or passive leg cycling (PLC). The FES condition actively cycled while receiving mild electrical stimulation to the quadriceps, hamstrings, and gluteal muscle groups. Exercise intensity was set at 40% to 60% of heart rate reserve, with exercise duration gradually increasing from 10 to 40 minutes per session over the course of the intervention. The PLC condition was identical to the FES condition, but did not receive electrical stimulation and did not actively cycle. Results: Eight PwMS (mean ± SD age = 52.9 ± 7.9; median [IQR] EDSS score = 6.3 [0.5]) completed the intervention. The FES cycling condition demonstrated a small decrease in lower limb strength asymmetry scores (1-torque_flexors /torque_ extensors) ∙ × 100). Mobility outcomes included the Timed 25-Foot Walk (T25FW) and the 2-Minute Walk (2MW). Participants received 24 weeks (3x/week) of either FES cycling or passive leg cycling (PLC). The FES condition actively cycled while receiving mild electrical stimulation to the quadriceps, hamstrings, and gluteal muscle groups. Exercise intensity was set at 40% to 60% of heart rate reserve, with exercise duration gradually increasing from 10 to 40 minutes per session over the course of the intervention. The PLC condition was identical to the FES condition, but did not receive electrical stimulation and did not actively cycle. Results: Eight PwMS (mean ± SD age = 52.9 ± 7.9; median [IQR] EDSS score = 6.3 [0.5]) completed the intervention. The FES cycling condition demonstrated a small decrease in KE asymmetry and change in T25FW (p = −0.43) and 2MW (p = −0.24). A moderate association was observed between change in KE asymmetry and change in T25FW (p = −0.31), while no association was observed with change in 2MW (p = −0.07). Conclusions: FES cycling may be efficacious for reducing lower limb strength asymmetry and improving mobility in PwMS who have mobility impairment. These preliminary results will inform future FES cycling investigations with larger sample sizes.

Supported by: None

Disclosure: Nothing to disclose.

Keywords: Complementary/alternative therapies in MS, Comprehensive care and MS, Functional electrical stimulation

ARE YOU ON TWITTER? IJMSC IS!

We frequently tweet about new IJMSC developments, and we don’t want you to be left out. Readers and reviewers: Keep current with IJMSC announcements and the latest free online content. Authors: We’re tweeting about your articles; don’t miss the opportunity to help spread the word about your research.

Find and follow us @IJMSCtweets
**(CAM01) Multiple Sclerosis Imbalance: Visual Rehabilitation**
Marcia Baptista Dias,1 Alice Estevo Dias1
1Rehabilitation and Scientific Research, Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil

**Background:** Imbalance is among the most debilitating symptoms in multiple sclerosis (MS), causing falls and reflecting, to a large extent, the dysfunctional integration of visual sensory signals. **Objectives:** This preliminary study aimed to show the effects of visual rehabilitation on balance in a small group of people with MS. **Methods:** Three people with MS presented signs and symptoms of body imbalance. All were evaluated before and after visual rehabilitation by a specialized optometrist, from ocular motility, cover test, and stereoscopy to chromatic and pupil analysis. Rehabilitation consisted of 7 sessions involving balance exercises associated with vision. **Results:** In the initial evaluations, participants presented the same pattern of body imbalance. After visual rehabilitation, improvements in body posture, static and dynamic balance, and overall physical performance were observed in all participants. **Conclusions:** The data obtained revealed that visual function contributes positively to physical performance were observed in all participants.

**Supported by:** None

**Disclosure:** Nothing to disclose

**Keywords:** Complementary/alternative therapies in MS

---

**(CAM02) Acupuncture and Electromagnetotherapy for Chronic Pain Relief in Multiple Sclerosis**
Alice Estevo Dias,1 Teresa Cristina Vieira1
1Scientific Research and Rehabilitation, Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil

**Background:** Chronic pain is common in people with multiple sclerosis (PwMS) with approximately 42% to 90% experiencing pain at some stage of the disease course. Pharmacologic treatment in multiple sclerosis (MS)-related pain is usually unsatisfactory and often has severe side effects, and therefore, a need for alternative methods of pain relief is critical. **Objectives:** To evaluate the effectiveness and analgesic efficiency of acupuncture associated with electromagnetotherapy for chronic pain relief in a PwMS group. **Methods:** A total of 12 patients with MS were included in this prospective study: 10 women and 2 men, aged between 40 and 74. Mean Expanded Disability Status Scale score was 4.8. 42% of patients were classified as having relapsing-remitting MS, 33% as secondary-progressive MS, and 25% as primary-progressive MS. All reported pain (10 = back, 2 = legs/feet), used pharmacologic treatment, underwent 15 acupuncture sessions and electromagnetic therapeutic equipment applications (Kenkobio), and answered a structured pain questionnaire. **Results:** The primary end point was reduction in pain intensity or elimination, while the secondary end point improved symptoms and quality of life. This preliminary study revealed that MS-related pain can have a significant impact on health, activity, and participation of people, drastically reducing the quality of life. **Conclusions:** Although our overall results suggest that these nonpharmacologic interventions had beneficial effects on chronic pain and were not harmful, studies with robust methodology are needed to assess safety and possible long-term effects, justifying the use of these interventions on chronic pain in MS.

**Supported by:** None

**Disclosure:** Nothing to disclose

**Keywords:** Complementary/alternative therapies in MS

---

**(CAM03) The Effects of Reflexology in People with Multiple Sclerosis**
Alice Estevo Dias,1 Evanda Soares Oliveira1
1Scientific Research and Rehabilitation, Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil

**Background:** Multiple sclerosis (MS) is associated with a wide variety of different physical and psychological symptoms that have a profound effect on quality of life. Complementary and alternative medicine (CAM) is a current treatment that seems effective in relieving symptoms of patients with MS. **Objectives:** To show the opinion of a group of people with MS about the effects of reflexology. **Methods:** This study involved 12 people with MS and healthy feet without injury, damage, thrombosis, infarction, lesion, or fractures, 7 (58%) women and 5 (42%) men, aged 25 to 72 years, and mean Expanded Disability Status Scale score 4.5. In the group reflexology interventions were performed within 10 weeks, 3 times/week for 45 minutes. Data were collected through a structured questionnaire, immediately after. **Results:** All expressed satisfaction with the interventions, among them, 7 (58%) reported reflexology benefits in both psychological symptoms and pain, and 5 (42%) in exclusively psychological. **Conclusions:** The results showed that, according to participants, reflexology in relieving anxiety, stress, depression, and pain was effective. Therefore, this method, as an efficient technique, can be recommended for people with MS. However, sufficient scientific evidence should support its effectiveness and safety.

**Supported by:** None

**Disclosure:** Nothing to disclose

**Keywords:** Complementary/alternative therapies in MS

---

**(CAM04) The Effects of CBD:THC Tincture Oil in Reducing Symptoms and Overall Symptom Management**
Aryn Sieber,1 Kristine Werner,2 Karen Careera,2 Ben Throwera,3 Jacqueline Rosenthal4
1CannaCauses Foundation, Los Angeles, CA; 2Smyrna, GA; 3Brookhaven, GA; 4Andrew C. Carlos MS Institute, Shepherd Center, Atlanta, GA

**Background:** It is now becoming more common for persons with multiple sclerosis (PwMS) to use cannabis to try to alleviate their multiple sclerosis (MS) symptoms. A survey of PwMS published in 2017 found that 47% of respondents considered using cannabis to treat their MS symptoms, 26% used cannabis for their MS symptoms, 20% have spoken with their physician about using cannabis, and 16% currently use cannabis (Coffield et al, Many reviews (Zhornitsky and Potvin, 2012; Jawahar et al, 2013; Koppel et al, 2014; Whiting et al, 2015) agree cannabis might have a positive effect on pain in MS. In addition to the legal status, limited research evidence remains a barrier to understanding the role cannabis can play in PwMS to alleviate symptoms. The amount of scientific research in this area is increasing; however, case reports and anecdotes exceed studies. Thus, data regarding cannabis use to treat pain, spasticity, neuropathy, and sleep quality in PwMS remain limited. **Objectives:** The purpose of this study is to investigate if medicinal cannabis CBD:THC oil tinctures 1) improve symptoms and 2) reduce overall symptom management medication dosages in PwMS. We hypothesize that PwMS will have improvements in these measures while using CBD:THC tinctures. **Methods:** Participants took CBD:THC tincture oil daily. Self-reported symptom and medication assessments rating a scale from 1 to 10 were completed at baseline prior to starting a tincture, and again after an average duration of 3-4 months. 32 PwMS, ages 25 and older are included in the study. There were significant reductions (P < .0001) in the following symptom management scores: pain (from a mean [SD] of 7.4 [2.0] to 3.9 [1.9], n = 45), spasticity (from a mean [SD] of 7.2 [1.9] to 3.3 [1.9], n = 31), neuropathy (from a mean [SD] of 4.5 [2.6] to 2.5, n = 25), and sleep (from a mean [SD] of 7.5 [1.9] to 3.0 [2.1], n = 34). Gabapentin intake was significantly reduced from a mean [SD] of 1581.3 [1284.6] mg to 625 [739.9] mg (N = 12). **P = 0.036**. There were no significant reductions in back/leg pain, tizanidine, or benzodiazepine intake. **Conclusions:** Although medicinal cannabis CBD:THC tincture oil shows promise in overall symptom reduction and symptom management medication dosage reduction in PwMS, researchers need to conduct additional studies, including clinical research studies, for PwMS using medicinal cannabis CBD:THC tincture oil. A larger sample size will allow inferential statistics to be performed. This study will further contribute to the evidence related to the efficacy of this intervention.

**Supported by:** None

**Disclosure:** Aryn Sieber: CannaCauses Foundation (consulting fee). Kristine Werner: Karen Caree, Ben Thrower, Jacqueline Rosenthal: Nothing to disclose.

**Keywords:** Complementary/alternative therapies in MS

---

**(CAM05) Challenges and Opportunities in Progressive Multiple Sclerosis Trials: Lessons from Lipoic Acid**
Carin S. Waslo,1, 2M. Mateo Paz Soldano,1, 2Mark S. Freedman,1 Pavle Repovic,4 Andrew J. Solomon,5 John R. Rinker5, Mitchell T. Wallin,6 Jodie K. Haselkorn,7 Rebecca I. Spann1
1Neurology, VA Portland Health Care System, Portland, OR; 2Neurology, Oregon Health & Science University, Portland, OR; 3Neurology, University of Utah, Salt Lake City, UT; 4Neurology, VA Salt Lake City HCS, Salt Lake City, UT; 5University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 6Multiple Sclerosis Center, University of California, San Diego, CA; 7In the Field, Enumclaw, WA

**Background:** Multiple sclerosis (MS)–related pain is usually unsatisfactory and often has severe side effects, and therefore, a need for alternative methods of pain relief is critical. **Objectives:** To evaluate the effectiveness and analgesic efficiency of lipoic acid in PwMS with approximately 42% to 90% experiencing pain at some stage of the disease course. Pharmacologic treatment in multiple sclerosis (MS)-related pain is usually unsatisfactory and often has severe side effects, and therefore, a need for alternative methods of pain relief is critical. **Methods:** A total of 12 patients with MS were included in this prospective study: 10 women and 2 men, aged between 25 and 74 years, and mean Expanded Disability Status Scale score 4.5. In the group reflexology interventions were performed within 10 weeks, 3 times/week for 45 minutes. Data were collected through a structured questionnaire, immediately after. **Results:** All expressed satisfaction with the interventions, among them, 7 (58%) reported reflexology benefits in both psychological symptoms and pain, and 5 (42%) in exclusively psychological. **Conclusions:** The results showed that, according to participants, reflexology in relieving anxiety, stress, depression, and pain was effective. Therefore, this method, as an efficient technique, can be recommended for people with MS. However, sufficient scientific evidence should support its effectiveness and safety.

**Supported by:** None

**Disclosure:** Nothing to disclose

**Keywords:** Complementary/alternative therapies in MS
Background: Exercise is one of the only complimentary strategies that improves symptoms of multiple sclerosis (MS) and slows disease progression and functional manifestations. There is further evidence that engaging in exercise regenerates neuroplasticity within the central nervous system. Such evidence supports exercise as a strategy that offers comparable results in patients within specified categories. The answer to each question is assigned a score of 1, 2, or 3, with composite scores ranging from 27-81; higher points indicate healthier choices. Between questionnaire administration, members have received monthly nutrition education, with 16 members receiving additional small-group nutrition education. Analysis examining 18-month results is planned. Results: Thirty-four of four intended rounds of data collection have occurred, with the fourth scheduled in February 2020. The mean (SD) baseline RYP score was 58.46 (8.5). The mean (SD) of the scores at 6 months increased, but not significantly, to 62.33 (7.7) (P = 1.00). Increases at 1 year were statistically significant, 63.71 (7.5) (< 0.001) compared to baseline. Paired t tests were used to identify statistical significance. The category showing the greatest improvement (9%) is the frequency in which members are eating meals together; the category showing the least improvement (4%) is enjoyment. Conclusions: Complete collection and analysis of changes between data collection points will be finalized for presentation of the poster.

Supported by: None


Keywords: Complementary/alternative therapies in MS, Disease-modifying treatments in MS

(CAM06) Exercise in Medicine: A Complementary Exercise Promotion Approach Within Comprehensive Multiple Sclerosis Care

Emma V. Richardson,1 Elizabeth Barstow,2 Matthew Fialit,3 Robert W. Moll

1Department of Physical Therapy, 2Department of Occupational Therapy, and 3Department of Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL

Background: Exercise is one of the only complimentary strategies that improves symptoms of multiple sclerosis (MS) and slows disease progression and functional manifestations. There is further evidence that engaging in exercise regenerates neuroplasticity within the central nervous system. Such evidence supports exercise as a strategy that offers comparable results in patients within specified categories. The answer to each question is assigned a score of 1, 2, or 3, with composite scores ranging from 27-81; higher points indicate healthier choices. Between questionnaire administration, members have received monthly nutrition education, with 16 members receiving additional small-group nutrition education. Analysis examining 18-month results is planned. Results: Thirty-four of four intended rounds of data collection have occurred, with the fourth scheduled in February 2020. The mean (SD) baseline RYP score was 58.46 (8.5). The mean (SD) of the scores at 6 months increased, but not significantly, to 62.33 (7.7) (P = 1.00). Increases at 1 year were statistically significant, 63.71 (7.5) (< 0.001) compared to baseline. Paired t tests were used to identify statistical significance. The category showing the greatest improvement (9%) is the frequency in which members are eating meals together; the category showing the least improvement (4%) is enjoyment. Conclusions: Complete collection and analysis of changes between data collection points will be finalized for presentation of the poster.

Supported by: None


Keywords: Complementary/alternative therapies in MS, Disease-modifying treatments in MS

(CR501) Seasonal Variation and Other Observations in Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-Associated Disease

Allison N. Black, Ahmed Z. Obaidat

Neurology, Medical College of Wisconsin, Milwaukee, WI

Background: Exercise is one of the only complimentary strategies that improves symptoms of multiple sclerosis (MS) and slows disease progression and functional manifestations. There is further evidence that engaging in exercise regenerates neuroplasticity within the central nervous system. Such evidence supports exercise as a strategy that offers comparable results in patients within specified categories. The answer to each question is assigned a score of 1, 2, or 3, with composite scores ranging from 27-81; higher points indicate healthier choices. Between questionnaire administration, members have received monthly nutrition education, with 16 members receiving additional small-group nutrition education. Analysis examining 18-month results is planned. Results: Thirty-four of four intended rounds of data collection have occurred, with the fourth scheduled in February 2020. The mean (SD) baseline RYP score was 58.46 (8.5). The mean (SD) of the scores at 6 months increased, but not significantly, to 62.33 (7.7) (P = 1.00). Increases at 1 year were statistically significant, 63.71 (7.5) (< 0.001) compared to baseline. Paired t tests were used to identify statistical significance. The category showing the greatest improvement (9%) is the frequency in which members are eating meals together; the category showing the least improvement (4%) is enjoyment. Conclusions: Complete collection and analysis of changes between data collection points will be finalized for presentation of the poster.

Supported by: None


Keywords: Complementary/alternative therapies in MS, Disease-modifying treatments in MS

(CAM07) Changes in Dietary Habits of Individuals Living with Multiple Sclerosis Enrolled in a Day Wellness Program

Zoe Edwards,3 Brian Hutchinson,3 Tiffany Malone3

1Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA; 2Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA

Background: Nutrition education for individuals who attend the Multiple Sclerosis Achievement Center (MSAC) focuses on overall health and prevention or management of comorbidities. While there has not been a multiple sclerosis (MS)–specific dietary pattern proven to reduce MS symptoms for all individuals, nutritional choices can affect management strategies. Members of the MSAC attend a weekly program that addresses physical, cognitive, and social well-being. On a monthly basis, nutrition education is provided to discuss diverse aspects of dietary habits and target strategies related to the challenges of living with MS. Some program topics include the importance of nutrition education through individualized consultations or small group discussions. Objectives: To examine the dietary changes of people with MS who participate in a day wellness program over an 18-month period and determine if changes in habits occur with general nutrition education during the day program. In addition, a comparison in dietary habits between general and individualized nutrition education will be examined. Methods: Fifty-two MSAC members have completed Rate Your Plate (RYP), a self-reported food-frequency questionnaire, every 6 months to monitor changes in dietary choices over a year. RYP consists of 27 questions focusing on typical dietary choices within specified categories. The answer to each question is assigned a score of 1, 2, or 3 points with composite scores ranging from 27-81; higher points indicate healthier choices. Between questionnaire administration, members have received monthly nutrition education, with 16 members receiving additional small-group nutrition education. Analysis examining 18-month results is planned. Results: Thirty-four of four intended rounds of data collection have occurred, with the fourth scheduled in February 2020. The mean (SD) baseline RYP score was 58.46 (8.5). The mean (SD) of the scores at 6 months increased, but not significantly, to 62.33 (7.7) (P = 1.00). Increases at 1 year were statistically significant, 63.71 (7.5) (< 0.001) compared to baseline. Paired t tests were used to identify statistical significance. The category showing the greatest improvement (9%) is the frequency in which members are eating meals together; the category showing the least improvement (4%) is enjoyment. Conclusions: Complete collection and analysis of changes between data collection points will be finalized for presentation of the poster.

Supported by: None


Keywords: Complementary/alternative therapies in MS, Disease-modifying treatments in MS

(CAM08) Changes in Dietary Habits of Individuals Living with Multiple Sclerosis Enrolled in a Day Wellness Program

Zoe Edwards,3 Brian Hutchinson,3 Tiffany Malone3

1Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA; 2Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA

Background: Nutrition education for individuals who attend the Multiple Sclerosis Achievement Center (MSAC) focuses on overall health and prevention or management of comorbidities. While there has not been a multiple sclerosis (MS)–specific dietary pattern proven to reduce MS symptoms for all individuals, nutritional choices can affect management strategies. Members of the MSAC attend a weekly program that addresses physical, cognitive, and social well-being. On a monthly basis, nutrition education is provided to discuss diverse aspects of dietary habits and target strategies related to the challenges of living with MS. Some program topics include the importance of nutrition education through individualized consultations or small group discussions. Objectives: To examine the dietary changes of people with MS who participate in a day wellness program over an 18-month period and determine if changes in habits occur with general nutrition education during the day program. In addition, a comparison in dietary habits between general and individualized nutrition education will be examined. Methods: Fifty-two MSAC members have completed Rate Your Plate (RYP), a self-reported food-frequency questionnaire, every 6 months to monitor changes in dietary choices over a year. RYP consists of 27 questions focusing on typical dietary choices within specified categories. The answer to each question is assigned a score of 1, 2, or 3 points with composite scores ranging from 27-81; higher points indicate healthier choices. Between questionnaire administration, members have received monthly nutrition education, with 16 members receiving additional small-group nutrition education. Analysis examining 18-month results is planned. Results: Thirty-four of four intended rounds of data collection have occurred, with the fourth scheduled in February 2020. The mean (SD) baseline RYP score was 58.46 (8.5). The mean (SD) of the scores at 6 months increased, but not significantly, to 62.33 (7.7) (P = 1.00). Increases at 1 year were statistically significant, 63.71 (7.5) (< 0.001) compared to baseline. Paired t tests were used to identify statistical significance. The category showing the greatest improvement (9%) is the frequency in which members are eating meals together; the category showing the least improvement (4%) is enjoyment. Conclusions: Complete collection and analysis of changes between data collection points will be finalized for presentation of the poster.

Supported by: None


Keywords: Complementary/alternative therapies in MS, Disease-modifying treatments in MS
Background: Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disorders can mimic multiple sclerosis (MS). MOG antibody seropositivity has been found in subsets of patients with demyelinating disease, especially those with optic neuritis and transverse myelitis. Improved MOG antibody-associated disease understanding is necessary to improve diagnosis timing and provide proper treatment. Objectives: To evaluate the characteristics of patients with a confirmed diagnosis of MOG antibody–associated disease. Methods: We report on the clinical and imaging characteristics of all patients who presented to our practice with optic neuritis or transverse myelitis, and tested positive for MOG antibody between August 2018 and January 2020. Results: We identified 11 patients, of which 9 (82%) were female. Ten (91%) patients presented between September and December. Optic neuritis preceded by a prodromal headache was the presenting symptom in all patients. Sixteen optic nerves in the 11 patients were symptomatic. Of the 16 symptomatic optic nerves, 12 (75%) nerves showed increased signal on diffusion-weighted imaging. Incomplete clinical recovery was observed in 11 (69%) optic nerves and ranged from no light perception to a mild decrease in visual acuity. Spinal cord lesions were present in 4 patients (36%). Poorly demarcated white matter brain T2 signal abnormalities were present in 7 patients (64%). Finally, patients younger than 40 years tended to have higher titers with 5/6 (83%) patients in this age group having a titer of 1:1000. No patients 40 years and older had a titer of 1:1000. All patients received treatment with prednisone or steroid-sparing agents (rituximab or mycophenolate). None of the treated patients relapsed over the duration of the study. One patient was initially misdiagnosed as having MS and was treated with several disease-modifying agents; he continued to relapse (with sustained disability) until the correct diagnosis was made in December. Our findings support the seasonal variation of MOG antibody–associated disease, with peak clinical presentation during fall and winter months. This may be due to the peak of viral respiratory infections in the fall and winter as preceding infections were reported in association with MOG antibody–associated disease. Increased diffusion-weighted imaging signal of optic nerves may provide insight into the mechanism of optic nerve damage. Incomplete recovery of optic neuritis is common but often mild and rarely resulted in blindness. The significance of higher antibody titer in younger individuals requires further investigation. Our observations contribute to the growing knowledge of MOG antibody–associated disease, a mimicker of MS. Our study was limited by a small sample size.

Supported by: None

Disclosure: Allison N. Block: Nothing to disclose. Ahmed Z. Obiedat: Alexion (sponsors’ bureau); Alexion Pharmaceutical, Celgene, EMD Serono, Genentech, Sanofi; Genzyme (consulting fee); Biogen, Novartis (consulting fee, speakers’ bureau); International Journal of MS Care (editorial board).

Keywords: Imaging and MS, Mimickers of MS, Natural history of MS

(CRS02) Multiple Surgeries and Misdiagnosis Before Multiple Sclerosis Diagnosis: A Case Report

Angel Lopez,1 Jeanie Figueroa-Amor,2 Astrid Diaz,2 Viviana Martinez,1 Ivonne Vicente,1 Angel China2

1San Juan Multiple Sclerosis Center, Guaynabo, PR; 2Department of Medicine, San Juan Bautista School of Medicine, Caguas, PR

Background: A delay in diagnosis of multiple sclerosis (MS) can increase the amount of disability in patients. Objectives: Not applicable. Methods: Case report. Case: A 50-year-old Puerto Rican man reported right leg weakness in 1994 with a severe headache that lasted 6 months. A year later the patient fell and afterwards started having gait difficulties, pain, and bowel and bladder problems. After computed tomography was done, he was diagnosed with herniated discs, and treated with physical, massage, and chiropractic therapies. Afterwards, he had frequent falls and facial palsy for 5 years. In these years he had several surgeries performed due to the leg and face symptoms. He was referred to neurologist and was treated with his symptoms after surgeries. Physiatrist evaluated and in 2017 performed brain and cervical magnetic resonance imaging and referred to neurologist. Patient was diagnosed with MS in 2018 and assigned an Expanded Disability Status Scale score of 6.0. The time from first symptom to diagnosis was 24 years and the amount of surgeries could have clinical delayed the disability that the patient presents. Results: Not applicable. Conclusions: This case brings attention to the importance of earlier diagnosis and treatment of MS to reduce disability and improve quality of life in patients. Also, it highlights that we still need to increase education to all health care professionals in Puerto Rico about symptoms, tests, and diagnostic criteria for MS.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Comprehensive care and MS, Natural history of MS

(CRS03) Head Trauma as Onset for Multiple Sclerosis Diagnosis: A Case Report

Astrid Diaz, Viviana Martinez, Ivonne Vicente, Cristina M. Bubi, Angel Lopez, Angel China
San Juan Multiple Sclerosis Center, Guaynabo, PR

Background: Recent studies found an increased risk of developing multiple sclerosis (MS) if head trauma was experienced during teenage years, even though the relationship of head injury and risk of developing MS is not clear among the adult population. Previous research in Puerto Rican patients with MS shows that 38.2% reported some type of trauma. Objectives: We aim to report a case of head injury and subsequent diagnosis of MS. Methods: Case report. Case: A 47-year-old Puerto Rican woman with no previous history of comorbidities. The patient was walking, fell, and had head trauma. Concerned, she went to general physician and ordered computed tomography, which was performed. Months later, the patient started presenting pain in right leg, but was diagnosed with urinary tract infection and treated. After this, patient developed episodes of nausea and high levels of leukocytes. In May 2019, she developed blurry vision that ended with vision loss in right eye. Ophthalmologist evaluated and referred to neuro-ophthalmologist, who ordered magnetic resonance imaging (MRI). She later developed loss of balance and increased falls and was subsequently diagnosed with MS in June 2019. Results: Not applicable. Conclusions: This case highlights the importance of creating awareness about patients who had head trauma and present neurologic symptoms. Performing tests like MRI as soon as symptoms start could help to achieve an early diagnosis and help reduce disability among patients with MS.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Comprehensive care and MS

(CRS04) Team Approach Yields Surprising Functional Progress and Quality-of-Life Changes in a Challenging Case of Neuromyelitis Optica

Clare T. Hartigan,1 Christopher Wells2

1Multiple Sclerosis Outpatient Rehabilitation, Shepherd Center, Atlanta, GA; 2Multiple Sclerosis Wellness Program, Shepherd Center, Atlanta, GA

Background: A 59-year-old female (DR) was diagnosed with neuromyelitis optica (NMO) in February 2016. She developed sudden onset of paralysis and had no voluntary movement from her neck down. DR spent extensive time in a nursing facility and eventually transferred home on a stretcher. At the time of her diagnosis, she was 5′5″ tall with body mass index (BMI) of 49.08. A rehabilitation team approach from May 2017 through February 2020 led to surprising functional progress and improved quality of life. Objectives: In May 2017 DR was referred to a neuro-ophthalmologist, MS Rehabilitation Program was dependent to participate in multiple center transfers, sitting balance, bed mobility, and bowel/bladder management. She was also suffering with severe muscle weakness (2/5 throughout), spasticity, joint contractures, and chronic pain from arthritis in her knees, back, and shoulders. Methods: DR attended MS Wellness appointments via stretcher, until she received a power wheelchair. Exercise specialist intervention was 2×/week and included pool program, dryland exercises for stretching, strengthening, and sitting balance. One year later (May 2018) she began slide board transfers. By 2019 transfers were via depression and she started using a hydraulic standing device during exercise specialist sessions. In October 2019 DR was referred to outpatient physical therapy (PT). Her strength was grossly 3-/5, she had contractures at bilateral hips/knees/ankles, and she was unable to stand or walk at home. Her BMI was 43.27. DR attended PT 2-3×/week for 30 sessions to include standing frame and soft tissue work for contractions, transfer training with 3-in-1 bedside commode, progressive gait training, and custom home program. Results: In November 2019, DR began outpatient supervision for transfers on/off bedside commode and began gait training in parallel bars (PBars) with bilateral MalleolocLo braces and heel wedges. Sit/stand and stepping in PBars progressed from Max A to Supervision. By mid-December 2019 she required Mod A to walk outside the PBars with front-wheeled bariatric walker (FWBW). At end of December 2019 she required Min A to walk up to 76 ft for exercise. In early January 2020 patient was able to walk 135 ft at a time with close stand by assist with FWBW and bilateral solid ankle foot orthoses. She walked over indoor and outdoor terrains including 5-degree ramps. After caregiver training, she became safe to stand and walk at home for exercise. Conclusions: After being completely paralyzed after NMO diagnoses in 2016, DR spent nearly 3 years attending a MS Wellness Program and then eventually outpatient PT. She progressed from being totally depen-
dent to requiring supervision for all transfers. She no longer had to use bed pads. Additionally, she learned to walk with stand-by assist indoor/ outdoor terrains with FWBW and bilateral ankle foot orthoses. DR’s functional gains and improved quality of life would have been very unlikely without a team approach. DR is to be commended for her determination, and as health care professionals we should always keep an open mind.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Complementary/alternative therapies in MS, Comprehensive care and MS, Wellness program

(CRS050) Differential Diagnosis and Treatment of Tumefactive Demyelination in a Teenaged Girl
Gillian R. Patton, Sarah Hopkins
Division of Neurology, Multiple Sclerosis and Neurominflammatory Disorders, Children’s Hospital of Philadelphia, Philadelphia, PA

Background: Tumefactive demyelination in pediatric patients is rare and associated with high morbidity and mortality. The differential diagnosis includes tumor, abscess, acute hemorrhagic leukoencephalitis, acute disseminated encephalomyelitis, and tumefactive multiple sclerosis (MS). Awareness of the differential and early treatment is essential as this presentation may be associated with death or severe morbidity within days.

Objectives: Review a case of tumefactive demyelination in a teenaged girl, and review the pertinent literature, including differential diagnosis, key clinical characteristics, and treatment options.

Methods: Medical record review and review of the literature.

Results: A 16-year-old girl, previously healthy and developmentally normal, presented with encephalopathy progressing quickly to left hemiparesis and global aphasia in the setting of recent upper respiratory infection with cough, headache, and otalgia. Head computed tomography demonstrated vasogenic edema of the left temporal and parietal lobes and 4 mm of midline shift to the right, without obvious underlying mass. Magnetic resonance imaging (MRI) of the brain revealed extensive confluent and expansile-appearing white matter signal abnormality of the left brainstem, internal capsule, and parietal and temporal lobes with associated microhemorrhages and left cerebral peduncle and pontine enhancement, suggestive of severe demyelinating disease, and her cerebrospinal fluid showed a neutrophilic pleocytosis with no identifiable pathogen. A brain biopsy showed no signs of neoplasm. She was promptly treated with high-dose prednisolone, and the course continued for 7 days in conjunction with 9 rounds of plasmapheresis. Cyclophosphamide was initiated with a plan for a 6-month course. Follow-up MRI of the brain 1 month after presentation demonstrated decreased extent of T2/fluid attenuation inversion recovery abnormality and development of cystic encephalomalacia along the left anterior temporal lobe with resolution of midline shift. She was transferred to the inpatient rehabilitation service for a 1 month stay. At discharge she had persistent right-sided weakness with spasticity but was able to ambulate using a single crutch, and had shown improvement in expressive and receptive aphasia.

Conclusions: Tumefactive demyelination requires rapid evaluation and treatment. The differential diagnosis includes acute hemorrhagic leukoencephalitis, which has a particularly high fatality rate. Early and judicious immunomodulatory treatment in these cases is lifesaving.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Disease-modifying treatments in MS, Imaging and MS, Immunology and MS

(CRS075) Case Report of Severe Multiple Sclerosis Relapse Due to B-Cell Reconstitution Post Alemtuzumab
Jennifer Chester,1 Tyler Kaplan2
1Kansas City Multiple Sclerosis Center, College Park Specialty Center, Overland Park, KS; 2Neuro-immunology, Rush University Medical Center and University of Utah, Chicago, IL

Background: Alemtuzumab is a pan-lymphocyte-depleting anti-CD52 antibody used in the treatment of multiple sclerosis (MS). However, there have been reports of severe exacerbated central nervous system inflammation following alemtuzumab infusion. Relapse often occurs with the repletion of B cells months after treatment, whereas T cells can take up to 3 years to replenish. B-cell reconstitution occurs when the memory B cells replenish more rapidly than the regulatory T cells. This has previously been seen with the use of rituximab as a B-cell-depleting therapy in disorders such as rheumatoid arthritis. Objectives: Here, we present a case of a 52-year-old woman diagnosed with MS in 2000. She had previously tried multiple disease-modifying therapies including interferon beta-1a, interferon beta-1b, glatiramer, natalizumab, and dimethyl fumarate. She was given round 1 of alemtuzumab in December 2018. In May 2019 she had an exacerbation that caused hospitalization for intravenous methylprednisolone and physical therapy. She made a full recovery to baseline. In July 2019 she had another exacerbation, presenting to the clinic with multiple new symptoms including ataxia, urinary incontinence, weakness, and numbness. She was treated with repository corticotropin injection with no improvement. This was immediately followed by another hospitalization for plasma exchange. Her symptoms continued to progress rapidly. Brain magnetic resonance imaging (MRI) showed development of innumerable enhancing lesions throughout the bilateral cerebral hemispheres and right lateral pons. Cervical spine MRI showed a new 5-mm enhancing lesion. MRI of thoracic cord showed several enhancing thalamic lesions consistent with active demyelinating disease. Due to her rapid deterioration, the decision was made to transfer her to another state to receive a higher level of care. After being evaluated it was determined that she likely had active demyelination related to B-cell reconstitution. She was again hospitalized and received 1 dose of rituximab. Unfortunately, as of October 2019, the patient has continued to decline.

Methods: NA.

Results: She was discharged home on hospice and passed away a week later. An autopsy was performed and the results are pending at this time.

Conclusions: This case signifies the importance of strict monitoring of B cells after alemtuzumab due to the risk of relapse as the B-cell population continues to recover. Further analysis is needed for optimal care of these patients.

Supported by: None
Disclosure: Jennifer Chester: Allergan, Biogen, Novartis, Sanofi Genzyme (speakers’ bureaus). Tyler Kaplan: Nothing to disclose.

Keywords: Disease-modifying treatments in MS, Immunology and MS, Nursing management in MS

(CRS057) A Long-Standing Case of Recurrent Transverse Myelitis Due to Myelin Oligodendrocyte Glycoprotein (MOG)-IgG Antibody Mimicking Multiple Sclerosis
Gina S. Perez, Peggy J. Wisdom, Nidhiben Anadani
Neurology, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Background: Myelin oligodendrocyte glycoprotein (MOG) IgG antibody causes central nervous system demyelination and mimics multiple sclerosis (MS). Patients with MOG-IgG typically present with recurrent or monophasic optic neuritis, transverse myelitis, conus medullaris lesion, brainstem encephalitis, steroid-dependent symptoms, and acute disseminated encephalomyelitis. Lack of testing for MOG-IgG in these patients can lead to an incorrect diagnosis of MS, and treatment with certain medications that can worsen MOG-IgG-associated disease. Objectives: To report a case of a patient with MOG-IgG antibody–mediated recurrent transverse myelitis who was diagnosed with possible MS for more than 15 years. Methods: A 66-year-old woman with a known diagnosis of possible MS presented to our clinic for follow-up. Her history dated back to 1989 when she had an episode of extreme fatigue, gait imbalance, and numbness in her hands and feet that resolved spontaneously. She had recurrent episodes of symptomatic myelitis in 1997 and 2001. On examination, she had spastic weakness of bilateral iliopsoas and finger extendors (left worse than right), brisk reflexes on the left hemibody with left ankle clonus, relative sensory level at T12, and spastic ataxic gait without assistance. Timed 25-foot walk was 6.86 seconds. Results: In 2001, magnetic resonance imaging (MRI) of the spinal cord showed several short segmental lesions in the cervical and thoracic spinal cord including the conus medullaris; MRI of the brain was normal. Cerebrospinal fluid (CSF) showed elevated protein, IgG synthesis rate, and CSF-specific oligoclonal bands. Aquaporin 4 antibody (AQP-4) in CSF was negative. She was diagnosed with possible MS given the lack of better explanation and was started on a combination of interferon beta-1a and mycophenolate. Since 2001, she did not have typical relapsing remitting specific lesions in her brain and persistently enhancing short segment lesions in the cervical and thoracic spinal cord in 2014 and 2016. Interferon beta-1a was stopped in 2017 and mycophenolate was continued. Serum MOG-IgG was tested and was positive in February 2019. Conclusions: MOG-IgG–mediated disease and MS show a relevant phenotypic, clinical, and radiologic overlap that can potentially lead to misdiagnosis and treatment. Objectives: Here, we present a case of MS might be ineffective or even harmful in MOG-IgG–associated disease. Before the diagnosis of MS, testing for MOG-IgG antibody should be considered in selected patients.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Comprehensive care and MS, MOG IgG antibody
(CRS08) Demographics, Clinical Characteristics, and Outcomes of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease Followed Up at Washington University in St. Louis

John R. Ciotti, Anne Cross, Salim Chahin
Washington University in St. Louis, St. Louis, MO

Background: Antibodies to myelin oligodendrocyte glycoprotein (MOG) have been associated with central nervous system demyelination that is distinct from other neuroinflammatory conditions. Our knowledge of the clinical spectrum of MOG antibody disease (MOGAD) is evolving, without clear definitions of prognosis and best treatments. Objectives: To report demographics, clinical characteristics, and treatment responses of our MOGAD cohort. Methods: Patients at Washington University were identified via diagnosis code and confirmed to have at least 1 positive MOG antibody test. Demographic, clinical course, estimated disability (extracted using published tools), laboratory, and treatment data were collected after institutional review board approval. Results: 24 patients with MOGAD were included. They were 75% female and 92% Caucasian with mean onset age of 43.5 (range 16.8-76.0) years. Average duration of follow-up was 4.0 (range 0.4-18.0) years. Initial symptoms exclusively included optic neuritis (17/24, 41%) bilateral acute optic neuritis (9/24), with 2/24 having both occur simultaneously. 12.5% (3/24) had concurrent involvement of other areas (brainstem, cerebral). A total of 42 attacks (including initial onset) were adjudicated; the annualized relapse rate was 0.46. 42% have had only a single attack. Attacks tended to be severe (estimated ΔExpanded Disability Status Scale [EDSS] score +3.3), followed by complete recovery in 58% have an EDSS score ≥ 4.0. 58% have an EDSS score ≥ 4.0. Conclusions: Our results are largely consistent with published reports suggests that cyclophosphamide has utility in early stages of treatment data were collected after institutional review board approval.

Supported by: None
Disclosure: John R. Ciotti: Nothing to disclose. Anne Cross: Biogen, Celgene, Novartis, TG Therapeutics (consulting fee); EMD Serono, Genentech/Roche (grant and personal fees). Salim Chahin: Biogen, Genentech, Novartis, Sanofi Genzyme, Teva Neuroscience (personal fees).

Keywords: MOG antibody disease

(CRS09) A Fatal Case of Alemtuzumab-Induced Immune Thrombocytopenic Purpura in a Patient with Relapsing Multiple Sclerosis

Leila Saadatpour, Rebecca Romero
Neurology, University of Texas Health Science Center at San Antonio, San Antonio, TX

Background: Alemtuzumab is a humanized monoclonal antibody against CD52 approved for relapsing types of multiple sclerosis (MS). Despite being an effective medication, there have been limitations of use for this medication due to various serious adverse effects. Common adverse effects include infections, transfusion reactions, and autoimmune responses such as hemolytic anemia, thrombocytopenia, and autoimmune thyroid and renal disease. Objectives: To review a case of refractory immune thrombocytopenic purpura (ITP) as a result of alemtuzumab therapy in a patient who presented with altered mental status and who was found to have multiple foci of intracranial bleeding (intracerebral hemorrhage [ICH]). Methods: Case report. Results: A 39-year-old woman was started on vedolizumab for Crohn disease in November 2019. Conclusions: ITP is a rare complication but can be lethal. Our patient’s ITP progressed despite her compliance with every-6-month blood count checks and receiving various treatments. The aim of this presentation is to bring the potentially serious complications of alemtuzumab to attention and consider substitute therapies if feasible.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Comprehensive care and MS, Disease-modifying treatments in MS, Immunology and MS

(CRS10) Colitis Associated with Teriflunomide

Neda Zarghami Esfahani,1 Gloria van Gelderen,1 Meghan C. Romba,2 Dhavan Parikh,2 Annette Wundes1
1Neurology, University of Washington, Seattle, WA; 2Gastroenterology, Everett Clinic, Everett, WA

Background: Teriflunomide is an oral disease-modifying therapy for relapsing-remitting multiple sclerosis (RRMS) that was approved in the United States in 2012. Gastrointestinal (GI) adverse effects occurred in 15%-17% of patients in the clinical trials, and, so far, 3 cases of colitis have been reported. Objectives: To report new-onset Crohn disease in a patient with multiple sclerosis while on teriflunomide. Methods: Case report and literature review. Results: A 49-year-old man with RRMS started teriflunomide in January 2018 after discontinuing glatiramer acetate due to injection fatigue and dimethyl fumarate due to GI intolerability. He developed persistent diarrhea and received bisacodyl, which showed no clinical improvement in his diarrhea. Repeat endoscopy showed normal-appearing gastric ulcers and mild chronic gastritis without active inflammation in the small and large intestine. GI disease improved with omeprazole and stopping ibuprofen; teriflunomide was reduced to 7 mg daily in December 2018. In August 2019, he had recurrence of significant diarrhea and was started on vedolizumab for Crohn disease. Conclusions: In 2017, Health Canada released a review on teriflunomide due to postmarketing reports of colitis and concluded that, while no definite link could be established, the patients and providers should be alerted to the occurrence of rare colitis cases. As of October 2019, per Genzyme, 3 cases of colitis while on teriflunomide are reported of which 2 were considered to be related to teriflunomide. We here report a case of new-onset of inflammatory colitis with endoscopic and pathologic features of Crohn disease while on teriflunomide and significant improvement after cessation of the drug, and suggest a potential causal relationship between the drug and development of colitis that warrants further investigation.

Supported by: None
Disclosure: Neda Zarghami Esfahani, Gloria van Gelderen, Meghan C. Romba, Dhavan Parikh: Nothing to disclose. Annette Wundes: Biogen (consulting fee); Biogen, AbbVie (contracted research).

Keywords: Colitis, Disease-modifying treatments in MS

(CRS11) Remarkable Recovery of Fulminant Multiple Sclerosis After Treatment Induction with Cyclophosphamide

Nicola Carlisle,1 Sam L. Hooshmand,2 Michelle Maynard,1 Ahmed Z. Obeidat3
1Neurology, Medical College of Wisconsin and Affiliated Hospitals, Milwaukee, WI; 2Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI; 3Immunology and MS

Background: Fulminant multiple sclerosis (MS) is rare, and the approach to treatment beyond first-line therapies (high-dose steroids, plasma exchange, and intravenous [IV] immunoglobulins) varies. Single case reports of diagnosis and treatment of fulminant MS can provide helpful resources for the clinician. Cyclophosphamide is an alkylating agent that suppresses T- and B-cell function, interleukin 12, and Th1 helper-type 1 (Th1) responses, thereby enhancing Th2, Th3 responses. Review of published reports suggests that cyclophosphamide has utility in early stages of MS during which inflammation predominates over degenerative processes in the central nervous system as seen by gadolinium (Gd)–enhancing lesions. Objectives: To describe the clinical course of a case of acute MS successfully treated with cyclophosphamide. Methods: Case study. Results: A 41-year-old woman with no medical history developed facial
(CRS12) Neurofibromatosis Type 1 and Multiple Sclerosis in the Same Patient
Sargon Bet-Shlimon, Annette Wundes, Gloria von Geldern
Neurology, University of Washington, Seattle, WA

Background: Neurofibromatosis type 1 (NF1) is an autosomal-dominant genetic disease involving primarily the skin and peripheral nervous system. Multiple sclerosis (MS) is a demyelinating disease of the central nervous system. White matter lesions on brain magnetic resonance imaging (MRI) can be seen in both diseases. Only a few cases have been reported to date describing patients with both MS and NF1.

Objectives: To describe 3 cases of comorbid NF1 and MS to raise awareness of the possibility for the rare co-occurrence of both conditions.

Methods: This is a detailed description of 3 cases and a literature review of co-occurring NF1 and MS. Electronic medical records, neuroimaging, and relevant ancillary tests were reviewed for all cases.

Results: Case 1: A 21-year-old man with NF1 presented with an episode of several days of bilateral distal limb paresthesia and was found to have bone and spine lesions, some of which were enhancing. Optic nerves with likely optic gliomas were due to NF1 as well as possible prior optic neuritis. Cerebrospinal fluid (CSF) showed positive oligoclonal bands. He was started on glatiramer acetate as disease-modifying therapy, which was advanced to natalizumab based on significant radiographic disease progression. Case 2: A 41-year-old woman with NF1 presented with optic neuritis (with improvement with high-dose steroids) and was found to have lesions on bone and spine MRI and positive oligoclonal bands in CSF. She was started on glatiramer acetate with clinical stability and only 1 new non-enhancing lesion on repeat MRI. Due to skin reactions on glatiramer acetate, she was changed to dimethyl fumarate. Case 3: A 40-year-old woman with NF1 presented with progressive gait changes. Based on MRI findings more suggestive of MS than NF1 and positive oligoclonal bands in CSF, she was diagnosed with primary progressive MS.

Conclusions: These cases demonstrate the rare co-occurrence of NF1 and MS as well as the heterogeneity of MS presentations within the NF1 patient population. These cases also demonstrate some of the diagnostic challenges that arise when making a new diagnosis of MS in patients with NF1, including the interpretation of MRI in differentiating suspected demyelinating lesions from lesions that are associated with NF1. It is unclear if the co-occurrence of NF1 and MS is coincidental or if these cases represent an unknown relationship between the 2 diseases.

Supported by: None
Disclosure: Annette Wundes: AbbVie, Alkermes (contracted research); Biogen (consulting fee, speakers’ bureau); Sargon Bet-Shlimon: Gloria von Geldern: Nothing to disclose.

Keywords: Diagnosis and management of MS, Epidemiology of MS, Imaging and MS

(DXT01) Maintenance of Working Status and Work Productivity in Persons with Multiple Sclerosis Treated with Dimethyl Fumarate: A 5-Year Analysis of the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry
Amber Salter,1, Samanthi Lancia,1 Gary Cutter,2 Robert F. Jones,3 Ruth Ann Marrie,1 Jason P. Mendoza,1 James B. Lewin1

1Biostatistics, Washington University School in St. Louis, School of Medicine, St. Louis, MO; 2Biostatistics, University of Alabama at Birmingham, Birmingham, AL; 3Cleveland Clinic, Cleveland, OH; 4Health Sciences Centre Winnipeg, University of Manitoba, Winnipeg, MB, Canada; 5Biogen Cambridge, Cambridge, MA; 6Biotekinn, London, UK

Background: Employment is often affected in persons with multiple sclerosis (MS), and changes in employment status are associated with reduced quality of life. However, there is limited research on the maintenance of employment and work productivity in persons with MS using a disease-modifying therapy.

Objectives: To evaluate working status and work productivity in persons with relapsing-remitting MS (RRMS) treated with dimethyl fumarate (DMD) for up to 5 years.

Methods: In this analysis, we included RRMS North American Research Committee on Multiple Sclerosis (NARCOMS) Registry participants from the United States who reported DMD initiation in any semianual update survey between Fall 2013 and Spring 2018; participants also had to have ≥21 year of follow-up data. The index survey was considered the survey when DMD was initiated. Work productivity was assessed by reported reduction in hours worked (yes/no) and number of work days missed. Time to change in working status (employed full-time to part-time) and work productivity (employed full-time to not working) was evaluated using the Kaplan-Meier method. Participants were censored at last follow-up or DMD discontinuation, whichever came first.

Results: A total of 608 participants with RRMS initiated DMD within the study period and had follow-up at least 1 year. There were 294 (48.4%) participants employed at initiation of DMD (full-time, 73.8%). Most employed participants were female (86.1%) and Caucasian (82.6%) and had a bachelor’s degree or higher education level (65.1%), and the mean (SD) age was 47.7 (9.5) years. The mean (SD) age at diagnosis was 36.0 (8.3) years. The median (interquartile range) PDDS level at initiation was 1 (0, 7) and follow-up was 2 (1, 3.5) years. Overall, 49 (16.7%) participants decreased employment; 13 (4%) changed from full-time to part-time status, and 36 (12%) changed from employed (full- or part-time) to not working. During follow-up, 31 (10.5%)...
reported reducing their hours worked and there was a median of 3 (1, 6) months of work lost. Of the 314 patients not employed, 23 (7.3%) participants went from not employed to employed. **Conclusions:** Among NARCOMS Registry participants who were treated with DMF for up to 5 years, most maintained their baseline level of working status and maintained stable levels of work productivity as assessed by missed work days and the proportion reducing work hours. The NARCOMS Registry provides an opportunity to longitudinally assess outcomes in DMF-treated persons with MS.

Supported by: Biogen. NARCOMS is a project of the CSMC.

Disclosure: Amber Salter: Circulation: Cardiovascular Imaging (statistical editor). Samantha Lancia: Nothing to disclose. Gary Cutter: AMO Pharmaceuticals, BioLineRx, Brainstorm Cell Therapeutics, Galmed Pharmaceuticals, Hixion Pharmaceuticals, Horizon Pharmaceuticals, Merck, Merck/Pfizer, Neurium, National Heart, Lung, and Blood Institute (protocol review committee); National Institute of Child Health and Human Development (OPRU oversight committee); Opharmzyme, Opho Biologics, Reata Pharmaceuticals, ReceptoGenel, Sanoft-Avenzo, Teva Pharmaceuticals (data and safety monitoring committees); Biogen, Click Therapeutics, Genentech, Genzyme, GW Pharmaceuticals, Klein Buendel Inc, MedDay, MedImmune, Osmotica Pharmaceuticals, Perception Neurosciences, Recursion Pharmaceuticals, Roche, Samoalliation, TG Therapeutics (consulting fee); Novartis (consulting fee, data and safety monitoring committees); Robert P. Fried, Biogen, Immune, Novartis (advisory committee, consulting fee); Genentech, EMD Serono, Genentech, Texas (consulting fee); Bath Ali Marnie–Multiple Sclerosis Journal-Exp Transl Clin (co-editor); Jason P. Mendoza, James B. Lewis: Biogen (ownership interest, salary).

**Key words:** Dimethyl fumarate, Disease-modifying treatments in MS

**DXT02** Early Effect of Ofatumumab on B-Cell Counts and Magnetic Resonance Imaging Activity in Relapsing Multiple Sclerosis Patients: Results from the APLIOS Study

Amit Bar-Or1; Edward J. Fox,2 Alexandra Goodyear,3 Inga Ludwig,4 Morten Bagger,4 Dieter A. Haering,4 Harald Kropshofer,4 Martin Merschhemke,4 Heinz Wiendl5

1Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock, TX; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ; 4Icahn School of Medicine at Mount Sinai, New York, NY; 5Novartis Pharmaceuticals Corporation, East Hanover, NJ; 6Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

**Background:** Siponimod (Mayzent) is a selective sphingosine 1-phosphate receptor (SIP1 and SIP2) modulator, approved in the United States for treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS (SPMS). In the phase 3 EXPAND registration trial in SPMS, siponimod significantly reduced risk of 3-month (primary end point) and 6-month confirmed disability progression (CDP) by 21% and 26%, respectively. **Objectives:** Assess efficacy and safety of siponimod in patients with active SPMS in subgroups of patients with MS duration (time since onset of first symptoms) of <16 or ≥16 years (median value at baseline). **Methods:** Post hoc analyses were performed in patients with active SPMS, defined as a relapse in the 2 years before screening and ≥16 years (siponimod n = 285; placebo, n = 142) and ≥16 years (siponimod n = 231; placebo, n = 121).

For MS duration ≥16 years, siponimod reduced 3- and 6-month CDP risk by 32.4% and 42.7%, respectively, vs placebo (3 month: siponimod n = 68 [23.9%], placebo n = 84 [33.8%], hazard ratio [HR] [95% CI]: 0.68 [0.47, 0.98], P = .0376; 6 month: siponimod n = 48 [16.8%], placebo n = 60 [28.2%], HR [95% CI]: 0.57 [0.38, 0.87], P = .0093).

For MS duration ≥16 years, siponimod had a trend towards reduced 3- and 6-month CDP risk of 31.9% and 27.1%, respectively, vs placebo (3 month: siponimod n = 61 [26.4%], placebo n = 43 [35.5%], HR [95% CI]: 0.68 [0.46, 0.99], P = .0540; 6 month: siponimod n = 51 [22.1%], placebo n = 34 [28.1%], HR [95% CI]: 0.73 [0.47, 1.13], P = .1544). Siponimod was generally well tolerated. Any AE rates: <16 years, 84.9% (siponimod), 75.4% (placebo); ≥16 years, 89.2% (siponimod), 81.8% (placebo).

**Conclusions:** In patients with active SPMS and MS duration ≥16 years, siponimod significantly reduced 3- and 6-month CDP risk compared with placebo. Siponimod extended progression-free survival vs placebo in those with duration ≥16 years. This may reflect the smaller size or more advanced disease in this subgroup.

Supported by: None

Disclosure: Amit Bar-Or: Atara Biotherapeutics, Bayer, Bayhill Therapeutics, Berlex, Biogen, BiMS, Celgene/Recepta, Diogenix, Eli Lilly, F. Hoffman-La Roche, Genentech, GlaxoSmithKline, Guthy-Jackson/CGP, Immucor, Janssen/Actelion, Mapi, MedImmune, Merck/EMD Serono, Novartis, Ono Pharma, Roche/Genentech, Sanofi Genzyme, Trebbia Neurosciences, susChem (consulting fee); Fred D. Lublin, Forward Pharma, Innate Immunotherapeutics, Mapi Pharma, MedDay Pharma, MedImmune, Novartis, Orion Biotechnology, Polpharma, ReceptoGenel, Regeneron, Roche Genentech, Sanofi Genzyme, Texas Neuroscience, TG Therapeutics (consulting fee); Alexion (consulting fee, research support); Multiple Sclerosis and Related Disorders (journal editor); National MS Society, Novartis Pharmaceuticals, Sanofi, Texas Neurosciences, Transparency Life Sciences (research support); Xiangyu Meng, Wendy Su: Novartis Pharmaceutical Corporation (sal-
(DXT04) Siponimod First-Dose Effects in Patients with Secondary Progressive Multiple Sclerosis Receiving Concomitant Selective Serotonin Reuptake Inhibitor Therapy

Amit Bar-Or1, Bruce A.C. Cree2, Le H. Hua3, Amos Katz4, Derrick Robertson5, Brandon Brown6, Desiree Dunlop7, Xiangyi Meng7, Wendy Su8

1Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 2Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 3Los Rove Center for Brain Health, Las Vegas, NV; 4U indo Cardinale MS Center, Freehold, NJ; 5University of South Florida, Multiple Sclerosis Center, Tampa, FL; 6Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background: Selective serotonin reuptake inhibitors (SSRIs), citalopram and escitalopram, are associated with prolonged QT and tachyarrhythmias. It is a known effect of sphingosine 1-phosphate (S1P) modulators. Siponimod is an S1P receptor type 1,5 modulator, and is metabolized mainly by CYP2C9, followed by CYP3A4. It is approved in the United States for relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. First-dose observation with siponimod varied in certain clinical conditions, but it is important to understand the cardiac effects in patients receiving concomitant SSRIs.

Objectives: Evaluate first-dose effects of siponimod in patients receiving concomitant SSRIs during the EXPAND trial.

Methods: Analyses included data for the overall siponimod group (with or without SSRI), and subgroups of concomitant siponimod and any SSRI at first dose (day 1), and concomitant siponimod and citalopram or escitalopram on day 1.

Results: In all, 1105 patients were randomized to siponimod; 167 received an SSRI on day 1 and 85 received citalopram or escitalopram. For those with extended monitoring, in the overall siponimod group, and the any SSRI and citalopram/escitalopram subgroups, most were discharged at 6 hours post first dose (91.1%, 91.4%, and 89.6%, respectively). Day 1 after first dose, 4 patients (0.4%) in the overall siponimod group had serious adverse events (AEs), 2 (0.2%) had bradycardia, and 1 (0.1%) had second-degree atrioventricular (AV) block; no serious AEs occurred in the any SSRI or citalopram/escitalopram subgroups. Few patients in the overall siponimod group had cardiac AEs on day 1: 29 patients (2.6%) had bradycardia, 2 (0.2%) had prolonged QT, 3 (0.3%) had second-degree AV block, and 3 (0.3%) had prolonged QT interval. Incidence of cardiac AEs was low in the any SSRI subgroup: 3 patients (1.8%) had bradycardia and 3 (1.8%) had prolonged QT interval, in the overall siponimod group, 3 patients (0.3%) discontinued drug due to first- or second-degree AV block, or bradycardia. No patient receiving SSRIs had a cardiac AE causing treatment discontinuation.

Conclusions: Concomitant SSRI use did not appear to affect cardiac outcomes or heart rate changes associated with siponimod treatment initiation.

Supported by: None

Disclosure: Amit Bar-Or: Alexion, Astra, Biogen, EMD Serono, Novartis, TG Therapeutics (consulting fee); Le H. Hua: Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis, Ono Pharmaceutical, Roche/Genentech, Sanofi Genzyme, Teva Neuroscience, Wyeth (consulting fee); Brandon Brown: Alexion, Astra, Biogen, EMD Serono, Novartis, TG Therapeutics (consulting fee); Xiangyi Meng: Biogen, Genentech, Genzyme, Novartis, Sanofi Genzyme (consulting fee), data safety monitoring board; Brandon Brown: Desiree Dunlop, Xiangyi Meng, Wendy Su: Novartis Pharmaceuticals Corporation (salary).

(DXT06) Real-World Effectiveness of Peginterferon Beta-1a Versus Interferon Beta-1a and Glatiramer Acetate in US Multiple Sclerosis Patients

Charles Makin1, Megan C. Vignos2, Robin L. Avila3

1University of Chicago Neurology, Chicago, IL; 2Biogen, Cambridge, MA

Background: Interferons (IFNs) and glatiramer acetate (GA) are effective in reducing relapses in relapsing-remitting multiple sclerosis (RRMS). Increased frequency of relapses and high magnetic resonance imaging lesion load are associated with an increased risk of MS progression. Objectives: To evaluate clinical and radiologic efficacy of IFN in patients with highly active RRMS. Methods: EVOLVE-MS-1 (trial acronym) was a phase III, NCT02634042, randomized, double-blind, placebo-controlled trial of subcutaneous peginterferon beta-1a (Pfizer, New York, NY) versus placebo with a 12-week run-in (baseline) and 52 weeks of treatment. P values for between-group comparisons were calculated using the multivariable linear model. Other outcomes included disability, brain T2 lesion volume (exploratory) and brain T1 lesion volume (secondary), and all-cause mortality. Results: Of 1216 patients randomized, 606 were newly diagnosed RRMS patients with an Expanded Disability Status Scale (EDSS) score of ≤5.5 who had not received IFN therapy before. (P values from between-group comparisons, n = 606). Conclusions: P values for between-group comparisons were calculated using the multivariable linear model. Other outcomes included disability, brain T2 lesion volume (exploratory) and brain T1 lesion volume (secondary), and all-cause mortality. Results: Of 1216 patients randomized, 606 were newly diagnosed RRMS patients with an Expanded Disability Status Scale (EDSS) score of ≤5.5 who had not received IFN therapy before. (P values from between-group comparisons, n = 606).
Peginterferon Beta-1a Users in the Plegridy (DXT08) Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Diagnosed Within 3 or 4 Years Prior to the CLARITY Study

Background: Cladribine tablets 3.5 mg/kg (CT3.5, cumulative dose over 2 years; N = 433) treatment significantly improved clinical and magnetic resonance imaging (MRI) outcomes vs placebo (N = 437) in relapsing-remitting multiple sclerosis (RRMS) in the 96-week CLARITY study. Prior analyses of CT3.5 showed that patients who discontinued treatment within 3 years of initiation (n = 75) had lower MRI activity and better clinical outcomes vs those who continued treatment for a longer duration (≥3 years). These preliminary findings suggest an increased risk of treatment discontinuation associated with injection site reactions (ISRs).

Methods: Using POP, a 5-year, phase 4 real-world study, we assessed the relationship between ISRs and discontinuation of peginterferon beta-1a. We included patients who initiated peginterferon beta-1a 1 or 2 years prior to study enrollment. We evaluated the relative risk (RR) of treatment discontinuation and its relationship with ISRs in new and experienced users of peginterferon beta-1a. We used a negative binomial model adjusting for disease duration, prior disease-modifying therapy utilization, and health care resource measures.

Results: New and experienced users of peginterferon beta-1a who had ISRs were more likely to discontinue treatment (RR: 1.37 [95% CI: 1.30-1.44] vs 1.14 [1.08-1.20]; P < 0.0001). This increased the number of patients achieving NEDA status using 3-month criteria to 0.41% vs 0.31% (P < 0.0001) and increased the number of patients who were relapse-free through week 96 (≥3 YND: 75.2% vs 65.2% vs 55.9% vs placebo). CT3.5 increased the probability of being free from 3- or 6-month CDP by 0.4% and 0.6% vs placebo. CT3.5 also significantly reduced the adjusted mean (SD) 3-month CDP at week 96 by 0.26 [0.14-0.38] vs 3.06 [2.28-3.84] lesions. CT3.5 also significantly reduced the adjusted mean (95% CI) number of new T1 gadolinium-enhancing lesions (<3 YND: 0.080 [0.080-0.1] vs 1.0 [0.73-1.36]; ≤3 YND: 0.11 [0.080-0.16] vs 0.93 [0.69-1.24]) and active T2 (<3 YND: 0.41 [0.33-0.5] vs 1.68 [1.36-2.06]; ≤3 YND: 0.41 [0.33-0.5] vs 1.63 [1.34-1.97]) lesions, and increased the number of patients achieving NEDA status using 3-month criteria to <3 YND: 40.4% vs 11.1% vs 4-YND: 39.2% vs 11.4% at 6-month CDP (≤3 YND: 41.2% vs 11.6%; ≤3 YND: 40.2% vs 12.3% vs placebo all P < 0.0001) at 96 weeks.

Conclusions: Overall, CT3.5 treatment improved clinical and MRI outcomes in CLARITY patients who were early in their disease course.<3 or 4 years newly diagnosed (YND) at study enrollment. Methods: Analyses were performed by treatment (CT3.5 vs placebo) and MS-duration groups (<3 YND, ≥3 YND at CLARITY enrollment). End points were relapse, 3- and 6-month confirmed disability progression (CPD; based on Expanded Disability Status Scale score), magnetic resonance imaging (MRI) activity, and no evidence of disease activity (NEDA) status (no relapse, CPD, or MRI activity). P values are nominal. Results: These MS-duration group analyses were carried out in 1126 patients: <3 YND: CT3.5 N = 228, placebo N = 207; ≥3 YND: CT3.5 N = 256, placebo N = 236. In both MS-duration groups, CT3.5 significantly reduced annualized relapse rate (<3 YND: 0.14 vs 0.37 [60.7% reduction]; ≤3 YND: 0.14 vs 0.36 [61.6% reduction]; P < 0.0001), and increased the number of patients who were relapse-free through week 96 (<3 YND: 75.2% vs 55.1%; ≤3 YND: 73.0% vs 55.9%) vs placebo. CT3.5 treatment increased the probability of being free from 3- or 6-month CDP by 0.4% and 0.6% vs placebo. CT3.5 also significantly reduced the adjusted mean (95% CI) number of new T1 gadolinium-enhancing lesions (<3 YND: 0.080 [0.080-0.1] vs 1.0 [0.73-1.36]; ≤3 YND: 0.11 [0.080-0.16] vs 0.93 [0.69-1.24]) and active T2 (<3 YND: 0.41 [0.33-0.5] vs 1.68 [1.36-2.06]; ≤3 YND: 0.41 [0.33-0.5] vs 1.63 [1.34-1.97]) lesions, and increased the number of patients achieving NEDA status using 3-month (<3 YND: 40.4% vs 11.1%; ≤3 YND: 39.2% vs 11.4%) vs 6-month CDP (<3 YND: 41.2% vs 11.6%; ≤3 YND: 40.2% vs 12.3%) vs placebo all P < 0.0001 at 96 weeks.

Conclusions: Overall, CT3.5 treatment improved clinical and MRI outcomes in CLARITY patients who were early in their disease course.2020
(DXT09) Exploration of Factors Which Influence Treatment Decisions of Patients with Multiple Sclerosis
Belinda Bardley, 1 John Haynes, 1 Edith Cicin, 1 Elise Horner, 1 K.-J. Lazarus, 1 Melanie McMurtie, 1 Richard A.L. Macdonnell2
1 Neurology, Austin Health, Heidelberg, VIC, Australia; 2 Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Parkville, VIC, Australia; 3 Austin Health and Florey Institute of Neuroscience and Mental Health, Melbourne, VIC, Australia
Background: The past 10 years have brought a wide variety of therapeutic options to Australian patients with relapsing-remitting multiple sclerosis (RRMS). In a complex treatment landscape for an unpredictable disease, it is important to understand how patients view the various factors that contribute to making an informed therapeutic choice. Objectives: Identify the factor rated by patients with RRMS (PwRRMS) as having the most influence on treatment choice. Methods: This noninterventional, exploratory study prospectively enrolled 78 patients assigned to 1 of 3 groups: 1) initial treatment (n = 25), 2) switching to alternate treatment (n = 27), and 3) stable on treatment (n = 26). Baseline demographic and MS data were collected. Participants completed the survey where they rated factors from most to least important: drug safety, efficacy, ease of use, mode of administration, mechanism of action, concern about disability progression, requirement for follow-up safety monitoring, balance of risk/benefit, and value of discussion with MS nurse and neurologist. Results: The factors ranked first by most participants in influencing treatment choice were (in order): 1) concern about disability (31/78 participants), 2) perception of efficacy (16/78), and 3) perception of safety (11/78). This ranking order was consistent across all groups. 97% of participants were satisfied with the process around choosing treatment, and 92% reported they felt extremely comfortable with their treatment decision. Conclusions: Our data indicates that concern about disability is the largest driving factor for PwRRMS choosing between treatments regardless of whether they are starting for the first time, planning a switch in therapy, or are currently stable on an MS medication.

Supported by: None
Disclosure: Belinda Bardley, Biogen Pty Ltd, Roche Pty Ltd (consulting fee); Merck Pty Ltd (contracted research, speakers’ bureau, travel support). John Haynes: Nothing to disclose. Edith Cicin: Biogen Pty Ltd (consulting fee, speakers’ bureau); Merck Pty Ltd, Novartis Pty Ltd (consulting fee); Teva Pty Ltd (speakers’ bureau). Elise Horner: Clene Nanomedicine, MedDay Pharmaceuticals, Roche Pty Ltd (travel to investigator meeting). K.-J. Lazarus: Biogen Pty Ltd (speakers bureau). Melanie McMurtie: Clene Nanomedicine, MedDay (travel to investigator meeting). Richard A.L. Macdonnell: Genzyme, Genus, Novartis, Roche Pty Ltd (consulting fee); Merck Pty Ltd (travel support).

Keywords: Comprehensive care and MS, Disease-modifying treatments in MS, Nursing management in MS

(DXT10) Siponimod Affects Disability Progression in Patients with Secondary Progressive Multiple Sclerosis: Independent of Relapse Activity: Results from the Phase 3 EXPAND Study
Bruce A.C. Cree, 1 Robert J. Fox, 1 Gavin Giovannoni, 2 Patrick Vemersch, 3 Amit Bar-Or, 5 Raif Gold, 4 Nicolas Rouyrre, 7 Goeril Karlsson, 7 Frank Dahlke, 7 Ludwig Kappos8
1 Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 2Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH; 3Queen Mary University of London, Blizard Institute, Barts and the London School of Medicine and Dentistry, London, United Kingdom; 4Department of Neurology, University of Lille, CHU Lille, Lille, France; 5Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 6Department of Neurology, St. Joseph’s Hospital/Rhode Island Hospital, Providence, Rhode Island, USA; 7Novartis Pharma AG, Basel, Switzerland; 8Departments of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Basel, Switzerland
Background: Siponimod (Mayzent) is a selective sphingosine 1-phosphate receptor (S1P 1, S1P 5) modulator, approved in the United States for the treatment of relapsing forms of multiple sclerosis (MS), including active secondary progressive MS (SPMS). In the phase 3, randomized, double-blind, placebo-controlled EXPAND trial, siponimod reduced the risk of 3- and 6-month confirmed disability progression (CDP) by 21% and 26%, respectively, compared with placebo, in patients with SPMS. Subgroup analysis of the EXPAND data suggest that a proportion of benefit of siponimod on CDP was attributable to effects on relapse-independent disability progression. Objectives: Assess the impact of siponimod on CDP in patients with or without relapses to uncouple treatment effects on CDP from those on relapses. Methods: In EXPAND, patients (aged 18-80 years) with SPMS and Expanded Disability Status Scale score of 0-6.5 were included in the study and received once-daily oral siponimod 2 mg or placebo for up to 3 years. We analyzed the impact of siponimod on CDP in a subgroup analysis using the Cox model on time to 3- and 6-month CDP in patients with or without relapses in the 1 and 2 years before study; principal stratum analysis to estimate the effect in patients who would not have had relapse on-study at the month 12, month 18, and month 24 timepoints, regardless of treatment; and Cox model on time to 3-/6-month CDP in the overall population, censoring at time of first relapse. Results: For nonrelapsing patients in the 1 and 2 years before study, risk reductions were 18% (hazard ratio [HR], 0.82 [CI: 0.66, 1.02]) and 13% (0.87 [0.68, 1.11]), respectively, for 3-month CDP, and 25% (0.75 [0.59, 0.96]) and 18% (0.82 [0.62, 1.08]), respectively, for 6-month CDP, for relapsing patients, risk reductions were 33% and 33% (3-month CDP, respectively), 30% and 37% (6-month CDP, respectively). Principal stratum estimates, siponimod reduced 3-month CDP by 14%-20% and 6-month CDP by 29%-33% in nonrelapsing patients across the 3 timepoints, suggesting that these patients achieved a large proportion of the effect in the overall population. Cox model censoring at relapse confirmed beneficial effects, reaching nominal statistical significance (6-month CDP: HR 0.77 [0.62, 0.96]). Conclusions: Siponimod reduces risk of CDP in patients with SPMS with or without relapses, indicating that the effects on disability are largely independent from those on relapses. Patients with or without relapses may thus benefit from treatment with siponimod.

Supported by: None
Disclosure: Bruce A.C. Cree: Akili, Alexion, Astara, Biogen, EMD Serono, Novartis, TG Therapeutics (consulting fee); Robert J. Fox: Actelion, EMD Serono, Genentech, Teva (consulting fee); Biogen, Novartis (consulting fee, contracted research); Genentech, Teva (consulting fee, contracted research); Novartis (consulting fee, contracted research). Nicolas Rouyrre, Goeril Karlsson, Frank Dahlke: Novartis Pharma AG (salary). Ludwig Kappos: Actelion, Almirall, Allergan, Almirall, Bayer, Biogen, BiomS, Celgene/Receptos, DiaSorin, Eli Lilly, Hoffmann-La Roche, Genentech, GlaxoSmithKline, GURth-Jackson/GGF, Immunic, Jansen/Actelion, Mayer Immunimmune, Merck/EMD Serono, Novartis, Osm Pharma, Roche/Genentech, Sanofi Genzyme, Teva Neuroscience, Wu/teh (consulting fee). Raif Gold: Mayer HealthCare, Biogen, Merck Serono, Novartis, Teva Neuroscience (consulting fee, research support); Celgene, Roche, Sanofi, Servier (consulting fee); SAGE, Thieme Verlag (editor); Limit Bar-Or; Astara Biotherapeutics, Bayer, Regshell (contracted research). Amit Bar-Or: Biogen, BioMS, Celgene/Receptos, Diasorin, Eli Lilly, Hoffmann-La Roche, Genentech, GlaxoSmithKline, Guthy-Jackson/GGF, Immunic, Jansen/Actelion, Mayer Immunimmune, Merck/EMD Serono, Novartis, Osm Pharma, Roche/Genentech, Sanofi Genzyme, Teva Neuroscience, Wu/teh (consulting fee). Patrick Vemersch: Bayer HealthCare, Biogen, Merck Serono, Novartis, Teva Neuroscience (consulting fee, contracted research); SAGE, Thieme Verlag (personal fees for serving as an editor).

Acknowledgments: Supported by: None

International Journal of MS Care

(DXT11) The Implications of Suboptimal Treatment Outcomes with Disease-Modifying Drugs in Employees with Multiple Sclerosis
Carrie M. Hersh, 1 Richard A. Brook, 2 Ian A. Beren, 3 Nicholas J. Rohrbacker, 3 Lori Lebson, 4 Christine Henke, 2 Amy L. Phillips1
1 Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV; 2Better Health Worldwide, Inc., Newhouse, NJ; 3 The HCMs Group, LLC, Pittsburgh, PA; 4EMD Serono, Inc, Rockland, MA; 5 Merck KGaA, Darmstadt, Germany; 6 Health Economics & Outcomes Research, EMD Serono, Inc, Rockland, MA
Background: A better understanding of the implications of suboptimal treatment outcomes in employees with multiple sclerosis (MS) may elucidate opportunities for improving care management. Objectives: To evaluate suboptimal treatment outcomes with disease-modifying drugs (DMDS) in patients with MS from an employer perspective. Methods: US Health Care CapEx Management-month database employees only were eligible if they had ≥ 2 claims with MS diagnoses (ICD-9 CM 340.xx/ICD-10 CM G35) from January 1, 2010–March 31, 2019, ≥ 1 once/twice-daily oral or any self-injectable DMD claim [first claim=index], continuous eligibility 6-months pre-[baseline] and 1-year post-index (follow-up), no baseline DMD, age 18-64. Suboptimal treatment outcomes were DMD treatment gap (≥6 months) and DMD discontinuation (treatment gap >60 days), DMD switch, or relapse (MS-related hospitalization, emergency room visit, or outpatient visit with corticosteroid ≥7 days). A 2-part logistic-GLM model evaluated costs controlling for age, tenure, marital status, race, exempt status, full-time/part-time, salary, location, Charlson Comorbidity Index, smoking, and relocation. Results: Of 2173 employees with ≥ 2 MS diagnoses, 48% [22.5%] met eligibil-
(DXT13) Disease-modifying Therapies: How Confident Are We That We Understand Their Risk? 

Carnette Roman,1 Christen Kutz,2 Timothy West2
1Rocky Mountain Multiple Sclerosis Clinic, Salt Lake City, UT; 2Colorado Springs Neurological Associates, Colorado Springs, CO

Background: An increasing number of therapeutic options are available for patients with multiple sclerosis (MS). Each medication has a unique efficacy and safety profile that needs to be critically evaluated to understand the risk and benefit for each patient's individual treatment plan. While most efficacy data are obtained in phase 3 trials, safety profiles may change over time as patients use these medications in a real-world setting. Participants in clinical trials are often younger and have fewer comorbidities than the general MS population. To understand the evolving nature of serious adverse events (SAEs), it is important to have up-to-date information on the incidence of these events balanced by the number of patients exposed to the medication, as well as the patient-years exposure.

Objectives: To compare rates of SAEs for approved MS disease-modifying therapies in relation to current patient exposures and patient-years of exposure.

Methods: A retrospective analysis was performed to obtain SAE data from the manufactures of the most commonly prescribed MS medications. Results: As of the writing of this abstract, cases of progressive multifocal leukoencephalopathy have been reported for natalizumab (825), fingolimod (30), dimethyl fumarate (8), ocrelizumab (8), teriflunomide (1), and alemtuzumab (1). Forty-five cases of cryptococcal meningitis have occurred with fingolimod. Multiple cases of Stevens-Johnson syndrome have occurred with a single fatal case of toxic epidermal necrolysis has been reported with teriflunomide. Thirteen cases of ischemic and hemorrhagic stroke or arterial dissection have been reported with alemtuzumab. This led to a recent update and boxed warning in the US prescribing information for alemtuzumab. The approximate number of patients exposed to alemtuzumab before this update was approximately 22,000, representing approximately 45,000 patient-years.

Conclusions: These findings suggest that newly approved medications may require 20,000+ patients with 40,000+ patient-years to uncover SAEs in the real-world setting. Current patient exposures for injectable, oral, and insubile MS medications range from 2,000 to over 500,000, while patient-years range from 10,000 to over 400,000. A conservative approach of above (and additional) SAE rates by patient exposure will be presented.

Supported by: None

Disclosure: Carnette Roman: Alexion, Biogen, Bristol Myers Squibb, Genentech, Novartis, Sanofi Genzyme (speakers' bureau); Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Sanofi Genzyme (consulting fee); Biogen, Bristol Myers Squibb, Genentech, Novartis, Sanofi Genzyme (advisory boards); Christen Kutz: Biogen, EMD Serono, Mallinckrodt, Novartis (consulting fee); Timothy West: Biogen, EMD Serono, Novartis (consulting fee, speakers' bureau); Genentech (consulting fee, Genzyme (speakers' bureau).

Keywords: Comparative safety, Disease-modifying treatments in MS

(DXT14) Long-term Safety and Efficacy of Eculizumab in Neuromyelitis Optica Spectrum Disorder

Dean Wingertchuk,1 Sean J. Pitlock,2 Achim Berthele,2 Kazue Fujihara,3,4,5 Ho Jin Kim,3 Michael Levy,6 Jacqueline Palace,3 Ichiro Nakashima,6,7 Murtur Terzi,2 Natalia Totolyan,1 Shanthi Viswanathan,1 Kai-Chen Wang,1,6 Kerstin Allan,6 Kenji P. Fujita,1 Marcus Younts,2 Rosin Armstrong2
1Mayo Clinic, Scottsdale, AZ; 2Mayo Clinic, Rochester, MN; 3Technical University of Munich, Munich, Germany; 4Tokyo University, Sendai, Japan; 5Fukushima Medical University, Fukushima City, Japan; 6Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan; 7National Cancer Center, Gayang, Korea, Republic of South Korea; 8Massachusetts General Hospital and Harvard Medical School, Boston, MA; 9John Hopkins University, Baltimore, MD; 10John Radcliffe Hospital, Oxford, United Kingdom; 11Tokyo Medical and Pharmaceutical University, Sendai, Japan; 12Onodukuz Mayas University, Samsun, Turkey; 13Fairyvul State Medical University of St Petersburg, St Petersburg, Russian Federation; 14Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; 15Cheng-Hsin General Hospital, Taipei, Taiwan; 16National Yang Ming University, Taipei, Taiwan; 17Alexion Pharmaceuticals, Boston, MA

Background: Neuromyelitis optica spectrum disorder (NMOSD) relapses can cause significant and irreversible neurologic disability. Eculizumab, a terminal complement inhibitor, reduces the risk of NMOSD relapse in patients with aquaporin-4 immunoglobulin G (AQP4-IgG)-positive NMOSD. In the PREVENT study, eculizumab reduced the risk of relapse by 94.2% vs placebo (hazard ratio 0.058 [95% CI 0.017, 0.197]; P < .0001). The rate of adverse events (AEs)/100 patient-years (PYs) was 749.3 and 1160.9 for eculizumab and placebo, respectively.

Objectives: To present combined long-term safety and efficacy data from the randomized, double-blind, placebo-controlled PREVENT study (trial registration: NCT01892345) and its ongoing
posters: disease-modifying therapy

Ophthalmology, UCSF Weill Institute for Neurosciences, San Francisco, CA; 1 Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany; 2 Department of Neurology, UKD, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany; 3 Kohn School of Medicine at Mount Sinai, New York, NY; 4 Viera Bio, Gaithersburg, MD; 5 Department of Neurology and Department of Ophthalmology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

Background: Neuromyelitis optica spectrum disorder (NOMSOD) is a rare, relapsing, autoimmune, inflammatory disease of the central nervous system. Disability accumulates with repeated attacks, severely affecting quality of life. Inebilizumab, an anti-CD19 monoclonal B-cell-depleting antibody, was assessed in N-MOmentum, a randomized, placebo-controlled, double-masked trial in patients with NMOSD. To assess the effectiveness of inebilizumab on disability outcomes in N-MOmentum and determine if severity of pre-existing disability influenced efficacy. Methods: Adults with NOMSOD and an Expanded Disability Status Scale (EDSS) score ≤8 were randomized 3:1 to receive inebilizumab 300 mg or placebo on days 1 and 15. The randomized controlled period (RCP) was 28 weeks or up to an adjudicated attack. The proportion of patients with disability worsening (EDSS score change ≥2 from a baseline of 0, ≥1 from a baseline of 1-5, or ≥0.5 from a baseline of ≥5) was assessed by logistic regression. Change from baseline in modified Rankin Scale scores was analyzed by the Wilcoxon–Mann–Whitney odds approach. Subgroup analysis by baseline EDSS score of the primary outcome (time to adjudicated attack) was performed by Cox proportional hazards regression. Results: The median (range) baseline EDSS score of the 174 patients receiving inebilizumab was 3.5 (0-8) and 4.0 (1-8) for the 56 receiving placebo; 18.0% and 30.4% had disability worsening during the RCP. At week 12, respectively. At the end of RCP, 15.5% of patients on inebilizumab and 33.9% on placebo had disability worsening; odds ratio (95% CI): 0.370 (0.185-0.739); P = .0049. Of the 9632 paired comparisons, modified Rankin Scale scores at end of RCP were better with inebilizumab than placebo in 51.5% of cases and were equal in 21.9% of cases; adjusted odds ratio (95% CI): 1.663 (1.195-2.385); P = .0023. Inebilizumab reduced the risk of attack compared with placebo in patients with baseline EDSS score in the lower (<5) or upper half (≥5) of the 10-point scale; hazard ratios (95% CI): 0.257 (0.120-0.552); P = .005 and 0.367 (0.137-0.981); P = .0456, respectively; the treatment effect was not significantly different (interaction test, P = .6363). Analysis of the pre-specified long-term, open-label follow-up data will be presented. In N-MOmentum, disability outcomes were significantly better with inebilizumab monotherapy than with placebo. Inebilizumab reduced the risk of the attack in patients with NOMSOD irrespective of the level of pre-existing disability.

Supported by: None

Disclosure: Dean Wingerchuk: MedImmune, Novartis, Biogen, Celgene, Genentech, TG Therapeutics, Arcus Medica, Reiscone (consulting fee); Teva BCT, Alexion Pharmaceuticals (fees for non-CME/CE services received directly from Alexion Pharmaceuticals (fees for non-CME/CE services received directly from Alexion Pharmaceuticals (all compensation paid directly to Mayo Clinic, consulting fee, contract research); Axima nue Encephalitis Alliance (all compensation paid directly to Mayo Clinic, consulting fee, contract research); Atellas (all compensation paid directly to Mayo Clinic, consulting fee); Autimmune Encephalitis Alliance (all compensation paid directly to Mayo Clinic, contract research); Grifols (all compensation paid directly to Mayo Clinic, contract research); MedImmune (all compensation paid directly to Mayo Clinic, consulting fee, contract research); UCB (consulting fee, personal compensation, personal fees); Teva BCT, Alexion Pharmaceuticals, Celrella, Eisi, HanAll BioPharma, Merck Serono, Novartis, Sanofi Genzyme, Teva-Hanadok, Vida Bio (consulting fee); Journal of Clinical Neurology (associate editor); MedImmune/VieBio (steering committee); Multiple Sclerosis Journal (co-editor); Michael Levy: Alexion Pharmaceuticals (consulting fee, contract research, fees for non-CME/CE services received directly from commercial interest or its agent, speakers’ bureau); Kanso Fujihara: Alexion Pharmaceuticals, Biogen, Chugai, Mitsubishi-Tanab, Novartis (consulting fee, fees for non-CME/CE services received directly from commercial interest or its agent); Aebi Medical, Bayer, Eisai, Roche, Teijin (fees for non-CME/CE services received directly from commercial interest or its agent); Ho Jin Kim: Alexion Pharmaceuticals, Celrella, Eisi, HanAll BioPharma, Merck Serono, Novartis, Sanofi Genzyme, Teva-Hanadok, Vida Bio (consulting fee); Journal of Clinical Neurology (associate editor); MedImmune/VieBio (steering committee); Multiple Sclerosis Journal (co-editor); Michael Levy: Alexion Pharmaceuticals (consulting fee, contract research, fees for non-CME/CE services received directly from commercial interest or its agent, speakers’ bureau); Genentech, Quest Diagnostics, VieBio (consulting fee, fees for non-CME/CE services received directly from commercial interest or its agent); Jacqueline Palmen: Biogen (scientific advisory board); LEG (consulting fee); GUDE (speaking engagement); Inebilizumab, Dysimmune, Sanofi (consulting fee); Merck Serono (meeting/lecture/workshop participation); Novartis, Roche, Argens (speakers’ bureau); UCB, VieBio, Roche (conference/lecture participation); Ichiro Nakashima: Alexion (consulting fee); Murat Teraz, Shandoi Viswa-nathab, Rui-Chen Wang: Nothing to disclose. Natalia Totsk: Alexion, Janssen, Novartis, Roche, Sanofi, Receptors Inc, BioRad (Russia) (consulted research); Merck (consulting fee); Roche, Sanofi (fees for lectures). Kerstin Allen, Marcus Youstat, Baizin Armstrong, Alexion Pharmaceuticals (ownership interest, salary); Kenji P. Fujita: Alexion Pharmaceuticals, Abylamy Pharmaceuticals (ownership interest, salary). Keywords: Long-term safety and efficacy of eculizumab in NOMSOD

(DXT5) Inebilizumab Reduces Neuromyelitis Optica Spectrum Disorder Disability Worsening: Outcomes and Long-Term Follow-up Data from the N-MOmentum Trial

Dean Wingerchuk,1 Romain Marignier,2 Jeffrey L. Bennett,3 Ho Jin Kim,4 Brian Weinshenker,5 Sean J. Pittock,6 Kazuo Fujihara,7 Friedemann Paul,8 Gary Cutter,9 Ari Green,9 Orhan Akis,10 Hans-Peter Hartung,11 Fred D. Lublin,12 Maureen A. Meade,13 Jorn Drappp,14 Gerard Barron,15 Soraya Madani,16 Dewie She,17 Daniel Cimbora,18 William Rees,19 John N. Ratchford,20 Eliezer Kitz,21 Bruce A. Cree22

1 Mayo Clinic, Scottsdale, AZ; 2 Lyon University Hospital, Lyon, France; 3 School of Medicine, University of Colorado, Aurora, CO; 4 Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South); 5 Neurology, Mayo Clinic, Rochester, MN; 6 Mayo Clinic, Rochester, MN; 7 Department of Multiple Sclerosis Therapeutics, Southern Tohoku Research Institute for Neuroscience (STRINS), Kariyama, Japan; 8 Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité – Universitätsmedizin Berlin, Berlin, Germany; 9 Biastistics, University of Alabama at Birmingham, Birmingham, Al; 10 Department of Neurology and Department of
(DXT16) Effectiveness of Delayed-Release Dimethyl Fumarate Relative to Duration of Prior Glatiramer Acetate in Patients Enrolled in the RESPOND STUDY

Derrick Robertson,1 Pavle Repovic,2 Stanley L. Cohen,3 Yang Mao-Draayer,4 Ray Su,3 and James B. Lewin1

1USF Multiple Sclerosis Center, Tampa, FL; 2Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, WA; 3Providence Multiple Sclerosis Center, Providence Brain Institute, Portland, OR; 4University of Michigan Medical School, Ann Arbor, MI; 5Biogen, Weston, MA; 6Neurology Center of San Antonio, San Antonio, TX; 7TG Therapeutics, Inc.,Seattle, WA; 8Providence Multiple Sclerosis Center, Providence Brain Institute, Portland, OR; 9Institute of Neurology, University of Oxford, Oxford, UK

Background: Dimethyl fumarate (DMF) has demonstrated efficacy and a favorable benefit-risk profile in clinical trials of patients with relapsing-remitting multiple sclerosis (RRMS). RESPOND (trial registration: NCT01903291), a phase 4, 12-month study, evaluated outcomes in patients with RRMS prescribed DMF after suboptimal response to glatiramer acetate (GA). Patients may have a suboptimal response to a disease-modifying therapy such as GA early after treatment initiation, or in some cases, after several years. Objectives: To evaluate relapse and patient-reported outcomes (PROs) over 12 months in patients with RRMS who switched to DMF after suboptimal response to GA in real-world practice and to explore whether time on prior GA may influence response to DMF. Methods: RESPOND was conducted at 63 sites in the United States between August 2013 and February 2016. Patients diagnosed with RRMS with a suboptimal response to GA (insufficient efficacy, intolerance, or poor adherence to GA) were enrolled. The median duration of prior GA was 36 months. This post hoc analysis compared treatment outcomes at 12 months following DMF initiation in subgroups of patients according to duration of prior GA treatment (≤36 vs >36 months). Results: Among patients treated with GA for ≤36 months [n = 177] and >36 months [n = 141], the ARR at 12 months prior to DMF was 0.588 (95% CI 0.49-0.70) and 0.369 (95% CI 0.28-0.49), whereas 12 months after switching to DMF, the ARR was 0.294 (95% CI 0.20-0.40) and 0.121 (95% CI 0.07-0.22), respectively [ARR reductions of 84% and 67%, respectively]. The estimated proportion of patients relapsed (PPR) at month 12 on DMF was 6.5% for patients who had received prior GA for ≤36 months and 9.8% for patients who had received prior GA for >36 months. PROs for quality of life, fatigue, disability, treatment satisfaction, depression, and depressive symptoms improved for remained stable in both subgroups. We will also present outcomes for RRMS stratified by disorders, confirming sufficient efficacy vs other. Conclusions: Improvements in ARR and PPR were observed in patients who switched to DMF earlier (<36 months prior GA treatment), and in patients who switched to DMF after being treated with GA for >36 months. ARR and PPR were numerically lower in the group who switched earlier, but these differences were not statistically significant between the two subgroups. Both groups demonstrated improvement or stability across several PROs.

Supported by: Biogen

Disclosure: Derrick Robertson; Acorda (speakers’ bureau); Actelion, MedDay, PCORI, TG Therapeutics (contracted research); Alexion, Celgene, Teva Neurosciences (consulting fee, speakers’ bureau); Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme (consulting fee, contracted research, speakers’ bureau); Macmillan; Alex R. Beeson: Acorda (speakers’ bureau); Biogen, EMD Serono, Genentech, Novartis (consulting fee, contracted research, speakers’ bureau); Biogen, Genentech, Novartis (consulting fee, contracted research, speakers’ bureau); Biogen; Merck (personal fees); National Heart, Lung, and Blood Institute (protocol review committee); Novartis (consulted for steering committee); EMD Serono (personal fees); Biogen, Genentech, Novartis, Sanofi Genzyme (consulting fee, contracted research, speakers’ bureau); Biogen, EMD Serono, Genentech (consulting fee, contracted research, speakers’ bureau); Biogen; EMD Serono, Sanofi Genzyme (consulting fee, contracted research, speakers’ bureau); Biogen; Merck (personal fees); National Heart, Lung, and Blood Institute (protocol review committee); Novartis (consulted for steering committee); EMD Serono (personal fees); Biogen, Genentech, Novartis, Sanofi Genzyme (consulting fee, contracted research, speakers’ bureau); Biogen; Genentech, Novartis, Sanofi Genzyme, Viela (consulting fee); Genentech (contracted research, speakers’ bureau); Genzyme (speakers’ bureau). Stanley L. Cohen: AbbVie, Adams, Alexion, Alitho, MedDay, Peak Therapeutics, Roche Genentech, Sage Therapeutics (contracted research); Biogen, Novartis (consulting fee, contracted research, speakers’ bureau); EMD Serono, Roche (consulting fee); Genentech (consulting fee, speakers’ bureau); Sanofi Genzyme (consulting fee, contracted research, speakers’ bureau); Sanofi Genzyme, Teva Neuroscience (speakers’ bureau). Yang Mao-Draayer: Bayer Pharmaceutical, Celgene, EMD Serono, Forward Pharma, Genentech, Tesa (contracted research, consulting fee, contracted research); Chugui, National Institute Allergic Infectious Diseases Autoimmune Center of Excellence UMI-1110557, NIH National Institute of Neurological Disorders and Stroke R01-N0800821, Novartis (contracted research). Ray Su; James B. Lewin: Biogen (ownership interest, salary). Jenna Borowski: Biogen (salary).

Keywords: Dimethyl fumarate, Disease-modifying treatments in MS

(DXT17) Long-term Follow-up Results from the Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Patients with Relapsing Multiple Sclerosis

Edward J. Fox1, Ivyl Wray2, Ray Su2,3,4, Anna H. Rutten2,5,6,7,8, Deren Huang,9 Ann D. Bass,1 Michael S. Weiss,1 Sean Power,1 Jenna Bosca,1 Koby Mak1

1Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock, TX; 2Hoe Neurology, Knoxville, TN; 3Arcadia Neurology Center, Arcadia, CA; 4Ohio State University, Columbus, OH; 5Mount Carmel Neurology, Westerville, OH; 6Neurology Center of San Antonio, San Antonio, TX; 7TG Therapeutics, New York, NY

Background: Ublituximab (UTX) is a novel monoclonal antibody targeting a unique epitope on the CD20 antigen and glyco-engineered for enhanced B-cell targeting through antibody-dependent cellular cytotoxicity. Two phase 3 trials, ULTIMATE I and II, are fully enrolled and are investigating the efficacy and safety of UTX in relapsing forms of multiple sclerosis (RRMS). Objectives: To evaluate the long-term safety and tolerability of UTX treatment in patients with RMS enrolled in the open-label extension (OLE) of a phase 2 trial. Methods: TG1101-RMS201 was a 52-week, phase 2, placebo-controlled, multicenter study of UTX in RMS. Subjects who completed RMS201 were eligible to continue treatment in the OLE, receiving 1-hour 450-mg UTX infusions every 24 weeks. Results: RMS201 enrolled 48 subjects and the primary end point was to evaluate B-cell depletion. Median B-cell depletion of >99% was observed at week 4 and maintained at week 48. At week 48, key observations included: 100% reduction in T1-Gd-enhancing lesions; 10.6% mean decrease in T2 lesion volume; 93% of subjects relapse free, and an annualized relapse rate (ARR) of 0.043 (95% CI 0.01-0.14); no opportunistic infections or common adverse event (AE) was infusions-related reactions (all grade 1-2). No discontinuations due to AEs were reported. UTX continues to be well tolerated, with a median duration of follow-up of 124.7 weeks, no drug-related discontinuations, and only 1 AE deemed at least possibly related to UTX that occurred in more than 1 patient, which was infusion-related reactions. Average quality of any RRMS all grade 1 or 2 in severity. At the time of presentation, long-term safety information will be presented for all patients on the OLE.

Conclusions: The phase 2 OLE data support that UTX continues to be safe, well tolerated, and effective with 1-hour infusions. These results support the ongoing phase 3 ULTIMATE program in RMS.

Supported by: None

Disclosure: Edward J. Fox; Biogen, Celgene, Chugui, EMD Serono, MedDay (consulting fee); Genentech/Roche, Sanofi Genzyme, Teva (speakers’ bureau). I. Ivyl Wray: TG Therapeutics (contracted research); Amy Lauver-Racker; Novartis, TG Therapeutics (contracted research); Sibyl Wray; Biogen, EMD Serono,
(DXT18) Adherence and Compliance with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis

Edward Fox,1 Lori Mayer,2 Angela Aungst,3 Alexandria Goodyear,4 Cecile Kerloeguen,5 Linda Macionis,5 Linda Rennie,6 Dee Stoneman,5 Martin Zalesak,5 Marina Ziehn,5 Richard Shubin,6 Deren Huang7

1Central Texas Neurology Consultants, Multiple Sclerosis Clinic of Central Texas, Round Rock, TX; 2Multiple Sclerosis Division of Department of Neurology University of South Florida, Tampa, FL; 3Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH

Background: Ofatumumab is the first fully human anti-CD20 monoclonal antibody, administered with a monthly 20 mg subcutaneous (s.c.) dose regimen. The current study evaluated adherence and compliance with Ofatumumab in the ASCLEPIOS I and II trials in relapsing-multiple sclerosis. Patients who completed the double-blind phase of the two trials were eligible for the open-label extension study AUTHIS. Objectives: To evaluate treatment discontinuation and compliance with Ofatumumab in the two phase 3 ASCLEPIOS I/II trials and to assess patients’ acceptance of transitioning to the AUTHIS study. Methods: In ASCLEPIOS I/II, patients were randomized (1:1) to Ofatumumab 20 mg s.c. (loading doses, administered at clinic visits days 1, 7, 14; maintenance, doses administered at home: every 4 weeks from week 4) or Teriflunomide 14 mg (orally once daily), for up to 30 study months. Here, we report on treatment discontinuation and compliance (defined as exposure to study drug [days]/on-treatment period [days] × 100%) in ASCLEPIOS trials and percentage of eligible ASCLEPIOS patients who accepted to transition to the AUTHIS study and the compliance in this study. Results: In ASCLEPIOS I, 7,539/9,227 (81.9%) randomized patients (OMB: 400/465 [86.0%]; TER: 359/462 [77.7%]) completed the study on treatment. The proportion of patients discontinuing treatment were OMB, 14.0%; TER, 21.2%. The most common reasons for discontinuation (>2% in any group) were patient/guardian decision (OMB: 4.9%; TER: 8.2%), adverse event (OMB: 5.2%; TER: 5.0%), and physician decision (OMB: 2.2%; TER: 6.5%). In ASCLEPIOS II, 753/955 (78.8%) patients were randomized (OMB: 380/465 [81.6%]; TER: 373/529 [70.8%]) completed the study on study drug. Proportion of patients discontinuing treatment were OMB, 20%; TER, 21.5%; reasons for discontinuation were patient/guardian decision (OMB: 7.3%; TER: 7.8%), adverse event (OMB: 5.6%; TER: 4.9%), and physician decision (OMB: 5.2%; TER: 6.8%). In both trials, compliance was high (>95% of patients falling in the ≥90% compliance category) across treatment groups. Approximately 90% of eligible patients consented to participate in the open-label study; compliance data will be presented. Conclusions: In ASCLEPIOS trials completion with open-administered s.c. OMB was high and fewer patients discontinued OMB as compared to TER. Most eligible patients accepted transition to the open-label AUTHIS extension study.

Supported by: None


Keywords: Disease-modifying treatments in MS

(DXT20) Glatiramer Acetate (GA) Provided by Mapi Pharma Is Equivalent to Commercially Available GA Preparations

Susanna Thibilien, Nadav Bleich Kimelman, Shai Rubnov, Laura Popper, Uri Danon, Ehud Marom

Mapi Pharma Ltd, Ness Ziona, Israel

Background: Glatiramer acetate (GA) is one of the first disease-modifying treatments approved for relapsing-remitting multiple sclerosis. Recently, several generic equivalents of GA were approved for marketing in the United States. Mapi is developing GA to be used in Glatiramer Acetate Depot (GA Depot) and in Mapi’s generic GA. Here, we present key characteristic data from physicochemical (structural) and biological (pharmacodynamic) assays that were conducted to compare Mapi’s GA and all US-approved GA equivalents. Objectives: To demonstrate through the results (physicochemical and biological) that Mapi’s GA is similar to US-approved GA equivalents. Methods: Mapi’s GA is produced using the same starting materials and basic chemistry as Copaxone. At least 5 batches of Copaxone, 1 batch of Glatacop (Sandoz), 1 batch of Glatiramer Acetate Injection (Mylan), and several batches of Mapi’s GA were analyzed for physicochemical properties (molecular weight distribution, impurities profile, amino-acid composition, and spectral fingerprint) and various structural signatures. A representative batch of Mapi’s GA was compared with three different commercially available GA preparations using a bioassay test (myelin oligodendrocyte glycoprotein–induced EAE in mice). Results: The selected tests and data presented here represent a portion of a broader set of physicochemical and biological assays that were conducted, with differences observed in the physicochemical properties or the structural signatures between Mapi’s GA and all other US-approved GA equivalents. Equivalent pharmacodynamic activity of Mapi’s GA to 3 commercially available GA preparations (Copaxone, Glatacop, and Glatiramer Acetate Injection) was demonstrated using MOG-induced EAE in mice. Conclusions: Mapi’s GA is equivalent to commercially available GA products in physicochemical properties, structural signatures, and biological activity as demonstrated by bioassay and complies with the US Food and Drug Administration’s guidance for generic GA. These results will support GA Depot and a new generic GA version commercialization by Mapi Pharma.

Supported by: None


Keywords: Disease-modifying treatments in MS

(DXT22) Characterization of Incidence and Time-to-Recurrence from Grade 3/4 Lymphopenia Lasting ≥26 Months in Patients with Multiple Sclerosis Treated with Cladribine Tablets

Gabriel Parda,1 Katil Rammohan,2 Thomas P. Leist,3 Julie Aldridge,4 Ciara Rosser,5 Axel Notling,6 Matt Mandel,7 Andrew Galazka,7 Daniel Jones,8 Giovanni Giovanni9

1Oklahoma Medical Research Foundation, Oklahoma City, OK; 2Department of Neuroscience, Multiple Sclerosis Center, University of Miami, Miami, FL; 3Jefferson University Hospital, Philadelphia, PA; 4EMD Serona Inc, Billerica, MA; 5Merck, Aboozn, Switzerland; 6Merck KGaA, Darmstadt, Germany; 7EMD Serona Inc, Rockland, MA; 8Blizzard Institute of Cell and Molecular Science, London, United Kingdom

Background: Patients with multiple sclerosis (MS) treated with cladribine tablets (CTs) are expected to experience lymphopenia because of its mechanism of action (MOA), and transient mild-to-moderate lymphopenia has been observed in most patients. Given that a reduction in overall lymphocyte counts is part of the MOA of cladribine, further studies on the severity of lymphopenia are warranted. Objectives: To examine the effect of CT 3.5 mg/kg (CT3.5, cumulative over 2 years) on grade 3/4 lymphopenia (ALC <500/mm3) lasting ≥26 months. Time to an episode and time to recovery were also assessed. Recovery from grade 3/4 lymphopenia is defined as a return to grade ≤2 lymphopenia. Results: Of the 923 patients randomized to CT3.5, 891 (96.5%) had baseline ALC within normal limits (grade 0), and in this subgroup, 212 (23.6%) had at least a single reading of grade 3/4 lymphopenia, and 33 (3.6%)

Supported by: None


Keywords: Disease-modifying treatments in MS

International Journal of MS Care 23

Posters: Disease-Modifying Therapy
had grade 3/4 lymphopenia lasting ≥6 months (38 episodes). More patients with grade 3/4 lymphopenia lasting ≥6 months were female (81.8% vs 66.1%), had used ≥1 prior disease-modifying drug (33.3% vs 19.5%), and had more severe disease (≥T2 lesions [93.9% vs 88.1%], ≥1 relapse [75.8% vs 53.9%], higher median score on Expanded Disability Status Scale [3.0 vs 2.0]) at baseline versus the overall patients with baseline ALC within normal limits. Of the 33 CT3.5-treated patients with grade 3/4 lymphopenia lasting ≥6 months, 26 (78.8%) had the episode of lymphopenia in patients 2 to 1 year of the core studies (64% vs 18%), with a median (Q1, Q3) time to first episode of 58.9 (51.1, 83.1) weeks. Of the 38 grade 3/4 lymphopenia (≥6 months) episodes, 27 (71.1%) lasted 24-48 weeks, and 11 (28.9%) lasted >48 weeks. Median (Q1, Q3) time to recovery from grade ≥3 lymphopenia (≥6 months) episode was 36.3 (28.4, 66.3) weeks. **Conclusions.** The incidence of grade 3/4 lymphopenia lasting ≥6 months in patients treated with CT3.5 was low. Most episodes (71.1%) of grade 3/4 lymphopenia lasting ≥6 months resolved within 6 months to 1 year.

**Supported by:** None

**Disclosure:** Gabriela Pardo, Alexion, Biogen, Celgene, EMD Serono, Novartis, Roche/Genentech, Sanofi Genzyme (speaker honoraria and also consulting fee); AbbVie, Adamas, Alexion, Biogen, EMD Serono, Roche/Genentech, Sanofi Genzyme, Novartis, Teva (research support to the institution); Alexion, Celgene, Roche/Genentech, Sanofi Genzyme (consulting fee); Biogen, EMD Serono, Novartis (consulting fee, research support to the institution).

**Unit cost trend** is defined as the percent change in unit cost and is determined on a per-member-per-year (PMPY) basis. Adherence, Disease-modifying treatments in MS, Economic issues and MS

**Background:** Multiple sclerosis (MS) affects ~1 million people in the United States and is the fourth largest specialty drug spend. Over the years many disease-modifying therapies (DMTs) have come to market, resulting in increased drug choice and spend. Patients often struggle with the cost and chronicity of these therapies. **Objectives:** Evaluate DMT utilization trends, contributing to a commercial MS population.

**Methods:** We analyzed DMT use data of 34.2 million beneficiaries utilizing a pharmacy benefit plan administered by a large pharmacy benefit manager for the 2-year period 2017-2018. Unit cost trend is defined as the cost and chronicity of these therapies.

**Results:** DMT use data of 34.2 million beneficiaries were obtained from a pharmacy benefit plan administered by a large pharmacy benefit manager for the 2-year period 2017-2018. Unit cost trend is defined as the percent change in unit cost and is determined on a per-member-per-year (PMPY) basis. Adherent patients were defined as an average medication possession ratio of ≥80%. Switching occurred when an alternative DMT claim occurred after the index DMT drug claim. **Result:** DMT prevalence was 0.09% in 2018. PMPY spend for DMT to treat MS decreased 4.8% in 2018, driven by a 7.8% utilization decrease. Utilization trend was negative over years, with reduced utilization of dimethyl fumarate (Gilenya [fingolimod], and Avonex (interferon beta-1a) accounted for more than 44% of DMT use. PMPY spend for DMT to treat MS decreased 4.8% in 2018, 4.5% in 2019, and 2.6% in 2020 (Figure 1). Subgroup analyses of patients in EXPAND with/without lesion activity or relapses prior to screening were also performed and will be presented. Analyses were for hypothesis generation without multiple comparison adjustment. 

**Results:** Treatment effects on EDSS (ΔEDSS = 0.81, p < .05) were seen on both MI and C. In SPMS, effects on MI from M6; effects on C were mostly nonsignificant. In EXPAND (N = 1645; siponimod, n = 1099; placebo, n = 546), overall treatment effects were detected over 27M for EDSS (P < .001), MI (P < .014), and C (P < .021). Significant EDSS were seen on MI (all P < .01) at M9 (−0.28), M15 (−0.34), and M18 (−0.34), and on C at M18 (−0.24, P < .05) and M27 (−0.24, P < .01). Significant effects on both MI and C. In EXPAND with/without lesion activity or relapses prior to screening were also performed and will be presented. Analyses were for hypothesis generation without multiple comparison adjustment. 

**Results:** Treatment effects on EDSS (ΔEDSS = 0.81, p < .05) were seen on both MI and C. In SPMS, effects on MI from M6; effects on C were mostly nonsignificant. In EXPAND (N = 1645; siponimod, n = 1099; placebo, n = 546), overall treatment effects were detected over 27M for EDSS (P < .001), MI (P < .014), and C (P < .021). Significant EDSS were seen on MI (all P < .01) at M9 (−0.28), M15 (−0.34), and M18 (−0.34), and on C at M18 (−0.24, P < .05) and M27 (−0.24, P < .01). Significant effects on both MI and C. In EXPAND with/without lesion activity or relapses prior to screening were also performed and will be presented. Analyses were for hypothesis generation without multiple comparison adjustment. 

**Results:** Treatment effects on EDSS (ΔEDSS = 0.81, p < .05) were seen on both MI and C. In SPMS, effects on MI from M6; effects on C were mostly nonsignificant. In EXPAND (N = 1645; siponimod, n = 1099; placebo, n = 546), overall treatment effects were detected over 27M for EDSS (P < .001), MI (P < .014), and C (P < .021). Significant EDSS were seen on MI (all P < .01) at M9 (−0.28), M15 (−0.34), and M18 (−0.34), and on C at M18 (−0.24, P < .05) and M27 (−0.24, P < .01). Significant effects on both MI and C. In EXPAND with/without lesion activity or relapses prior to screening were also performed and will be presented. Analyses were for hypothesis generation without multiple comparison adjustment. 

**Results:** Treatment effects on EDSS (ΔEDSS = 0.81, p < .05) were seen on both MI and C. In SPMS, effects on MI from M6; effects on C were mostly nonsignificant. In EXPAND (N = 1645; siponimod, n = 1099; placebo, n = 546), overall treatment effects were detected over 27M for EDSS (P < .001), MI (P < .014), and C (P < .021). Significant EDSS were seen on MI (all P < .01) at M9 (−0.28), M15 (−0.34), and M18 (−0.34), and on C at M18 (−0.24, P < .05) and M27 (−0.24, P < .01). Significant effects on both MI and C. In EXPAND with/without lesion activity or relapses prior to screening were also performed and will be presented. Analyses were for hypothesis generation without multiple comparison adjustment. 

**Results:** Treatment effects on EDSS (ΔEDSS = 0.81, p < .05) were seen on both MI and C. In SPMS, effects on MI from M6; effects on C were mostly nonsignificant. In EXPAND (N = 1645; siponimod, n = 1099; placebo, n = 546), overall treatment effects were detected over 27M for EDSS (P < .001), MI (P < .014), and C (P < .021). Significant EDSS were seen on MI (all P < .01) at M9 (−0.28), M15 (−0.34), and M18 (−0.34), and on C at M18 (−0.24, P < .05) and M27 (−0.24, P < .01). Significant effects on both MI and C. In EXPAND with/without lesion activity or relapses prior to screening were also performed and will be presented. Analyses were for hypothesis generation without multiple comparison adjustment. 

**Results:** Treatment effects on EDSS (ΔEDSS = 0.81, p < .05) were seen on both MI and C. In SPMS, effects on MI from M6; effects on C were mostly nonsignificant. In EXPAND (N = 1645; siponimod, n = 1099; placebo, n = 546), overall treatment effects were detected over 27M for EDSS (P < .001), MI (P < .014), and C (P < .021). Significant EDSS were seen on MI (all P < .01) at M9 (−0.28), M15 (−0.34), and M18 (−0.34), and on C at M18 (−0.24, P < .05) and M27 (−0.24, P < .01). Significant effects on both MI and C. In EXPAND with/without lesion activity or relapses prior to screening were also performed and will be presented. Analyses were for hypothesis generation without multiple comparison adjustment.
(DXT26) Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets in the CLARITY and CLARITY Extension Studies

Gavin Giovanni,1 Giancarlo Comi,2 Kattil Rammohan,3 Peter Rieckmann,4 Patrick Vermersch,5 Fernando Dangond,6 Birgit Keller,7 Dominic Jack7
1Queen Mary University of London, London, United Kingdom; 2Department of Neurology and Institute of Experimental Neurology, Universita Vito-Salute San Raffaele, Milan, Italy; 3Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 4Department of Neurology, Medical Park Loipl, and University of Erlangen, Erlangen, Germany; 5University of Lille, Lille, France; 6EMD Serono Inc, Billerica, MA; 7Merck KGaA, Darmstadt, Germany

Background: Treatment with cladribine tablets 10 mg [cumulative dose 3.5 mg/kg [CT3.5] over 2 years] in CLARITY and CLARITY Extension reduced relapse rate and slowed disability progression vs placebo in patients with relapsing-remitting multiple sclerosis (RRMS).

Objectives: The objective of this post hoc analysis was to evaluate long-term disease stability in patients with Expanded Disability Status Scale (EDSS) 3.5 mg/kg [CT3.5] over 2 years of active treatment as expected. Recovery time from lymphopenia was studied in older and younger patients relative to placebo-treated patients.

Methods: Patients randomized to CT3.5 in CLARITY and then randomized to placebo in CLARITY Extension, with at least 1 postbaseline EDSS measurement, were included (CT3.5; n = 98).

This analysis assessed EDSS score over time (from CLARITY randomization to end of follow up in CLARITY Extension) including the bridging interval between studies) at 6-month intervals, and separately time to 3- and 6-month confirmed EDSS score progression from CLARITY baseline. EDSS score worsening or improvement in each year was defined as any increase or decrease, respectively, in minimum EDSS score at 6-month intervals, all other classes were classified as stable. An increase or decrease was defined as an EDSS score change of 1.5 points (baseline EDSS 0), 1 point (baseline EDSS ≤5), or 0.5 point (baseline EDSS ≤6.5).

Results: Five years after CLARITY baseline, median EDSS remained stable compared with baseline values. Median EDSS score (95% CI) for patients in the CP3.5 group was 2.5 [2.0-3.5] compared with 3.0 [2.5-3.5] at baseline. In each 12-month period, EDSS score stability [≤1.5 points] in 50% of patients, improvement in 21%-30% of patients, and worsening in 0%-25%. During year 5 in the CP3.5 group, EDSS stability was observed in 53.9% of patients, improvement in 21.3%, and worsening in 24.7%. Less than 30% of patients reached 3- or 6-month confirmed EDSS progression by year 5.

Conclusions: EDSS score was stable up to 5 years post-CLARITY baseline for the CP3.5 group. Between 20%-30% of patients demonstrated improvement in EDSS score vs baseline each year.

Supported by: None

Disclosure: Gavin Giovanni: AbbVie, Actelion, Almirall, Asta Bio, Bayer Schering Pharma, Five Prime, Genzyme (contracted research); Almirall, Pfizer Inc, Protein Discovery Laboratories, Sanofi Genzyme, Teva Pharmaceuticals Industries Ltd, UCB, Vertex Pharmaceuticals (consulting fee); Biogen, Ironwood, Merck and Co, Novartis (consulting fee, unrelated research support).


Peter Rieckmann: Bayer Schering Pharma, Biogen, Boehringer-Ingelheim, Genzyme, Merck, Novartis, Sanofi-Aventis, Serum Symposia International Foundation, Teva Pharmaceutical Industries (speakers’ bureau); Patrick Vermersch: Almirall, Celgene, Novartis, Roche (consulting fee); Bayer, Biogen, Merck KGaA, Sanofi Genzyme (consulting fee, research support).

Fernando Dangond: EMD Serono, Inc (a business of Merck KGaA, Darmstadt, Germany) (salary); Birgit Keller-Dominic Jack: Merck KGaA (salary).

Keywords: Disease-modifying treatments in MS, Immunology and MS.
Background: In the phase 3 CLARITY study, patients with relapsing-remitting multiple sclerosis (MS) treated with cladribine tablets (CTs) 10 mg [3.5 mg/kg (CT3.5) or 5.25 mg/kg cumulative dose over 2 years], showed significant reductions in annualized relapse rate (P < .001), time to 3-month (mo) sustained change in Expanded Disability Status Scale (EDSS) score (P ≤ .03), and lesion activity on brain magnetic resonance imaging (MRI), all P < .001 vs placebo. However, the efficacy of CTs has not been fully characterized in patients transitioning to active second- or third-line therapy, for which baseline EDSS scores of ≥3.5 or ≤3.0, respectively, can be used as a proxy definition. Objectives: To examine differences between placebo and CT3.5 on clinical and MRI end points and in attainment of no evidence of disease activity (NEDA) in patients with baseline EDSS scores of ≥3.5 or ≤3.0 in CLARITY: Methods: In this post hoc analysis, week 96 data from CLARITY were retrospectively analyzed across patients with baseline EDSS score ≥3.5 or ≤3.0 for relapses, 3- or 6-mo confirmed disability progression (CDP, per EDSS score changes), new T1 gadolinium-enhancing (Gd+) lesions, active T2 lesions, and NEDA. Results: Baseline characteristics were evenly distributed across treatment groups. Relapse, T1 Gd+ lesion, and T2 lesion numbers were greater in placebo-treated vs CT3.5-treated patients for both baseline EDSS groups (all P < .0001, nominal significance) at week 96. For patients with baseline EDSS score ≥3.5, CT3.5 treatment resulted in improvements in qualifying relapses (Kaplan-Meier estimates at last event: 78.3% vs 60.3%), 3-month CDP (83.5% vs 69.4%), and 6-month CDP (88.1% vs 78.2%) vs placebo. Differences between CT3.5 and placebo for the baseline EDSS ≥3.5 group were: 81.1% vs 61.0% in qualifying relapse, 86.3% vs 80.6% in 3-month CDP, and 92.0% vs 87.2% in 6-month CDP. Odds ratios (ORs) favored CT3.5 vs placebo for NEDA based on either 3-month (OR: 4.40) and 6-month CDP (OR: 4.11) in the baseline EDSS ≥3.5 group and in the baseline EDSS ≤3.0 group (ORs: 3.0 and 2.9 for OR for 6-month CDP: 4.62; all P < .0001, nominal significance). Conclusions: CT treatment resulted in similar improvements in relapse and MRI outcomes regardless of patient baseline EDSS score. The effect of CTs on NEDA composites was also favorable across patients with baseline EDSS score ≥3.5 or ≤3.0.

Supported by: None

Disclosure: Giancarlo Conci; Almirall SpA, Biogen, Biogen Italia SpA, Celgene Group, EXCEMED, H. Hoffman-La Roche, Forward Pharma, Genzyme Corporation, Genzyme Europe, MedDay, Merck KGaA, Merck Serono SpA, Novartis, Roche SpA, Sanofi Genzyme, Teva Italia SpA, Teva Pharmaceutical Industries Ltd (consulting fee). Gabriel Paredes; AbbVie, Adamas, Alkermes, Sanofi Genzyme, Teva (research support); Alexion, Celgene, Sanofi Genzyme (consulting fee); Biogen, EMD Serono, Novartis, Roche/Genentech (consulting fee, research support). Fernando Dangond, Julie Aldridge, Caroline Lemieux: EMD Serono, Inc (a business of Merck KGaA, Darmstadt, Germany) (salary). Kazuti Ramachandran: Acorda, Biogen, EMD Serono, Genzyme, Novartis, Roche/Genentech, Sanofi-Aventis, Teva Neurosciences (speakers’ bureau).

Keywords: Disease-modifying treatments in MS

(DXT29) ACAPELLA: Real-World Experience with Ocrelizumab: An Observational Study Evaluating Safety in Patients with Relapsing and Progressive Multiple Sclerosis, Year 3 Data

Hannah M. Geils, Indra C. Stribling, Joshua D. Katz, Ellen S. Lathi

The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis (MS). Immunoglobulin levels were monitored during the phase 3 trials, and 1.5% of patients developed low immunoglobulin G (IgG) values after 2-3 years of OCR treatment, potentially increasing the risk of infections. The JC virus (JCV) antibody index used to stratify PML risk in patients treated with natalizumab was not studied and the impact of long-term B-cell suppression on JCV and IgG titers is unknown. Objectives: As part of the ACAPELLA trial, a prospective study with a primary objective of assessing OCR-associated adverse events in a real-world MS population, we sought to evaluate the impact of OCR treatment on immunoglobulin levels and JCV antibody titers.

Results: As of December 2019, 291 patients have been treated with OCR and enrolled in ACAPELLA: 181 have been treated for at least 12 months, 131 have been treated for at least 18 months, and 84 subjects have reached 24 months. Two hundred eighty-one of the total 291 subjects had IgG levels drawn at baseline. Twenty-seven subjects (10%) had IgG levels below the lower limit of normal of baseline. Of the 27 patients with low IgG at baseline, 12 subjects had IgG levels <1.5. In our 2-year data, 3 patients had a change in JCV status from positive to negative between 12 and 24 months of treatment duration. Year 3 data are characterized in the poster. Conclusions: The frequency of persistent hypogammaglobulinemia was low in this cohort of patients and thus far has not been associated with an increased risk of infection. Three patients had a change in JCV status from positive to negative, and the effect of JCV index in the remaining subjects is further characterized.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Disease-modifying treatments in MS, Immunology and MS, Ocrelizumab

(DXT30) ACAPELLA: Hypogammaglobulinemia and JC Virus Status in Ocrelizumab-Treated Patients, Year 2 Data

Hannah M. Geils, Indra C. Stribling, Joshua D. Katz, Ellen S. Lathi

The Elliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis (MS). Immunoglobulin levels were monitored during the phase 3 trials, and 1.5% of patients developed low immunoglobulin G (IgG) values after 2-3 years of OCR treatment, potentially increasing the risk of infections. The JC virus (JCV) antibody index used to stratify PML risk in patients treated with natalizumab was not studied and the impact of long-term B-cell suppression on JCV and IgG titers is unknown. Objectives: As part of the ACAPELLA trial, a prospective study with a primary objective of assessing OCR-associated adverse events in a real-world MS population, we sought to evaluate the impact of OCR treatment on immunoglobulin levels and JCV antibody titers.

Results: As of December 2019, 291 patients have been treated with OCR and enrolled in ACAPELLA: 181 have been treated for at least 12 months, 131 have been treated for at least 18 months, and 84 subjects have reached 24 months. Two hundred eighty-one of the total 291 subjects had IgG levels drawn at baseline. Twenty-seven subjects (10%) had IgG levels below the lower limit of normal of baseline. Of the 27 patients with low IgG at baseline, 12 subjects had IgG levels <1.5. In our 2-year data, 3 patients had a change in JCV status from positive to negative between 12 and 24 months of treatment duration. Year 3 data are characterized in the poster. Conclusions: The frequency of persistent hypogammaglobulinemia was low in this cohort of patients and thus far has not been associated with an increased risk of infection. Three patients had a change in JCV status from positive to negative, and the effect of JCV index in the remaining subjects is further characterized.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Disease-modifying treatments in MS, Immunology and MS, Ocrelizumab

(DXT31) Impact of Eculizumab on Hospitalization Rates and Relapse Treatment in Patients with Neuromyelitis Optica Spectrum Disorder: Phase 3 PREVENT Study

Ho Jin Kim,1 Sean J. Pittuck,2 Achim Berthele,3 Kazuo Fujihara,4 Michael Levy,5 Jacqueline Palace,1 Ichiro Nakoshima,6,7 Murad Terzi,8 Natalia Totalyan,9 Shanzhi Viswanathan,10 Kai-Chen Wang,11 Amy Pace,12 Kenji P. Fujita,16 Marcus Yountz,16 Roisin Armstrong,16 Dean Wingerchuk10

Abstract: The objective of the PREVENT study was to assess the safety and efficacy of intravenous eculizumab in patients with active relapsing-remitting neuromyelitis optica spectrum disorder (NMOSD). A total of 342 patients with relapsing-remitting NMOSD were randomized to receive either eculizumab on a monthly basis or placebo for 2 years. The primary end point was the proportion of patients who had at least one relapse over the course of 2 years. The results of the PREVENT study showed that eculizumab significantly reduced the risk of relapse compared to placebo and improved clinical outcomes in patients with relapsing-remitting NMOSD. In addition, eculizumab was associated with a reduction in hospitalization rates and an overall improvement in quality of life. These findings support the use of eculizumab in the management of relapsing-remitting NMOSD.
Background: Relapses resulting in hospitalization are common in patients with the rare autoimmune inflammatory disease neuromyelitis optica spectrum disorder (NMOSD). The randomized, double-blind, placebo-controlled PREVENT study (trial registration: NCT01892345) assessed the safety and efficacy of eculizumab in aquaporin-4 immunoglobulin G (AQP4-IgG)–positive NMOSD. Eculizumab significantly reduced the risk of adjudicated relapse compared with placebo (primary end point).

Objectives: To evaluate rates of relapse-related hospitalization and associated treatment in patients with AQP4-IgG–positive NMOSD receiving eculizumab vs placebo in the PREVENT study.

Methods: Patients with AQP4-IgG–positive NMOSD were randomized 2:1 to receive eculizumab (maintenance dose, 1200 mg/2 weeks, n = 96) or placebo (n = 48) without stable corticosteroid treatment in the immediate pre-index hospitalization period. Results: The median exposure to treatment was 89.43 weeks for eculizumab and 41.29 weeks for placebo. The overall annualized hospitalization rates were 0.26 and 0.78 (P < .0001) in the eculizumab and placebo groups, respectively. The annualized relapse-related hospitalization rate was significantly lower in the eculizumab group than in the placebo group: 0.04 vs 0.31, respectively (P < .0001). The annualized relapse-related use of intravenous methylprednisolone, plasma exchange, and high-dose oral corticosteroids for eculizumab vs placebo was 0.07 vs 0.42 (P < .0001), and 0.04 vs 0.11 (P = .0733), respectively.

Conclusions: Treatment with eculizumab significantly reduced relapse-related hospitalizations and their associated treatment rates in patients with AQP4-IgG–positive NMOSD vs placebo, which may have a favorable effect on health-resource utilization.

Disclosure: None

Supported by: None

(DXT33) ACAPELLA: B-Cell Reconstitution in Ocrelizumab-Treated Patients

Objectives: To determine the frequency of patients on OCR who had clinical or magnetic resonance imaging (MRI) evidence of ICT, compared to 8 subjects who did not have B-cell reconstitution.

Methods: As of December 2019, 291 patients had been treated with OCR and enrolled in ACAPELLA: 181 had been treated for at least 12 months, 131 had been treated for 18 months, and 84 subjects had reached 24 months. Of the 291 subjects, 207 had CD19 values drawn at an infusion. One hundred eighteen subjects (57%) displayed ≥1 cell/μL; 81 subjects (39%) had between 1-15 cells/μL; 32 (16%) between 16-79 cells/μL, and 5 (2%) ≥79 cells/μL. Thirteen patients with B-cell reconstitution at 12 months had early reconstitution with further infusions. Two of the subjects with CD19 values >15 cells/μL had clinical or magnetic resonance imaging evidence of ICT, compared to 8 subjects who did not have B-cell reconstitution.

Conclusions: Although many patients displayed some B-cell repopulation prior to their next dose (113 subjects), CD19 counts of >79 cells/μL were uncommon (5 subjects). Subjects with early B-cell reconstitution at 1 infusion were likely to continue to show early repopulation at future infusions. Thus far, we have found no significant correlation between B-cell repopulation and either disease activity or adverse events.

Disclosure: None

Supported by: None

(DXT34) Revealing the Immune Cell Subtype Reconstitution Profile in Cladribine-Treated Patients at the 96-Week Timepoint (CLARITY) Using Deconvolution Algorithms

Irina Kalatskaya1, Giovino Giovanni2, Thomas P. Leist1, Per Saelberg-Sorensen3, Ursula Boscher4, Julie DeMartino5, Alex Rolfe1

Background: Cladribine tablets (CTs) cumulative licensed dose of 3.5 mg/kg (CT3.5), administered as 2 short oral courses over 2 years, transiently reduces total lymphocyte counts, with median values returning to normal range within 11 months and median B cells by 6 months. Clinical efficacy of CTs is sustained beyond lymphocyte recovery. Flow cytometric observations suggest long-lasting reductions in memory B cells. Objectives: Characterize immune cell transcriptomic signatures in peripheral blood from patients with relapsing-remitting multiple sclerosis during immune reconstitution at 96 weeks in the CLARITY study using advanced computational algorithms to correlate these signatures with corresponding flow cytometry data of main lymphocyte subtypes. Methods: Gene expression data (U133 Plus 2.0 array) in whole blood samples at 96 weeks were available from patients randomized to placebo (n = 57), CT3.5 (n = 62), or CT 5.25 mg/kg (CT25.5, n = 70). These were analyzed with the CIBERSORT deconvolution algorithm (to estimate absolute fractions of 22 immune cell subtypes) and the xCell signature-based method (cell type enrichment analysis for 43 immune cell subtypes).

Keywords: Disease-modifying treatments in MS, Ocrelizumab

Disclosure: Nothing to disclose

Supported by: None

(Research) Medica, Restone (consulting fee); Ternumo BCT, Alexion Pharmaceuticals (fees for non-CME/CE services received directly from commercial interest or its agent).

Keywords: Hospitalization in NMOSD

Disclosure: Hospitalization in NMOSD

Supported by: None

(DXT33) ACAPELLA: B-Cell Reconstitution in Ocrelizumab-Treated Patients

Indian C. Sribuling, Hannah M. Geils, Joshua D. Katz, Ellen S. Lathi
The Eliot Lewis Center for Multiple Sclerosis Care, Wellesley, MA

Background: Ocrelizumab (OCR) is a humanized anti-CD20 monoclonal antibody approved for the treatment of relapsing remitting (RRMS) and primary progressive multiple sclerosis (PPMS). In the OPERA trials, circulating CD19+ B-cell counts dropped to 0 within 14 days of OCR infusion. Median time to repletion, defined as ≥79 cells/μL, was 72 (range 33-86) days. Up to 5% of patients showed B-cell repletion during treatment. We sought to determine the frequency of patients on OCR who have significant B-cell reconstitution at the time of their next 6-month dose, and to determine if there is a correlation between early B-cell reconstitution and disease breakthrough or adverse events (AEs).

Objectives: As part of the ACAPELLA trial, a prospective study with a primary objective of assessing OCR-associated AEIs in a real-world multiple sclerosis population, we sought to evaluate the frequency and duration of early B-cell reconstitution and its relationship to disease activity and AEs.

Methods: All subjects receiving OCR at the Eliot Lewis Center since March 2017 who consented to participate had serum immunoglobulin levels, JC virus testing, and lymphocyte subset counts on the day of each infusion prior to receiving OCR. Subjects were followed up prospectively and monitored for the occurrence of infections and other serious AEs.

Results: As of December 2019, 291 patients had been treated with OCR and enrolled in ACAPELLA: 181 had been treated for at least 12 months, 131 had been treated for 18 months, and 84 subjects had reached 24 months. Of the 291 subjects, 207 had CD19 values drawn at an infusion. One hundred eighteen subjects (57%) displayed ≥1 cell/μL; 81 subjects (39%) had between 1-15 cells/μL; 32 (16%) between 16-79 cells/μL, and 5 (2%) ≥79 cells/μL. Thirteen patients with B-cell reconstitution at 12 months had early reconstitution with further infusions. Two of the subjects with CD19 values >15 cells/μL had clinical or magnetic resonance imaging evidence of ICT, compared to 8 subjects who did not have B-cell reconstitution.

Conclusions: Although many patients displayed some B-cell repopulation prior to their next dose (113 subjects), CD19 counts of >79 cells/μL were uncommon (5 subjects). Subjects with early B-cell reconstitution at 1 infusion were likely to continue to show early repopulation at future infusions. Thus far, we have found no significant correlation between B-cell repopulation and either disease activity or adverse events.

Disclosure: None

Supported by: None
Wilcoxon rank sum tests compared between treatment arms. Spearman rank correlation coefficient was used to measure the relationship between signatures and cell counts. P values < .05 were considered nominally significant. Results: At 96 weeks, the relative abundance of naive B cells in CT3-5 and CT5-25-treated patients was significantly higher vs placebo. Plasma cells and class-switched memory B cells were significantly reduced with CTs vs placebo. The M2 macrophage signature was significantly enriched with CTs vs placebo. Cell abundance of both naive and memory CD4+ and CD8+ was significantly reduced with CTs vs placebo. Deconvolution signature scores were positively and significantly correlated with corresponding flow cytometry data (r: 0.68-0.72 CD19+ B cells, 0.71 CD4+ T cells, 0.67-0.69 CD8+ T cells). Conclusions: At 96 weeks following CT treatment in year 2, changes in leukocyte subsets suggested a shift towards an anti-inflammatory phenotype were detected.

Supported by: None

Disclosure: Irina Kalatskaya, Julie DeMartino, Alex Rolfe; EMD Serono, Inc (a business of Merck KGaA, Darmstadt, Germany) (salary); Gaetan Giovanni-anni; AbbVie, Acadzel, Abnirall, Astra Bio, Bayer Schering Pharma, Free Prime, GlaxoSmithKline, GW Pharma, Merck KGaA, Pfizer Inc; Protein Discovery Laboratories, Sanofi Genzyme, Teva Pharmaceuticals Industries Ltd, UCB, Ver- tex Pharmaceuticals (consulting fee); Biogen, Ironwood, Merck and Co, Novartis (consulting fee, unrelated research support). Thomas P. Leit; Biogen, EMD Serono, GenentechRoche, Janssen, Novartis, Teva (consulting fee), Per Sjoelberg-Sverrensen: Biogen (advisory board, research support); Biogen, Sanofi-Aventis (speakers’ bureau); Genzyme (research support, speakers’ bureau), Glaxosmith- kline (advisory board, steering committees); MedDay Pharmaceuticals (advisory board); Merck KGaA, Novartis, Teva (advisory board, research support, speakers’ bureau, steering committees); Roche (research support). Ursula Bucher; Merck Serono SA (a business of Merck KGaA, Darmstadt, Germany) (salary).

Keywords: Disease-modifying treatments in MS, Immunology and MS

(DXT35) Real-World Experience with Ocrelizumab: A Safety Analysis

Jamie Bolling,1 Ryan McNiff,1 Aaron Carlson,1 Carlos Vervloet Sollero,1 Trisham V. Gyang1

1Neurology, University of Florida, Gainesville, FL; 2U Health, University of Florida, Gainesville, FL

Background: Ocrelizumab is a humanized monoclonal antibody that selectively targets B lymphocytes, resulting in their depletion. The US Food and Drug Administration approved its use in 2017 for relapsing-remitting and primary-progressive multiple sclerosis (MS). Pooled safety analysis from phase 3 clinical trials revealed an increase incidence of infection, infusion reaction (IR), and malignancy in ocrelizumab patient groups. Objectives: We present a real-world safety analysis of ocrelizumab in clinical practice. Methods: The University of Florida MS Clinic identified subjects as those treated with ocrelizumab prescribed in clinic through electronic medical records. The study collected longitudinal safety laboratories including complete blood count, lymphocyte subset counts, and immunoglobulin levels. The study also captured clinical data including disease course, prior disease-modifying therapies, IR, and occurrence of major clinical events. Analysis of the data assessed trends in laboratories and occurrence of adverse events (AEs). Results: Data from 39 of a potential 200 subjects suggests that white blood cell, neutrophil, lymphocyte, and T-cell counts continuously produce the most abnormal results after initiation of ocrelizumab. Nine subjects had urinary tract infections, and 2 subjects had respiratory tract infections. A case of sepsis and appendicitis resulted in 1 hospitalization. There were 12 IRs reported, and 1 subject discontinued treatment due to bronchospasm. Only 1 subject reported a diagnosis of intraductal carcinoma. Conclusions: The data reveals that infections and IRs are common among patients treated with ocrelizumab, while malignancies occur but are rare. Of infections, urinary tract infections pose the largest concern, although noninfectious malignancies and secondary infections also occurred. Although IRs were common, they tended to be acute and easily resolved with the exception of 1 discontinuation. There is a need for more data to corroborate trends in laboratory values and potential correlation with AEs. Early findings suggest a significant trend in abnormal laboratory values, reported infections, and IRs.

Supported by: None

Disclosure: Jamie Bolling, Ryan McNiff, Carlos Vervloet Sollero, Trishan V. Gyang; Sanofi Genzyme (consulting fee), Sanofi-Aventis (contracted research); Sanofi Genzyme (consulting fee).

Keywords: Comprehensive care and MS, Disease-modifying treatments in MS, Treatment safety analysis in MS

(DXT36) Effect of Evobrutinib, a Bruton’s Tyrosine Kinase Inhibitor, on Immune Cell and Immunoglobulin Levels over 48 Weeks in a Phase 2 Study in Relapsing Multiple Sclerosis

Xavier Montalban,1,3 Jamie Shaw,1 Sana Syed,2 Fernando Dangond,2 Emily C. Martin,3 Roland Grenningloh,1 Martin S. Weber,4 on behalf of the Evobrutinib Phase 2 Study Group

1Vall d’Hebron University Hospital, Barcelona, Spain; 2St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 3EMD Serona Research & Development Institute, Inc (a business of Merck KGaA, Darmstadt, Germany), Berliner, HAI; 4Institute of Neurology and Department of Neurology, University Medical Center, Göttingen, Germany

Background: Bruton’s tyrosine kinase (BTK) plays an important role in proinflammatory pathways potentially involved in multiple sclerosis (MS). Consequently, BTK inhibition is being investigated as a potential therapeutic approach for MS. Evobrutinib, a highly selective BTK inhibitor (BTKi), has a dual mechanism of action, affecting both B cells and monocytes through inhibition of B-cell receptor, Fc receptor, and granulocyte–macrophage colony-stimulating factor receptor signaling, and has demonstrated clinical efficacy in MS in a phase 2 study (trial registration: NCT02975349; Montalban et al, ECTRIMS 2018 [P322]).

Objectives: To examine the effect of evobrutinib on immune cells and immunoglobulins (Ig) over 48 weeks. Methods: Patients aged 18-65 with active relapsing–remitting MS or secondary progressive MS and superimposed relapses were randomized to receive either double-blind evobrutinib (25 mg once daily [qd], 75 mg qd, or 75 mg twice daily), placebo, or open-label dimethyl fumarate 240 mg (reference arm). After 24 weeks, placebo-treated patients were switched to evobrutinib 25 mg qd. No other treatment arms were included in the original allocation. Safety of evobrutinib, including assessment of B-cell count and Ig level, was a key secondary end point; investigations of the effects of evobrutinib on B-cell subsets, T-cell subsets, and natural killer cells in peripheral blood over 48 weeks were exploratory. Results: Of 267 patients randomized to treatment, 227 patients completed 48 weeks of treatment. No clinically relevant changes were found in any treatment group. Conclusions: Data from 39 of a potential 200 subjects suggest that white blood cell, neutrophil, lymphocyte, and T-cell counts continuously produce the most abnormal results after initiation of ocrelizumab. Nine subjects had urinary tract infections, and 2 subjects had respiratory tract infections. A case of sepsis and appendicitis resulted in 1 hospitalization. There were 12 IRs reported, and 1 subject discontinued treatment due to bronchospasm. Only 1 subject reported a diagnosis of intraductal carcinoma. Conclusions: The data reveals that infections and IRs are common among patients treated with ocrelizumab, while malignancies occur but are rare. Of infections, urinary tract infections pose the largest concern, although noninfectious malignancies and secondary infections also occurred. Although IRs were common, they tended to be acute and easily resolved with the exception of 1 discontinuation. There is a need for more data to corroborate trends in laboratory values and potential correlation with AEs. Early findings suggest a significant trend in abnormal laboratory values, reported infections, and IRs.

Supported by: EMD Serono, Inc, Rockland, MA, USA, a business of Merck KGaA, Darmstadt, Germany

Disclosure: Xavier Montalban; Biogen, Merck Serono, Sanofi Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, Roche, Celgene, Actelion, National MS Society, MS International Federation, EXCEMED (speaking honoraria and travel expenses for participation in scientific meetings, steering committee member of clinical trials or participation in advisory boards of clinical trials). Jamie Shaw; Sana Syed, Fernando Dangond, Emily C. Martin, Roland Grenningloh; EMD Serono (salary). Martin S. Weber; Biogen, Merck Serono, Novartis, Roche, Teva, Bayer, Genzyme (travel funding and/or speaker honoraria); Deutsche Forschungsge- meinschaft (DFG; WE 354751-5), Novartis, Teva, Biogen, F. Hoffmann-La Roche, Merck, ProFuture Programm of the Universitätsmedizin Göttingen (research support); PLoS One (editor).

Keywords: Clinical trials, Disease-modifying treatments in MS, Immunology and MS

(DXT37) Effect of Teriflunomide on Brain Volumetric Loss in Patients with Relapsing Multiple Sclerosis of Differing Ages in TEMSO

Jiwan Oh,1 Jens Wuerfel,2 Bhupendra O. Khatri,1 Aaron E. Miller,1 Jihad Said Inshasi,5 Albert Saiz,1 Alex L. Lublin,2 Elizabeth M. Poole,7 Till Sprenger8,9

1University of Toronto, Toronto, ON, Canada; 2Medical Imaging Analysis Center (MIAC AG) and Department of Biomedical Engineering, University of Basel, Basel, Switzerland; 3Center for Neurological Disorders at Wheaton Franciscan Healthcare, Milwaukee, WI; 4Icahn School of Medicine at Mount Sinai, The Corinne Goldsmith Dickinson Center for Multiple Sclerosis, New York, NY; 5Dubai Medical College, Dubai, United Arab Emirates; 6Department of Neurology, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; 7Sanofi, Cambridge, MA; 8DKD Helios Klinikum Wiesbaden, Wiesbaden, Germany; 9University Hospital Basel, Basel, Switzerland

Supported by: None

Disclosure: Jamie Bolling, Ryan McNiff, Carlos Vervloet Sollero, Trisham V. Gyang; Sanofi Genzyme (consulting fee), Sanofi-Aventis (contracted research); Sanofi Genzyme (consulting fee).

Keywords: Comprehensive care and MS, Disease-modifying treatments in MS, Treatment safety analysis in MS

International Journal of MS Care
Background: Teriflunomide significantly reduced brain volume loss (108 weeks). BVL was assessed as annualized percentage brain volume change (PBVC) from baseline using SIENA at years 1 and 2 in patients stratified by age: ≤25 years, >25 to 35 years, >35 to 45 years, and ≥45 years. Treatment group comparisons of median PBVC values were made via ranked analysis of covariance, adjusted for region, age, Expanded Disability Status Scale stratum, and baseline normalized brain volume. Data are presented at year 2 for all patients treated with teriflunomide 14 mg vs placebo, and for patients aged >45 years treated with teriflunomide 14 mg vs placebo. Results: The median annualized PBVC in all patients was 30.6% lower in the teriflunomide 14 mg group (n = 235) vs placebo (n = 234; P = .0001). In patients >45 years, the median annualized PBVC was 35.0% lower in the teriflunomide 14 mg group (n = 49) vs placebo (n = 48; P = .0098). Conclusions: Teriflunomide decelerated disease-related brain atrophy in patients with RMS compared with placebo, including in patients aged >45 years.

Supported by: Sanofi

Disclosure: Jianwei Oi: Biogen, Roche (consulting or speaking fees, research support); Celgene, EMD Serono, Genzyme, Novartis (consulting or speaking fees); Sanofi (scientific advisor). Actelion, Biogen, Genentech, Novartis, Sanofi (consulting/honorarium [consulting work, speaker programs]); Alexion, Biogen, Genentech, Novartis, Sanofi (consulting/honorarium [consulting work, speaker programs]), contracted research); Ra Pharmaceuticals (consulted research); Aaron E. Miller: Accordant Health Services, Adams Pharmaceuticals, Celgene, EMD Serono, Genentech/Roche, Mallinckrodt Pharmaceuticals [Questcor], Mapix Pharma [consulting fees]; Biogen, Novartis (consulting fees, contracted research); Genentech, Questcor, Roche, Sanofi (contracted research). Ihab Said Ismail: Nothing to disclose. Albert Saiz: Bayer, Biogen, Merck-Serono, Novartis, Roche, Sanoﬁ, Teva (consulting or speaking fees, research support); Bayer, Genentech, Merck, Novartis, Roche, Sanoﬁ, Teva (consulting fees, speaker programs); Ludwig Kappos: University Hospital Basel has received the following, used exclusively for research support: steering committee, advisory board, and consultancies from Actelion, Alexion, Bayer, Biogen, Biogen, Genentech, Genzyme, Merck, Novartis, Roche, Swiss National Research Foundation (license fees for Neurostatus products, grants); Bayer, Biogen, Merck, Novartis, Sanofi, Teva (consulting fees, speaker programs); Ludwig Kappos’ institution (University Hospital Basel) has received the following, used exclusively for research support: steering committee, advisory board, and consultancies from Actelion, Alexion, Bayer, Biogen, Biogen, Genentech, Genzyme, Merck, Novartis, Roche, Swiss National Research Foundation (license fees for Neurostatus products, grants).

Supported by: None

Disclosure: John Delucò: Biogen, EMD Serono, Canadian MS Society, National MS Society, Consortium of Multiple Sclerosis Centers (CMSC) (grant funding); Celgene Corporation, Biogen, CMS, Novartis, Sanoﬁ, Genzyme, Canadian MS Society, EXCEMED (consulting fee). Jeffrey A. Cohen: Convelo, Mylan, Population Council Multiple Sclerosis Journal (editor, consulting fee). Bruce A. Cree: Akili, Alexion, Biogen, EMD Serono, Novartis, TG Therapeutics (consulting fee). Hangyoun Liu: James K. Sheffield, Diego Silva: Bristol-Myers Squibb (salary). Giancarlo Comi: Ambrì-Primo, Biogen, Celgene Corporation, EXCEMED, Forward Pharma, Genzyme, Merck, Novartis, Roche, Sanoﬁ, Teva (consulting fee). Lud- dig Kappos: Bayer, Biogen, Genentech, Genzyme, Merck, Novartis, Roche, Sanoﬁ, Teva (educational activities); Bayer, Biogen, European Union, Innovus, Merck, Novartis, Roche, Swiss MS Society, Swiss National Research Foundation (license fees for Neurostatus products, grants); Bayer, Biogen, Merck, Novartis, Sanofi, Teva (consulting or speaking fees, research support); Ludwig Kappos’ institution (University Hospital Basel) has received the following, used exclusively for research support: steering committee, advisory board, and consultancies from Actelion, Alexion, Bayer, Biogen, Biogen, Genentech, Genzyme, Merck, Novartis, Roche, Swiss National Research Foundation (license fees for Neurostatus products, grants). Bhupendra Doshi: Biogen, Roche (consulting or speaking fees, research support). Supported by: Swiss National Research Foundation (contracted research). Jihad Said Inshasi: Nothing to disclose. Albert Saiz: Bayer, Biogen, Genentech, Genzyme, Merck, Novartis, Roche, Sanoﬁ, Teva (consulting or speaking fees, research support); Bayer, Genentech, Merck, Novartis, Roche, Sanoﬁ, Teva (consulting or speaking fees); Ludwig Kappos’ institution (University Hospital Basel) has received the following, used exclusively for research support: steering committee, advisory board, and consultancies from Actelion, Alexion, Bayer, Biogen, Biogen, Genentech, Genzyme, Merck, Novartis, Roche, Swiss National Research Foundation (license fees for Neurostatus products, grants).

Keywords: Disease-modifying treatments in MS

(DXT40) Effect of the S1P1/5 Receptor Modulator Ozanimod on Cognitive Processing Speed in Subjects with Relapsing Multiple Sclerosis: Design of the ENLIGHTEN Study

Jan V. Riolo,1 Ling Yang,2 Thomas Rana,2 Robert Zivadinov,3 Lauren B. Krupp,4 Jonathan Calkow;1 Old Salt Shave;2 Robert T. Naismith,4 Diego Silva,1 John Delucò2

1Bristol-Myers Squibb, Summit, NJ; 2Buffalo Neuroimaging Analysis Center, Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, The State University of New York, Buffalo, NY; 3Stony Brook Technology Park, East Setauket, NY; Minneapolis Clinic of Neurology, Golden Valley, MN; 4UT Southwestern Medical Center, Dallas, TX; 5Washington University School of Medicine, St. Louis, MO

Kessler Foundation, West Orange, New Jersey and Departments of Physical Medicine and Rehabilitation, and Neurology, Rutgers – New Jersey Medical School, Newark, NJ

Background: In patients with multiple sclerosis (PwMS), slowed cognitive processing speed emerges as an early deficit. The Symbol Digit Modality Test (SDMT) is a preferred measure of cognitive function in PwMS. Ozanimod, a selective S1P1 and S1P5 modulator, was well tolerated and more effective than weekly intramuscular interferon β-1a (IFN) 30 μg on clinical and magnetic resonance imaging (MRI) end points in the phase 3 RADIANCE and SUNBEAM studies. The SUNBEAM study demonstrated a nominally significant (P < .05) improvement in SDMT with ozanimod HCl 1 or 0.5 mg/day over IFN 30 μg/wk; however, the study was not designed to evaluate SDMT as a primary end point. Objectives: The primary objective of ENLIGHTEN (trial registration: NCT04140305) is to describe clinically meaningful changes in SDMT (>4-point or 10% change from baseline) over 3 years in patients with early relapsing multiple sclerosis (RMS) treated with ozanimod HCl 1 mg/day. Secondary objectives are to describe changes from baseline in whole brain and substructure volume; MRI measures of disease activity; patient-reported outcomes (PROs) and quality of life (QOL); disability status based on Timed 25-Foot Walk, 9-Hole Peg Test, and Expanded Disability Status Scale (EDSS); and safety of ozanimod. The study also will explore the correlation between changes in cognitive processing speed and whole brain and substructure volume, and the cor-
relation between changes in cognitive processing speed and PROs and QOL. Methods: This ongoing multicenter, open-label study is recruiting 250 patients with RMS (aged 18-65 years) in the United States and Canada. Participants will receive ozanimod HCI 1 mg/day (equivalent to ozanimod 0.92 mg) for 3 years. Key inclusion criteria are diagnosis of multiple sclerosis per 2010 or 2017 McDonald criteria, ≤5 years since diagnosis, ≥1 approved RMS disease-modifying therapy, EDSS score ≤3.0, ≤1200 mg/2 weeks dose, and ≤30 days of corticosteroid use within 30 days of screening. Participants are allocated to ozanimod (n = 96) or placebo (n = 47), with stable-dose regimen continued for ≥6 months at the close of the 3-year period. Disease activity, disability status, and safety will be assessed over 3 years of ozanimod therapy. Conclusions: This study will determine if ozanimod has a clinically meaningful benefit on cognitive processing speed in patients with RMS. Supported by: None.

Disclosure: Jon V. Riolo, Long Yang, Thomas Rano, Dirio Silva; Bristol-Myers Squibb (salary); Robert Zivadinov; Celgene Corporation, EMD Serono, Sanofi Genzyme, Novartis (consulting fee); Larisa Miller, Imran Tanvir, Roisin Armstrong, Dean Wingerchuk; Biogen, Novartis (consulting fee); Biogen, Laurie Foundation, National Institutes of Health, National Multiple Sclerosis Society, Novartis, US Department of Defense (grant support); Genentech (data monitoring board); pharmaceutical and biotechnology companies for use of Fatigue Severity Scale (royalty); Jonathan Cañadell; Celgene Corporation (research support, compensation for consultancy, administrative, expert witness, work for hired or retained, work for contracted), EMD Serono (consultation fee), Genentech, TG Therapeutics (data monitoring committees); Michael Levy; Alexion Pharmaceuticals (consulting fee, compensation for non-clinical work, fees for non-CME/CE services received directly from commercial interest or its agent); Achim Berghede; Alexion Pharmaceuticals (consulting fee, contracted research, fees for non-CME/CE services received directly from commercial interest or its agent, speakers' bureaus); Haibo Jin; Alexion Pharmaceuticals, Celgene, Eisai, HanAll BioPharma, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok; Biogen, Biocon, Boehringer Ingelheim, Boehringer-Ingelheim, Biogen: Biogen, Roche (consulting fee, contracted research); MedImmune; Vela Bio (contracting committee); Multiple Sclerosis Journal (co-editor). Michael Levy; Alexion Pharmaceuticals (consulting fee, contracted research, fees for non-CME/CE services received directly from commercial interest or its agent, speakers' bureaus); Genentech, Quest Diagnostics, Vela Bio (consulting fee, fees for non-CME/CE services received directly from commercial interest or its agent); UCB; Vela Bio, Roche (conference lecture participation). Jean-Paul Pitzko; Alexion Pharmaceuticals (all compensation paid directly to Mayo Clinic, consulting fee, contracted research); Anaela; Biogen, Genentech (compensation paid directly to Mayo Clinic, consultant research); Takeda; Biogen, Genentech (all compensation paid directly to Mayo Clinic, consultant research), MedImmune (all compensation paid directly to Mayo Clinic, consulting fee, contracted research), UCB (consulting fee, personal compensation for attending UCB advisory board meeting in Stockholm, Sweden, on Sept 10, 2019); Marat Tera; Zhanshi Viswanathan, Kai-Chen Wang; Nothing to disclose. Natalia Tarnowska; Alexion, Janssen, Novartis, Roche, Sanofi, Recepto Inc, Biocad (Russia) (contracted research); Roche, Sanofi (fee for lectures). Dean Wingerchuk: null.

Keywords: Cognition and MS, Disease-modifying treatments in MS

(DXT41) Eculizumab Benefits a Broad Range of Patients with Aquaporin-4 Antibody–Positive Neuromyelitis Optica Spectrum Disorder: The Phase 3 PREVENT Study Kazuo Fujihara,1,2,3 Achim Berghede,1 Haibo Jin,2 Michael Levy,1 Ichiro Nakahara,1,4 Celio Orea-Guerrero,5 Jacqueline Palace,2,6 Sean J. Pittke,2,7 Murat Terzic,2 Natalia Tarnowska,2,8 Shadi Saida,9,10,11 Kaci-Chen Wang,12 Marcus Yountz,4 Larisa Miller,13 Imran Tanvir,14 Riswin Armstrong,15 Dean Wingerchuk16

School, Boston, MA; 7Johns Hopkins University, Baltimore, MD; 8Tohoku Medical and Pharmaceutical University, Sendai, Japan; 9Hospital Universitario Clinico San Carlos, Madrid, Spain; 10John Radcliffe Hospital, Oxford, United Kingdom; 11Mayo Clinic, Rochester, MN; 12Onkudokuz Mayis University, Samsun, Turkey; 13First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation; 14Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; 15National Yang Ming University, Taipei, Taiwan; 16Cheng-Hsin General Hospital, Taipei, Taiwan; 17Alexion Pharmaceuticals, Boston, MA; 18Mayo Clinic, Scottsdale, AZ

Background: Antibodies to the aquaporin-4 (AQP4) water channel in neuromyelitis optica spectrum disorder (NMOSD) are reported to trigger the complement cascade, which is implicated in neuronal injury. The terminal complement inhibitor eculizumab is the first treatment approved for patients with NMOSD associated with time since diagnosis, relapse history, disability burden, or prior IST use.

Conclusions: The data from this post hoc subgroup analysis suggest that eculizumab reduced relapse risk compared with placebo in patients with AQP4-immunoglobulin G–positive NMOSD, regardless of time since NMOSD diagnosis, relapse history, disability burden, or prior IST use.

Disclosure: Kazuo Fujihara; Alexion Pharmaceuticals, Biogen, Chugai, Mitusbishi-Tanuki, Novartis (consulting fee, fees for non-CME/CE services received directly from commercial interest or its agent); Aash Medical, Bayer, Eisai, Roche, Tejin (fees for non-CME/CE services received directly from commercial interest or its agent). Achim Berghede; Alexion Pharmaceuticals (consulting fee, contracted research, fees for non-CME/CE services received directly from commercial interest or its agent, speakers' bureaus). Haibo Jin; Alexion Pharmaceuticals, Celldriver, Eisai, HanAll BioPharma, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok; Biogen, Biocon, Boehringer Ingelheim, Biogen; Biogen, Roche (consulting fee, contracted research); MedImmune; Vela Bio (contracting committee); Multiple Sclerosis Journal (co-editor). Michael Levy; Alexion Pharmaceuticals (consulting fee, contracted research, fees for non-CME/CE services received directly from commercial interest or its agent, speakers' bureaus); Genentech, Quest Diagnostics, Vela Bio (consulting fee, fees for non-CME/CE services received directly from commercial interest or its agent); UCB; Vela Bio, Roche (conference/lecture participation). Jean-Paul Pitzko; Alexion Pharmaceuticals (all compensation paid directly to Mayo Clinic, consulting fee, contracted research); Anaela; Biogen, Genentech (compensation paid directly to Mayo Clinic, consultant research), Takeda; Biogen, Genentech (all compensation paid directly to Mayo Clinic, consultant research), MedImmune (all compensation paid directly to Mayo Clinic, consulting fee, contracted research), UCB (consulting fee, personal compensation for attending UCB advisory board meeting in Stockholm, Sweden, on Sept 10, 2019); Marat Terzic; Zhanshi Viswanathan, Kai-Chen Wang; Nothing to disclose. Natalia Tarnowska; Alexion, Janssen, Novartis, Roche, Sanofi, Recepto Inc, Biocad (Russia) (contracted research); Roche, Sanofi (fee for lectures). Dean Wingerchuk: null.

Keywords: Cognition and MS, Disease-modifying treatments in MS

(DXT42) Rationale and Design of CLASSIC-MS Study Evaluating Long-Term Efficacy for Patients with Multiple Sclerosis Treated with Cladribine Tablets Alexey Belyakov,1 Jorge Correa-Calle,1 Gilles Edan,2 Mark S. Freedman,3 Gavin Giannopoulos,4 Xavier Montalban,2,5 Kolli Raman,2 Thomas P. Leist,1 Dustin Stafleu,6 Bassem Yamaoui,7 Belen Garcia-Alonso,7 Aida Aydemir,8 Elisabetta Verdun di Cantogno,9 CLASSIC-MS Study Group 1Pirogov Russian National Research Medical University, Moscow, Russia; 2IFENI Institute, Buenos Aires, Argentina; 3Department of Neurology, University Hospital of Rennes, Rennes, France; 4University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 5Queen Mary University of London, London, United Kingdom; 6Centre d’Esporles Multiple de Catalunya (ICamit), Hospital Universitario Vall d’Hebron, Barcelona, Spain; 7St. Michael’s Hospital, University of Toronto, Toronto, ON, Canada; 8Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 9Jefferson University Hospital, Philadelphia, PA; 10Buch Medical College, Chicago, IL; 11Department of Neurology, American University of Beirut Medical Center, Beirut, Lebanon; 12Buenos Aires, Germany; 13EMD Serona Research & Development Institute Inc, Billerca, MA

Background: Cladribine tablets 10 mg (CT; cumulative dose 3.5 mg/kg over 2 years) has demonstrated efficacy vs placebo over 2 years in CLARITY, CLARITY Extension, and ORACLE-MS, showing sustained efficacy without further active treatment in CLARITY Extension. Objectives: CLASSIC-MS will explore long-term efficacy and real-world treatment patterns in patients who participated in these trials. Long-term safety in this
population has been assessed in the PREMIERE registry.

**Methods:** CLAS-M is an exploratory phase 4 study of patients with MS, or those with a first clinical demyelinating event enrolled into the phase 3 trials and who received ≥1 course of CT or placebo (N = 1946). Following pre-baseline screening and assessment for eligibility, long-term retrospective data will be obtained from medical records at study visit 1; prospective data will be collected at study visits 1 and 2. Patients will be enrolled for 17 months from approximately Q3 2019 to Q4 2020. Last patient last visit is expected in Q1 2021. Primary objective: evaluation of long-term mobility after treatment with CT or placebo. Secondary objective: assess differences in clinical and magnetic resonance imaging characteristics in long-term responders vs nonresponders. Tertiary end points: real-world treatment patterns, duration of clinical outcomes, quality of life and cognition. Hypothesis: clinical outcomes of long-term treatment and differences in genetics between long-term responders and those who are not. Results: In 2018, a second feasibility survey was sent to 225 centers; 110 centers provided positive responses and were included, representing 48% of sites originally enrolled in the phase 3 studies. In total 115 centers were not included (81 were not willing to participate; 13 dropped; 16 were nonresponders; 5 were rejected). Conclusions: CLAS-M will provide valuable information on the long-term efficacy of CT in patients with MS. Supported by: None

**Disclosure:** Alexey Boyko: Biogen, Schering, Merck, Teva, Novartis, Sanofi Genzyme, Actelion, Biocad, Genentech (consulting fee, participated in clinical trials supported by); Jorge Carballeda: Merck-Serono Argentina, Merck LATAM, Merck-Serono LATAM (vaccine member); Merck-Serono Argentina, Merck-Latam-Serono, Biogen Genzyme, Actelion Argentina, Teva Pharma (fees for non-CME/CME services received directly from commercial interest or its agents). Gilles Edan: Biogen, Genzyme, Merck Serono, Novartis, Roche, Teva Pharma (consulting fee). Mark S. Freedman: Actelion, Bayer HealthCare, Biogen, Chugai, EMD Canada, Genzyme, F. Hoffmann-La Roche, Novartis, Sanofi, Teva (consulting fee). Gavin Giovannianni: AbbVie, Actelion, Atara Bio, Almirall, Bayer Schering Pharma, Biogen, Five Prime, GlaxoSmithKline, GW Pharma, Merck & Co, Merck KGaG, Pfizer Inc, Protein Discovery Laboratories, Tessa Pharmaceutical Industries Ltd, Sanofi Genzyme, UCB (speakers’ bureau); AbbVie, Actelion, Atara Bio, Almirall, Bayer Schering Pharma, Biogen, Five Prime, GlaxoSmithKline, GW Pharma, Merck & Co, and Merck KGaG, Pfizer Inc, Protein Discovery Laboratories, Tessa Pharmaceutical Industries Ltd, Sanofi Genzyme, UCB, (consulting fee); Biogen, Merck & Co, Novartis, Ironwood (research support); Vertex Pharmacueticals, Ironwood, Novartis (consulting fee; speakers’ bureau); Xavier Montalban: Biogen, Merck Serono, Genentech, Genzyme, Novartis, Samff-Aventis, Tessa Pharmaceuticals, Roche, Celgene, Actelion, National MS Society, MS International Federation, EXCEMED (consulting fee, speakers’ bureau). Kottam Ramnath: EMD Serono, Biogen, Sanofi-Aventis, Genzyme, Novartis, Tessa Neurosciences, Acadia, Roche/Genentech (consulting fee, speakers’ bureau). Thomas P. Leis: Acorda, Bayer, Biogen, Daiichi, EMD Serono, Novartis, Ono, Pfizer, Teva Neurosciences (consulting fee); Dusan Stefausk: Acorda, Biogen, Teva Neurosciences (consulting fee, speakers’ bureau); Elan, EMD Serono (speakers’ bureau); Merck Serono (consulting fee); Banam Yamao: Bayer, Biogen, Genzyme, MyoKardia, Sanofi-Servier, and has received research grants from Bayer, Biogen, Merck-Serono, Pfizer (consulting fee for speakers’ bureau). Belden García-Abreu, Elisabetta Verdun di Cantogno: Merck KGaA (salary). Aída Ayudín: EMD Serono (salary).

**Keywords:** Disease-modifying treatments in MS, Management of activities of daily living in MS, Real-world treatment patterns

**Posters: Disease-Modifying Therapy**

(DXT44) Real-World Patterns of Disease Progression in Patients with Multiple Sclerosis Who Are Adherent Versus Nonadherent to Disease-Modifying Treatments over 6 Years

Lylene Amezeta,1 Mikki J. Williams,1 Jia Zhu2, Terrie Livingston3

1University of Southern California, Los Angeles, CA; 2Joe Life Wellness Group, Newman, GA; 3EMD Serono Inc, Rockland, MA

**Background:** Multiple sclerosis (MS) is a chronic disease that requires long-term treatment for most patients. Disease-modifying treatment (DMP) adherence is often an issue for patients with MS, and evidence suggests that nonadherence can affect outcomes. Data are needed to understand the impact of long-term DMP use on clinical outcomes. Objectives: To assess the impact of long-term DMP adherence on MS disease progression in the real world. Methods: A retrospective cohort analysis of MarketScan Commercial enrollees from 2011-2017 was performed. MS was defined as ≥3 ICD-9/10 (340.3/G35) diagnosis claims or ≥1 diagnosis and ≥1 DMT claim [age 18 and 65 years at index] with index date during the first diagnosis period. N = 1703. Patients were stratified into adherence status of ≥80% and <80% continuous treatment from 1 year preindex, with a follow-up of 23 years of continuous enrollment and up to 6 years. Adherent-users as medication possession ratio (MPR) ≥ 0.8 in follow-up, and non-adherent users as 0 < MPR < 0.8. Propensity score greedy matching was used to balance population characteristics (age, gender, geography, comorbidities, relapse) 1 year preindex. We compared the average number of relapses, defined as a 26%, respectively. Objectives: Assess efficacy and safety of siponimod in patients with active SPMS in subgroups of patients aged <45 and ≥45 years (median value) at baseline. Methods: Post hoc analyses were performed in subgroups of patients with active SPMS, defined as a relapse in the 2 years before screening and/or ≥1 T1 gadolinium-enhancing lesion at baseline, randomized to siponimod 2 mg daily or placebo. Efficacy end points included: time to 3- and 6-month CDP (as per Expanded Disability Status Scale standard deviation units [AE] of 2). Nonproportionality leading to treatment discontinuation were also assessed. Analyses for hypothesis generation only; no adjustment for multiple comparisons. Results: There were 779 patients with active SPMS: 306 patients aged <45 years (siponimod, n = 213; placebo, n = 93) and 473 patients aged ≥45 years (siponimod, n = 203; placebo, n = 180). In those <45 years, siponimod reduced risk of 3-month CDP by 31.9% compared with placebo (siponimod, n = 57 [26.8%]; placebo, n = 55 [37.6%]; hazard ratio [HR] [95% CI]: 0.68 [0.45, 1.04]; P = 0.0734), and reduced 6-month CDP risk by 39.5% [siponimod, n = 44 [20.7%]; placebo, n = 50 [32.2%]; HR [95% CI]: 0.61 [0.38, 0.96]; P = 0.0339]. In the sub-group of patients ≥45 years, siponimod reduced the risk of 3-month and 6-month CDP by 31.5% and 33.1%, respectively, vs placebo (3-month; siponimod, n = 72 [23.8%]; placebo, n = 56 [32.9%]; HR [95% CI]: 0.69 [0.48, 0.97]; P = 0.0340; 6-month: siponimod, n = 55 [18.2%]; placebo, n = 44 [25.9%]; HR [95% CI]: 0.67 [0.45, 1.01]; P = 0.0471). Siponimod was generally well tolerated in both subgroups. Also, AE were similar for siponimod and placebo in patients ≥45 years (82.6% vs 82.8%, and slightly higher for siponimod in those <45 years [89.8% vs 75.9%]. Rates of AEs and AEs leading to discontinuation were similar between groups. Conclusions: In EXPAND, siponimod provided similar clinical effects in reducing CDP risk in patients aged <45 years and ≥45 years with active SPMS.

Supported by: None

**Disclosure:** Le H. Huu: Biogen, Celgene, EMD Serono, Genentech, Genzyme, Novartis (consulting fee). Amit Bar-Or: Atara Biotherapeutics, Bayer, Bayhill Therapeutics, Berlex, Biogen, BioMS, Celgene/Receptio, Diogenix, Eli Lilly, F. Hoffmann-La Roche, Genentech, GlaxoSmithKline, Gush-Jackson/GGF, Immunic, Janusun/Actelion, Mapi, MedImmune, Merck/EMD Serono, Novartis, Ono Pharma, Roche/Genentech, Sanofi Genzyme, Tesv Neuroscience, Wyeth (consulting fee). Fred D. Lublin: AbbVie, Acorda Therapeutics, Apothea, Aureum Pharmacueticals, Bayer HealthCare, BMS, Biogen, Clincensia, EMD Serono, Foudor Pharma, Innate Immunotherapeutics, Mapi Pharma, MedDay Pharma, MedImmune, Novartis, Orion Biotechnology, Polpharma, Receptus/Celgene, Regeneron, Roche Genentech, Sanofi Genzyme, Tesv Neuroscience, TG Therapeutics (consulting fee); Actelion (consulting fee, research support); Multiple Sclerotics and Related Disorders (journal) (editor); National MS Society, Novartis Pharmaceuticals, Sanofi, Tesv Neurosciences, Transparency International (consulting fee, research support); National MS Society, Novartis Pharmaceuticals, Sanofi, Tesv Neurosciences, Transparency International (consulting fee); National MS Society, Novartis Pharmaceuticals, Sanofi, Tesv Neurosciences, Transparency International (consulting fee, research support); National MS Society, Novartis Pharmaceuticals, Sanofi, Tesv Neurosciences, Transparency International (consulting fee). Youssef Chahune: EMD Serono Inc, Rockland, MA.
hospitalization with a primary diagnosis of 340/G35 or an outpatient visit with a diagnosis of G35 plus a pharmacy or medical claim for a qualifying corticosteroid within 7 days, between 2 cohorts using Pois-
sion regression model. We also compared the time to first relapse, time to
cane/walker use, and time to wheelchair use between 2 cohorts using Cox-
proportionally hazard model. Results: 15,617 patients with MS were
identified (42% adherent, 43% nonadherent, 15% non-DMT treated). Of
these patients, baseline labs were analyzed. When baseline standardi-
zed differences of all baseline characteristics between 2 comparison
groups were <0.1. Adherent users had significantly lower average
number of relapses (0.153) than nonadherent (0.201) users (annualized
relapse rate ratio: 0.76, 95 CI: 0.74-0.79, P < .001). Adherent users had
significantly lower time to first relapse (hazard ratio [HR] = 0.82,
95 CI: 0.77-0.87, P < .001), cane/walker use (HR = 0.81, 95 CI: 0.71-
0.93, P = .003), and wheelchair use (HR = 0.60, 95 CI: 0.51-
0.70, P < .001). Conclusions: This study highlights the importance of
DMT adherence in slowing disease progression. Indicators of MS-related
disability were found to be related to adherence, suggesting a lower rate
of disability progression over time. Further research is needed to better
understand barriers of adherence with DMTs.

Supported by: None

Disclosure: Luisana Amorena, Biogen (consulting fee, research support); California
Community Foundation, MedDay, NIH National Institute of Neurological
Disorders and Stroke, National MS Society (research support); EMD Serona,
Novartis (consulting fee), Mitzi Williams: EMD Serona, Inc (employer received
funding for study); Jai Life Wellness Group (salary); Izai Zhou, Terrie Livingson:
EMD Serona, Inc (a business of Merck KGaA, Darmstadt, Germany) (salary).

Keywords: Disease-modifying treatments in MS

(DXT46) Cognitive Performance and Disability Across Age Groups in Teriflunomide-Treated Patients in the Teri-
PRO Study
Lori H. Travis,1 Dennis Chinichiglia,2 Shupendra O. Khatri,3 José Macor-Lallana,4 Min Su
Park,5 Patrick Vermersch,5 Alex Lublin,2 Elizabeth M. Poole,2 Patricia K. Coyte2
1Phoenix Neurological Associates, Phoenix, AZ; 2Department of Neurology, CIMA
Hospital, San José, Costa Rica; 3Center for Neurological Disorders at Weill Cornell
Healthcare, Milwaukee, WI; 4Hospital Virgen de la Arrixaca, Universidad Católica
San Antonio de Murcia, Murcia, Spain; 5Department of Neurology, Tufts University
Hospital, Boston, MA, and Tufts University School of Medicine; 6Department of Neurology,
University of Lille, INSERM U995, CHU Lille, Lille, France; Sanofi, Cambridge, MA; 5Stony Brook University, Stony Brook, NY

Background: The Teri-PRO study (trial registration: NCT01895335)

evaluated patient-reported outcomes, including cognition, in teriflunomide-
treated patients with relapsing forms of multiple sclerosis (MS) in a
real-world setting. It is unknown whether treatment effects on cognitive
performance are influenced by patient age and/or physical disability. We
assessed the relationship between DMT and EDSS scores across all age groups.

Objectives: We evaluated the effects of teriflunomide treatment on cogni-
tion across age groups, in the context of disability. Methods: Teri-PRO
was a phase 4, multicenter, prospecitive, single-arm, open-label, real-
world study assessing treatment satisfaction of teriflunomide 7 mg or 14
mg over 48 weeks using patient-reported outcomes. Cognitive perfor-
ance, measured using the Symbol Digit Modalities Test (SDMT), and
disability, assessed with the Expanded Disability Status Scale (EDSS),
were assessed at SDMT and EDSS endpoint visits. SDMT and EDSS scores
were calculated as the ratio of correct responses [scale 0-1]. Patient improvement was computed as
the change in score from baseline to 48 weeks; Spearman correlation
assessed the relationship between SDMT and EDSS outcomes.

Results: SDMT and EDSS data were available in 839 patients (≤ 25 years: n = 21;
≤ 35 years: n = 105; > 35 to 45 years: n = 243; > 45 to 55 years:
n = 279; and > 55 years: n = 191). Baseline mean SDMT scores across all age groups were similar (≤ 25 years: 0.99; > 25 to 35 years: 0.98;
> 35 to 45 years: 0.98; > 45 to 55 years: 0.97; and > 55 years: 0.97), and remained stable through week 48 (least squares mean change ranged
from −0.01 to +0.01 across groups). At baseline, mean EDSS scores
were higher with advancing age, from 1.52 in patients ≤ 25 years to
4.12 in patients ≤ 55 years. Least squares mean EDSS changes from
baseline to week 48 were not significant, except in patients > 45 to 55
years (p = 0.13, P = 0.0079). Cognition and disability were not correlated in
any age group (Spearman correlations, < 25 years: P = 0.2; ≥ 25 years:
P = 0.02, P = 9; > 35 to 45 years: P = 0.09, P = 0.2; > 45 to 55
years: ≤ 0.05, P = 4; > 55 years: 0.04, P ≤ 0.6) or in the overall popula-

Conclusions: Across all age groups, patients in Teri-PRO had similarly high cognitive function at baseline, and cognitive performance after 48 weeks of teriflunomide treatment was stable. SDMT and EDSS were not significantly correlated.

Supported by: Sanofi

Disclosure: Lori H. Travis: Acorda, Biogen, Mallinckrodt, Novartis, Pfizer (con-
sulting fee); Biogen (grant/research support); EMD Serona, Genzyme (consulting fee,
grant/research support); Dennis Chinichiglia: Aucion, Genzyme, Novartis,
Stendahl (educational support); Bayer (educational support, speaker honoraria);
Glaxo (speaker honoraria); Merck Serono, Roche (compensation on scientific advis-
ory board, educational support). Shupendra O. Khatri: Acorda, Celgene, Serono,
Teva (consulting/honorarium [consulting work, speaker programs]); Alexion,
Biogen, Genentech, Novartis, Sanofi (consulting/honorarium [consulting work,
speaker programs], contractual research); Ro Pharmaceuticals (contractual research).
José Macor-Lallana: Almirall, Biogen, Celgene, Genzyme, Merck, Novartis, Roche,
Teva (honoraria for consulting or presentations). Min Su Park: Bayer, Genentech,
Merck Serono, Novartis (consulting fees, honoraria, or scientific committee sup-
port); Patrick Vermersch: Almirall, Biogen, Celgene, Merck, Novartis, Roche,
Sanofi, Servier, Teva (consulting and/or speaking fees and research support).
Alex Lublin,2 Elizabeth M. Poole,2 Sanofi (salary); Patricia K. Coyte: Accordant, Alex-
ion, Bayer, Biogen, Celgene, Sanofi Genzyme, GlaxoSmithKline, Mylan, Sanofi,
TG Therapeutics (consulting fees and/or speaking fees); Actelion, Alkermes, Cor-
rina LLD, MedDay, National Institute of Neurological Disorders and Stroke,
National Institute on Aging and MS, Cognition and MS, Disease-modifying treatments in MS.

International Journal of MS Care

32

Evidence-based practice in disease-modifying therapy in MS.
(DXT48) Efficacy of Subcutaneous Interferon Beta-1a in Patients with a First Clinical Demyelinating Event: REFLEX Study – Outcomes in Patients Stratified by 2017 McDonald Criteria

Mark S. Freedman,1 Ludwig Kappos,2 Giancarlo Comi,3 Nicola De Stefano,4 Sanjeev Roy,1 Delphine Issard6

1University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2Neurologic Clinic and Polyclinic, Departments of Medicine, Clinical Research, Biomedicine and Genome Engineering, University Hospital of Basel, Basel, Switzerland; 3Department of Neurology and Institute of Experimental Neurology, University Vito-Salute San Raffaele, Ospedale San Raffaele, Milan, Italy; 4Department of Neurological and Behavioural Sciences, University of Siena, Siena, Italy; 5Merck KGaA, Aubonne, Switzerland; 6Cytel Inc, Geneva, Switzerland

Background: The REFLEX (Rebif FLEXible dosing in early multiple sclerosis [MS]) trial demonstrated that subcutaneous interferon beta-1a (sc IFNβ-1a) reduced conversion to MS (McDonald 2005 criteria) and to clinically definite MS (CDMS) vs placebo in patients with a first clinical event suggestive of MS. A retrospective analysis of the study showed that the overall results were unchanged by the application of the McDonald 2010 MS criteria. The revised 2017 McDonald MS criteria include the presence of cerebrospinal fluid–specific oligodendral lesions, symptomatic lesions, and cortical lesions to aid MS diagnosis. Objectives: Assess the effects of sc IFNβ-1a on time to McDonald 2005 criteria MS (time to next relapse, Expanded Disability Status Scale [EDSS] progression, or McDonald criteria positive magnetic resonance imaging lesion or lesion evolution in CDMS) vs time to relapse or EDSS progression, and annualized relapse rate (ARR) during REFLEX, stratified by retrospective diagnosis at baseline in patients that either meet or do not meet the updated McDonald 2017 MS criteria. Methods: During REFLEX, patients were randomized to either sc IFNβ-1a 44 μg once weekly or placebo. Kaplan–Meier curves were used to estimate time to McDonald 2005 MS and time to CDMS by treatment group and for each McDonald 2017 subgroup. Results: As the detection of oligodendral lesions was optional during REFLEX, only a small number of patients were added from the McDonald 2010 analysis. A total of 235/517 patients were classed as McDonald 2017–positive at baseline (40 of whom were McDonald 2010–negative but had positive oligodendral bands) and McDonald 2017–negative subgroups. Kaplan–Meier curves were used to estimate time to McDonald 2005 MS and time to CDMS by treatment group and for each McDonald 2017 subgroup. Conclusions: The treatment effects of sc IFNβ-1a observed in McDonald 2010 patients on time to McDonald 2005 MS and CDMS were maintained in the McDonald 2017 positive subgroup, although there were only a small number of additional patients when the 2017 criteria were applied.

Supported by: None

Disclosure: Mark S. Freedman: Actelion, Bayer HealthCare, Biogen, Chugai, EMD Canada, Genzyme, F. Hoffmann-La Roche, Novartis, Sanoﬁ, Teva (consulting fee); EMD Serono, Genzyme (speakers’ bureau). Ludwig Kappos: Institutional funding: Actelion, Addex, Bayer HealthCare, Biogen, Bionica, Genzyme, Eli Lilly, Merck KGaA, Mitsubishi, Novartis, Ono Pharma, Pfizer, Receptor, Sanofi, Santhera, Sintxis, Teva, UCSF, Xenoport (consulting fee); Institutional funding: Bayer, Biogen, CSL Bering, Genzyme, Merck, Novartis, Sanoﬁ, Teva (educational activities); Institutional funding: Bayer, Biogen, Europeans Union, Innoven, Merck, Novartis, Roche, Swiss MS Society, Swiss National Research Foundation (conducted research); Institutional funding: Bayer, Biogen, Merck, Novartis, Sanoﬁ, Teva (speakers’ bureau); Institutional funding: Neurostatus products (receipt of intellectual property right/patient holder). Giancarlo Comi: MedDay, EXCEMED, Novartis, Teva Pharmaceutical Industries Ltd, Teva Italia Srl, Sanoﬁ Genzyme, Genzyme Corporation, Genzyme Europe, Merck KGaA, Merck Serono S.p.A., Celgene Group, Biogen, Biogen Italia Srl, F. Hoffmann-La Roche, Roche SpA, Almirall SpA, Forward Pharma (consulting fee, speakers’ bureau). Nicola De Stefano: Biogen, Teva, Novartis, Sanoﬁ Genzyme, Roche, Merck Serono (consulting fee); Sanofi-Aventis, Sanoﬁ Genzyme, Roche, Merck Serono (travel). Sanjeev Roy: Roche, Merck Serono (consulting fee); EMD Serono, Genzyme, Genzyme Europe, Merck KGaA, Aubonne, Switzerland (salary). Delphine Issard: Cytel Inc (salary); Merck KGaA (consulting fee).

Keywords: Diagnosis, Biomarkers, Disease-modifying treatments in MS

(DXT49) Post Hoc Analysis of Efficacy of Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis Aged Over and Under 30 Years in the CLARITY Study

Mark S. Freedman,1 Gabriel Pardo,1 Nicola De Stefano,2 Julie Aldridge,1 Sana Syed,1 Yann Huyer,1 Andrew Galazka,1 Caroline Lemieux,1 Gavin Giovannoni1

1University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 2Oklahoma Medical Research Foundation, Oklahoma City, OK; 3University of Siena, Siena, Italy; 4EMD Serono Inc, Billerica, MA; 5Merck KGaA, Darmstadt, Germany; 6Merck, Aubonne, Switzerland; 7EMD Serono, Genzyme Corporation, Genzyme Europe, Merck KGaA, Aubonne, Switzerland, 8ON, Canada; 9Blizard Institute of Cell and Molecular Science, London, United Kingdom

Background: Efficacy of cladribine tablets 3.5 mg/kg (CT3.5, cumulative dose over 2 years) has been reported in relapsing-remitting multiple sclerosis (RRMS) in the 96-week CLARITY study. Prior post hoc analyses of CLARITY found that CT3.5 treatment resulted in similar benefits across the age spectrums of the studied patients in risk reduction of relapse and odds of remaining free from disease activity. Objectives: This post hoc analysis further examined efficacy outcomes of CT3.5 in CLARITY patients aged ≤30 and >30 years at study enrollment. Methods: Analyses were performed by treatment (CT3.5 vs placebo) and age subgroup (≤30 and >30 years), a relatively young age cutoff with adequate N needed for analysis. Assessment of relapse rate and relapse-free rates were based on the effects of CT3.5 on annualized relapse rate [ARR], 3- and 6-month confirmed disability progression (CDP, based on Expanded Disability Status Scale), magnetic resonance imaging (MRI) activity, and no evidence of disease activity (NEDA) status (no relapse, 3- or 6-month CDP, or MRI activity). P values are nominal. Results: This analysis was carried out in 870 patients; ≤30 years: CT3.5 N = 109, placebo N = 102; >30 years: CT3.5 N = 324, placebo N=335. In both age subgroups, CT3.5 significantly reduced adjusted ARR (95% CI) ≤30 years: 0.16 [0.10-0.23] vs 0.48 [0.38-0.60]; >30 years: 0.15 [0.12-0.18] vs 0.31 [0.27-0.37]; P < 0.001, and increased the percentage of patients who were relapse-free through week 96 (≤30 years: 73.4% vs 44.1%; >30 years: 64.7% vs 57.3%); vs placebo. CT3.5 treatment increased the odds of being free from 3- or 6-month CDP through week 96 (≤3-month CDP at week 96 in both age subgroups: 0.84-0.88 vs 0.76 [both subgroups]; 6-month CDP at week 96: 0.89-0.94 vs 0.83-0.86) vs placebo. CT3.5 also significantly reduced the adjusted ARR, NEDA status, and 3-month CDP at week 96 (≤30 years: 0.22 [0.15-0.33] vs 1.37 [0.97-1.93]; >30 years: 0.05 [0.03-0.08] vs 0.77 [0.61-0.98]) and active T2 (≤30 years: 0.68 [0.53-0.88] vs 2.20 [1.73-2.81]; >30 years: 0.26 [0.21-0.32] vs 1.19 [1.01-1.41]) lesions, and increased the number of patients achieving NEDA status using 3-month (≤30 years: 30.3% vs 2.9%; >30 years: 44.5% vs 17.3%) or 6-month (≤30 years: 30.3% vs 2.9%; >30 years: 46.3% vs 17.9%) CDP vs placebo (all P < 0.001) at 96 weeks. Conclusions: CT3.5 treatment improved clinical and MRI outcomes in both younger and older patients in CLARITY. Relapse and disability outcomes appeared mostly similar between the age subgroups; however, the >30 years subgroup appeared to have a greater reduction in MRI lesion activity and a higher rate of achieving NEDA status.

Supported by: None

Disclosure: Mark S. Freedman: Actelion, Bayer HealthCare, Biogen, Chugai, EMD Canada, Genzyme, F. Hoffmann-La Roche, Novartis, Sanoﬁ, Teva Pharmaceutical USA (consulting fee); Gabriel Pardo: AbbVie, Adamas, Alkermes, Sanoﬁ Genzyme, Teva (research support); Alexson, Celgene, Sanoﬁ Genzyme (consulting fee); Biogen, EMD Serono, Novartis, Roche/Genentech (consulting fee, research support). Nicola De Stefano: Bayer Schering AG, Merck Serono SA, Novartis Pharma AG, Novartis-Aventis, Serono Sympoia International Foundation, Teva Pharmaceutical Industries (consulting fee); Julie Aldridge: Sanoﬁ Syngenta (a business of Sanoﬁ-Genzyme, a business of Merck KGaA, Darmstadt, Germany) (salary). Yann Huyer: Merck KGaA (salary). Andrew Galazka: Merck KGaA, Aubonne, Switzerland (a business of Merck KGaA, Darmstadt, Germany) (salary). Gavin Giovannoni: AbbVie, Actelion, Almirall, Atura Bio, Bayer Schering Pharma, Five Prime, GlaxoSmithKline, GW Pharma, Merck KGaA, Pfizer Inc, Protein Discovery Laboratories, Sanoﬁ Genzyme, Teva Pharmaceutical Industries Ltd, UCSF, Vertex Pharmaceuticals (consulting fee, research support). Biogen, Ironwood, Merck and Co, Novartis (consulting fee, unrelated research support).

Keywords: Disease-modifying treatments in MS

(DXT50) Prevalence of Serious Adverse Pregnancy Outcomes After Exposure to Interferon Betas Before or During Pregnancy: Stratification by Characteristics of Pregnant Women with Multiple Sclerosis in a Register-Based Cohort Study in Finland and Sweden

International Journal of MS Care 33

Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 18 September 2020
Disease-modifying treatments in MS, MS and the caregiver/family, Sustained in Relapsing Multiple Sclerosis Patients
Fumarate and Dimethyl Fumarate Are Observed and (DXT51) High Rates of Adherence to Oral Diroximel
Roche (contracted research); Teva (speakers' bureau).
Kapadia, Sibyl Wray6
Orebro, Sweden; 10University College London, London, United Kingdom
*Disclosure: Biogen, EMD Serono, Novartis (speakers' bureau); Biogen, Novartis, Sanofi Genzyme (consulting fee, speakers' bureau); Alexion, Biogen, Genentech, EMD Serono (contracted research). Mary Kay Fink, Elzbieta Jasinska, Pavle Repovic, Cortnee Roman, Hailu Chen, Shivani Kapadia: Biogen (ownership interest, salary). Sibyl Wray: Alkermes Inc, Biogen, Celgene, Genentech/Roche, Sanofi Genzyme, Novartis, TG Therapeutics (consulting research); Biogen, EMD Serono, Genentech/Roche, Novartis, Genentech (consulting fee, speakers' bureau).

**Keywords:** Disease-modifying treatments in MS, MS and the caregiver/family, Pregnancy and MS

**DXT52**

**Efficacy and Safety of Eculizumab in Patients with Neuromyelitis Optica Spectrum Disorder Previously Treated with Rituximab: The Phase 3 PREVENT Study**

Michael Levy,1,2 Achim Berthele,3 Ho Jin Kim,4 Kazuo Fujihara,4,5 Ichiro Nakashima,4,5 Celia Oreja-Guevara,6 Jacqueline Palacio,7 Sean J. Pittuck,7 Murat Terzi,7 Natalia Totolache,7 Shabani Viswanathan,8 Kai-Chen Wang,10,11 Amy Pace,10,11 Marcus Yountz,11 Eva Laurant-Ny,1,11 Dean Wingerd1,11

**1Massachusetts General Hospital and Harvard Medical School, Boston, MA; 2Ihones Hopkins University, Baltimore, MD; 3Technical University of Munich, Munich, Germany; 4National Cancer Center, Goyang, Korea, Republic of (South); 5Southern TOHOKU Research Institute for Neuroscience (STRINS), Koriyama, Japan; 6Tohoku University, Sendai, Japan; 7Fukushima Medical University, Fukushima City, Japan; 8Tokyo Medical and Dental University, Hospital, Tokyo; 9Sanatorio Clinico San Juan de Dios, Madrid, Spain; 10John Radcliffe Hospital, Oxford, United Kingdom; 11Mayo Clinic, Rochester, MN; 12Gondouz Mayis University, Samsun, Turkey; 13First Pavlov State Medical University of St Petersburg, St Petersburg, Russian Federation; 14Kuala Lumpur Hospital, Kuala Lumpur, Malaysia; 15National Yang Ming University, Taipei, Taiwan; 16Cheng-Hsin General Hospital, Taipei, Taiwan; 17Alexion Pharmaceuticales, Boston, MA; 18Alexion Pharmaceuticals, Zurich, Switzerland; 19Mayo Clinic, Scottsdale, AZ

**Background:** In the PREVENT study, eculizumab was associated with a significant reduction in relapse risk vs placebo and was well tolerated. In total, 46 patients (26/96 receiving eculizumab, 20/47 receiving placebo) had been previously treated with a monoclonal antibody rituximab. **Objectives:** To describe the efficacy and safety of eculizumab in patients in the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (trial registration: NCT01792345) who had previously received rituximab. **Methods:** Adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (NMO) received eculizumab (maintenance dose, 1200 mg/2 weeks) or placebo with/
Facilitate Sharing of Data: My MS Manager and Multiple Sclerosis @ Point of Care

**Methods:** Since 2017, My MS Manager app (available to patients with any prior rituximab treatment) has been available to patients with PPMS, with current enrollment near 500 patients. We conducted a retrospective chart review of veterans with MS seen in the MS Clinic and General Neurology Clinic at Veterans Affairs Greater Los Angeles Healthcare System who were on DMTs from January 1, 2010, to December 31, 2019. Demographic data and the following data points were collected: past medical history, date of diagnosis, duration of MS, characteristics related to DMT use such as prescription refill history, reason for discontinuation, duration of medication use, and response to DMTs. Results: To date we have screened 100 electronic medical records of veterans with MS on DMTs. We documented 220 trials of DMT in 100 patients enrolled in our study. Among these 100 patients, the most commonly prescribed DMTs were interferon-beta and glatiramer acetate. Adherence rates observed were highest among veterans on infused DMTs and lowest among veterans on injectable DMTs. Approximately 20% of patients discontinued the injectable DMTs due to inefficacy, compared to 10% for oral DMTs and 10% for infused DMTs. Injectable DMTs were discontinued in 20% of veterans due to adverse drug reactions, compared to 8% for oral DMTs and 4% for infused DMTs. Data collection and analysis are ongoing and may help us identify barriers to DMT adherence in veterans with MS. Conclusions: Preliminary results of our study suggest differences in adherence to DMTs and possible reasons for discontinuation of DMTs in veterans with MS.

**Supported by:** None

**Disclosure:** Nothing to disclose.

**Keywords:** Comprehensive care and MS, Disease-modifying treatments in MS, MS phenotypes

---

**Multisclerosis Therapy in Veterans with Multiple Sclerosis**

Nomi Wu, Eric Williamson, Jeremy Liu, Christine Lo, Hyginh Su, Andrea Hanssen, Sunita Dergulat

**Pharmacy and Neurology, VA Greater Los Angeles Healthcare System, Los Angeles, CA**

**Disease-modifying therapy (DMT) is the preferred treatment approach for multiple sclerosis (MS) and has been shown to reduce the rate of relapse and slow disease progression. Poor adherence is associated with an increased risk of relapse leading to an increase in morbidity outcomes as well as overall costs as well as patient satisfaction. Understanding why and how DMTs are discontinued is important to ensure optimal treatment choices.**

**Background:** For the current study, veterans were defined as patients who have a diagnosis of MS and served in the military. The researchers conducted a retrospective chart review of veterans with MS seen in the MS Clinic and General Neurology Clinic at Veterans Affairs Greater Los Angeles Healthcare System who were on DMTs from January 1, 2010, to December 31, 2019. Demographic data and the following data points were collected: past medical history, date of diagnosis, duration of MS, characteristics related to DMT use such as prescription refill history, reason for discontinuation, duration of medication use, and response to DMTs.

**Results:** To date, we have screened 100 electronic medical records of veterans with MS on DMTs. We documented 220 trials of DMT in 100 patients enrolled in our study. Among these 100 patients, the most commonly prescribed DMTs were interferon-beta and glatiramer acetate. Adherence rates observed were highest among veterans on infused DMTs and lowest among veterans on injectable DMTs. Approximately 20% of patients discontinued the injectable DMTs due to inefficacy, compared to 10% for oral DMTs and 10% for infused DMTs. Injectable DMTs were discontinued in 20% of veterans due to adverse drug reactions, compared to 8% for oral DMTs and 4% for infused DMTs. Data collection and analysis are ongoing and may help us identify barriers to DMT adherence in veterans with MS.

**Conclusions:** Preliminary results of our study suggest differences in adherence to DMTs and possible reasons for discontinuation of DMTs in veterans with MS.

**Supported by:** None

**Disclosure:** Nothing to disclose.

**Keywords:** Disease-modifying treatments in MS, Medication adherence
(DXT55) Herpes Zoster Virus (HZV) Infections Among Multiple Sclerosis Patients Treated with Various Disease-Modifying Therapies
Nicola Carloli,1 Sam I. Hooshmand,1 Michelle Maynard,2 Leah Hoffman,2 Ahmed Z. Obeidat1
1Neurology, Medical College of Wisconsin and Affiliated Hospitals, Milwaukee, WI; 2Neurosciences, Froedtert and the Medical College of Wisconsin, Milwaukee, WI; 3Pharmacy, Froedtert and the Medical College of Wisconsin, Milwaukee, WI; 4Neurology, Medical College of Wisconsin, Milwaukee, WI.

Background: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) may increase the risk for opportunistic infections, including herpes zoster (HZV). The relative frequency of HZV infection in the treated MS population is unknown. Furthermore, the relative distribution of reported cases per age group and gender is unknown. Objectives: To stratify the frequency of voluntarily reported HZV infections by DMT, age, and gender. Methods: We queried the Food and Drug Administration Adverse Event Reporting System (FAERS) for adverse events (“herpes zoster” and “varicella”) reported in patients with MS between January 1999 and June 2019 receiving interferon beta (IFNβ), glatiramer acetate (GA), natalizumab (NAT), fingolimod (FIN), teriflunomide (TFR), dimethyl fumarate (DMF), alemtuzumab (AEL), and ocrelizumab (OCR). We excluded reports where the “suspect drug” included 2 or more DMTs. We stratified the reports for each DMT, by year of report, age, and gender. Results: 3352 reports met our inclusion criteria. Mean (SD) annual report rates were highest for patients treated with NAT at 89.9 (19.4) and lowest for GA at 2.1 (2.5). Other DMTs: FIN 70.3 (27.3); DMF 39.6; AEL 55.3 (5.27); TFR 22.8 (15.7); OCR 22.6 (18.7) and TER 10.4 (4.7). Reports were 4.7x more in females (ranging from 2.3x for ALE to 8.2x for IFNβ). The highest percentage of reports was in the sixth decade of life for all DMTs except ALE (fourth decade). Several reports were in individuals younger than 40 (25.0%). Conclusions: Reports of HZV infections varied based on the DMT used, patient age, and gender. HZV reports were nearly fivefold more frequent in females than males, and reports among patients younger than 40 were higher than expected. Database limitations precluded calculations of incidence. We encourage further investigations of the incidence and risk mitigation strategies (including vaccination practices) of HZV in patients with MS on DMTs regardless of age and gender of the patient.

Supported by: None

Disclosure: Nicola Carloli, Sam I. Hooshmand, Michelle Maynard, Leah Hoffman: Nothing to disclose. Ahmed Z. Obeidat: Alexion, Bingen (consulting fee, speakers’ bureau); Celgene, EMD Serono, Genentech, Sanofi (consulting fee); International Journal of MS Care (editorial board); Novartis (speakers’ bureau).

Keywords: Disease-modifying treatments in MS

(DXT56) Potential Weight Changes Among Patients with Multiple Sclerosis Undergoing Treatment with Ocrevus (Ocrelizumab)
Olivia Wei,1 Elizabeth S. Gromisch,2,3 Lindsay O. Neo,4 Jennifer A. Ruiz,2,4 Peter Wade2,3
1University of Lille, Lille, France; 2Blizard Institute of Cell and Molecular Science, University of London, United Kingdom; 3Queen Mary University of London, London, United Kingdom; 4Department of Neurology, Danish MS Center, University of Copenhagen, Copenhagen, Denmark; 5Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 6Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ; 7Merck KGaA, Darmstadt, Germany; 8Merck KGaA, Aubonne, Switzerland

Background: Cladribine tablets (CT) 10 mg, cumulative dose 3.5 mg/kg (CT3.5; N = 433) over 2 years showed efficacy vs placebo (N = 437) in patients with relapsing multiple sclerosis (MS) in the CLARITY study. Objectives: Explore (post hoc) the relationship between baseline Expanded Disability Status Scale (EDSS) score and risk of progression to secondary progressive MS (SPM) over 2 years of ocrelizumab (OCR) treatment. Methods: As progression to SPM was not recorded during the trial, a proxy composite definition was used: confirmed disability progression (CDP), CDP within the leading EDSS-defined functional score (FS), EDSS score postbaseline ≥ 4.0, pyramidal FS ≥ 2, all conditions met for at least 3 months (mg) in the absence of a relapse. Patients progressing to EDSS score ≥ 4.0 were defined by having >1 postbaseline EDSS score ≥ 4.0 with 3- or 6-month CDP. In this post hoc analysis, odds ratios (ORs) and corresponding CIs are estimated by a logistic regression model with treatment and baseline EDSS score ≤ 3.0 or ≤ 3.5 as fixed effects. Results: Overall, proxy SPM progression was seen in 6.7% of CT3.5 patients vs 25% of those on OCR. Patients on OCR had a median change of 0.37 ± 17.30 kg. Changes in weight were negatively correlated with EDSS scores (p = 0.18, P = 0.045), with patients having weight gain having a median EDSS score of 3 (range: 0.7-13.0) and patients having weight loss having a median EDSS score of 4.0 (range: 1.5-7.5). There were no other significant associations. Conclusions: Findings from this preliminary study suggest that weight changes after ocrelizumab are frequently seen, with most patients either gaining or losing weight. As the EDSS score was the only variable associated with weight changes, further investigation is warranted to understand the underlying phenomenon, as well as the normal distribution of weight changes for persons with MS under more controlled time frames and across all levels of EDSS.

Supported by: None

Disclosure: Olivia Wei, Elizabeth S. Gromisch, Lindsay O. Neo, Jennifer A. Ruiz: Nothing to disclose. Peter Wade: Biogen, Celgene, EMD Serono, Genentech, Malinckrodt, Novartis, Sanofi Genzyme (speakers’ bureaus).

Keywords: Disease-modifying treatments in MS, Weight change

(DXT57) FAST: Faster and Safe Administration of Tysabri
Patricia A. Pagnotta
Neurology Associates, PA, and MS Center of Greater Orlando, Maitland, FL

Background: Natalizumab (Tysabri) has been US Food and Drug Administration approved since 2004, and the incidence of infusion reactions is extremely low and has not increased over the 10 years of actual clinical study done for Tysabri. Patients sometimes comment on the burden of being infused monthly and being in the infusion center for 2 hours. In fact, many patients refuse the hour of observation after they are comfortable with infusions. Therefore, it is possible to reduce the amount of infusion time for natalizumab safely? Objectives: To determine if natalizumab can safely be given over 30 minutes vs the standard 60-min-

Disclosure: Patricia A. Pagnotta: Nothing to disclose.

Keywords: Disease-modifying treatments in MS, Tolerability

(DXT58) Reduction of Risk of Secondary Progressive Multiple Sclerosis within 2 Years of Treatment with Cladribine Tablets: An Analysis of the CLARITY Study
Patrick Vermersch,1 Gavin Giovannoni,2,3 Per Soelberg-Sorensen,4 Katli Rammohan,3 Stuart Cook,1 Birgit Keller,5 Sanjeev Ray1
1University of Lille, Lille, France; 2Blizard Institute of Cell and Molecular Science, London, United Kingdom; 3Queen Mary University of London, London, United Kingdom; 4Department of Neurology, Danish MS Center, University of Copenhagen, Copenhagen, Denmark; 5Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 6Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ; 7Merck KGaA, Darmstadt, Germany; 8Merck KGaA, Aubonne, Switzerland

Background: In the CLARITY study of interferon β-1a (125 µg SQ weekly) vs placebo (PBO) for 2 years, patients with secondary progressive multiple sclerosis (SPM) were enrolled. Objectives: To determine if cladribine (CLAD) could reduce the risk of SPM compared to interferon β-1a (IFNβ). Methods: To determine if cladribine could reduce the risk of SPM compared to interferon β-1a (IFNβ). A total of 2562 patients with relapsing-remitting multiple sclerosis were randomized to cladribine (CT3.5 n = 1281; placebo n = 1281) or placebo (PBO). The primary endpoint was time to SPM, defined as two 6-month CDPs in the same EDSS-defined FS, any FS progression, or achieving an EDSS score of 6.0. The secondary endpoint was confirmed SPM, defined by two 3-month CDPs in the leading EDSS-defined FS, any FS progression, or achieving an EDSS score of 6.0. Results: A total of 306 patients (12%) reached the primary endpoint (2.4% vs 12.5), while 54 patients (2.1%) reached the confirmed SPM endpoint (2.2% vs 4.9). Conclusions: Cladribine reduced the risk of SPM compared to interferon β-1a (125 ìg SQ weekly) significantly, as well as reducing confirmed SPM. This study may have implications for the treatment of secondary progressive multiple sclerosis.

Disclosure: Patrick Vermersch: Nothing to disclose. Gavin Giovannoni: Biogen (consulting fee, speakers’ bureau); Celgene, EMD Serono, Genentech, Sanofi Genzyme (speakers’ bureau).

Keywords: Disease-modifying treatments in MS, Multiple sclerosis

Posters: Disease-Modifying Therapy
International Journal of MS Care
36
proxy SPMS component vs placebo. Proportions of patients with at least 1 EDSS reduction ≥3.5 were 6.4% (95% CI: 4.4, 8.5%; P = .0004). Corresponding proportions for patients with 3-month EDSS score ≥6.0 were 3.5% vs 8.0% (CT3.5 vs placebo; OR 0.4 [95% CI: 0.24, 0.66]; P = .0004). Corresponding proportions for patients with 6-month EDSS score ≥6.0 were 2.8% vs 5.8% (CT3.5 vs placebo; OR 0.48 [95% CI: 0.22, 1.02]; P = .0566). Subgroup analysis by baseline EDSS score showed that in patients with baseline EDSS score ≤3.0, 0.8% vs 4.3% had at least 1 EDSS score ≥6.0 (CT3.5 vs placebo; OR 0.18 [95% CI: 0.04, 0.81]; P = .0262). In patients with baseline EDSS score <3.5, the corresponding proportions were 16.2% vs 29.9% (CT3.5 vs placebo; OR 0.45 [95% CI: 0.26, 0.79]; P = .0051).

Conclusions: The risks of progressing to SPMS (proxy) within 2 years of treatment were significantly reduced with CT3.5 compared to placebo, regardless of baseline EDSS score (<3.0 or ≥3.5).

Supported by: None

Disclosure: Patrick Vermersch, Alim드리, Celgene, Novartis, Roche (consulting fee); Biogen, Merck KGaA, Sanofi Genzyme, Teva (consulting fee, research support).

Paper: None

Keywords: Disease-modifying treatments in MS

(DXT59) The CLARITY Study: Efficacy Outcomes Among Patients Who Received Disease-Modifying Drugs Prior to Treatment with Cladribine Tablets

Patrick Vermersch,1 Kohli Rammohan,1 Doris Damjan,2 Gerard Hardy,1
Schiffer L. Wong3
1University of Lille, Lille, France; 2Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 3EMD Serono Inc, Billerica, MA; 4Merck KGaA, Darmstadt, Germany

Background: Cladribine tablets (CTs) 10 mg, [cumulative dose 3.5 mg/kg (CT3.5) over 2 years] showed efficacy vs placebo in patients with relapsing-remitting multiple sclerosis (RRMS) in the pivotal phase 3 HEROClad study. The CLARITY study included patients treated with ≥2 disease-modifying drugs (DMDs) prior to study entry (patients treated with ≥2 DMDs prior to study entry were excluded). A total of 433 patients were randomized to CT3.5 and 437 patients to placebo. Objectives: To report clinical outcomes and magnetic resonance imaging (MRI) lesion counts in the subgroup of patients from CLARITY who had used a DMD at any time prior to randomization. Methods: Post hoc analysis of efficacy, annualized relapse rate (ARR), relapse-free rate, MRI activity, and time to 3-month and 6-month confirmed EDSS score progression (CDP) stratified by the cohort of patients who had received a prior DMD treatment before entering the CLARITY study. P values less than 0.05 were considered nominally significant. Results: Of those patients who received a prior DMD (interferon beta [IFN]-1b, IFN-1b, glatiramer acetate, or natalizumab), 110 were randomized to CT3.5 and 132 received placebo. Among patients with prior DMD use, CT3.5, compared to placebo, resulted in a nominally significant reduction in ARR (CT3.5, 0.22; placebo, 0.42; P < .005), a higher relapse-free rate (CT3.5, 70.4%; placebo, 55.9%; P = .0004), a numerically lower risk of 3-month (hazard ratio [HR] = 0.64; 95% CI: 0.0189, 1.0819; P = .1589) and 6-month (HR = 0.62, 95% CI: 0.2071) CDP, and reductions in the brain lesion counts (P < .001 for each type of lesion).

Conclusions: Among patients who were pretreated with either IFN-1b, IFN-1b, glatiramer acetate, or natalizumab, efficacy outcomes were similar to those seen in the full CLARITY active RRMS population, wherein patients who received CT3.5 showed statistically significant improvements in efficacy outcomes compared to placebo.

Supported by: None

Disclosure: Patrick Vermersch, Alim드리, Celgene, Novartis, Roche (consulting fee); Biogen, Merck KGaA, Sanofi Genzyme, Teva (consulting fee, research support).

Paper: None

Keywords: Disease-modifying treatments in MS

International Journal of MS Care

Posters: Disease-Modifying Therapy

(DXT60) Correlations Between Four Common Measures of Cognition in Patients with Secondary Progressive Multiple Sclerosis

Ralph H.B. Benedict,1 Xiangyi Meng,2 Amit Bar-Or3, Bruce A.C. Cree,4 Robert J. Fox,5
Patrick Vermersch,6 Wendy Su,7 Ludwig Kappos7
1University at Buffalo, State University of New York, Buffalo, NY; 2Novartis Pharmaceuticals Corporation, East Hanover, New Jersey; 3Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 4Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA; 5Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH; 6Department of Medicine, Clinical Research, Biomedicine, and Biomedical Engineering, Neurologic Clinic and Policlinic, University Hospital Basel, University of Basel, Basel, Switzerland

Background: Cognitive impairment is common in patients with secondary progressive multiple sclerosis (SPMS). The oral Symbol Digit Modality Test (SDMT), Paced Auditory Serial Addition Test (PASAT), Symbol Digit Modalities Test (SDMT), Paced Auditory Serial Addition Test (PASAT), and Brief Visuospatial Memory Test-Revised (BVMT-R) were used from the EXPAND study to examine cognitive changes in the EXPAND study. This analysis evaluates whether these tests are redundant or complementary in progressive disease. Objectives: To evaluate relationship between common cognitive tests in patients with SPMS and identify whether these tests provide unique insights on disease progression. Methods: EXPAND was a 36-month, randomized, placebo-controlled trial of siponimod (Mayzent) 2 mg/day in patients with SPMS. Cross-sectional, pairwise Pearson correlations (r) between SDMT, PASAT, and BVMT-R total learning (TL) and delayed recall (DR) indices were calculated by treatment group and combined. Correlations were examined for baseline and change in scores from first postbaseline measurement to month 24. Correlations were strong (r > 0.6), intermediate (0.40-0.60), or weak (<0.40).<r>Correlations were weak between all tests (r = 0.05-0.17; p < 0.05 in many cases).</r>Conclusions: Cognitive outcomes were correlated at baseline, confirming large overlap in variance for BVMT-R indices and intermediate shared variance for all measures at a single time point. Weak correlations of change from month 24 to baseline, SDMT, PASAT, and BVMT-R may suggest that each test tracks different aspects of cognitive decline and/or has different test characteristics when applied repeatedly in patients with SPMS.

Supported by: None

Disclosure: Ralph H.B. Benedict,1 Acorda, Mallinckrodt, National Institutes of Health, National MS Society (contracted research); Biogen (CMC speaking fees, consulting fee, contracted research); Celgene, EMD Serono (CMC speaking fees, consulting fee, contracted research); Genentech, Genzyme, Novartis (consulting fee, contracted research); Psychological Assessment Resources, Inc (royalty); Roche, Sano, Takeda, Varaci (consulting fee); Xiangyi Meng, Wendy Su: Novartis Pharmaceuticals Corporation (salary). Amit Bar-Or: Atara Biotherapeutics, Bayer, Bayhill Therapeutics, Berlex, Biogen, Boehrns, Celgene/Receptos, Diogenes, Eli Lilly, Lilly, Hoffman-La Roche, Genentech, GlaxoSmithKline, Guthy-Jackson/GGF, Immuno, Januvet/Actelion, Map, MedImmune, Merck/EMD Serono, Novartis, Orphan Pharmacia, Roche/Genentech, Sanofi Genzyme, Teya Neuroscience, Wyeth (consulting fee). Bruce A.C. Cree: Akebi, Alexion, Atara, Biogen, EMD Serono, Novartis, TGen Therapeutics (consulting fee); Robert J. Fox: Actelion, EMD Serono, Genentech, Teya (consulting fee); Biogen (consulting fee, contracted research); Biogen, Merck, Novartis (consulting fee, contracted research); Biogen, Merck, Novartis (consulting fee, contracted research); Ludwig Kappos: Actelion, Akerna, Allergan, Alim드리, Bayer, Biogen, Celgene, CSE Behring, dh-imp, European Union, EXCEMED, GeNeuro, Genzyme, Merck, Mitsubishi Tanabe Pharma, Novartis, Pfizer, ReceptoGenetec, Roche, Roche Research Foundations, Sanofi-Aventis, SanoBetta, Swiss Multiple Sclerosis Society, Swiss National Research Foundations, UCB Pharma, Viasense (contracted research); Neurostatus (license fees).

Keywords: Disease-modifying treatments in MS
(DXT61) Injection-Related Reactions with Subcutaneous Administration of Ofatumumab in Relapsing Multiple Sclerosis: Pooled Analysis of the Phase 3 ASCLEPIOS I and II Trials

Rathnakar Pingili,1 Amit Bar-Or2 Jeffrey A. Cohen,3 Patrick K. Coyle,4 Anne H. Cross,5 Stephen L. Hauser,6 Ludwig Kappos,7 Cecile Kerloeguen,8 Ayan Das Gupta,9 Valentine Jehl,10 Dieter A. Haering,11 Krishnan Ramanathan,12 Martin Merschmehk13
1Novartis Pharmaceuticals Corporation, East Hanover, NJ; 2Center for Neuroimmunology and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 3Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH; 4Stanzy Brook University, Stony Brook, NY; 5Department of Neurology, Division of Neuroimmunology, Washington University School of Medicine, St Louis, MO; 6University of California, San Francisco, San Francisco, CA; 7University of Pennsylvania, Philadelphia, PA; 8Molecular Stethoscope, Symbiotix (scientific advisory board member [stock options received]); Annexon, Bionure, Actelion, Minoryx, Receptos, Santhera (consulting fee, steering committee; advisory board; support for educational activities); Bayer Healthcare (consulting fee, speakers’ bureau, steering committee; advisory board; support for educational activities; license fees for Neurostatus products; grants); Biogen, Merck (consulting fee, steering committee, advisory board; support for educational activities; license fees for Neurostatus products; grants); Roche Foundation (grants); Sanofi (consulting fee, speakers’ bureau, steering committee; advisory board; support for educational activities); Novartis, Roche (consulting fee, contracted research, speakers’ bureau, steering committee; advisory board; support for educational activities; license fees for Neurostatus products; grants); Roche Research Foundation (grants); Sanofi (consulting fee, speakers’ bureau, steering committee; advisory board; support for educational activities); Teva (consulting fee, steering committee; advisory board; support for educational activities; license fees for Neurostatus products).

Background: Ofatumumab, the first fully human anti-CD20 monoclonal antibody, with a monthly 20 mg subcutaneous (s.c.) dosing regimen, demonstrated superior efficacy (reductions in clinical relapses by 51%-59%, disability worsening by 33%-34%, and gadolinium-enhancing lesions by 94%-98%) vs teriflunomide in the two phase 3 ASCLEPIOS I/II relapsing multiple sclerosis (RMS) trials. Injection-related reactions (IRRs) were the most common adverse events (AEs) observed.

Objectives: To characterize adverse events (AEs) and local injection reactions (LIRs) associated with ofatumumab in patients with RMS.

Methods: In the pooled ASCLEPIOS I/II trials, patients were randomized (1:1) to receive s.c. ofatumumab 20 mg (n = 946) (loading dose: days 1, 7 and 14; maintenance dose: every 6 months) during a follow-up of 2 years. The first injection was 14.4% with ofatumumab vs 7.5% with teriflunomide. The incidence of systemic IRRs decreased with subsequent doses and was similar to the matching placebo injections in the teriflunomide group. Most IRRs (99.8%) were grade 1/2 in severity; grade 3 IRRs were 0.2%.

Results: Ofatumumab was well tolerated and was similar to the matching placebo injections in the teriflunomide group. Most IRRs (99.8%) were grade 1/2 in severity; grade 3 IRRs were 0.2%.

Conclusions: Supportive

Supported by: None

Disclosure: Rathnakar Pingili, Cecile Kerloeguen, Ayan Das Gupta, Valentine Jehl, Dieter A. Haering, Krishnan Ramanathan, Martin Merschmehk: Novartis (salary). Amit Bar-Or: Atara Biotherapeutics, Biogen, Celgene, EMD Serono, Genentech/Roche, GlaxoSmithKline, Meda, Immune, Merck, Novartis, ReceptoRx, Sanofi Genzyme (consulting fee, grant support, speakers’ bureau). Jeffrey A. Cohen: Adamant, Convedo, Mylan, Population Council (consulting fee); Multiple Sclerosis Journal (co-editor). Patricia K. Coyle: Accordant, Alexion, Bayer, Biogen, Celgene, Sanofi Genzyme, GlaxoSmithKline, Mylan, Serono, TG Therapeutics (consulting fee); Actelion, Alkermes, Corrona LLD, MedDay, National Institute of Neurological Diseases and Stroke, PCORI (contracted research); Genentech/Roche, Novartis (consulting fee, contracted research). Anne H. Cross: Academic CME (CE provider) (speaking and preparation of slides for CME talks); Biogen, Celgene, TG Therapeutics (consulting fee); EMD Serono (consulting fee, speaking engagements); Genentech, Roche (consultation research, speakers’ bureau); Novartis (consulting fee, for non-CME/CE service received directly from commercial interest or its agent, scientific advisory board for ASCLEPIOS I and II; Projects in Knowledge (CE provider) (preparation of educational manuscripts; activities); Rockpointe (Potomac Center for Medical Education) (CE provider) (speakers’ bureau). Stephen L. Hauser: Alector (scientific advisory board member [stock options received]); Anaxxon, Bionure, Molecular Sloth, Symbiotix (scientific advisory board member [stock options previously received]); F. Hoffman-La Roche (travel support/reimbursement and writing support for anti-CD20 meetings and presentations); Neurona (board of directors); Amgen (stock ownership)); Neurostatus (travel reimbursement for anti-CD20 meeting and presentations). Ludwig Kappos: Actelion, Misnjorpe, ReceptoRx, Santhera (consulting fee, steering committee; advisory board); Allergan, Almirall, CSL Behring, Pfizer (support for educational activities); Bayer Healthcare (consulting fee, speakers’ bureau, steering committee; advisory board; support for educational activities; license fees for Neurostatus products; grants); Biogen, Merck (consulting fee, steering committee; advisory board; support for educational activities; license fees for Neurostatus products; grants); Celgene, Genzyme (consulting fee, steering committee; advisory board; support for educational activities); Desitin (support of educational activities); Novartis, Roche (consulting fee, contracted research, speakers’ bureau, steering committee; advisory board; support for educational activities; license fees for Neurostatus products; grants); Roche Research Foundation (grants); Sanofi (consulting fee, speakers’ bureau, steering committee; advisory board; support for educational activities); Teva (consulting fee, steering committee; advisory board; support for educational activities; license fees for Neurostatus products).

Keywords: Disease-modifying treatments in MS, Immunology and MS, Injections-related reactions

(DXT62) Real-World Treatment Patterns in Patients with Multiple Sclerosis Using Disease-Modifying Therapies

Robert J. Fox,† Rina Mehta,† Tim Pham,‡ Julie Park,‡ Kathleen Wilson,‡ Machaon Fung,§ Anne J. Schmidt,∥ Judit T. Hohlfeld§
1Cleveland Clinic, Cleveland, OH; 2Bristol-Myers Squibb, Summit, NJ; 3IBM Watson Health, Cambridge, MA

Background: Numerous disease-modifying therapies (DMTs) have been approved for the treatment of multiple sclerosis (MS) in the past decade, and few studies have assessed patterns of use among all approved DMTs.

Objectives: This study characterized patterns of DMT use in patients with newly diagnosed MS. Methods: Adults newly diagnosed with MS were identified from January 2007 to October 2017 using the IBM MarketScan Commercial and Medicare databases. Patients had at least 12 months of continuous enrollment prior to their initial MS diagnosis and 2 years of follow-up. Up to 3 DMT lines of therapy (LOTs) were reported during a follow-up of 2 to 10.5 years. Discontinuation or switch of therapy was assessed. Results: Of 29,647 patients with at least 2 years of follow-up from MS diagnosis, 14,627 were treated with DMTs. Of these, 49% had 1 DMT LOT during follow-up, 25% had 2 LOTs, and 27% had 3 LOTs. Injectable (subcutaneous or intramuscular) DMTs, comprised increasingly to State (GA), interferon beta-1a (IFNβ-1a) (subcutaneous and intramuscular), interferon beta-1b (IFNβ-1b), and peginterferon beta-1a (pegIFNβ-1a), were used by 87% of patients as first LOT, 68% as second LOT, and 67% as third LOT. Oral DMTs, including dimethyl fumarate, fingolimod, and teriflunomide, were used by 11% of patients as first LOT, but increased to 30% of patients by the third LOT. Overall, the most frequent reasons for discontinuation or switch of therapy were: intolerance, nonadherence, treatment failure, patient preference, or insurance reasons. Conclusions: Of 29,647 patients with at least 2 years of follow-up from MS diagnosis, 14,627 were treated with DMTs. Of these, 49% had 1 DMT LOT during follow-up, 25% had 2 LOTs, and 27% had 3 LOTs. Injectable (subcutaneous or intramuscular) DMTs, comprised increasingly to State (GA), interferon beta-1a (IFNβ-1a) (subcutaneous and intramuscular), interferon beta-1b (IFNβ-1b), and peginterferon beta-1a (pegIFNβ-1a), were used by 87% of patients as first LOT, 68% as second LOT, and 67% as third LOT. Oral DMTs, including dimethyl fumarate, fingolimod, and teriflunomide, were used by 11% of patients as first LOT, but increased to 30% of patients by the third LOT. Overall, the most frequent reasons for discontinuation or switch of therapy were: intolerance, nonadherence, treatment failure, patient preference, or insurance reasons.

Supported by: None

Disclosure: Robert J. Fox: Actelion, Biogen, Celgene, EMD Serono, Genentech, Immunuc, Novartis, Sanofi, Teva, TG Therapeutics (consulting fee); Actelion, Biogen, Immunuc, Novartis (advisory committee); Biogen, Novartis, clinical trial contract and research grant funding); Rina Mehta, Tim Pham: Bristol-Myers Squibb (employment). Julie Park, Kathleen Wilson, Machaon Fung: IBM Watson Health (employment).

Keywords: Disease-modifying treatments in MS, Treatment patterns

(DXT63) Associations Between Treatment Satisfaction, Medication Beliefs, and Adherence to Disease-Modifying Therapies in Patients with Multiple Sclerosis Among Adult Saudis: A Tertiary Care Center Experience

Rala F. Alariak
King Fahad Medical City, Riyadh, Saudi Arabia

International Journal of MS Care

38
Background: Multiple sclerosis (MS) is considered one of the most common neuroimmune diseases that leads to major disabilities in an affected patient with a significant burden and consequences to patients and their families. Even though there is no available cure for MS, the past 2 decades witnessed a promising future for MS treatment drugs, specifically disease-modifying therapies (DMTs), to reduce MS relapse and delay disability. Adherence to DMTs has a significant impact on treatment outcomes and is considered a critical factor in therapeutic success. Accordingly, the need to examine this issue in Saudi Arabia stands.

Objectives: To identify the factors associated with adherence to DMT medications among patients with MS in Saudi Arabia. To evaluate the relationship between treatment satisfaction, medication beliefs, and DMT adherence and other factors.

Methods: A survey was conducted in 2019 in neuromedicine clinics in King Fahad Medical City, Gothenburg, Sweden, and Institute of Neurology and Physiology, University of Gothenburg, Sweden. A total of 239 usable surveys were analyzed. The survey measured self-reported DMT adherence (doses taken divided by doses prescribed during previous 2-week period—adherence ≥20.80), DMT satisfaction using the Treatment Satisfaction Questionnaire for Medication version II, medication beliefs using the Beliefs About Medicines Questionnaire, and demographic and clinical covariates. Relationships between variables were examined using multivariate logistic regression.

Results: Final analyses included 239 usable surveys. Mean ± SD participant age was 35.07 ± 9.7 years. Most respondents were female (74.9%), taking an injectable DMT (49%), and adherent to DMT (64.4%). Significant predictors of DMT adherence were DMT experience (naive vs experienced [odds ratio (OR), 3.722; 95% CI, 2.030-6.871; P = .0003]), DMT route (oral vs injectable; OR, 0.974; 95% CI, 0.950-0.995; P = .012), DMT satisfaction (OR, 0.950; 95% CI, 0.926-0.975; P < .001).

Conclusions: In patients with MS sampled from KFMC’s Data Base, medication beliefs was not significantly associated with DMT adherence while global satisfaction was significantly associated with DMT adherence. Based on significant predictors, patients taking injectable DMTs and patients with previous experience with another DMT(s) are at higher risk for nonadherence. Future research is warranted to assess relationships between variables in more diverse MS populations.

Supported by: None

Disclosure: Rola F. Alarieh: King Fahad Medical City (ownership interest).

Keywords: Adherence to therapy, Disease-modifying treatments in MS

(DXT66) Longitudinal Disability Follow-up in Patients with 6-Month Confirmed Disability Improvement or 6-Month Confirmed Disability Worsening in the CARE-MS and Extension Studies

Background: Multiple sclerosis (MS) is considered one of the most common neuroimmune diseases that leads to major disabilities in an affected patient with a significant burden and consequences to patients and their families. Even though there is no available cure for MS, the past 2 decades witnessed a promising future for MS treatment drugs, specifically disease-modifying therapies (DMTs), to reduce MS relapse and delay disability. Adherence to DMTs has a significant impact on treatment outcomes and is considered a critical factor in therapeutic success. Accordingly, the need to examine this issue in Saudi Arabia stands.

Objectives: To identify the factors associated with adherence to DMT medications among patients with MS in Saudi Arabia. To evaluate the relationship between treatment satisfaction, medication beliefs, and DMT adherence and other factors.

Methods: A survey was conducted in 2019 in neuromedicine clinics in King Fahad Medical City, Gothenburg, Sweden, and Institute of Neurology and Physiology, University of Gothenburg, Sweden. A total of 239 usable surveys were analyzed. The survey measured self-reported DMT adherence (doses taken divided by doses prescribed during previous 2-week period—adherence ≥20.80), DMT satisfaction using the Treatment Satisfaction Questionnaire for Medication version II, medication beliefs using the Beliefs About Medicines Questionnaire, and demographic and clinical covariates. Relationships between variables were examined using multivariate logistic regression.

Results: Final analyses included 239 usable surveys. Mean ± SD participant age was 35.07 ± 9.7 years. Most respondents were female (74.9%), taking an injectable DMT (49%), and adherent to DMT (64.4%). Significant predictors of DMT adherence were DMT experience (naive vs experienced [odds ratio (OR), 3.722; 95% CI, 2.030-6.871; P = .0003]), DMT route (oral vs injectable; OR, 0.974; 95% CI, 0.950-0.995; P = .012), DMT satisfaction (OR, 0.950; 95% CI, 0.926-0.975; P < .001).

Conclusions: In patients with MS sampled from KFMC’s Data Base, medication beliefs was not significantly associated with DMT adherence while global satisfaction was significantly associated with DMT adherence. Based on significant predictors, patients taking injectable DMTs and patients with previous experience with another DMT(s) are at higher risk for nonadherence. Future research is warranted to assess relationships between variables in more diverse MS populations.

Supported by: None

Disclosure: Rola F. Alarieh: King Fahad Medical City (ownership interest).

Keywords: Adherence to therapy, Disease-modifying treatments in MS
(DXT66) Clinical Benefits of Eculizumab Monotherapy in Neuromyelitis Optica Spectrum Disorder: Findings from the Phase 3 PREVENT Study

Jean H. Pittock,1 Achim Berthele,2 Ho Jin Kim,3 Kazuo Fujihara,4,5,6 Michael Levy,7 Ichiro Nakashima,8,9 Celia Ortega-Guarena,10 Jacqui Smedley,11 Murat Terzi,12 Natalia Totolyan,13 Kai-Chen Wang,13,14 Amy Pace,15 Marcus Yountz,15,16 Larisa Miller,17 Guido Sabatella,18 Boisin Armstrong,19 Dean Wingerchuk20

Background: In the PREVENT study in patients with aquaporin-4 immunoglobulin G–positive (AQP4-IgG+) neuromyelitis optica spectrum disorder (NOMOS), eculizumab was associated with a significant reduction in relapse risk vs placebo and was well tolerated. The time course of relapses in prespecified subgroups suggested a treatment effect consistent with that in the overall population, regardless of use of permitted concomitant immunosuppressive or immunomodulatory therapy (IST) (exclusion of corticosteroids or mitoxantrone was excluded). Objectives: To examine the efficacy of eculizumab relative to patients in groups with AQP4-IgG+ NOMOS who did not receive concomitant IST during the randomized, double-blind, placebo-controlled, phase 3 PREVENT trial (trial registration: NCT101892345). Methods: Adverse events (AEs), NOMOS relapse rates, and eculizumab receipt during acute treatment maintenance dose, 1200 mg/2 weeks, n = 96) or placebo (n = 47) with/without concomitant IST. A post hoc descriptive analysis of clinical outcomes was performed using data from patients who did not receive concomitant IST during PREVENT (ie eculizumab monotherapy or placebo without concomitant IST subgroup). Clinical outcomes comprised relapses, hospitalizations and acute treatment for relapses, and worsening of Expanded Disability Status Scale (EDSS) or Hauser Ambulation Index (HAI) scores. Results: Of 34 patients in the no-IST subgroup, 10 had never received IST for NOMOS and 14 had previously received rituximab. Adjudicated relapses occurred in 0/21 patients receiving eculizumab monotherapy and 7/13 (53.8%) receiving placebo (P < .0001; post hoc analysis). In the placebo group, 6/13 patients (46.2%) were hospitalized for adjudicated relapses, 3 (23.1%) received plasma exchange, 4 (30.8%) were treated with acute intravenous methylprednisolone, and 1 (7.7%) received high-dose oral corticosteroids. EDSS scores worsened in 1/21 patients (4.8%) receiving eculizumab monotherapy and 5/13 (38.5%) patients receiving placebo. HAI scores worsened in 1/21 patients (4.8%) receiving eculizumab monotherapy and 4/13 (30.8%) patients receiving placebo. Conclusions: These data further characterize the substantial efficacy of eculizumab monotherapy in reducing relapse risk in patients with AQP4-IgG+ NOMOS. Patients receiving eculizumab monotherapy were spared relapse-associated hospitalizations and acute treatments, and most (95%) did not experience disability worsening. Long-term results from PREVENT’s open-label extension will be presented.

Supported by: None

Disclosure: Jean H. Pittock, Alexion Pharmaceuticals (all compensation paid directly to Mayo Clinic, consulting fee, contract research); AstraZeneca (all compensation paid directly to Mayo Clinic, consulting fee, contract research); Genentech (all compensation paid directly to Mayo Clinic, consulting fee, contract research); Mitsubishi Tanabe Pharma (contracted research); UCB (consulting fee, personal compensation for attending UCB advisory board meeting in Stockholm, Sweden, on Sept 10, 2019); Achim Berthele, Alexion Pharmaceuticals (consulting fee, contract research, fees for non-CME/CE services received directly from commercial interest or its agent, speaker bureau); Ho Jin Kim, Alexion Pharmaceuticals, Celltrion, Eisai, HanAll BioPharma, Merck Serono, Novartis, Sanofi Genzyme, Teva-Hanovia, Viela Bio (consulting fee); Journal of Clinical Neurology (associate editor); Multiple Sclerosis Journal (co-editor); Kazuo Fujihara, Alexion Pharmaceuticals, Biogen, Chugai, Mitsubishi-Tanabe, Novartis (consulting fee, fees for non-CME/CE services received directly from commercial interest or its agent); Asahi Medical, Bayer, Eisai, Roche, Teijin (fees for non-CME/CE services received directly from commercial interest or its agent); Michael Levy, Alexion Pharmaceuticals (consulting contract research, fees for non-CME/CE services received directly from commercial interest or its agent); Genentech, Quest Diagnostics, Viela Bio (consulting fee, fees for non-CME/CE services received directly from commercial interest or its agent); Ichiro Nakashima, Alexion (consulting fee); Celia Ortega-Guarena, Alexion Pharmaceuticals, Merck, Novartis, Roche, Sanofi (consulting fee, contracted research); Jacqueline Palace, Biogen, Chugai (consulted research); LEK, Viela Bio, Guidedpoint (consulting fee); Merck Serono (meeting/lecture/workshop participation); Novartis, Roche, Argex (speakers’ bureaus); UCB, Viela Bio, Roche (conference/lecture participation); Murat Terzi, Shanthi Viswanathan, Kai-Chen Wang: Nothing to disclose. Natalia Totolyan: Alexion, Janzen, Novartis, Roche, Sanofi, Receptos Inc, Biocad (Russia (consulted research); Merck (consulting fee); Roche, Sanofi (fees for lectures). Amy Pace, Marcus Yountz, Guido Sabatella, Boisin Armstrong, Alexion Pharmaceuticals (ownership interest, salary). Larisa Miller, Alexion Pharmaceuticals (RSU, salary). Dean Wingerchuk: MedImmune, Novartis, Biogen, Celgene, Genentech, TG Therapeutics, Arcus Media, Reitune (consulting fee); Terumo BCT, Alexion Pharmaceuticals (fees for non-CME/CE services received directly from commercial interest or its agent).

Keywords: Eculizumab monotherapy in NOMOS

(DXT67) Cognitive Functions over the Course of 5 Years in Multiple Sclerosis Patients Treated with Disease-Modifying Therapies

Serkan Ozakbas,1,2 Cavid Babai,2 Ibaa Alasan,3 Ozge Sagici,3 Yasemin Simsek,3 Pinar Yigil3

Department of Neurology, Dokuz Eylul University, Izmir, Turkey; 2Dokuz Eylul University, Izmir, Turkey; 3Department of Biostatistics, Dokuz Eylul University, Izmir, Turkey

Background: Cognitive decline is common in multiple sclerosis (MS). Disease-modifying therapies (DMTs) are applied to delay or prevent disease progression in MS. While this has mostly been proven for physical status, comprehensive data on cognitive functions are not yet available.

Objectives: We aimed to present 5 years of cognitive data of patients treated with DMTs. Methods: In total, 756 patients with MS who were reassessed at 12-month intervals with different cognitive tests over the course of 5 years (fingolimod: 70.1%, interferons: 71.9%, GA: 75%, P > .05). Cognition improved in some patients (fingolimod: 11.2%, interferons: 9.6%, GA: 8%, P > .05). More than 80% of patients remained stable or improved. The most significant improvement was observed in SDMT, and it was significantly higher than CVLT-II and BVMT-R (30.7%, 18.6%, and 17.6%, respectively, P < .05). Conclusions: In conclusion, cognitive functions remain stable under DMTs over 5 years. This condition has not shown a relationship with the type of medication. Furthermore, SDMT seems to be the best predictor for cognitive change over time.

Supported by: None

Disclosure: None to disclose

Keywords: Disease-modifying treatments in MS, Psychological issues and MS

(DXT69) One-Year Interim Analysis of Real-World Patient-Reported Outcomes in Relapsing-Remitting Multiple Sclerosis Patients Transitioning to Alemizumab (PRO-ACT Study)

BPR: Wang, Francois meuse,1 Jacqueline Nicholas,2 Susan Mozicatto,3 Benjamin Gucker,4 Elizabeth M. Meola,4 Tomaro A. Miller5

1Hope Neurology, Knoxville, TN; 2Clinique Neuro-Outaouais, Gatineau, QC, Canada; 3OhioHealth Multiple Sclerosis Center, Columbus, OH; 4Sanofi, Cambridge, MA; 5Advanced Neurology of Colorado, Fort Collins, CO

Background: Clinical trials of alemtuzumab have demonstrated its 9-year efficacy and safety, but real-world data are limited. PRO-ACT assesses patient-reported outcomes (PROs), safety, and treatment sequencing in adults with relapsing-remitting multiple sclerosis (RRMS) transitioning...
from prior disease-modifying therapy to alemtuzumab in the United States and Canada. The overall 1-year ARR in the PRO-ACT study was 0.32. The primary endpoint evaluated changes in overall satisfaction on the Treatment Satisfaction Questionnaire for Medication v1.4 (TSQM; scale 0-100); higher scores indicate greater satisfaction, after transitioning to alemtuzumab. The SMD between baseline and the year 1 endpoint was 1.14 (0.97), indicating that alemtuzumab resulted in improved outcomes.

**Methods:** PRO-ACT is an ongoing 24-month, prospective, multicenter, noninterventional, single-arm, observational study. The primary endpoint evaluates changes in overall satisfaction on the Treatment Satisfaction Questionnaire for Medication v1.4 (TSQM; scale 0-100); higher scores indicate greater satisfaction after transitioning to alemtuzumab. The SMD between baseline and the year 1 endpoint was 1.14 (0.97), indicating that alemtuzumab resulted in improved outcomes.

**Results:** As of September 2019, enrollment was complete (N = 200 patients). The mean TSQM score improved from baseline to year 1 (0.9) for overall satisfaction (50.3 vs 66.55; P < .0001) and effectiveness (49.3 vs 60.7; P < .0001) domains; scores were unchanged for side effects (77.6 vs 75.5) and convenience (70.3 vs 70.7). Mean scores for other PROs showed improvement at year 1 vs baseline: MSIS-29 physical impact scale (52.4 vs 47.8; P < .001), MSIS-29 psychological impact scale (53.4 vs 47.9; P < .001), and MS-5 (12.8 vs 11.7; P < .001). Scores remained stable on the PDDS (3.1 vs 3.2). Mean hours of weekly employment productivity lost decreased from 11.4 at baseline to 7.4 at Y1 (P < .05). Incidence of adverse events was 92% and serious adverse events was 11%. Quality of life (QoL) (SF-36) was stable at Y1 (P < .05). Conclusions: PROs improved during the first year of alemtuzumab treatment after transitioning from another therapy. Alemtuzumab safety in Y1 was consistent with the pivotal studies.

**Supported by:** Sanofi

**Disclosure:** Sibyl Wray, Alkergen, Biogen, Celgene, Genentech, Novartis, Sanofi, TG Therapeutics (consulting, principal investigator, and/or speaking fees).

**Francisco Jacome:** Biogen, Merck Serono, Novartis, Roche, Sanofi (honoraria for presentations, advisory board participation, research funding, and for an infusion clinic).

**Jacqueline Nicholas:** Biogen, Celgene, EMD Serono, Genentech, Multiple Sclerosis Association of America, National MS Society, Novartis, PCORI, Sanofi (consulting, research, and/or speaking).

**Sibyl Wray:** Bayer, Biogen, Celgene, Genentech, Novartis, Sanofi (employee, may hold stock and/or stock options).

**Keywords:** Age, Disease-modifying treatments in MS.

---

**Posters: Disease-Modifying Therapy**

**DXT71**

**Efficacy and Safety of Teriflunomide in Patients with Relapsing Multiple Sclerosis of Varying Disease Duration: Analysis of Pooled Clinical Trials**

**Stanley Cohen,1 Albert Saiz,2 David Rag,3 Mauro Zaffaroni,4 Sandra Vukusic,5 Steve Vucić,6 Jivan Oh,7 Klaus Tel-Wiel,8 Anat Achiron,9 Darren P. Baker,10 Janneke Wingerden,11 Elizabeth M. Poolo,12 Bhupendra O. Khatri13

1 Providence Brain and Spine Institute, Portland, OR; 2 Department of Neurology, Hospital Universitario de Canarias, La Laguna, Santa Cruz de Tenerife, Spain; 3 Department of Biostatistics and Investigative Biometrics Augsburg Pi; 4 University of Barcelona, Barcelona, Spain; 5 Manchester Centre for Clinical Neurosciences, Salford, United Kingdom; 6 MS Centre, Gallerate Hospital, Gallerate, Italy; 7 University Hospital of Lyon, Bron, France; 8 Department of Medicine, University of Sydney, Sydney, NSW, Australia; 9 University of Toronto, Toronto, ON, Canada; 10 Neurological Fachtarztzentrum Berlin, Berlin, Germany; 11 Sanofi Canada, Mississauga, Canada; 12 Sanofi, Cambridge, MA; 13 Sanofi, Amsterdam, Netherlands; 14 Center for Neurological Disorders at Wheatsen Franciscan Healthcare, Milwaukee, WI

**Background:** Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing forms of multiple sclerosis (MS) or relapsing-remitting MS (RRMS), depending on the local label. **Objectives:** To report the 1-year interim results of the real-world safety and effectiveness of teriflunomide in patients with RRMS stratified by disease duration. **Methods:** This was a pooled efficacy and safety analysis using data from the phase 2 study (trial registration: NCT01487096) and the phase 3 TEMSO (NCT00134563, NCT00803049), TOWER (NCT00715881), and TENERE (NCT00833337) core and extension studies. Patients receiving placebo or teriflunomide 14 mg were stratified by disease duration at baseline (≤ 5 years, >5 to 10 years, >10 years). **Results:** In the core period, ARR was lower in patients treated with teriflunomide 14 mg compared with placebo across disease duration subgroups: ≤ 5 years (0.33 [n = 272] vs 0.56 [n = 251], P = 0.013), >5 to 10 years (0.46 [n = 278] vs 0.70 [n = 268], P = 0.011), >5 to 10 years (0.39 [n = 191] vs 0.52 [n = 164], P = 0.057), and >10 years (0.33 [n = 154] vs 0.58 [n = 129], P = 0.005). In the core extension period (up to year 13), ARRs in teriflunomide-treated patients were similar regardless of disease duration: ≤ 1 year (0.19 [n = 276], >1 to 5 years (0.22 [n = 699]), >5 to 10 years (0.26 [n = 393]), and >10 years (0.25 [n = 325]). At year 13, 6-month CDW rates for each group were 48.3% (≤ 5 years), 37.1% (>1 to 5 years), 52.6% (>5 to 10 years), and 56.8% (>10 years). From core study baseline to year 10 (the last time point at which all groups had at least 10 patients), ARRs were stable and no cases of serious adverse events were observed. **Conclusions:** Teriflunomide 14 mg reduced relapses across all patients regardless of disease duration vs placebo in the core studies. Over 13 years, ARR remained low and EDSS score increased minimally. Safety outcomes from baseline to year 13 were consistent across disease duration subgroups.

**Supported by:** Sanofi

**Disclosure:** Stanley Cohen: AbbVie (research support); Biogen, Novartis, Sanofi (advisory boards, research steering committees, research support, and speaking honoraria); Biogen (employment, consulting, scientific advisory board, speaking, or other activities); EMD Serono, Genentech, Pfizer Therapeutics (employment, consulting, or other activities).
**DXT74**

**An Analysis of the Relationship Between Cladribine Dose and Risk of Malignancies in Patients with Multiple Sclerosis**

Stuart Cook,1 Giovino Giovannini,2,3 Thomas P. Leist,1 Giancarlo Comi,2,4 Axel Nolting,5 Elke Sylvester,5 Dominik Jack,1 Doris Damian,1,2 Andrew Gallo3

1Rutgers, The State University of New Jersey, New Jersey Medical School, Newark, NJ; 2Blizzard Institute of Cell and Molecular Science, London, United Kingdom; 3Queen Mary University of London, London, United Kingdom; 4Jefferson University Hospital, Philadelphia, PA; 5Department of Neurology and Institute of Experimental Neurology, Università Vita-Salute San Raffaele, Milan, Italy; 6Merck Serono SpA, Billerica, MA; 7Merck, Aubonne, Switzerland

**Background:** Malignancy risk was previously characterized in a monotherapy oral cohort of patients with multiple sclerosis (MS) treated with cladribine tablets (CTs) 10 mg (3.5 mg/kg cumulative dose over 2 years; referred to as CT3.5) including cumulative data up to February 2015. In clinical trials, an imbalance in the number of malignancies in CT3.5 vs placebo was observed, suggesting malignancy risk may be increased.

**Objectives:** To provide a more detailed assessment of malignancy using safety data integrated from clinical trials and a safety follow-up registry (up to May 2017), to further characterize the malignancy risk of CTs in patients with MS and investigate whether there is a dose-dependent risk.

**Methods:** Cohorts were monotherapy oral: patients with MS receiving CTs at any dose as a monotherapy; all exposed: patients with MS receiving any formulation of cladribine to provide a larger cohort to identify rare events such as malignancies. **Results:** In the monotherapy oral cohort, patient numbers (patient-years [PYs]) were: placebo N = 641 (2275), CT3.5 N = 923 (3754), CT5.25 mg/kg (CT5.25) N = 632 (2610). The incidence per 100 PYs for malignant tumors during the entire follow up was: placebo: 0.13, CT3.5: 0.27, and CT5.25: 0.23. The risk difference vs placebo was: CT3.5: 0.14 [95% CI (−0.14 to 0.38)] and CT5.25: 0.10 [(−0.18 to 0.39)] in CLARITY CT5.35 patients randomized to CT3.5 in CLARITY Extension [N = 195 for each treatment group], incidence per 100 PYs by CLARITY CT dose was: 0.55 (CT3.5, 1301 PYs) and 0.31 (CT5.25, 1286 PYs) for the entire follow up, 0.91 (CT3.5, 790 PYs) and 0.52 (CT5.25, 784 PYs) for the period following initiation (initial 1 month after randomization). An analysis of all exposed cohort (cladribine N = 1976; placebo N = 802) stratified by cumulative cladribine dose gave the number of patients with a malignant event [incidence per 100 PYs] as: ≥0.35 mg/kg = 6 (0.37), >3.5–5.25 = 14 (0.40), >5.25–7.0 = 6 (0.29), >7.0–8.75 = 8 (0.46), ≥8.75 = 2 (0.21). No hematological malignancies were observed at any time in the pooled dataset. **Conclusions:** Overall, there was no clear evidence of a dose effect of cladribine on malignancy risk in patients with MS based on >9500 PYs of cladribine exposure.

**Supported by:** None

**Disclosure:** Stuart Cook; Actinobac Biomed Inc, Biogen, Merck KGaA, Tesa Pharmaceuticals (advisory board); Bayer HealthCare (advisory board, grant support); University of Pennsylvania Research Avenues (consulting fee); Genovis; Giovannini; AbBiVi, Axicent, Almirall, Abaa Bio, Bayer Schering Pharma, Five Prime, GlaxoSmithKline, GW Pharma, Merck KGaA, Pfizer Inc, Protein Discovery Laboratories, Sanofi Genzyme, Tesa Pharmaceuticals Industries Ltd, UCB, Ver tex Pharmaceuticals (consulting fee); Biogen, Ironwood, Merck and Co, Novartis (consulting fee, unrelated research support). Thomas P. Leist: Acorda, Bayer, Biogen, Dacichi, EMD Serono, Novartis, Ono, Pfizer, Teva Neuroscience (consulting fee). Giancarlo Comi: Almirall Spa, Biogen, Biogen Italia SpA, Celgene Group, EXCEMED, F. Hoffman-La Roche, Forward Pharma, Genzyme Corporation, Genzyme Europe, MedDay, Medir, Merck KGaA, Merck Serono SpA, Novartis, Roche SpA, Sanofi Genzyme, Teva Italia Srl, Tesa Pharmaceutical Industries Ltd (consulting fee). Anal Nolting, Elke Sylvester, Dominik Jack; Doris Damian, Andrew Gallo3.

**Keywords:** Disease-modifying treatments in MS
Patient Clinical Profiles and Therapy Selection Drivers
Virginia R. Schobel, 1 Jennifer Robinson 2

Background: With the approval of siponimod (BAF), cladribine (CdA) and dimethyl fumarate (DFM) in the United States, the number of oral disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS) has grown. Objectives: To compare clinical, treatment history, and switch drivers among patients with MS recently switched to an oral DMT. Methods: In February 2019, 209 US neurologists contributed to a cross-sectional, retrospective chart audit of patients with MS (n = 1003 total; n = 718 relapsing-remitting MS [RRMS]) switched to a new DMT after no more than 3 months since their first DMT no more than 3 months prior (ie, new-start patients) has been available at switch. Analyses will be updated with February 2020 data. Results: Most patients recently switched to an oral DMT were diagnosed with RRMS (87%-92%). Oral DMTs constituted 43% of RRMS switches, with 11% switched to teriflunomide (TLF). 16% to fingolimod (FTY), 11% to demethyl fumarate (DMF). Oral switches were predominantly first switches (85%-89%); such switches were frequently due to efficacy (39%-43%) or tolerability (25%-29%). Patients switched to FTY were more likely to have switched from another oral DMT compared to those switched to DFM (21% vs 7%, P < .05). Desire for a high-efficacy DMT drove more FTY switch selection (60% vs TLF: 32%, DFM: 35%, P < .05), whereas patient request (30% vs FTY: 15%; P < .05) and lack of monitoring (16% vs FTY: 2%; P < .05) were more influential in DMT switches and long-term safety in TLF switches (39% vs FTY: 20%; P < .05). Compared to the established oral DMTs, candidates for alternative BAF, CdA, or DFM switches were less likely to be diagnosed with RRMS and more likely to have had a second or later switch. Patients with RRMS considered CdA candidates were more likely to have switched from an oral DMT compared to noncandidates (22% vs 12%; P < .05); administration type preference (43% vs 26%; P < .05), good tolerability preference (49% vs 38%; P < .05), and long-term safety (34% vs 22%; P < .05) drove more of the switched-to DMT selections among CdA candidates. DFM candidates were more likely to have switched from another oral DMT compared to noncandidates (34% vs 16%; P < .05). Conclusions: Switches to established oral DMTs are typically first switches among patients with RRMS, although FTY may be reserved as a high-efficacy option for patients in whom a prior oral DMT failed. Oral class impact will grow within the switch segment with the availability of new oral options; however, the recently approved therapies will initially be niched as later line options. 2020 chart audit data will assess early adoption patterns and selection drivers among patients switched to BAF, CdA, or DFM.

Supported by: None Disclosure: Nothing to disclose Keywords: Disease-modifying treatments in MS

(DXT75) Allentuzumab Maintains Efficacy on Clinical and Magnetic Resonance Imaging Lesion Outcomes, Including Slowing of Brain Volume Loss, Over 9 Years in Relapsing-Remitting Multiple Sclerosis Patients: CARE-MS II Follow-up (TOPAZ Study)
Barry A. Singer, 1 Roald Alroughani, 2 Ann D. Bass, 3 Simon Broderick, 4 Yang Mao-Draayer, 5 Hans-Peter Hartung, 6 Eva Kubala Havrdova, 7 Ho Jin Kim, 8 Kunia Nakamura, 9 Carlos Alvarez-Rivola, 10 Patrick Vermersch, 11 Silvi Wray, 12 Zico Choudhury, 13 Nadia Daizadzer, 14 Salman Afzal, 15 Giancarlo Comi, 16 and Malhotra of the CARE-MS II, CAMMS03409, and TOPAZ Investigators

The MS Center for Innovations in Care, Missouri Baptist Medical Center, St. Louis, MO; 2Amin Hospital, Shariq, Kuwait; 3Neurology Center of San Antonio, San Antonio, TX; 4Griffith University School of Medicine, Gold Coast Campus, Southport, QLD, Australia; 5University of Michigan Medical School, Ann Arbor, MI; 6Department of Neurology, UKD, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; 7First Medical Faculty, Charles University, Prague, Czech Republic; 8Research Institute and Hospital of National Cancer Center, Goyang, Korea, Republic of (South); 9Cleveland Clinic, Cleveland, OH; 10Clinica Universidad de Navarra, Pamplona, Spain; 11University of Warms and Mazury, Olsztyn, Poland; 12University of Lille, INSERM U995, CHU Lille, Lille, France; 13Hope Neurology, Knoxville, TN; 14Sonassi, Cambridge, MA; 15University Vita-Salute San Raffaele, Milan, Italy

Background: In CARE-MS II (trial registration: NCT00548405), allentuzumab (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved clinical/magnetic resonance imaging (MRI) outcomes vs subcutaneous interferon beta-1a (SC IFN-β1a) over 2 years (y) in patients with RRMS with inadequate response to prior therapy. Efficacy was maintained in a 4-year extension study (NCT00930553), wherein patients could receive additional allentuzumab courses (12 mg/day on 3 days, 12 months apart) as needed for disease activity, or receive other disease-modifying therapy (DMT) per investigator discretion. Further follow-up was available in an additional 5-year extension, TOPAZ (NCT02255656). Objectives: Evaluate the efficacy and safety of allentuzumab in CARE-MS II patients over 9 years. Methods: At investigator discretion, patients in TOPAZ can receive additional as-needed allentuzumab (≥12 months apart, no criteria) or receive other DMT (at any time). Results: From core study baseline through year 9, 288/435 (66%) CARE-MS II allentuzumab-treated patients remained on study; 41% received either additional allentuzumab or another DMT through year 9. Annualized relapse rate was 0.19 in years 3-9. From core study baseline through year 9, 66% of patients had stable/improved Expanded Disability Status Scale (EDSS) scores, and 43% had no EDSS worsening compared to baseline 

Support Updated with December 2019 data will be included at presentation. Disclosure: None Disclosure: Nothing to disclose Keywords: Disease-modifying treatments in MS

(DXT76) First-Line Ocrelizumab Use for Relapsing-Remitting Multiple Sclerosis in the United States: Trend and Comparison to Glatiramer Acetate and Dimethyl Fumarate
Virginia R. Schobel, 1 Jennifer Robinson 2

Background: In March 2017, ocrelizumab (OCR) was approved for the treatment of relapsing-remitting and primary progressive multiple sclerosis (MS), irrespective of prior therapy exposure. The relapsing-remitting MS (RRMS) indication was updated in July 2019 to encompass all relapsing forms of MS, including clinically isolated syndrome, RRMS, and active secondary progressive MS. Objectives: To trend OCR uptake among previously treatment-naïve patients with RRMS and compare characteristics of patients with RRMS initiated on first-line OCR to those initiated on one of the more established platform disease-modifying therapies (DMTs), glatiramer acetate (GA) or dimethyl fumarate (DFM). Methods: A retrospective, cross-sectional chart audit of patients with MS who initiated their first DMT no more than 3 months prior (ie, new-start patients) has been conducted with US neurologists (2016 n = 242; 2017 n = 274; 2018 n = 213) each December. Data were based on contributed RRMS patient chart reviews (2016 n = 777; 2017 n = 801; 2018 n = 758). GA includes patients treated with either a branded or generic agent. December 2019 data will be included at presentation. Results: In 2018, OCR was prescribed to 7%, GA to 32%, and DFM to 19% of new-start patients with RRMS—stable with prior years. Although neurologists are more likely to agree with risk factors suggesting OCR vs patients with RMS (57% vs 38% in 2017; P < .05), statement agreement did not correlate significantly with OCR share. While OCR patients were more likely to be male (OCR: 43%; GA: 24%; DFM: 26%); mean age or age category allocation did not differ between subgroups. Patients with RRMS initiated on OCR were more likely to have a perceived unfavorable long-term prognosis (OCR: 49%; GA: 11%; DMF: 8%) and to be having disability progression (OCR: 24%; GA: 11%; DMF: 9%). In comparison, patients taking GA and DFM were more likely to have no symptoms per the modified Rankin Scale (OCR: 5%; GA: 29%; DMF: 33%). Patients taking OCR had a greater mean T2 lesion burden at the most recent magnetic resonance imaging scan (OCR: 6.9; GA: 4.3; DMF: 4.1) and compared to platform DMTs, OCR is most likely to be selected when a high-efficacy agent is required, suggesting a poor long-term prognosis at the time of DMT treatment initiation. Supported by: None Disclosure: Nothing to disclose Keywords: Disease-modifying treatments in MS

Posters: Disease-Modifying Therapy

International Journal of MS Care 43

Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 18 September 2020
Brain volume (BV) change was −1.22%, median percent BV change was 0.5% annually over years 3-9. Incidence of overall adverse events (AEs) and infections declined through year 9; cumulative thyroid AE incidence was 43.7% and immune thrombocytopenia (ITP) incidence was 3.7% (1 new case of ITP, 14 months after the fourth alemtuzumab course, was observed at year 9). No new cases of nephropathy were reported. Efficacy and safety in SC IFNβ-1a-treated patients from the core study with 9 years of follow-up in the extension were consistent with those treated with alemtuzumab both in the core and extension. Conclusions: Efficacy of alemtuzumab on clinical, MRI, and BV loss outcomes was maintained over 9 years in CARE-MS II patients, with 41% receiving no further treatment through year 9. Safety in year 9 in this study was consistent with that of previous years.

Supported by: Sanofi, Bayer Healthcare Pharmaceuticals

Disclosure: Barry A. Singer, AbbVie, Biogen, Novartis, Roche, Sanofi (research support; speaking and/or consulting); Acorda, Alexion, Bayer, Celgene, EMD Serono, Genentech, Teva, TG Therapeutics (speaking and/or consulting); Allergan, MedImmune (research support). Ratel Alroughani: Bayer, Biogen, Biologix, Genpharm, GlassSmithKline, Lundbeck, Merck Serono, Novartis, Sanofi (speaker honoraria, scientific advisory boards, research grants). Ann D. Bass: Biogen, EMD Serono, MedImmune, Novartis, Roche–Genentech, Sanofi, TG Therapeutics (consulting fees for non-CME services from commercial interests or their agents speaking engagements or educational support). Samir Badar: Biogen, Merck Serono, Novo Nordisk, Sanofi (conference travel sponsorship, honoraria for advisory board participation); Biogen (conference travel sponsorship, honoraria for advisory board participation, speaker honoraria, unencumbered research grant); Genzyme (speaker honoraria). Yang Mao-Draayer: Acorda, Bayer, Biogen, Celgene, Chugai, EMD Serono, Genzyme, Novartis, Quester, Teva Neuroimmune (consulting fees and/or grant support); NIH National Institute of Allergy and Infectious Diseases Autoimmune Center of Excellence, NIH National Institute of Neurological Disorders and Stroke R01-NS080821 (grant support). Hans-Peter Hartung: Bayer, Biogen, CSL Behring, Grifols, Merck Serono, Novartis, Roche, Sanofi (consulting and/or speaking fees). Katerina Hrabavcova: Actelion, Biogen, Merck Serono, Novartis, Receptos, Roche, Sanofi, Teva (honoraria, grant support); Ministry of Education of Czech Republic [PROGRES Q27/LF1] (support). Jin Kim: Bayer Schering, Biogen, Cellerion, Eisai, HanAll BioPharma, Novartis (consulting and speaking fees); Zai ChaoSheng, Bayer Schering, Merck Serono, Novartis, OLEA Medical, Roche, Sanofi, Synthorx (consulting and speaking fees); Hampson W. Selman: Biogen, Merck, Novartis, Roche, Sanofi, Synthorx (consulting and speaking fees); Patrick Vermeersch: Almirall, Biogen, Celgene, Genentech, Merck, Novartis, OLEA Medical, Roche, Sanofi, Synthorx (consulting and speaking fees); Kwanwoof W. Selman: Biogen, Merck, Novartis, Roche, Sanofi, Synthorx (consulting and speaking fees). Gokmen Cem: Actelion (consulting fee); Bayer Schering, Merck Serono, Novartis, Teva (consulting fee, lecture fees); Biogen Dompé, Sanofi, Taro Symposia International Foundation (lecture fee).

Keywords: Disease-modifying treatments in MS

(DXT79) Efficacy of Ocrelizumab Treatment on Cognitive Functions in Persons with Multiple Sclerosis

Serkan Ozakbas,1 Ozge Sagici,2 Zuhul Absaloningan,3 Tuoba Ozdrozba,4 Pinar Yigit5
1Department of Neurology, Dokuz Eylul University, Izmir, Turkey; 2Dokuz Eylul University, Izmir, Turkey

Background: Ocrelizumab is the first treatment which could be used for progressive forms of multiple sclerosis (MS). Generally ocrelizumab trials in MS investigate side effect and safety properties. There are limited studies examining effects of ocrelizumab on cognition in patients with MS (PwMS). Objectives: The aim of this study was to evaluate the efficacy of ocrelizumab treatment on cognitive functions in PwMS. Methods: In total, 35 PwMS were included in this study. The participants’ clinical characteristics such as MS type, disease duration, and Expanded Disability Status Scale (EDSS) scores were recorded. Cognitive function was evaluated with The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) battery, which consists of the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test (CVLT), and the Brief Visuospatial Memory Test–Revised (BVMT-R). The assessment was done at baseline and in the follow-up at 6 and 12 months after the treatment. Results: The average disease duration was 16.84 ± 8.19 and EDSS score was 6.23 ± 1.43. Participants’ clinical characteristics of the disease were 11.4% relapsing-remitting (RRMS), 57.1% in (n = 20) secondary progressive (SPMS), and 31.4% (n = 11) primary progressive MS (PPMS). BVMT-R and CVLT-II scores were significantly increased 0.21 ± 0.32 and 0.53 ± 0.70 at month 6, respectively, compared to baseline assessment. 20.71 ± 7.85 vs 23.68 ± 7.05, 45.03 ± 11.97 vs 49.43 ± 12.45.

Keywords: Disease-modifying treatments in MS

(DXT78) The FLUENT Study: Changes in Immune Cell Profile, and in Clinical and Safety Outcomes, in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis

Yang Mao-Draayer,1 Jeffrey A. Cohen,2 Amit Bar-Or3, May H. Han,4 Barry A. Singer,5 Nina Joaicy,6 Scott Kolodny,6 Chelsea Elam,6 Xiangyi Meng,6 Marina Ziehn,6 Ho Jaitly,6 Scott Kolodny,6 Chelsea Elam,6 Xiangyi Meng,6 Marina Ziehn,6
1Department of Neurology, Dokuz Eylul University, Izmir, Turkey; 2Dokuz Eylul University, Izmir, Turkey
EPIDEMIOLOGY AND GENETICS

(EP01) Determining the Effect of Early Versus Later Diagnosis of Multiple Sclerosis on Long-Term Prognosis in a Real-World Setting

Jikkku Zachariah,1 Rebecca Schor,2 Tim Quezada,3 Thomas F. Scott1,2

1Department of Neurology and Neuroscience Institute, Allegheny General Hospital, Allegheny Health Network, Pittsburgh, PA; 2Highmark Health Data Science R&D, Highmark Health, Pittsburgh, PA; 3Department of Neurology, Drexel University College of Medicine, Philadelphia, PA

Background: Early treatment of multiple sclerosis (MS) is recommended based on studies involving patients identified early with clinically isolated syndromes. Although early diagnosis and subsequent early treatment might have a beneficial effect on patient outcomes, little is clinically important. Additionally, to better understand the effects of ocrelizumab treatment on cognitive functions, it is necessary to perform studies with longer follow-up periods.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Disease-modifying treatments in MS, Psychological issues and MS

(EP02) Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)

Kottil Rammohan,1 David Li1,2 June Halper,3 Sara McCurdy Murphy,4 Trent Wallace,5 Lisa Patton,6 Sarah Chrisant,7 Chao Zheng,6 Seema Khurana6

1Department of Neurology, Multiple Sclerosis Center, University of Miami, Miami, FL; 2The University of British Columbia, Vancouver, BC, Canada; 3CEO-CMSc, Hackensack, NJ; 4CRB, Social & Scientific Systems, Inc, Silver Spring, MD; 5CRB, Social & Scientific Systems, Inc, Durham, NC; 6University of Miami, Miami, FL

Background: The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) is a longitudinal registry studying the course of multiple sclerosis (MS) within the disease-modifying era. Objectives: To examine motor performance metrics of upper and lower extremities. Our initial observations about EDSS, 25-foot timed walk, and the Nine-Hole Peg Test (NHPT) are reported below.

Results: EDSS scores and 25-foot walk times were available in 572 patients and upper extremity function in 571 patients. A mean walking speed of 4.9 seconds was recorded in patients with an EDSS score of 0 (n = 100). 5.0 seconds remained the mean speed until an EDSS score of 3 (n = 37), where a mean speed of 5.6 seconds was recorded. Walking truly became affected at an EDSS score of 3.5 (n = 25), where mean speed of 6.1 seconds was recorded. Thereafter, mean speed progressively declined at every EDSS score increase. For an EDSS score of 4.0 (n = 25), mean speed was 7.9 seconds; for an EDSS score of 4.5 (n = 6), mean speed was 9.1 seconds and continued to increase until an EDSS score of 6.5 (n = 10), where mean speed was 16.8 seconds. For the NHPT, patients with an EDSS score of 0 (n = 96) had a mean speed of 19.4 seconds in the dominant and 20.7 seconds in the nondominant hand. Hand function remained unimpaired until an EDSS score of 2.0, and significant slowing occurred in patients with EDSS scores ranging from 2.5 to 6.5. For an EDSS score of 2.5 (n = 40), mean speed was 24.7 seconds in the dominant and 24 seconds in the nondominant hand. For an EDSS score of 4.0 (n = 26), mean speed was 26.1 seconds in the dominant and 26.6 seconds in the nondominant hand. For an EDSS score of 6.5 (n = 15), hand function had declined to a mean speed of 39.1 seconds for the dominant and 49.8 seconds for the nondominant hand.

Conclusions: A linear correlation of the 25-foot walk speed to EDSS score increases was remarkable, reiterating the commonly held belief that the EDSS is a “walking scale.” Decline in hand function at an EDSS score of 2.5 was unexpected, because hands are often perceived to be unaffected early in MS and seldom observed as impaired by patients. Progressive decline of hand function at every EDSS score increase would suggest that the NHPT test is a good marker of declining hand function and should be included in clinical monitoring of patients.

Supported by: None

Disclosure: Kottil Rammohan: Alexion, Biogen, EMD Serono, Genentech, Novartis (consulting fee, grant); Department of Defense, TG Therapeutics (grant); Genzyme (consulting fee). David Li: Roche, Sanofi Genzyme (contracted research). UBC MS/MRI Research Group (salary); Vertex Pharmaceuticals (consulting fee). June Halper, Sara McCurdy Murphy, Trent Wallace, Lisa Patton, Sarah Chrisant, Chao Zheng, Seema Khurana: Nothing to disclose.

Keywords: Epidemiology of MS

(EP03) Increase in Family Recurrence in Patients Diagnosed with Multiple Sclerosis in the Years 2017-2019 in Hispanic Population of Puerto Rico

Viviana Martinez, Astrid Diaz, Cristina M. Rubi, Ivonne Vicente, Angel Chinea

San Juan Multiple Sclerosis Center, Guaynabo, PR

Background: Multiple sclerosis (MS) is a neurodegenerative disease in which the immune system damages the central nervous system. The cause of MS is not known, but several studies look at environmental, immunologic, geographic, and genetic factors. Thus, MS is not considered hereditary, but rather polygenic. However, there are several cases of patients with family history of MS in several relative degrees. Objectives: Evaluate the risk of MS recurrence of patients diagnosed with MS in recent years in Puerto Rico (PR), including any type of degree relative. Methods: For this data, from the Puerto Rican MS Registry (PRMS Registry) of all patients diagnosed in the years 2017, 2018, and 2019 registered at present in PR were analyzed. Results: Overall 11.4% (45/396) of patients had family recurrence of MS. For 2017, 9.7% (14/143) of patients had family history of MS of at least 1 family member. For 2018, 8.3% (14/167) of patients presented family history of MS. Lastly, for 2019 a total of 19.7% (17/86) of patients reported having family history of MS. Conclusions: A slight increase in recurrence was observed when compared to the previous study from 2013 to 2016 (10.2%). Further investigations need to be done to elucidate the genetic aspects of family recurrence of MS among the Puerto Rican population. The genetic mix of Caucasian, African, and Taino races could have an influence on genetic risk among this population. Also, it is important to keep this study ongoing to analyze familial risk in the Hispanic population and compare it to other ethnic groups.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Epidemiology of MS, Genetics and MS

(EP04) Diet Quality and Nutritional Adequacy of Micronutrients Among People with Relapsing-Remitting Multiple Sclerosis: An Analysis of Weighed Food Records

Tylor J. Tichonick,1 Linda G. Snelson2,3 Terry L. Wolski1

1Department of Health, Physical Education, and Recreation, University of Hartford, West Hartford, CT; 2School of Business, University of Hartford, West Hartford, CT; 3Department of Dietetics and Nutrition, University of Hartford, West Hartford, CT

Background: Relapsing-remitting multiple sclerosis (RRMS) has many possible causes and is characterized by periodic attacks of neurological symptoms. Objectives: To evaluate the diet quality of RRMS patients and the adequacy of their nutritional intake. Methods: RRMS patients were recruited in 2016 and 2017. Results: A total of 114 RRMS participants were recruited. The mean age of participants was 41.6 ± 13.2 years, and 62% were female. The mean body mass index (BMI) was 30.3 ± 8.6 kg/m², and 52% of participants were overweight. The mean daily energy intake was 1685 ± 438 kcal, and the mean daily protein intake was 51 ± 15.67 g. Conclusion: RRMS patients had a lower diet quality and nutritional adequacy compared to the general population. This study has suggested that ocrelizumab treatment could be affected positively on verbal and visual learning/memory. On the other hand, there was no positive or negative effect on information processing speed. In view most of our patients being in progressive form, the protective or positive effect of ocrelizumab on cognitive functions is clinically important. Additionally, to better understand the protective or positive effect of ocrelizumab treatment on cognitive functions, it is necessary to perform studies with longer follow-up periods.
Background: Multiple sclerosis (MS) is a neurodegenerative disease that affects nearly 1 million in the United States. Poor diet quality and micronutrient deficiencies have been reported in several studies and are associated with more severe disease. However, previous work has relied on diet screens and questionnaires for data collection. Thus, these findings may be influenced by the lack of precise data collection instruments such as weighed food records. Objectives: Weighed food records were used to evaluate diet quality and usual intake of micronutrients from people with diagnosed relapsing-remitting MS (RRMS). Methods: As part of a pilot intervention study comparing the Wahls and Swank diets, 3 weighed food records were collected on 2 weekdays and 1 weekend day over a 3-week period for each of the n = 95 participants and again at a baseline visit from the n = 87 non-excluded participants. Food records obtained from all participants were analyzed at the University of Minnesota Nutrition Coordinating Center. Diet quality was assessed using the Healthy Eating Index (HEI), which compares food groups and selected nutrient intakes to the Dietary Guidelines for Americans. Mean intake of each micronutrient was calculated for each individual and adjusted using the National Cancer Institute method to estimate usual intake. Usual intake of each micronutrient was then evaluated with the estimated average requirement cutpoint method for each life stage group and combined by weighted means to assess the overall nutritional adequacy of each individual for the group. Results: Preliminary analyses indicate that this cohort has an HEI score of 61 ± 12, which suggests that diet quality needs improvement. Furthermore, this cohort has high prevalence of inadequate intake for vitamins D 92.9%, E 61.4%, C 50.8%, A 35.3%, folate 31.0%, and B2 22.8%, and minerals including calcium 49.8%, magnesium 45.8%, and zinc 19.5%. However, low prevalence of inadequate intake for niacin 0.2%, thiamin 7.5%, riboflavin 3.0%, B6 5.4%, phosphorus 2.0%, copper 6.6%, and selenium 1.0%. Conclusions: Diet quality is low and intake of several micronutrients is inadequate in this cohort with RRMS. These findings confirm observations from previous studies that poor diet quality and inadequate intake of micronutrients is common among those with RRMS. These findings may lead to new dietary strategies to manage symptoms and improve quality of life among those with MS.

Supported by: None
Disclosure: Nothing to disclose
Keywords: MS, Caregiver/Family

FAMILY AND CAREGIVERS

(FAM01) Characterizing Predictors of Resilience Among Family Caregivers of People with Advanced Multiple Sclerosis Disability: Work in Progress
Afolasade Falokalade,1 Odyssey McKeena,2 Mark S. Freedman,2 Marcia Finlayson,3 Amy E. Latimer-Cheung,2 Lara A. Piltz1
1Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 3School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada; 4Kinesiology and Health Studies, Queen’s University, Kingston, ON, Canada
Background: Providing ongoing support can adversely affect physical, psychological, and social health of care partners of people with advanced multiple sclerosis (MS). However, some care partners have also reported positive experiences and benefits of MS caregiving (eg, greater sense of commitment and pride in the role). This variability highlights the importance of understanding protective factors that can buffer against the adverse effects of caregiving. Psychological resilience describes positive adaptations to stressful situations and includes individual, community, and societal level factors. Research in other caregiving contexts has shown that resilience is associated with improved health outcomes and lower levels of caregiver burden. Unfortunately, there is limited research on resilience in the context of MS caregiving. Generating this knowledge is important to guide the development of interventions to enhance resilience and to identify individuals most likely to benefit from future intervention. Objectives: To examine the relationships between resilience and a comprehensive set of individual, community, and societal level factors in the context of MS caregiving. Methods: A cross-sectional survey study. We are collecting data as part of a pilot randomized controlled trial evaluating the feasibility and efficacy of a dyadic physical activity program for people with advanced MS and their care partners. Eligibility criteria include care partners who: 1) are ≥18 years old, 2) provide ≥1 hour/day of care, 3) are inactive, 4) are asymptomatic, and 5) are able to communicate in English. Care partners will complete demographics and general health questionnaires. The following scales will also be administered: 1) Caregiving Tasks in MS Scale, 2) Connor-Davidson Resilience Scale, 3) Interpersonal Support Evaluation List-12, 4) Coping with MS Caregiving Inventory, 5) Measure of Experiential Aspects of Participation, and 6) Godin Leisure-Time Exercise Questionnaire. We will conduct regression modelling to identify predictors of resilience among care partners. Results: Data collection is ongoing. Anticipated completion date is March 2020. We will present findings on resilience and associated factors among MS care partners.

Supported by: None
Disclosure: Nothing to disclose
Keywords: MS and the caregiver/family

INTERNET AND INFORMATION SERVICES

(IS01) North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) Model for Implementing OpenClinica Insight for Data Sharing and Visualization
Peter Gilbertson,1 Trent Wallace,2 Lydia Rogers,3 Sara McCurdy Murphy,3 Lisa Patton,3 Sarah Chrisianti,1 David Li,4 June Halper,5 Kanti Ramamohan5
1Health Services, Clark County School District, Las Vegas, NV; 2Kent, WA
Background: Fatigue, defined as the difficulty or inability to perform tasks due to a lack of sufficient energy, is one of the key symptoms of multiple sclerosis (MS). The level of fatigue is difficult to quantify and explain to a person without the condition. Interactions between persons with MS (PsWMS) and those without (PsWO) with whom they have interpersonal relationships can be damaged by this lack of understanding. The Roy Adaptation Model (RAM) (Roy C Sr, Andrews HA. The Roy Adaptation Model, 2nd ed. Appleton and Lange; 1999 ) provides a nursing framework through which to assess, intervene, and evaluate the effective communication between PsWMS and PsWO. The RAM views persons or groups of persons as interdependent entities in constant interaction with their environment. A central portion of the theory, the interdependence adaptive mode, focuses on the communication between a person and his or her significant other/support group. Clear understanding of the message sent and received and the ensuring healthy adaptations to their interactive communication resulting in behavioral change are the goals. Objectives: By quantifying the amount of energy each activity takes, PsWMS will be able to communicate more clearly their level of energy and, inversely, their level of fatigue. Relational stress will decrease and communication between PsWMS and PsWO will improve. Methods: A MS support group composed of 23 persons, some with advanced MS, were selected to participated in a 2-hour educational, interactive session, which focused on defining units of energy and describing how many may be needed for both activities of daily living and special events. The PsWO “tried on” different symptoms of MS throughout the session to gain a better understanding of the challenges facing the PsWMS. At the same time, the PsWMS focused on self-assessment and became more aware of the frustrations expressed by the PsWO. Both subgroups practiced active listening techniques. Results: After 2 months, all 23 persons reported improved relationships due to decreased stress and a better understanding of the effects of MS. Conclusions: Teaching a simple method of communicating MS fatigue greatly improved the quality of life of PsWMS and those with whom they interact. Using units of energy within conversations improved communication and enabled more positive interdependent interactions with caregivers, family members, and their colleagues in the workplace.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Fatigue, Management of activities of daily living in MS, MS and the caregiver/family

Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 18 September 2020
Background: The North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) is a clinic-based longitudinal registry of sites located in the United States and Canada. Active since 2015, the registry engages a public-private partnership aiming to improve multiple sclerosis (MS) care and understanding as a database of clinical records and patient-centered outcomes. With enrollment, yearly follow-up and exacerbation-based visits, patients provide demographic, medical history, attack history, and health productivity information supplemented with physician-collected physical and cognitive assessments. In just a few years the registry has generated several hundred thousand points of data on a wide variety of health-related topics from the current 22 participating sites. The registry includes data from standardized interviews and physician evaluations and is adding self-administered patient-reported outcomes in the coming months. Objectives: To develop a model to share aggregated data from individual sites to enable participating sites and industry partners the ability to view and analyze larger, multisite datasets for research and exploration. Methods: OpenClinica is an open-source software-as-a-service electronic data collection (EDC) system most often used for data collection and data management in a clinical setting. OpenClinica Insight, built on the open-source Metabase platform, is a data reporting and sharing tool available as part of OpenClinica’s Enterprise system that connects directly to the EDC database and allows real-time data access, visualization, and downloading. To implement Insight, the team coordinated with project leadership, industry, and cooperating investigators to develop a process for defining roles and relationships, defining appropriate summary charts and graphs to summarize collected data, and defining data access parameters and restrictions. Results: OpenClinica Insight provides a platform to leverage limited standardized patient-derived data on a prospective basis. The platform is useful and end-user friendly and allows for efficient information sharing across the pool of geographically diverse clinical research sites to provide insights into local, regional, and continental patterns and standards of MS care. Conclusions: OpenClinica Insight is a powerful tool to report information from OpenClinica Enterprise, and the model developed for NARCRMS should serve as an example for integrating informatics from large industry partners the ability to view and analyze larger, multisite datasets for research and exploration.

Methods: OpenClinica is an open-source software-as-a-service electronic data collection (EDC) system most often used for data collection and data management in a clinical setting.

Objectives: To develop a model to share aggregated data from individual sites to enable participating sites and industry partners the ability to view and analyze larger, multisite datasets for research and exploration.

Results: OpenClinica Insight provides a platform to leverage limited standardized patient-derived data on a prospective basis. The platform is useful and end-user friendly and allows for efficient information sharing across the pool of geographically diverse clinical research sites to provide insights into local, regional, and continental patterns and standards of MS care.

Conclusions: OpenClinica Insight is a powerful tool to report information from OpenClinica Enterprise, and the model developed for NARCRMS should serve as an example for integrating informatics from large industry partners the ability to view and analyze larger, multisite datasets for research and exploration.
(IMG03) Cerebellar Connectivity Is Associated with Verbal Memory Impairment in Multiple Sclerosis
Mark D. Zuppichini,1 Kathryn West,2 Dinoh Sivakolundu,2 Dorin T. Okuda,3 Bart Rypma4
1School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, TX; 2School of Behavioral and Brain Sciences, University of Texas at Dallas, Richardson, TX; 3UT Southwestern Medical Center, Dallas, TX; 4Nursing, State University of New York at Stony Brook, NY; 5icometrix, Chicago, IL; 6Icometrix, Leuven, Belgium

Background: Network connectivity is disrupted in multiple sclerosis (MS) and is related to cognitive function. Verbal memory impairment is a core cognitive domain disrupted in MS. Methods: 45 patients with MS and 23 healthy controls completed a verbal memory task (Selective Reminding Task [SRT]) and underwent magnetic resonance imaging. Resting-state (RS) functional connectivity analysis and diffusion kurtosis imaging were used to assess functional and structural connectivity, respectively. Results: The MS group performed significantly worse on SRT trial 1 (t(66) = 2.18, P = .033), SRT trial 3 (t(66) = 2.20, P = .031), SRT trial 6 (t(66) = 2.44, P = .017), and SRT Delayed Recall (t(66) = 2.27, P = .026). Resting-state analysis of cerebellar-cortical connectivity revealed significant differences between the cerebellum and several cortical areas. In MS, higher connectivity was observed between the cerebel- luc and superior frontal gyrus, precuneus, supramarginal gyrus, medial frontal, inferior frontal, middle temporal, and parahippocampal gyrus (P < .05, FWE-corrected). Correlation analysis within the MS group revealed significant correlations between SRT Delayed Recall scores and connectivity values between the cerebellum and parahippocampal gyrus, fusiform gyrus, insula, cingulate, inferior frontal gyrus, uncus, middle temporal gyrus, and angular gyrus (P < .05, FWE-corrected). We observed higher cerebellar connectivity in memory-impaired patients with MS between the cerebellum and the left parahippocampal gyrus compared to memory-preserved patients with MS. Diffusion analysis showed that axonal volume of the middle cerebellar peduncle significantly explained variability in SRT Delayed Recall scores in patients with MS over and above age and education (F(1,32) = 4.62, P = .039, R2 = 0.17, ΔR2 = 0.12). Conclusions: Abnormal resting-state and structural connectivity between the cerebellum and cortical areas, specifically the left parahippocampal gyrus, may contribute to verbal memory impairment observed in MS.

Supported by: None

Disclosure: Mark D. Zuppichini, Kathryn West, Dinoh Sivakolundu, Bart Rypma: Nothing to disclose. Dorin T. Okuda: Acorda (speaking fees); Biogen (contracted research); EMD Serono, Genentech, Novartis, Tesa (consulting fees); Genzyme (consulting fees). Kathryn West: Nothing to disclose. Dinoh Sivakolundu: Nothing to disclose. Bart Rypma: Nothing to disclose. Dorin T. Okuda: Acorda (speaking fees); Biogen (contracted research); EMD Serono, Genentech, Novartis, Tesa (consulting fees); Genzyme (consulting fees). Kathryn West: Nothing to disclose.

Keywords: Imaging and MS, Memory, Psychological issues and MS

(IMG04) The Association Between Magnetic Resonance Imaging Brain Volumes and Computed Cognitive Scores of People with Multiple Sclerosis
1Rapparport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; 2South Shore Neurologic Associates, Patchogue, NY; 3Washington Neuropsychology Research Group, Washington, DC; Nursing, State University of New York at Stony Brook, Stony Brook, NY; Icometrix, Chicago, IL; Icometrix, Leuven, Belgium

Background: Cognitive impairment is common and disabling among people with multiple sclerosis (PwMS) but is not often monitored or only monitored on the periphery. Methods: Participants were tested with the CAB and underwent brain magnetic resonance imaging (MRI) within specified time intervals. The global cognitive score (GCS) is the average of age and education-adjusted scores of the various cognitive domains (memory, information processing speed, attention, executive function, motor, and verbal). Whole brain volume (WBV), gray matter volume (GMV), white matter volume (WMV), thalamic volume, hippocampal volume, white matter lesion volume, and lateral ventricles volume were assessed by Icometrix, a fully automatic, low-dose and lesion segmentation and quantification software, that uses 3D T1-weighted and fluid-attenuated inversion recovery (FLAIR) MRI. Results: 201 PwMS were tested with both CAB and MRI within 180 days (age: 52.3 ± 11.4; 143 [71%] female). Significant correlations were found between the GCS and WBV, WMV, GMV, thalamic volume, and FLAIR lesion volume (Spearman rho: 0.33, 0.3, 0.43, 0.4, 0.26, P < .01, respectively). Correlation coefficients remained significant but decreased as the time between MRI and CAB increased. The number of impaired cognitive domains was also associated with both lesion volume and GMV (rho = 0.25, 0.44; P < .05, < .01, respectively). The only cognitive domain score that was associated with hippocampal volume was memory (rho = 0.27, P < .05). Conclusions: Computed cognitive scores are significantly associated with quantified MRI. These findings demonstrate the added information that can be derived from integrating digital assessment tools into the routine clinical assessment of PwMS.

Supported by: None


Keywords: Computed cognitive scores, Magnetic resonance imaging, Quantified MRI

(IMG05) Analysis of Demyelinating Injuries in Magnetic Resonance Imaging People with Multiple Sclerosis
Dyana Fernandes Sr., Ana Canzaniere, Juliana Rhein, Liliana Russo
Associação Brasileira de Esclerose Multiplo, São Paulo/SP, Brazil

Background: Multiple sclerosis (MS) is a demyelinating autoimmune disease in which the immune system affects the myelin sheath of neurons, resulting in several clinical manifestations. Magnetic resonance imaging (MRI) is essential for understanding MS, as it allows objective visualization of both acute and chronic lesions. Signs and symptoms of MS are often determined by the location of the lesions and often affect people’s quality of life. Objectives: To analyze MRI lesions in a group of individuals with MS. Methods: Ten individuals with MS participated. Retrospective MRI analyses were performed in the database over a period of 1 year with the Doctor Neurologist of the Civil Social Institution for MS, in the city of São Paulo, in 2019, where the individuals present MRI at the consultation. Results: Data from both sexes were used, being 60% women and 40% men, minimum age of 29 and maximum of 59. Of these individuals, 50% had the recurrent remitting clinical subtype, 30% secondary progressive, and 20% primary progressive; 40% had been diagnosed for over 10 years. Regarding Expanded Disability Status Scale score, most (70%) were between 4.5 and 6.5 and 50% had outbreaks for more than 3 years. The images revealed white matter lesions, T2 and fluid-attenuated inversion recovery hyperintensities, with contrast uptake in T1-weighted images, with predominantly juxtaocular involvement with 12%; 11% in the corpus callosum; followed by 8% in the temporal, periventricular regions; 6% in the cervical and thoracic regions; 4% in the subcortical, frontal, cerebellar, and parietal regions; and finally 2% in the bridge, bulb, and thalamic regions. The most frequent types of injuries are atrophy 12% and Black roller 4% with less incidence in the bridge and bulb. Conclusions: This paper suggests some areas that are most affected by the disease through MRI, and in our study population, the greatest involve- ment was brain and a small percentage was at the medullary level, generating motor, sensory, and cognitive impairment. Studies of this kind favor health professionals in understanding the evolution of the disease and the development of neurorehabilitation techniques. Further studies in this line should be conducted with a larger number of participants, so that we can have a better idea about the incidence of the affected areas.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Injuries, Imaging and MS

MULTIDISCIPLINARY CARE

(MDCO1) Social Assistance Intervention in Multiple Sclerosis
Alice Esteiro Dias,1 Priscila S. Santos2
1Scientific Research and 2Social Service, Brazilian Association of Multiple Sclerosis, São Paulo, Brazil
Background: People with multiple sclerosis (PwMS) have complex symptoms and different types of needs. These demands include how to manage physical disability, as well as how to organize daily life and restructure social roles in the family and at work. Objectives: To identify difficulties and obstacles experienced by PwMS, highlighting the work of social service in promoting physical, psychological, and social well-being. Methods: The sample involved 113 PwMS, 82 women and 29 men, aged 17 to 77 years (mean [SD] = 41 [11.38]). All answered the semistructured sociodemographic questionnaire containing 30 questions, developed specifically for this population. Results: Despite the highlighted needs, lack of knowledge about treatment, rehabilitation, and maintenance of quality of life was widely identified among the participants. In this sense, specific referrals and specializes guidance pertinent to our country were carried out as follows: n = 117/100% health (high-cost medicines), n = 35/30% social security (retirement), n = 23/20% education (educational institutions), n = 59/50% judicialization (medicine demand in lawsuits). Conclusions: The individual reception procedure was necessary and sensitive for understanding the demands through the questionnaire. The difficulties identified in this study determined social assistance actions directed to the development of joint actions with multidisciplinary and interdisciplinary teams, which directly affected the quality of life of patients with all types of MS.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Management of activities of daily living in MS, MS and the caregiver/family

(MDC02) Is a 2-Week Intensive Day Program an Effective Approach to Provide Outpatient Services for People with Multiple Sclerosis?
Clare T. Hartigan,1 Tracy Walker2
1Multiple Sclerosis Outpatient Rehabilitation and 2Virginia C. Crawford Research Institute, Shepherd Center, Atlanta, GA
Background: A unique 1-week intensive MS day program rehabilitation model was initiated in 2012 and continues to evolve. The goal of the program is to educate and provide patients, families, and caregivers with a structured plan to improve overall health and wellness. Our interdisciplinary team would like to share “lessons learned the hard way” over the past 7 years and to report the most recent patient outcomes. Objectives: 1) Identify key factors that may indicate appropriateness for patient enrollment in an intensive day program (DP). 2) Identify “lessons learned” over the past 7 years. 3) Present results of objective patient outcome measures. Methods: Patients are evaluated to determine appropriateness for participation in a 2-week intensive DP. To qualify for DP, they must require skilled services for physical therapy (PT), occupational therapy (OT), speech therapy (ST), and wellness. Additionally, they may also receive nursing, counseling, and vocational rehabilitation as appropriate. It is mandatory that a caregiver/family member be present for all sessions. Pre and post outcome measures used to assess change include Modified Fatigue Impact Scale (MFIS), Fatigue Severity Scale (FSS), Symbol Digit Modalities Test (SDMT), Nine-Hole Peg Test (NHPT), and Timed 25 Foot Walk (T25FW). Results: Expanded Disability Status Scale (EDSS) scores ranged from 2.5 to 9.0 with 67% of patients having EDSS score 5.0 or greater. Patient and family feedback regarding DP has generally been positive. The most frequent negative comments are that too much information is presented and becomes overwhelming, not enough rest breaks are given, and the days are too long. Despite reports of being too intensive, a large majority of participants have shown progress on outcome measures. Percentage of patients whose scores improved are as follows: MFIS 70%, FSS 90%, SDMT 70%, NHPT 67% (right) 87% (left), and T25FW 75% (note 3 patients went from being nonambulatory to walking with a rollator). A more detailed report of the data will be ready at the time of presentation.
Conclusions: Multiple factors need to be considered prior to recommending DP to persons with MS. To achieve success, patients/families must be willing to modify old behaviors and staff must adapt session intensity so as not to overwhelm or over-fatigue patients. An interdisciplinary community outlet at the end of the first week has proven valuable to patient/families. Changes to the structure of the DP have been incorporated based on patient feedback. Re-evaluations 2 months post-DP are encouraged.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Comprehensive care and MS, Day program outcomes

(MDC03) The Waiting Room: A Successful Experience in the Multiple Sclerosis Care and Treatment Center (CATEM)
Ione R. Fernandes, Ana C. Sera, Maria L. Santos, Rodrigo N. Fonseca, Vanessa D. Vale, Natali M. Marques, Elisa Melo, Charles P. Tilbery
Santa Casa de Misericórdia, São Paulo, Brazil
Background: The constant waiting of patients for the call for medical consultation is a reality in the Brazilian public service. The National Policy for Humanization (NPH) of the Brazilian Ministry of Health (MH) advocates a welcoming, strengthening, and wholesome care, with the adoption of measures and communication among multidisciplinary professionals. One of the practices used by the health team to share experiences, feelings, and knowledge between patients of professionals is the Waiting Room Group. The Multiple Sclerosis Care and Treatment Center (MSCTC), established in 1997 at the Neurology Clinic of Santa Casa de Sao Paulo, attends through the Unified Health System (UHS) every Friday morning and has about 500 registered patients who make use of several therapies for treatment of multiple sclerosis (MS). To minimize the waiting period, the “Waiting Room” project was created in 2013, consisting of patients, family members, caregivers, social worker, nurse, physiotherapist, psychologist, and neuropsychologist, among others, to provide a welcoming space to minimize anxiety and fear, advise on their rights, inform about the disease and its complications, types of treatment, importance of adoption and adherence of exercise routines, and hospital policy and routines, and providing patients, family members, and caregivers with a space of permanence in order to receive feedback or discuss issues in their daily life in their role in their treatment. Objectives: To describe the experience of the Waiting Room Group as part of humanized care for patients with MS, their family members, and caregivers. Methods: Welcoming, integration, and interaction are the key words: the earlier patients talk about and share their experiences with those who are starting their treatment, their anxiety and doubts are minimized. The doctor, psychologist, social worker, nurse, and physiotherapist participate in all meetings, as well as other invited professionals. During the meetings, the doubts presented by the participants are clarified and provide topics for discussion in the next meetings. Results: Not applicable. Conclusions: This project has been developed for 6 years and has been successful, with an average participation of 500 patients per year.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Comprehensive care and MS, Interdisciplinary team, MS and the caregiver/family

(MDC05) Implementation of a Pharmacist-Led Immunization Program in a Center for Comprehensive Multiple Sclerosis (MS) Care
Lauren Long, Ryan Fuller
Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA
Background: In 2019, the American Academy of Neurology issued a practice guideline update for vaccinations in patients with multiple sclerosis (MS). In this guideline, they recommend providers “assess and reassess vaccination status of patients with MS before prescribing immunosuppressive or immunomodulating (ISIM) therapy and should vaccines these patients.” Also in 2019, ecucizumab was the first US Food and Drug Administration (FDA) treatment approved for neuromyelitis optica spectrum disorder (NMOSD). Prior to starting, the FDA requires patients receive 2 types of meningococcal vaccines (MenACWY plus MenB-4C or MenB-HPdp) at least 2 weeks prior to starting ecucizumab. MS centers need to create an efficient process to ensure patients receive vaccines in a timely fashion to reduce harm from vaccine-preventable diseases and start of patient’s disease-modifying therapy (DMD). In 2002, Pennsylvania allowed pharmacists to provide immunizations to patients under a collaborative practice agreement or a direct order from a provider. At the Hospital of the University of Pennsylvania, there are 2 clinical pharmacists dedicated full-time to the MS Center. Little information is available literature addressing vaccinators to patients with multiple sclerosis and prior to starting DMTs, and the utilization of MS clinical pharmacists and a health-system based specialty pharmacy in providing this unmet need. Objectives: The purpose of this quantitative pilot study will be to review the results of a pharmacist-led immunization program imbedded within a 1-provider MS clinic. Methods: Patients will be identified by provider referrals and pharmacist comprehensive chart reviews of newly diagnosed patients and patients starting ISIM and ecucizumab therapy. Results: Data will be analyzed with descriptive statistics. Conclusions: It is anticipated this pilot study will increase rates of vaccination of patients with MS, reduce time to start DMT, and increase awareness of vaccine-preventable diseases.
(MDC06) The African American Experience and Multiple Sclerosis
Marie LeGrand

Multiple Sclerosis Association of America, Chicago, IL

Background: Incidence rates of multiple sclerosis (MS) have been found to be higher in both black males and black females vs white males and white females. In particular, black females have a 47% higher risk for MS when compared to white females. Disease progression is significantly faster in black patients with MS in both brain and retinal measures. Magnetic resonance imaging scans show whole brain and gray and white matter atrophy to occur twice as fast in African Americans compared to Caucasian Americans. African American patients also show quicker atrophy of the thalamus, a possible link to cognitive impairment. Furthermore, African Americans are dying from MS at an earlier age, suggesting that MS burden weighs disproportionately across race demographics. To fully understand, the Multiple Sclerosis Association of America (MSAA) launched the African American MS Advisory Board. Objectives: The African American Experience & Multiple Sclerosis initiative included 11 MS clinicians and 16 African Americans affected by MS. The meeting’s objectives were to 1) create a dialogue allowing both groups to share their views on the problems that African Americans with MS are facing; 2) evaluate programmatic initiatives that address the unmet needs; 3) gather from the meeting to aid in the development of an actionable plan, tailored educational offerings, and services provided; and 4) identify next steps to continue building on the work of the African American committees. Methods: Participants attended a half-day meeting, sharing their views on problems African Americans with MS are facing. Sessions included moderated discussions and a brief presentation, emphasizing the need for research and the importance in developing programmatic initiatives. Results: Key findings from the meeting in Atlanta elucidated the aforementioned performance gaps experienced by MS clinicians responsible for treating African Americans with MS. Characteristics of patients with MS less likely to see neurologists include the following: 1) lack of health insurance, 2) lower income, 3) African American, 4) living in rural areas, and 5) illness longer than 15 years. Conversely, patients cared for by a neurologist are more likely to 1) undergo diagnostic tests, 2) undergo treatment-related tests, 3) be treated with disease-modifying therapies, 4) receive medication for symptoms, and 5) report their providers had a treatment plan. The presence of these gaps requires behavioral change on the behalf of MS clinicians that will appropriately address barriers in treatment and access to care. Conclusions: Data from this comprehensive initiative will drive the materials and information for a set of multifaceted interventions to improve the knowledge, competence, and/or performance of MS clinicians who are currently treating, or have the potential to treat, black patients with MS. The anticipated result is to better identify and detect early signs of disease progression and timely therapeutic intervention.

Supported by: None
Disclosure: Nothing to disclose

Keywords: African American and MS, Comprehensive care and MS

(MDC08) Late-Onset Multiple Sclerosis: Comorbidity and Disease Progression
Smathorn Thakolwiboon, Miria Avila, Pavida Pachariyanon, Jie Pan, Amputch Karukote, Gyeongmo Sohn

Neurology and Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX

Background: Late-onset multiple sclerosis (LOMS) defined as multiple sclerosis (MS) with clinical onset after the age of 50. Previous studies have demonstrated that late onset is a poor prognostic factor for MS. Moreover, several comorbidities such as hypertension, diabetes, and dyslipidemia were reported in association with poor clinical outcome in patients with MS. Although the prevalence of comorbidity is increased in the aging population, the roles of comorbidity in LOMS has not been explored in details. Objectives: To evaluate the influence of comorbidities in LOMS. Methods: This retrospective study included 38 patients with MS with clinical onset after the age of 50. Demographic, clinical, radiologic, and laboratory findings were collected. The survival analysis was performed to identify the comorbidities that associated with the progression of disease (NEDA status or disease progression). Results: The median follow-up was 26 (IQR 12-45.75) months. Forty-five percent of participants remained on NEDA status until the last follow-up. Furthermore, 30% of participants experienced disease progression (HR 1.58, 95% CI 1.01-5.12, P = .049). Interestingly, there was no significant difference in disease progression risk between well-controlled HTN and normotensive patients with LOMS (HR 1.58, 95% CI 0.28-9.01, P = .608). Diabetes, dyslipidemia, coronary artery disease, stroke, obesity, hypothyroidism, depression, and anxiety were not significantly associated with MS progression in the late-onset population. Conclusions: Our cohort study suggests that HTN is a modifiable risk factor of disease progression in LOMS. Previous studies have demonstrated that HTN can potentiate neurodegenerative process. Larger prospective studies are needed to further explore the interaction between HTN and disease-modifying therapy and the effect of antihypertensive agents.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Comorbidities, Comprehensive care, and MS

(MDC09) Comparing Patient Perceptions on Multiple Sclerosis Management and Care: A Subanalysis of Geographic Differences
Sarah A. Morrow,1,2 Alexey Boyko,3 Heidi Thompson,4 Maija Pontaga, Nektaria Alexandri6

1Western University, London, ON, Canada; 2Clinical Neurological Sciences, London Health Sciences Centre, London, ON, Canada; 3New York University School of Medicine, New York, NY, USA; 4University of Alabama at Birmingham, Birmingham, AL, USA; 5Medical University of South Carolina, Charleston, SC, USA; 6Eskisehir Osmangazi University, Eskisehir, Turkey

Objectives: There is much evidence in the literature on the potential to treat, black patients with MS. The anticipated result is to better identify and detect early signs of disease progression and timely therapeutic intervention.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Comorbidities, Comprehensive care, and MS

International Journal of MS Care
Background: The MS in the 21st Century initiative is led by a steering group of international multiple sclerosis (MS) specialists and patient advocates with a current focus of improving education and communication between health care professionals and people with MS (PwMS).

Objectives: To compare the perceptions of PwMS on MS management and care across 2 geographical regions: Europe and North America (United States and Canada). Particular emphasis was on patient support at diagnosis, treatment decisions, and communication. Methods: An electronic survey was developed to gain insight into patients' opinions on unmet needs in MS management. The surveys were conducted at 2 international patient meetings in 2017 and 2018. Multiple answers were solicited in response to 10 questions. Results: A total of 55 PwMS from Europe and 46 from North America completed the survey. PwMS in Europe listed a lack of time in medical appointments as their biggest challenge at diagnosis (60.0%), whereas PwMS in North America reported understanding disease progression to be their biggest challenge (57.8%). European PwMS reported greater levels of additional patient support available in their clinics [ie, MS nurse (67.3%), information about employment (21.2%), or psychological support (25.0%)], whereas 26.1% of North American PwMS reported no additional support. PwMS in Europe reported being less involved in treatment decisions, with 20.5% saying they were not involved, compared with 2.4% in North America. European PwMS placed more importance on the safety of their treatment (57.7%), whereas PwMS in North America placed more importance on the efficacy of their treatment (71.7%). Conclusions: There were distinct geographical variations between PwMS's perceptions and priorities relating to MS care, education, and treatment decisions. European PwMS reported less time in appointments and lower involvement in treatment decisions than North American PwMS, however they also reported greater levels of support and education outside of their neurologist appointments including greater access to specialist MS nurses.

Methods of Care (MOC01) Understanding the Health Care Provider–Patient Relationship in Treating Multiple Sclerosis

Beth Schneider
MyHealthTeams, San Francisco, CA

Background: Health care providers (HCPs) play a critical role in treating patients with multiple sclerosis (MS), especially in helping patients get on treatment to help slow progression. An online survey of patients with MS as well as natural language analysis of organic interactions on a social network provided insight into the relationship between HCPs and their patients with MS. Understanding the HCP-patient dynamic is crucial to improving the interactions as well as identifying tools and educational materials to help patients better manage MS.

Objectives: A 2-pronged approach was undertaken. First, an online survey was completed by 658 US members of MyMSTeam in April to September 2019. Multiple answers were solicited in response to 10 questions. Results: A total of 55 PwMS from Europe and 46 from North America completed the survey. PwMS in Europe listed a lack of time in medical appointments as their biggest challenge at diagnosis (60.0%), whereas PwMS in North America reported understanding disease progression to be their biggest challenge (57.8%). European PwMS reported greater levels of additional patient support available in their clinics [ie, MS nurse (67.3%), information about employment (21.2%), or psychological support (25.0%)], whereas 26.1% of North American PwMS reported no additional support. PwMS in Europe reported being less involved in treatment decisions, with 20.5% saying they were not involved, compared with 2.4% in North America. European PwMS placed more importance on the safety of their treatment (57.7%), whereas PwMS in North America placed more importance on the efficacy of their treatment (71.7%). Conclusions: There were distinct geographical variations between PwMS’s perceptions and priorities relating to MS care, education, and treatment decisions. European PwMS reported less time in appointments and lower involvement in treatment decisions than North American PwMS, however they also reported greater levels of support and education outside of their neurologist appointments including greater access to specialist MS nurses.

Supported by: None

Disclosure: Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, John Beauvais, Jodie K. Haselkorn

1 Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT; 2Psychology Service, VA Connecticut Healthcare System, West Haven, CT; 3Department of Neurology, University of Connecticut School of Medicine, Farmington, CT; 4Departments of Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT; 5Department of Rehabilitation Medicine, University of Washington, Seattle, WA; 6Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA; 7Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA; 8Department of Psychiatry, Yale School of Medicine, New Haven, CT; 9Department of Epidemiology, University of Washington, Seattle, WA

Background: It is important that persons with multiple sclerosis (MS) attend their scheduled appointments to maintain continuity of care and promote successful self-management. A recent study examined missed appointments in veterans with MS and developed a model that included 7 predictor variables (suboptimal disease-modifying therapy [DMT] adherence [>80%], emergency visits, age, distance, and histories of posttraumatic stress disorder, chronic obstructive pulmonary disease, and congestive heart failure). However, to date, there is limited information on appointment cancellations, which is a different appointment attendance behavior but can also disrupt care.

Methods: Administrative data between January 1, 2013, and December 31, 2015, were extracted from the VA MS Center of Excellence Data Repository, an electronic health record–based dataset composed of US veterans receiving services at any Veterans Affairs (VA) medical center. The cancellation rate was calculated by dividing the number of cancelled appointments (excluding “no shows”) by the total number of scheduled appointments during this 2-year timeframe. Bivariate analyses were conducted to examine demographic and clinical characteristic differences between individuals with and without high rates of cancellations, and variables with a P value of <.10 were entered into a logistic regression.

Results: Over 96% (n = 3623) had at least 1 cancelled appointment, with a median cancellation rate of 2.5%. Flags for high rates of cancellations included 1 or more inpatient hospitalization (odds ratio [OR]: 1.78), wheelchair issuance (OR: 1.48), distance (>241 miles away; OR: 1.47), gender (male; OR: 1.28), suboptimal DMT adherence (OR: 1.26), and history of a mood disorder (OR: 1.28).

Conclusions: Canceled appointments are prevalent among veterans with MS. The similarities and differences in the variables included in the cancelled and missed appointments highlight both malleable and nonmalleable factors associated with each type of appointment attendance behavior. While further information is needed to elucidate the reasons behind these cancelled appointments, these results may help clinicians identify individuals at risk for higher rates of cancellations and to plan targeted interventions.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Appointment attendance, Comprehensive care and MS, Shared decision making

Methods of Care (MOC02) Cancelling Clinic Appointments: What Factors Are Associated with Higher Rates of Cancellations in Patients with Multiple Sclerosis

Elizabeth S. Gromisch, Aaron P. Turner, Steven L. Leipertz, John Beauvais, Jodie K. Haselkorn

1 Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT; 2Psychology Service, VA Connecticut Healthcare System, West Haven, CT; 3Department of Neurology, University of Connecticut School of Medicine, Farmington, CT; 4Departments of Medicine and Medical Sciences, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT; 5Department of Rehabilitation Medicine, University of Washington, Seattle, WA; 6Rehabilitation Care Service, VA Puget Sound Health Care System, Seattle, WA; 7Multiple Sclerosis Center of Excellence West, Veterans Affairs, Seattle, WA; 8Department of Psychiatry, Yale School of Medicine, New Haven, CT; 9Department of Epidemiology, University of Washington, Seattle, WA

Background: The MS in the 21st Century initiative is led by a steering group of international multiple sclerosis (MS) specialists and patient advocates with a current focus of improving education and communication between health care professionals and people with MS (PwMS).

Objectives: To compare the perceptions of PwMS on MS management and care across 2 geographical regions: Europe and North America (United States and Canada). Particular emphasis was on patient support at diagnosis, treatment decisions, and communication. Methods: An electronic survey was developed to gain insight into patients’ opinions on unmet needs in MS management. The surveys were conducted at 2 international patient meetings in 2017 and 2018. Multiple answers were solicited in response to 10 questions. Results: A total of 55 PwMS from Europe and 46 from North America completed the survey. PwMS in Europe listed a lack of time in medical appointments as their biggest challenge at diagnosis (60.0%), whereas PwMS in North America reported understanding disease progression to be their biggest challenge (57.8%). European PwMS reported greater levels of additional patient support available in their clinics [ie, MS nurse (67.3%), information about employment (21.2%), or psychological support (25.0%)], whereas 26.1% of North American PwMS reported no additional support. PwMS in Europe reported being less involved in treatment decisions, with 20.5% saying they were not involved, compared with 2.4% in North America. European PwMS placed more importance on the safety of their treatment (57.7%), whereas PwMS in North America placed more importance on the efficacy of their treatment (71.7%). Conclusions: There were distinct geographical variations between PwMS’s perceptions and priorities relating to MS care, education, and treatment decisions. European PwMS reported less time in appointments and lower involvement in treatment decisions than North American PwMS, however they also reported greater levels of support and education outside of their neurologist appointments including greater access to specialist MS nurses.

Supported by: None

Disclosure: Beth Schneider: MyHealthTeams (contracted research).

Keywords: Comprehensive care and MS, Management of activities of daily living in MS, Psychological issues and MS

(MOC03) From Therapy Enrollment to First Dose: A Quality Improvement Initiative for Multiple Sclerosis Care

Jami Bolling, Ryan McNair, Trish Wall Y. Gyang, Carlos Vervaat Sollers, Aaron Carlson

1Neurology, University of Florida, Gainesville, FL; 2UHF Health, University of Florida, Gainesville, FL

Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 18 September 2020
Background: Timely treatment is important for reducing relapses and risk of disability in people with multiple sclerosis (MS). However, disease-modifying medications entail a complex enrollment process that can delay treatment initiation. Objectives: This pilot study tracked individuals initiating the enrollment process for ocrelizumab and natalizumab at the University of Florida (UF) MS Clinic. Methods: This quality improvement initiative captured all relevant documents, including enrollment forms, insurance communications, referrals, and other documentation. We monitored the dates of completion, signature, fax, and local medical record upload for all forms. Results: Preliminary data from January 1, 2019, to October 1, 2019, captured 19 patients enrolled in either medication. Of these 19 patients, 6 received treatment as of October 2019. On average, enrollment submission to treatment initiation took 56 (range, 5-135) days. Of the remaining 13 awaiting treatment, the average interval from enrollment to October 2019 was 83 (range, 4-175) days. Overall, 11 quantifiable delays were identified, resulting in 17 recorded contacts. Of the 11 delays, 45.5% were insurance-related, 36.4% were clerical delays, and 18.1% were related to patient compliance. Most delays occurred in patients referred to outside infusion centers for treatment. Five of 13 ocrelizumab patients initiated treatment as of October 2019. Four of the 5 patients were infused at UF. The 8 patients awaiting treatment were referred to outside infusion centers and averaged 101 days without treatment as of October 2019. Two of 4 natalizumab patients have received treatment, both infused at UF. For the 2 awaiting treatment, both were referred to outside infusion centers and have waited an average of 71 days for treatment as of October 2019. Conclusions: Preliminary analysis suggests that insurance-related delays were the largest barrier to treatment initiation. Referring patients to outside centers further impeded the process. The results indicate that revisions to standard operating procedures for insurance inquiries and referrals may be beneficial. Moreover, while clerical errors were common, they were quickly resolved. Patient compliance issues, though rare, had the most enduring effect on treatment initiation.

Support: None

Disclosure: Jamie Bolting, Ryan McNiff, Tizikhan V. Gungor, Carols Verne 
Sellers: Nothing to disclose. Aaron Carlson: Novartis Pharmaceutical (contracted research); Sanofi Genzyme (consulting fee).

Keywords: Comprehensive care and MS, Quality improvement

(MOC04) Nurse Telephone Encounters in a Multiple Sclerosis Clinic in 2020

Janice Lake, Colleen Harris, Sharon Peters, Jackie Gaythorpe
University of Calgary MS Clinic, Calgary, AB, Canada

Background: With the growing treatment landscape in multiple sclerosis (MS), nurses are being challenged with a constantly increasing workload, and more of their time is being spent on telephone encounters. Preliminary data collected from January 1 to March 31, 2020 at the University of Calgary MS Clinic showed that 50% of nursing time was devoted to telephone encounters, and 30% of those encounters dealt with issues around disease-modifying therapies (DMTs). In 2001 there were 3 Health Canada–approved DMT options as compared to 12 approved DMTs at this time in 2020. Increased patient therapy choice has required more nursing time to educate patients on treatment expectations, potential adverse effects, and adherence to more complex medication protocols. There is a need to understand the type, frequency, and time spent on telephone encounters, which will assist MS Nurses to develop efficient and effective management protocols. Objectives: To determine the frequency, type, and duration of nurse telephone encounters. To compare work previously done in the MS Clinic by Harris et al in 2001. Methods: Patient telephone encounters will be analyzed from January 1, 2020, to the end of March 2020. A telephone call log designed based on previous workload analysis at the University of Calgary MS Clinic will be used to capture the type, duration, and frequency of calls. Results: Telephone encounters are ongoing, with data analysis completed April 1, 2020. Conclusions: Analyzing telephone encounters will provide information to assist with the development of workload management strategies.

Support: None

Disclosure: Janice Lake; Sanofi Genzyme (consulting fee). Colleen Harris; Bio 
gen, Merck Serono, Novartis, Roche, Sanofi Genzyme (consulting fee). Sharon Peters, Jackie Gaythorpe: Nothing to disclose.

Keywords: Comprehensive care and MS

(MOC05) Pioneering Multiple Sclerosis Center Program with MSHA Certification to Improve Patient Care and Experience

Jennifer R. Hillner, Jennifer L. Rusk
Neurology/MS, OSF HealthCare Illinois Neurological Institute, Peoria, IL

Background: The OSF HealthCare Illinois Neurological Institute’s Multiple Sclerosis Center is a Certified Comprehensive MS Center located in Peoria, Illinois, serving over 2100 patients and is focused on providing excellence in multiple sclerosis (MS) care for patients and families in need of diagnosis, treatment, education, and research. Like many MS Centers we are fortunate to have physicians, nurses, physical therapists, occupational therapists, and a registered dietician who are specialized in MS. However, we came to realize there were opportunities in our level of patient care and experience with the potential to be transformed if we invested in our medical office assistants and our MS patient navigators through MSHA Certification. Certified employees are able to deliver a higher level of care, better connect patients to resources, and also better support our comprehensive care team, which allows our center to ensure all members are working at the height of their licensure. We set a goal to in May 2019 to have a mission partner in every job role of our MS Center to be certified in MS. We propose that achieving this level of certification in each and every MS Center around the world is a goal worth aspiring to in our combined fight against MS. Objectives: MSHA certification within our medical office assistant and MS patient navigator job roles in 2019. In addition, lower risks associated with delayed treatment, removing barriers to care, increasing clinical competency, and employee efficiency in tasks such as prior authorizations for disease-modifying therapies. Methods: Investing in team study and elevating employees through MSHA certification. We also brought our team to Consortium of Multiple Sclerosis Centers (CMSC) for education, networking, and patient resource opportunities. Results: The OSF HealthCare Illinois Neurological Institute’s MS Center has an employee in every job role who is MSHA Certified. MSHA certification has given our team members greater context and compassion through a deeper understanding of MS at a professional level. We increased efficiency and decreased delay of care in the office and also the time it took to obtain prior authorizations. Our certified employees are also perceived by patients as improved level of empathy and confidence with patients. MSHA certification has fostered greater dedication and drive passion while motivating our MS care team as a whole. Conclusions: MS is a complex and lifelong neurologic disease that requires all individuals involved with patient care to have a basic level of knowledge of the disease. The MSHA certification of our employees is a pioneering strategy that has elevated the level of care and experience we provide to our patients with MS by empowering our employees through the education and understanding of MS. MSHA certification is an effective tool for efficient and empathetic health care delivery to those individuals living with MS.

Support: None

Disclosure: Nothing to disclose.

Keywords: Comprehensive care and MS, MSHA certification

(MOC06) Conceptualizing Access Through the Perspectives of Canadians with Multiple Sclerosis

Julie Patrin, Mary Ann McColl, Catherine Donnelly, Marcela Finlayson
1Rehabilitation Sciences, Queen’s University, Kingston, ON, Canada; 2School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada

Background: Access to health care is vital to the health and well-being of people with chronic conditions like multiple sclerosis (MS). Access is often measured using service utilization as a proxy. Utilization measures do not capture the complexity of experiences of care that populations with chronic illness face. The Candidacy Framework offers an alternative to utilization measures, by examining the dynamic process a patient must engage in, with the health care system and all components of it, to negotiate their eligibility for care, which is described as one’s candidacy. The process of accessing care is examined from the perspective of vulnerable populations and considers the impact of social patterning and health system environments on this process. Objectives: To investigate access to health care for the management of MS, in a Canadian context, from the perspective of persons with MS. Methods: This study design was qualitative, with 2019-2020 data collection and analysis. Forty-eight individuals with MS living across 7 communities in Ontario were recruited primarily through the MS Society of Canada to participate in 1 of 5 focus groups or 10 individual telephone interviews. The sessions were digitally recorded and transcribed. The transcriptions were then analyzed using constant comparative methods. Additionally, the data was re-interpreted in light of the Candidacy Framework to determine its align-
School of Rehabilitation Therapy, Queen's University, Kingston, ON, Canada; in relation to accessing care to manage their MS.

2) identify the most pressing concerns Canadians with MS have issues in access to health care.

Background: Current Canadian literature demonstrates that persons with multiple sclerosis (MS) are high users of health care services, yet still have multiple unmet needs and low satisfaction with health care services. International studies showing similar results suggest this may be related to issues in access to health care. Objectives: We aimed to 1) describe the health care service use of Canadians with MS in managing their condition; 2) identify the most pressing concerns Canadians with MS have in relation to accessing health care service in the community. Data were analyzed using descriptive statistics. Access concerns were prioritized by calculating a Needs Index (NI).

Methods: The aims were addressed using an online cross-sectional survey guided by Concern Report Methodology. Inclusion criteria were: older than 18 years, a Canadian citizen, and self-reported diagnosis of MS. Data were collected about health care service use and the importance and satisfaction with access to health care service in the community. Data were analyzed using descriptive statistics. Access concerns were prioritized by calculating a Needs Index (NI).

Results: To date, 211 persons with MS have completed the survey. Participants were predominantly female (86%), with a mean (SD) age of 46.4 (11.7), living with relapsing remitting MS (77%), with varying levels of disability ranging from 0-7 on the Patient-Determined Disease Steps (median: 2). Preliminary findings indicate that nearly all participants had a regular neurologist (97%), and many of whom practice in an MS clinic (83%). Most individuals also had a general practitioner (96%). Participants on average visited their neurologist 3 times a year (SD: 0.7) and their general practitioner 4.6 times (SD: 3). Concerns regarding access to care were: 1) affordability of complementary care (example: massage therapy, yoga, naturopathic care) (NI: 33.8) and physiotherapy and occupational therapy (NI: 29.7), both aimed at improving wellness; 2) availability of health care providers with MS-related knowledge in their communities to guide their care plan (NI: 33.7); and 3) communication between health care providers to ensure coordination of care (NI: 29.2).

Conclusions: Preliminary findings suggest that for persons with MS, merely having regular neurologists and general practitioners is not considered satisfactory access to care. Persons with MS identified concerns regarding the availability of affordable health care services aimed at maintaining wellness. They also had concerns regarding the availability of community providers with sufficient MS-related knowledge to guide their referrals and care plans. Targeting policy reform promoting the coverage of health care services aimed at preventative and maintenance care may be a critical step in improving care for this population.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Access to health care, Comprehensive care and MS

(MOC07) Access to Health Care for Canadians with Multiple Sclerosis: Prioritizing Concerns

Julie Petrin,1 Mary Ann McColl,1 Simon French,1 Catherine Donnelly,1 Marcia Finlayson1

1School of Rehabilitation Therapy, Queen's University, Kingston, ON, Canada; 2Rehabilitation Sciences, Queen's University, Kingston, ON, Canada; 3Chiropractic, Macquarie University, Sydney, Australia

Background: Current Canadian literature demonstrates that persons with multiple sclerosis (MS) are high users of health care services, yet still have multiple unmet needs and low satisfaction with health care services. International studies showing similar results suggest this may be related to issues in access to health care. Objectives: We aimed to 1) describe the health care service use of Canadians with MS in managing their condition; 2) identify the most pressing concerns Canadians with MS have in relation to accessing health care service in the community. Data were analyzed using descriptive statistics. Access concerns were prioritized by calculating a Needs Index (NI).

Methods: The aims were addressed using an online cross-sectional survey guided by Concern Report Methodology. Inclusion criteria were: older than 18 years, a Canadian citizen, and self-reported diagnosis of MS. Data were collected about health care service use and the importance and satisfaction with access to health care service in the community. Data were analyzed using descriptive statistics. Access concerns were prioritized by calculating a Needs Index (NI).

Results: To date, 211 persons with MS have completed the survey. Participants were predominantly female (86%), with a mean (SD) age of 46.4 (11.7), living with relapsing remitting MS (77%), with varying levels of disability ranging from 0-7 on the Patient-Determined Disease Steps (median: 2). Preliminary findings indicate that nearly all participants had a regular neurologist (97%), and many of whom practice in an MS clinic (83%). Most individuals also had a general practitioner (96%). Participants on average visited their neurologist 3 times a year (SD: 0.7) and their general practitioner 4.6 times (SD: 3). Concerns regarding access to care were: 1) affordability of complementary care (example: massage therapy, yoga, naturopathic care) (NI: 33.8) and physiotherapy and occupational therapy (NI: 29.7), both aimed at improving wellness; 2) availability of health care providers with MS-related knowledge in their communities to guide their care plan (NI: 33.7); and 3) communication between health care providers to ensure coordination of care (NI: 29.2).

Conclusions: Preliminary findings suggest that for persons with MS, merely having regular neurologists and general practitioners is not considered satisfactory access to care. Persons with MS identified concerns regarding the availability of affordable health care services aimed at maintaining wellness. They also had concerns regarding the availability of community providers with sufficient MS-related knowledge to guide their referrals and care plans. Targeting policy reform promoting the coverage of health care services aimed at preventative and maintenance care may be a critical step in improving care for this population.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Access to health care, Comprehensive care and MS

(MOC08) Use of a Clinical Decision Support Tool to Support Monitoring and Care of Patients with Multiple Sclerosis Receiving Disease-Modifying Therapy

Lisa M. Mitchell,1 Mitchell T. Wollin,2 Natasha M. Antonovich3

1School of Rehabilitation Therapy, Queen's University, Kingston, ON, Canada; 2Rehabilitation Sciences, Queen's University, Kingston, ON, Canada; 3Chiropractic, Macquarie University, Sydney, Australia

Background: Current Canadian literature demonstrates that persons with multiple sclerosis (MS) are high users of health care services, yet still have multiple unmet needs and low satisfaction with health care services. International studies showing similar results suggest this may be related to issues in access to health care. Objectives: We aimed to 1) describe the health care service use of Canadians with MS in managing their condition; 2) identify the most pressing concerns Canadians with MS have in relation to accessing health care service in the community. Data were analyzed using descriptive statistics. Access concerns were prioritized by calculating a Needs Index (NI).

Methods: The aims were addressed using an online cross-sectional survey guided by Concern Report Methodology. Inclusion criteria were: older than 18 years, a Canadian citizen, and self-reported diagnosis of MS. Data were collected about health care service use and the importance and satisfaction with access to health care service in the community. Data were analyzed using descriptive statistics. Access concerns were prioritized by calculating a Needs Index (NI).

Results: To date, 211 persons with MS have completed the survey. Participants were predominantly female (86%), with a mean (SD) age of 46.4 (11.7), living with relapsing remitting MS (77%), with varying levels of disability ranging from 0-7 on the Patient-Determined Disease Steps (median: 2). Preliminary findings indicate that nearly all participants had a regular neurologist (97%), and many of whom practice in an MS clinic (83%). Most individuals also had a general practitioner (96%). Participants on average visited their neurologist 3 times a year (SD: 0.7) and their general practitioner 4.6 times (SD: 3). Concerns regarding access to care were: 1) affordability of complementary care (example: massage therapy, yoga, naturopathic care) (NI: 33.8) and physiotherapy and occupational therapy (NI: 29.7), both aimed at improving wellness; 2) availability of health care providers with MS-related knowledge in their communities to guide their care plan (NI: 33.7); and 3) communication between health care providers to ensure coordination of care (NI: 29.2).

Conclusions: Preliminary findings suggest that for persons with MS, merely having regular neurologists and general practitioners is not considered satisfactory access to care. Persons with MS identified concerns regarding the availability of affordable health care services aimed at maintaining wellness. They also had concerns regarding the availability of community providers with sufficient MS-related knowledge to guide their referrals and care plans. Targeting policy reform promoting the coverage of health care services aimed at preventative and maintenance care may be a critical step in improving care for this population.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Access to health care, Comprehensive care and MS
measures yielded P values > 0.05 at both visit 1 and visit 2, save for the CAB-GC-OS regression. A significant difference was not observed (P > 0.05) in the percent change between visit 1 and 2 when comparing the following OCT measurements with the CAB GCS: GC-DODOS, N/TOS, PMB-OS, and MV-DODOS. Significance was observed (P < 0.05) of N/T-OD and PMB-OD. Conclusions: The relationships of global RNFL densities to global CAB scores remained the same after a year, which suggests that OCT and cognitive change are not rate limiting factors in disease progression. Non-significance between percent changes suggests that OCT and cognitive scores change at similar rates at least within a year's period. A larger longitudinal study is suggested to further determine the relationship between OCT and cognitive changes over greater lengths of time.

Supported by: None.

Disclosure: Mark Cudlanich, Avorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Sanoft, Teva (consulting fee); Jared Srinivasan, Olivia Kazimieat, Daniel Golon, Timothy Fratig: Nothing to disclose. Glen Donegan, NeuroTrax (salary). Jeffrey Wilken: Biogen (consulted research); EMD Serono (speakers' bureau); Genzyme (consulted research, speakers' bureau). Robert C. Sergnet: Biogen, Clene Nanomedicine, Heidelberg Engineering GmbH, Janssen Global Services, LLC, Medtronic, Merck & Co Inc (consulting fee). Biogen, Clene Nanomedicine, Janssen Global Services, LLC, Medtronic, Nightstar, Genica NV (consulted research); Biogen, Genzyme Corporation, Novartis Pharmaceutical Corporation, Teva Pharmaceutical Industrial Ltd (speakers' bureau).

Keywords: Comprehensive care and MS, Equipment in MS, Natural history of MS

(MOC11) Improving Understanding of Clinical Phenotype for Patients with Multiple Sclerosis: Design and Implementation of Smarttools in Electronic Health Record Systems

Thomas Grader-Beck,1 Yujie Wang,2 Kathryn C. Fitzgerald,2 Peter A. Calabresi,2 Ellen M. Mowry

1School of Medicine, Johns Hopkins University, Baltimore, MD; 2Neurology, Johns Hopkins University School of Medicine, Baltimore, MD

Background: Patients with multiple sclerosis (MS) frequently require complex clinical care and decision making, including monitoring for relapses, chronic immunosuppressive therapy, and extensive serological and imaging work-up. Modern electronic health record (EHR) systems offer the opportunity to facilitate understanding of each patient’s clinical phenotype by allowing discrete data collection, as well as summarization and presentation of critical information to providers. However, such tools often require custom design and build, for which many institutions do not have assigned resources. Objectives: To implement a comprehensive set of EHR-based Smarttools for patients with MS that can be shared among institutions, improves data quality and understanding of patient phenotype. Methods: The Epic EHR system was used to develop several Smarttools. A Smartform was designed to allow discrete data collection on items considered critical by MS experts. Content included date of diagnosis, documentation of relapse characteristics, such as date, duration and therapies, current and past immunosuppressive therapy, critical imaging and results of CSF studies. Longitudinal capture of disease impact was incorporated, including number of falls and ability to walk since last visit. Logic was applied to conditionally display the Smartform for patients with a diagnosis of MS. A synopsis was designed to visualize longitudinal data, and a SmartPhrase was implemented to automate documentation of discrete data in provider notes. Results: Version 1 of the MS SmartForm was implemented in August 2017. Over the course of 18 months, data on approximately 1000 unique patients were collected. The Smartform was found to be easily accessible and easy to navigate by providers, and the completion rate was high. Based on the initial experience, version 2 of the Smartform was designed and was recently implemented with minor modifications to minimize erroneous data collection, and a predefined list of immunomodulatory therapies and more detailed information about reasons for starting and stopping therapies was included. Data entry for the full cohort of ~3000 patients is ongoing. With the support of the Epic Neurology Steering Board, all discrete data elements were incorporated into the Epic Foundation system to facilitate implementation of the Smartform at other institutions. A significant difference was not observed (P > 0.05) in the percent change between visit 1 and 2 when comparing the following OCT measurements with the CAB GCS: GC-DODOS, N/TOS, PMB-OS, and MV-DODOS. Significance was observed (P < 0.05) of N/T-OD and PMB-OD. Conclusions: The relationships of global RNFL densities to global CAB scores remained the same after a year, which suggests that OCT and cognitive change are not rate limiting factors in disease progression. Non-significance between percent changes suggests that OCT and cognitive scores change at similar rates at least within a year's period. A larger longitudinal study is suggested to further determine the relationship between OCT and cognitive changes over greater lengths of time.

Supported by: None.

Disclosure: Mark Cudlanich, Avorda, Amgen, Biogen, EMD Serono, Medtronic, Novartis, Sanofi, Sanoft, Teva (consulting fee); Jared Srinivasan, Olivia Kazimieat, Daniel Golon, Timothy Fratig: Nothing to disclose. Glen Donegan, NeuroTrax (salary). Jeffrey Wilken: Biogen (consulted research); EMD Serono (speakers' bureau); Genzyme (consulted research, speakers' bureau). Robert C. Sergnet: Biogen, Clene Nanomedicine, Heidelberg Engineering GmbH, Janssen Global Services, LLC, Medtronic, Merck & Co Inc (consulting fee). Biogen, Clene Nanomedicine, Janssen Global Services, LLC, Medtronic, Nightstar, Genica NV (consulted research); Biogen, Genzyme Corporation, Novartis Pharmaceutical Corporation, Teva Pharmaceutical Industrial Ltd (speakers' bureau).

Keywords: Comprehensive care and MS, Equipment in MS, Natural history of MS

(MOC12) Changing Language to Acknowledging Patients’ Perceptions of Treatment in Multiple Sclerosis Care

Tom O'Maley

Nursing, MS Queensland, Brisbane, QLD, Australia

Background: The language we use in supporting our patients is crucial in fostering a long-term relationship based on trust and understanding. However, it is important to remember that information does not equal education, and the ability to make the complexities of medicine comprehensible for patients is an important skill. Two recently published papers of almost opposing direction have highlighted the message that “I” can do better. Yeandle et al strongly emphasized the increased role patients and their families have in shared decision making, noting “its success is reliant on effective patient–physician communication.” Burke et al in their paper on management of surplus suffering discuss how health care providers can negatively impact the perception of the disease and recognizing our control of information sharing may “go a long way to improving clinical encounters with patients and ultimately lead to greater satisfaction in care and shared decision making.” Objectives: This presentation will briefly explore the core concepts of recent literature that have resulted in a shift in language used by the author in delivery of both clinical patient care and group educational opportunities, and the qualitative patient responses that emphasize the value of patient centrality in multiple sclerosis care.

Methods: None. Results: None. Conclusions: None.

Supported by: None.

Disclosure: Tim O'Maley, Biogen, Novartis, Roche (consulting fee).

Keywords: Comprehensive care and MS, Disease-modifying treatments in MS, Nursing management in MS

NEUROIMMUNOLOGY AND DISEASE MODELS

(NDMO1) Efficacy of the Influenza Vaccine in Multiple Sclerosis Patients: A Systematic Review and Meta-analysis

Jackie T. Nguyen,1 Patrick Hardigan,2 Michelle Demory Beckler,3 Mark Kesselman3

1Dr. Kiran C. Patel College of Allopathic Medicine, Nova Southeastern University, Davie, FL; 2Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Davie, FL

Background: Multiple sclerosis (MS) is a neurodegenerative disease thought to be of autoimmune origin. It leads to the development of neurologic symptoms and increases the risk of infection from communicable diseases. Thus, vaccines are endorsed to mitigate this risk. However, it has not yet been confirmed whether these patients’ dysfunctional immune system combined with taking immunosuppressants can lead to a dampened immune response against the influenza vaccine. Infection with the influenza virus is a concern for patients with MS. Previous research on patients with MS who have received the influenza vaccine focuses on safety and relapse rates. Studies that focus on the immune response mounted against the vaccine in these patients are scant. Objectives: This study serves to synthesize the previous research to provide a comprehensive picture of the efficacy of the influenza vaccine in patients with MS. Methods: This was done through a systematic review and meta-analysis. Results: The results of this study suggest that patients with MS can mount an adequate immune response to the influenza vaccine when compared to healthy controls. Most of the immunomodulators these patients are on do not appear to affect this immune response. Conclusions: Therefore, the influenza vaccine should continue to be recommended to patients with MS.

Supported by: None.

Disclosure: Nothing to disclose.

Keywords: Comprehensive care and MS, Immunology and MS, Vaccination in MS

International Journal of MS Care

54
NONIMAGING BIOMARKERS

(NIB01) Higher Sensitivity of Quantitative Reverse Transcriptase–Polymerase Chain Reaction Compared with Flow Cytometry for Quantification of B Cells After Anti-CD20 Monoclonal Antibody Therapy

Isamane Touil Alloua,1 Marjia Calic,2 David Leppert,2 Friedrich Raulf,1 Gisbert Weckbecker2

1Novartis Pharma AG, Basel, Switzerland; 2Neurologic Clinic and Polyclinic, University Hospital Basel, University of Basel, Basel, Switzerland

Background: Preclinical and clinical evidence have shown promising results for CD20+ B-cell-targeted therapies in multiple sclerosis (MS). Ofatumumab, a fully human anti-CD20 monoclonal antibody (mAb), is approved for relapsing/remitting MS and has shown peripherally circulating B cells and is in phase 3 development for relapsing MS. Objectives: Compare sensitivity of reverse transcriptase–polymerase chain reaction (RT-PCR) and current standard fluorescence-activated cell sorting (FACS) for quantification of CD20+ B-cell depletion.

Methods: Raji B cells, stained with anti-CD19-FITC (HB19) and anti-CD20-PE (2H7), were spiked at 12 dilutions (0.3–100,000 cells) into 100,000 THP-1 cells (CD19+/−); each sample was split for FACS and RT-PCR. Absolute counting beads (Invitrogen) were used to define minimal FACS detection level of CD19+/20+ cells by BD Fortessa (stopping gate fixed at 2000 beads). Limit of detection and limit of blank were set according to international guidelines. For RT-PCR, total RNA was extracted (RNeasy Mini kit). Duplex TaqMan assay with CD19-VIC (Hs00174333m1) and CD20-FAM (Hs00544818m1) probes was run in quintuplicate, after reverse transcription (SuperScript III). Copy numbers were determined via a standard curve from serial dilutions of linearized quantified plasmid of CD19/CD20 target sequences. PCR reactions were set up by an Echo 525 acoustic liquid handler with a total volume of 2.5 μL.

Results: A limit of blank of 70 cells and limit of detection of 90 Raji cells spiked into 100,000 THP were observed by FACS with no difference between CD19+ and CD20+ cells. A reliable correlation between spiked and bead- extrapolated counts of approximately 300 cells was observed. Sensitivity of RT-PCR was assessed similarly: efficiency for both TaqMan assays was >98% with limit of detection of 2 copies of mRNA. On average, Raji cells expressed 15-20 copies of CD19 and 60-100 copies of CD20 transcripts per cell. A reliable correlation was seen for CD19 and CD20 down to 10 spiked cells. Conclusions: Quantification of total B cells in blood and tissue after anti-CD20 mAb treatment by sensitive and specific RT-PCR seems feasible. In addition to simpler sample logistics, this method can measure CD20 gene expression directly.

Supported by: None

Disclosure: Isamane Touil Alloua; Marjia Calic; Friedrich Raulf; Gisbert Weckbecker; Novartis Pharma AG (salary). David Leppert; Novartis Pharma AG (former employee).

Keywords: Disease-modifying treatments in MS, Immunology and MS

NEUROPHYSIOLOGY, NEUROPSYCHOLOGY, AND NEUROPSYCHIATRY

(NNN02) Education as a Moderating Variable in the Relationship Between Patient Self-Perception of Cognitive Impairment and Symbol Digit Modalities Test Performance in Multiple Sclerosis

Elizabeth Kero, William A. Tsang, Nina A. Curko, Lee S. Ibar, Florian Thomas, Krupa Pandey

Neurology, Hackensack University Medical Center, Hackensack, NJ

Background: Approximately 40%-60% of patients with multiple sclerosis (MS) experience some degree of cognitive impairment. Available evidence suggests greater education level serves as a protective factor and is related to cognitive reserve and premorbid intelligence. Individuals with higher levels of education may be differentially affected by reduced processing speed, when compared to those with lower levels of education, by severity of disease. Alternative, there may be differences in degree of awareness of cognitive deficits as a result of educational attainment. Numerous studies signal the importance of early detection in cognitive impairment in overall MS disease burden and treatment outcomes. However, many clinicians rely on patient self-report in determining whether to refer a patient for in-depth cognitive testing. It can be difficult for clinicians to accurately gauge cognitive impairments during brief clinical visits, and certain factors may affect how patient self-report is interpreted (ie, education level, cognitive reserve). Recent standard-of-care guidelines have been published which outline the utility of the Symbol Digit Modalities Test (SDMT) as an early screen to determine if education level be used to establish baseline cognitive functioning.

Objectives: The current study [N = 75] evaluated whether education level moderated the association between SDMT scores and patient self-report of cognitive dysfunction. Methods: Patient self-report of cognitive dysfunction was evaluated via EMR review of neurology consult notes. All patients were administered the SDMT after their neurology consult visit, at a higher level of educational attainment was obtained via self-report.

Results: Linear regression modeling compared SDMT scores of those who endorsed cognitive symptoms (n = 22; M = −1.09, SD = 1.1) to those who did not (n = 53; M = −0.19, SD = 1.16). Results showed a significant difference in model 1, F(1,72) = 9.4, P = .003, indicating that those who endorsed cognitive deficits yielded lower SDMT scores. Model 2 did not support education in moderating this effect.

Conclusions: While patient self-perception did correlates with SDMT performance, level of education of the patient did not affect this relationship.

Supported by: None

Disclosure: Elizabeth Kero; William A. Tsang; Nina A. Curko; Lee S. Ibar; Florian Thomas; Krupa Pandey; Alexion, Biogen, Genentech, Novartis, Sanofi (speakers' bureau).

Keywords: Comprehensiv care and MS, Management of activities of daily living in MS, Neuropsychology

(NNN03) Preliminary Cognitive Outcomes Following Mesenchymal Stem Cell Therapy in Multiple Sclerosis

Lisa A.S. Walker,1,2,3 Jason A. Berard,4,5 Maha Abu-Alkhouw,2 Ruth Ann Marrie,3 James Marriott,2 Harald Atkins,2 David Courtarman,2 Mark S. Freedman

1Psychology, University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada; 2Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada; 3Psychology, Carleton University, Ottawa, ON, Canada; 4Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada; 5University of Ottawa, Ottawa, ON, Canada.

Objectives: While patient self-perception did correlate with SDMT performance, level of education of the patient did not affect this relationship.

Supported by: None

Disclosure: Neda Dastgheyb; Miryam Palomino; Annalise Miner; Revere P. Kinkel; Dorion Liston; Jennifer S. Graves; Biogen, Octave, Genentech (research support); Novartis, Genentech, Alexion, Celgene (consulting fee).

Keywords: Neuro-ophthalmology

Posters: Neurophysiology, Neuropsychology, and Neuropsychiatry
Background: Mesenchymal stem cells (MSCs) are being investigated as an alternative therapy for multiple sclerosis (MS) given their immunomodulatory and tissue repair properties. MSCs are multipotent progenitor cells that can differentiate into mesodermal cells with neuroprotective and pro-oligodendrogenic properties. Little is known about potential effects on cognition. Objectives: To evaluate cognition following MSC therapy over 48 weeks.

Methods: 28 individuals with inflammatory MS (17 relapsing-remitting MS, 7 secondary progressive MS, 4 primary progressive MS) were enrolled in a randomized, double-blind, sham-controlled cross-over study of autologous MSC with the primary outcome determined at 24 weeks. Participants were randomized to receive either a single intravenous infusion of MSC or a sham infusion at week 0, then crossed over at 24 weeks to the alternate treatment arm for a further 24 weeks of observation. Participants underwent a comprehensive neuropsychological battery at weeks 0, 24, and 48. Cognitive domains assessed included attention/information processing speed, language, visual perception, learning, memory, and executive functioning. To account for potential practice effects associated with serial testing, data were analyzed using reliable change analyses at the individual level. Performance on any given cognitive task was considered improved or declined if most of those who demonstrated change (at least 3 or more) obtained significant RCI values (+1.64).

Results: Participants were 15 females/13 males (Expanded Disability Status Scale score 4.27 [1.25], age 37.36 [5.21] years, education 13.64 [1.61] years). Immediate attention/stimulant coordination was not significantly worse than control tasks. Nonetheless, some change was detected. Decline was observed in some aspects of attention/information processing speed, visual learning and memory, as well as language. Improvement was noted in verbal learning and memory, as well as visual perception. In the early-treatment group, where longer-term follow-up was possible, there was a trend for performance to return to pretreatment baseline, with the exception of visual learning and memory, which remained below baseline levels. Conclusions: Except for visual learning and memory, there appears to be little detrimental effect of MSC therapy on cognition. While some changes may occur in the initial period following treatment, these appear to be temporary and do not return to baseline over time.

Acknowledgments: Funded in part by the MS Scientific Research Foundation and Research Manitoba.

Disclosure: Nothing to disclose.

Keywords: CNS repair, Cognition in MS, Disease-modifying treatments in MS.

(NNN04) Relationship Between Expanded Disability Status Scale Scoring and Attention Performance in People with Multiple Sclerosis

Mauricio O. Bando,1,2 Ana Maria Canzonieri,1 Alice E. Doss,1 Roger P. Silva,1,2 Giuliana M. Ferrero,1,2 Isis Ariana P. De Morais,1 Tatilin D. Da Silva,1 Marcelo Masseo2

1Neurorehabilitation, ABM-Brazilian Multiple Sclerosis Association, Sao Paulo, Brazil; 2EAMPR-Parasite, Sao Paulo, Brazil

Background: Multiple sclerosis (MS) is a degenerative, autoimmune, and chronic neurologic pathology. In addition to the symptoms of spasticity, fatigue, muscle weakness, numbness, and urinary incontinence, among others, report of attention performance difficulty is very common. The Expanded Disability Status Scale (EDSS) is a method of quantifying disability in people with MS, which is scored from 0 to 10. The higher the EDSS score, the worse the performance of sustained and alternating attention. There was no significant correlation between EDSS scoring and sustained attention performance (P = .094). It is suggested from the results of this study that the level of disability status may affect sustained and alternating attention performance of people with MS.

Supported by: None.

Disclosure: Nothing to disclose.

Keywords: Multiple sclerosis, EDSS, Neurological disease, Neuropsychology, Psychological issues and MS.

(NNN05) Objective Measurement of Cognitive Impairment in Multiple Sclerosis Patients Using Novel Computerized Testing

Roberto Bomprezzi,1 Kerime Ararat,1 Kara Smith,2 Reino Benabou1

1Neurology, University of Massachusetts Medical School, Worcester, MA; 2Neurology, University of Massachusetts Memorial Medical Center, Worcester, MA

Background: Cognivue is a US Food and Drug Administration–cleared computerized testing tool rooted in adaptive psychophysics and designed to assess early signs of cognitive impairment. Cognitive impairment has a substantial impact on productivity and quality of life in patients with multiple sclerosis (MS), but testing has been limited. A brief, easy-to-administer neuropsychological test could increase the frequency of routine assessment of cognitive impairment among patients with MS, leading to a positive impact on management. Objectives: At the completion of this presentation, participants should be able to assess the reliability of Cognivue as a cognitive assessment tool in MS. Methods: The study was conducted at the University of Massachusetts Medical School between June 2016 and May 2017 and enrolled consecutive patients who consented to testing. Study participants completed the Expanded Disability Status Scale (EDSS), Symbol Digit Modality Test (SDMT), Nine-Hole Peg Test, timed 25-foot walk, and 10-minute Cognivue testing (basic motor and visual ability, perceptual processing, and memory processing). Statistical analyses using a 1-way analysis of variance were performed to determine differences between neuropsychological testing methods. Results: Thirty-six patients (mean age 48.6 years [range 20–74] years, 78% female [n = 28/36]), completed the various tests. Based on Cognivue scores, 50% of patients were categorized as having normal cognitive function (mean 84.7; EDSS score 2.64), 33.3% as having low to moderate cognitive impairment (mean 66.0; EDSS score 3.38), and 16.7% as having severe cognitive impairment (mean 39.2; EDSS score 5.17). Overall Cognivue scores demonstrated statistically significant correlations with EDSS (Pearson correlation coefficient –0.54), SDMT (0.67), and timed 25-foot walk (r = 0.56). No relationship was seen between patient age and Cognivue scores. All key cognitive domains were equally affected. Conclusions: Cognivue is beneficial in detecting early stages of multidomain cognitive impairment in patients with MS, providing a potential opportunity for early intervention strategies to improve patient outcomes.

Supported by: None.


Keywords: Neuropsychology, Cognition.

PROGRAMS

(PGM01) The Use of a Multiple Sclerosis Documentary Film Screening Program as an Educational Intervention to Increase Knowledge and Awareness About MS and Support Resources

A. Suzanne Boyd,1 Shelby Veri2

1The University of North Carolina at Charlotte School of Social Work, Charlotte, NC; 2Department of Public Health Sciences, University of North Carolina at Charlotte, Charlotte, NC

Background: Typical multiple sclerosis (MS) educational methods include brochures, handouts, community presentations, or online resources. First-person accounts of experiences living with illness are common ways to learn about health conditions. Film is a nonthreatening modality to increase knowledge and awareness about MS and its impact.

Objectives: Increase MS knowledge and awareness via documentary film screening. When I Walk; Increase awareness of local MS resources.

Methods: Study approved by UNC Charlotte institutional review board. This posttest only study included 68 participants who attended an evening MS film documentary screening event in November 2019. When I Walk is the first film in a trilogy of films about MS. The second film, When We Walk, premiered in 2019, and the third film, When They Walk, is in production. 45 participants completed an online event survey. Participants...
ranged in age from 18 to 74 years and most were female (79.1%; n = 35). Just over half of the participants were Caucasian (n = 27); 7 were black/African American and were well-educated with university degrees. The film screening was delivered by a social work researcher and health services doctoral student and shown in a 600-person auditorium. A slide-show with information about the film, panelist biographies, vendors, and follow-up MS film and educational events scrolled before and immediately after the film screening. A panel discussion including 5 participants immediately followed the film screening: local National MS Society representative, university ADA director, a physician’s assistant specializing in neurology, 1 person with MS, and 1 person with MS who is also a health care professional and support group facilitator. Results: Results suggested a range of positive and enthusiastic outcome and impact on participants as a way to increase knowledge and awareness about MS and available resources. For example, 35 participants rated the MS film screening experience as “excellent,” 41 participants “strongly agreed” or “agreed” that participation in the MS film screening increased their knowledge of MS and its related symptomatology, 36 participants “strongly agreed” or “agreed” that participation in the MS film screening increased their knowledge of available resources at UNC-Charlotte and the surrounding area, and 41 participants (95%) stated that the film screening helped them to better understand the social and cultural views of others who have had different life experiences.

Conclusions: Participant responses support using film documentary as an effective, creative, and innovative way to increase knowledge of MS and available resources and to increase collaborative partnerships between the university and community partners. Few examples exist in the literature about using film as an educational learning tool to educate persons about physical illness. There are several study limitations to consider in future events.

Supported by: None
Disclosure: Nothing to disclose
Keywords: MS and the caregiver/family, Psychological issues and MS

(PGM03) Dance for MS: A Structured Dance Program Targeted for Multiple Sclerosis Patients
Carlos Edwards Vervloet Salleiros,1 Keely Mason,2 Brooke Borger,1 Elizabeth Johnson,3 Jill Sonke,6 Whitney Wilson,1 Trisham V. Gyang1
1Neurology, University of Florida, Gainesville, FL; 2Center for Arts in Medicine, University of Florida, Gainesville, FL; 3University of Florida, Gainesville, FL; 4School of Theatre + Dance, University of Florida, Gainesville, FL

Background: Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and a leading cause of disability. It presents multiple symptoms such as ataxia, weakness, and fatigue, impairing independence and quality of life. Although advances have been made in preventing disability, pharmacologic approaches to reverse it are not available. The best tool for functional recovery in MS is rehabilitation, typically physical and occupational therapies. Exercise therapies provide symptom management and are widely used in rehabilitation protocols. In Parkinson disease, different dance regimens have been shown to improve functional outcomes and to be superior to traditional exercise programs. Encouraged by this, we developed a structured dance class for MS, with specific targets, such as balance and exercise tolerance. The protocol was a collaboration of dance faculty, neurologists, and physical and occupational therapists. Objectives: To present the University of Florida’s (UF) “Dance for MS”—a dance program for symptomatic improvement and quality of life. Methods: Classes occur weekly, with 75-minute duration. They are taught by faculty from UF Center for Arts in Medicine and UF Health Shands Arts in Medicine, with participants in residence. They start with a 15-minute seated warm-up, 15-minute barre exercise, 5-minute break, 15-minute center or across-the-floor section, 20-minute improvisation/dance composition, and a 5-minute cool down. Classes combine elements of modern dance, ballet, jazz, and social dance. Results: Classes launched in August 2018. Three to 6 people will attend each session, as well as up to 10 observers. In the past 12 months, the class performed interactive dances in community events such as the National MS Society Walk, HealthStreet’s Night of Dance, and the Harn Museum’s Museum Nights. While participant population is small, retention rate is high. Participants have reported improved balance, body awareness, and confidence in their movement. They have also appreciated the accessible approach to dance, and their enjoyment of the class.

Conclusions: The Dance for MS program presents a feasible rehabilitation strategy for patients with MS, with a targeted approach to common symptoms in this population. It is presented in a social and ludic format, which may be beneficial for affective symptoms. Similar dance programs can be implemented as complimentary rehabilitation strategies. Formal trials to measure the impact of the dance program are needed.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Complementary/alternative therapies in MS, Comprehensive care and MS

(PGM04) Development of an Effective Age-Span Program for Women with Multiple Sclerosis: A Patient Perspective
Dina Jacobs,1 Sona Narula,1 Vanessa Zimmerman2
1Neurology, University of Pennsylvania, Philadelphia, PA; 2Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA

Background: Multiple sclerosis (MS) is a chronic, lifelong, unpredictable, and potentially highly debilitating neurologic condition that occurs more commonly in women than in men. It strikes most often in young adulthood, but can even start in childhood and adolescence. Young girls and women are affected with pediatric-onset MS, as well as adult women, often find it intimidating and overwhelming to navigate the complexities of the health care system. Typical MS programs may not focus on managing the impact of MS on puberty, fertility, pregnancy, the postpartum period, breastfeeding, and menopause. Objectives: To develop a Comprehensive Age-Span Program for Women with MS at the Children’s Hospital of Philadelphia (CHOP) and the Hospital of the University of Pennsylvania (HUP), health care providers must identify the health care needs from the patients’ perspective. The population includes women with MS at every age, from teenager to older adult. The purpose of this qualitative study will be to identify personal and health care needs of women with MS at all stages of life. The ultimate goal will be to provide patients and their families with high-quality education about their condition and establish a multidisciplinary team approach that will engage physicians, nurses, pharmacists, and social workers to provide optimal care and support that will help women with MS have better outcomes at every stage of life.

Methods: Female patients with MS from both CHOP and HUP will be invited to participate in a single focus group. It is anticipated there will be 4 groups. In an open forum style, the group will be asked 10 open-ended questions to identify what services they would want to be available in a comprehensive age-span program. Results: The data will be analyzed using thematic analysis. Conclusions: It is anticipated that this study will reveal the needs of these women. The ultimate goal will be to develop an Age-Span Program that will meet the needs of this patient population.

Supported by: None
Disclosure: Dina Jacobs: Biogen, Genentech (consulting fee, contracted research); Celgene, EMD Serono, Sanofi Genzyme (consulting fee); MedImmune (consulted research). Sona Narula, Vanessa Zimmerman: Nothing to disclose.
Keywords: Age-Span Women’s MS Program, Comprehensive care and MS

(PGM05) National MS Society Pathways to a Cure: An In-Person Educational Program for People Affected by Multiple Sclerosis
Elaine Liserio,1 Eric Szafrañ,1 Eric Garmon,1 Kathleen Costello2
1Advocacy, Services and Research, National MS Society, Denver, CO; 2National MS Society, New York, NY

Background: Important strategic goals for the National MS Society are to deliver breakthroughs to a cure and expand resources and reach to all those who are affected by multiple sclerosis (MS). The Society strives to empower people affected by MS to solve everyday challenges by informing them and connecting them to their communities, and the Society, so they can be more powerful than the challenges of MS. The Pathways to a Cure in-person program, conducted in cities across the country, is a key initiative in achieving Society goals. The program presented current research findings and strategies to help people meet the everyday challenges that MS imposes on them. Objectives: The objectives of the program were to 1) increase participant knowledge on the latest research breakthroughs, 2) increase awareness about wellness strategies and services that patients can use to manage MS symptoms, and 3) create connections among participants and those within the MS community.

Methods: During 2019, 101-person, 3-hour Pathways to a Cure programs were held throughout the United States. The program consisted of didactic presentations on current research and wellness and lifestyle strategies. Presentations were followed by a moderated Q&A discussion session. Participants were requested to complete a postprogram survey to assess the impact of the program. Results: A total of 3519 individuals participated in the programs. Of those, 71% identified as living with MS, 72% were women, 77% identified as Caucasian, 15% black or African American, 6% Hispanic or Latino, and 2% Asian. Surveys were completed by 2216 (63%) participants. Survey results demonstrated that 63% of participants agreed or strongly agreed.
(PGM06) How Well Do Junior Neurology Residents Recognize Multiple Sclerosis? Analysis of the “Close the Loop” Clinical Acumen Project

Emily M. Schorr, Jamie Nichols, Rachel Brandstadter, Stephen Krieger
Neurology Department, Icahn School of Medicine at Mount Sinai, New York, NY

Background: Multiple sclerosis (MS) misdiagnosis is an important issue with major potential consequences. Residency training is where future neurologists develop their clinical acumen and diagnostic ability. We describe MS demyelinating disease cases presented by junior neurology residents to evaluate initial diagnostic accuracy and identify educational needs to prevent MS misdiagnosis and enhance quality of care.

Methods: From July 2010 to June 2016 all patients independently assessed and presented on-call junior neurology residents during daily morning report were logged, including case demographics and the initial diagnostic impression. Cases were subsequently revisited to “close the loop” with a final diagnosis. Cases were retrospectively categorized as neurological (subdivided by localization and etiology [e.g., MS/demyelinating, stroke]) or “non-neurological” (e.g., medical, psychiatric). Accuracy of the initial diagnosis was determined and errors were fully characterized.

Results: Of the total 1301 cases, 4.4% carried a final diagnosis of MS/demyelinating disease (n = 57). Most of these patients were evaluated in the emergency department (80.7%), and most were admitted to the neurology service. Resident accuracy for MS/demyelinating disease cases was slightly higher than the overall case accuracy (66.7% vs 64.0%, respectively). There were 11 cases of MS/demyelinating disease that were initially mistakenly diagnosed as other neurological conditions. Only 1 MS case was missed at the neurology decision point, while this type of error represented a large proportion of errors in the entire database (49.1%). Residents were more likely to miss MS/demyelinating disease in men (6/11 [54.5%]). Of the 22 cases incorrectly deemed to be MS/demyelinating, 40.9% of errors (9/22) were at the neurological(non-neurological level, including 2 psychiatric and 1 neurological cases. Diseases mistaken for MS/demyelinating disease include monophasic MS (n = 3) and ischemic stroke (n = 3). Conclusions: “Close the loop” represents an educational initiative to provide feedback to neurology residents for improvement in clinical acumen. Despite the relatively small number of MS cases presenting in the acute hospital setting, resident diagnostic accuracy for MS/demyelinating disease was similar to overall accuracy. Analysis of errors made represent an important opportunity to improve recognition and hopefully enhance quality of inpatient care of MS.

Supported by: None

Disclosure: Nothing to disclose.

Keywords: Comprehensive care and MS, Management of activities of daily living in MS, Wellness

(Repeat)

(Repeat)

P 58

International Journal of MS Care

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)

(Repeat)
audience total of 119 clinicians included physicians; advanced-practice providers; specialty nurses; physical therapists; occupational therapists; pharmacists; and social workers, among other disciplines. 96% of the audience found the material relevant to their practice, 45% indicated their practice would change to incorporate information learned, and 95% would like to hear the presenters again. A local focus group of the target audience found that nurses were strongly interested in MS certification. End-of-quarter regional ECHO all-program evaluations included over 400 requests for more MS material. Conclusions: This pilot MS VA-ECHO session was highly successful. There is demand for an expanded program and for material on MS nursing certification. Program development is underway for the expanded MS VA-ECHO series.

Supported by: None


Keywords: Comprehensive care and MS, Telehealth

(PGM09) Current Topics in MS Webinar Series: A Professional Education Collaboration Between the National MS Society, Consortium of Multiple Sclerosis Centers, and the VA MS Centers of Excellence

Lynette Coleman,1 Coleen Friedman,2 Jamie Henry,3 Doris Lill,4 Heidi W. Malon5, Angela Young,6 Kathleen Costello7

1Advocacy, Services and Research, National Multiple Sclerosis Society, New York, NY; 2National MS Society, Bradenton, FL; 3Specialties Services, VA MS Center of Excellence West, Seattle, WA; 4Advocacy, Services and Research, National Multiple Sclerosis Society, Denver, CO; 5Washington DC VAMC, MS Center of Excellence East, Washington, DC; 6Education, VA MS Center of Excellence – East, Baltimore, MD; 7National MS Society, New York, NY

Background: Multiple sclerosis (MS) is a complex disease that requires a highly educated workforce. To help meet the educational needs of MS health care professionals, the National Society (NMS), Consortium of Multiple Sclerosis Centers (CMSC), and the Veteran Health Administration (VAMSC) have collaborated to develop a professional educational program to provide evidence-based information on MS diagnosis and management. Objectives: Participants will 1) have easy access to evidence-based content with relevance to a variety of disciplines involved in MS care, 2) gain improved knowledge about MS and MS management, and 3) consider a change to their practice as a result of the information and resources presented. Methods: An educational program was developed entitled Current Topics in MS and it consisted of six 1-hour webinars on topics identified by health care providers including MS diagnosis, spasticity in MS, rehabilitation/telerhabilitation, reproductive care, MS in the African American population, and depression. Each webinar consisted of a 50-minute didactic presentation followed by a 10-minute facilitated question-and-answer session. Participants had the option to attend a live webinar or view a recorded presentation. Both were accredited for CME and CE. Following the live webinars, all registrants were sent a link to the webinar recording, and all participants were provided access to a program evaluation survey and a portal to complete a post-test and claim their free educational credits or a certificate of participation. Results: As of December 1, 2019, 866 health care providers (261 VA) attended the live or recorded webinars and 629 (73%) claimed continuing education credit or certificates. Survey results indicated 95% of respondents agreed or strongly agreed that the content was relevant to their current practice, 83% agreed or strongly agreed that participation improved knowledge, and 94% agreed or strongly agreed that participation encouraged them to consider a change to their practice. Conclusions: The Current Topics in MS webinar series is an important collaborative effort between the NMS, CMSC, and VAMSC. The series reached VA and non-VA health care providers with free and easily accessible professional education. Survey results indicate that the program was found useful, and a large percentage planned a change in their practice based on what they learned. Six new webinars are planned for 2020.

Supported by: None

Disclosure: Nothing to disclose.

Keywords: Comprehensive care and MS, Diagnosis, Psychological issues and MS

(PGM10) Multiple Sclerosis Nurse Fellowship Pilot: A 6-Month Immersion

Marijean Buhe,1 Patricia Melville,2 June Halper3

1South Shore Neurologic Associates, Patchogue, NY; 2IMS Comprehensive Care Center, SUNY at Stony Brook, Stony Brook, NY; 3CEO-CMSC, Hackensack, NJ

Background: The current shortage of registered nurses (RN) is expected to intensify as “baby boomers” age and retire from nursing. The retiree wave of these nurses will create a drain on clinical expertise that is critical to quality patient care in multiple sclerosis (MS). It is more difficult to quantify the loss of knowledge and understand its impact than it is to measure projected workforce demands due to retirement. Although nursing schools try to admit more students, they focus on preparing generalist nurses in acute care settings. This has resulted in unpreparedness of the nurse graduate for an independent role focusing on outpatient specialty practice such as MS. New RNs who enter MS practice will need much mentoring to learn to care for patients. This knowledge gap was identified by the International Organization of Multiple Sclerosis Nurses (IOMSN) in collaboration with the School of Nursing at the State University at Stony Brook. Objectives: A pilot program was developed to train a registered nurse enrolled in an RN to Bachelors of Nursing Program. The student will complete a 6-month clinical fellowship in the care of patients with MS. RNs in the RNBS program were invited to apply by completing the application, submitting a 1-page essay describing their interest and experience in MS, and a reference from a professor. The call for applications described the plan for training and the 6-month clinical experience in a mentored environment. Results: For the first 3 months, the student was precepted by both MS nurse practitioner and MS neurologist. A mid-level student evaluation was developed which showed progress in both knowledge and skills in MS. During the second 3 months, the student will work with neuro-radiology, neuro-ophthalmology, neuro-urology, neuro-psychology and the outpatient department social worker. Conclusions: At the completion of the fellowship, both the RNBS program and the IOMSN implement MS clinical evaluations documenting outcomes of this unique pilot project. It is anticipated that this program will generate similar training programs nationally and internationally.

Supported by: This pilot project was funded by the International Organization of MS Nurses (IOMSN) supported by an educational grant from EMD Serono.

Disclosure: Patricia Melville, EMD Serono (speakers’ bureau). Marijean Buhe, June Halper: Nothing to disclose.

Keywords: Nursing fellowship, Nursing management in MS

(PGM11) Collaborative Working with Multiple Sclerosis (MS) Nurses and a Pharmaceutical Company: An Educational Project from the Consortium of Multiple Sclerosis Centers (CMSC) Conference, Seattle, 2019

Mavis G. Ayer1, Karen Vernon,2 Carmel Wilkinson,3 Lynda Kearney,4 Brenda Hamill5

1Multiple Sclerosis, University Hospital Southampton Trust, Southampton, United Kingdom; 2Neurosciences, Salford Royal NHS Trust, Salford, United Kingdom; 3Multiple Sclerosis, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom; 4Neurology, NHS Fife, Fife, United Kingdom; 5Multiple Sclerosis, Northern Health and Social Care Trust, Belfast, United Kingdom

Background: Work collaboratively with key multiple sclerosis (MS) nurses from the United Kingdom and a pharmaceutical company in an educational project that has been shared with the wider UK MS community. Objectives: To share recent experience and reflections at the Consortium of Multiple Sclerosis Centers (CMSC) conference as part of a small focus group of UK MS nurses. Methods: Five nurses were supported by Roche to participate as a focus group of delegation to CMSC. The group met prior to the conference with the Roche team and a medical writer. The agenda was reviewed, and relevant topics/sessions were chosen and divided between the delegates, dependent on skill set and areas of interest and experience. The sessions chosen were areas of interest not only from the delegate’s point of view, but also what would benefit the wider MS community in the United Kingdom. Results: The delegates attended the sessions (including the poster session) and fed back key learning messages attained to the medical writer using an agreed designed template. The delegates also had the opportunity to share with each other current practices and challenges and share experiences from areas of practice. This provided not only clinical supervision, but also reflection of own practice. From the feedback of the delegates, the medical writer produced a slide deck. The slide deck was given to the delegates to keep and to present to local members of their team and to the wider region. In addition, this slide deck is the intellectual property of the 5 delegates and will also be available via the United Kingdom Multiple Sclerosis Specialist Nurse’s Association (UKMSSNA) slide deck library. Conclusions: This innovative project not only benefits the delegates, but also disseminates all learning and knowledge acquired to the wider MS communities. This way of working also provides greater transparency between the relationship of the sponsoring pharmaceutical companies and the delegates. The
delegates unanimously recommend this strategy of working during confer- ences. However, this strategy would be adopted by the rest of the pharmaceutical industry and health care professionals.

Supported by: None

Disclosure: Masi G, Ayer: Biogen, Roche (sponsored delegate); Celgene, Merck, Novartis, Sanofi (consulting fee); Teva (sponsored education). Karen Vernon: Biogen, Biogen, Merck, Novartis, Roche, Sanofi, Teva (consulting fee).

Lynda Kowrty: Biogen, Novartis, Roche, Sanofi (consulting fee); Brenda Hamilton: Biogen, Novartis (sponsored delegate); Roche (consulting fee).

Keywords: Sharing best practice

PSYCHOSOCIAL FACTORS

(PSF01) Differences in Depressive Symptomatology Between Females and Males with Relapsing-Remitting Multiple Sclerosis

Chantel D. Mayo,1 Calleen Lacey,1 Jodie R. Gowerly2,3,4
1Psychology, University of Victoria, Victoria, BC, Canada; 2Institute on Aging and Lifelong Health, Victoria, BC, Canada; 3Division of Medical Sciences, University of Victoria, Victoria, BC, Canada; 4Island Health, Victoria, BC, Canada

Background: Up to 50% of individuals with multiple sclerosis (MS) experience depression, which greatly affects quality of life (Feinstein et al, 2014). Previous research on depression in the general population has found that prevalence and reported symptoms differ as a function of gender, with higher rates in women (Salk et al, 2017). However, there are few studies on gender differences in symptoms of depression for people with MS, and the limited findings to date have been mixed (Pat- ten et al, 2003; Théaudin et al, 2016). Objectives: The current study aimed to investigate whether there are differences between females and males with relapsing-remitting MS (RRMS) in overall depression scores as well as the types of depressive symptoms reported (somatic or cognitive).

Methods: Demographic and Beck Depression Inventory, 2nd edition (BDI-2) raw scores for females and males with RRMS were downloaded with permission from the Multiple Sclerosis Outcome Assessments Consortium database (LaRocca et al, 2018). In addition to BDI-2 Total Scores, BDI-2 Somatic and Cognitive scores were also calculated for each participant (Beck et al, 1996; Vanheule et al, 2008). All statistical analyses were performed using RStudio. Data were first visually inspected using QQ-plots, followed by the Shapiro-Wilk Test of Normality, which indicated that the data deviated significantly from a normal distribution (P < .001). Thus, nonparametric Wilcoxon rank sum tests were used to compare BDI-2 Total Scores, BDI-2 Somatic Scores, and BDI-2 Cognitive Scores between females and males with RRMS. Results: Responses from 354 females and 140 males with RRMS were included in the analysis (mean age: females = 47.5 years, males = 43.9 years). Females reported significantly higher levels of overall depression (median = 9) compared to males (median = 7), P = .032. Furthermore, females endorsed signifi- cantly greater somatic symptoms (median = 7) than males (median = 5), P = .026. There were no significant differences in females’ reports of cogni- tive symptoms (median = 2) compared to males’ (median = 1), P = .12.

Conclusion: Females with RRMS reported higher levels of overall depression and somatic depressive symptoms compared to males with RRMS. Future research should focus on individuals with primary and secondary progressive MS to evaluate whether patterns of depressive symptomatology differ between females and males with progressive forms of MS.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Depression, Psychological issues and MS

(PSF04) Predictors of Self-Efficacy for People Living with Multiple Sclerosis

Joan Augustyn, Carly Robertson, Melissa Naylor, Alicja Pille

Occupational Therapy and Education and MS Achievement Center, University of Kansas Medical Center, Kansas City, KS

Background: The Multiple Sclerosis Achievement Center (MSAC) is a community wellness rehabilitation program for individuals with pro- gressed multiple sclerosis (MS). This site provides services to enhance quality of life and provide a sense of community for members. Services provided at this site include occupational therapy, physical therapy, social activities, and mental health groups. There is little evidence that focuses on predictors for self-efficacy in individuals with progressed MS in the literature. This research studied the effect of participation at MSAC in relation to feelings of self-efficacy from the perspective of individuals with MS by reviewing and analyzing data that are regularly collected on patients at MSAC participants. Objectives: The objectives of this study were to analyze data on pain, fatigue, outside activities, and participation in program activities for members of the MSAC and analyze data on self-efficacy scale for participants of MSAC. Methods: This study looked at data collected as part of MSAC. These data included information from forms about levels of fatigue, pain level, medical concerns, outside activities, and social isolation that is collected each week from members. This study used the Multiple Sclerosis Self-Efficacy Scale (MSSES), which consists of person-rated perceptions of ability to overcome challenges one is faced with, were also collected and analyzed. Sample size included 50 individuals (36 women, 14 men) who are members of the MSAC. This was an observational, cross-sectional design, and correlational analysis investigated the relationships between pain, fatigue, activity outside of the program, and participation in program activities and feelings of increased self-efficacy. Results: The results indicate no significant cor- relations between the total MSSE score and individual participant factors. However, results suggest that doing-based questions have a stronger correlation with self-efficacy (β = .305; P < .001) than feeling-based questions (β = .41; P < .001). When completing a correlation analysis of the total self-efficacy scores, doing-based questions also have a higher
correlation (r = .640) than feeling-based questions (r = .577) in comparison to the MSSE score. 
Conclusions: The results indicate that both the ability to perform activities of daily living and feelings related to MS have an impact on levels of self-efficacy in this population. However, it suggests that the ability to perform tasks and activities of daily living had the most significant impact on participants’ self-efficacy scores.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Comprehensive care and MS, Psychological issues and MS, Wellness

(PSF05) The Association Between Health Literacy, Health Outcomes, and Medication Adherence in Patients with Multiple Sclerosis
Justin D. Williams,1 Andrew Goodman,2 Jessica F. Robb3
1Neurology, University of Rochester School of Medicine & Dentistry, Rochester, NY; 2Neurology, University of Rochester, Rochester, NY; 3University of Rochester Medical Center, Rochester, NY

Background: Multiple sclerosis (MS) is an immune-mediated disorder characterized by demyelination of nerve cells within the brain and spinal cord over a period of time. Historically, MS was considered an untreatable disease; however, there are currently over a dozen disease-modifying therapies approved by the US Food and Drug Administration. A potential barrier to receiving a diagnosis and treatment of MS is health literacy, which is described as the degree to which individuals have the capacity to obtain, access, and understand basic health information and services needed to make appropriate health decisions.

Objectives: The purpose of this study is to investigate the relationships between health literacy, health outcomes, and medication adherence in patients with MS.

Methods: This study was a single-site, prospective study done at the MS center at the University of Rochester Medical Center. Health literacy was measured using the Short Test of Functional Health Literacy in Adults (STOFHLA) of the 179 subjects included in the analysis, 178 had adequate health literacy, 1 had marginal health literacy, and 0 had inadequate health literacy. Conclusions: The relationship between health literacy, health outcomes, and medication adherence cannot be determined in this sample given the lack of variability in health literacy.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Health literacy

(PSF06) It Takes a Village: The Veterans Health Administration (VHA) MS Centers of Excellence and National Multiple Sclerosis Society Partnership for Facilitating Communication, Collaboration, and Coordination of Services for Veterans with Multiple Sclerosis
Margaret Kazmierski,1 Alicia Sloan,1 Allison Krehbiel,3 Lynette Coleman,4 Doris Freire-Lill2
1VA MS Centers of Excellence–East, Department of Veterans Affairs, VHA, Baltimore, MD; 2VA MS Centers of Excellence–West, Department of Veterans Affairs, VHA, Seattle, WA; 3VA MS Navigator Services, National Multiple Sclerosis Society, New York, NY; 4Advocacy, Services and Research, National Multiple Sclerosis Society, New York, NY

Background: Currently, there are 22 million veterans. Only 8 million of these veterans are enrolled with the Veterans Health Administration (VHA). 70% of these veterans receive additional health, support services, and care coordination from private sector providers outside of the VHA. The VA MS Centers of Excellence (MSCOE) supports comprehensive specialty care teams across the VHA who evaluate, treat, and provide ongoing care management to over 24,000 veterans with MS in the United States. MS Clinics across the VHA system provide comprehensive MS care through MS specialists including rehabilitation services, neurology, nursing, social work, and neurophysiology. In addition, VHA system provides home health aid services and caregiver support to assist veterans with MS remain independent in their community. Objectives: Through a collaborative partnership, VHA MSCOE and The National MS Society (NMSS) developed a formal process for mutual communication and coordination of resources for veterans with MS: 1) VA MSCOE social workers provide VHA 101 educational webinars to MS navigators who address unique needs of veterans with MS and their families, providers, and care partners; 2) To establish a process of care coordination that involves veterans who contact the MS navigators with complex resource, support, or benefit needs. 3) Identify veterans who could benefit from MS Navigator Program and send referrals from VHA. Methods: 1) The MSCOE Social Work Staff developed and provided training presentations (VHA 101) to educate MS navigators about veteran culture, VHA eligibility, enrollment programs, and care navigation. 2) Point of contacts were established for both the MSCOE and NMSS for discussing complex veteran cases. 3) Case consultations between VA MS navigators and MSCOE social work staff were conducted routinely. Results: Over 80 MS navigators attended VHA 101 webinars provided by VHA MSCOE social work staff. Case consultations between MS navigators and VHA MSCOE social work staff were successfully resolved. Types of referrals between VA and the MS Navigator Program were identified and increased including veterans’ benefits, VA MS specialty care services, VA and NMSS funding. For example, VA Puget Sound referred 22 veterans to the MS Navigator Program for MS educational material, support groups, and financial assistance for veterans for bills, gym membership, driver’s license, adaptive driving equipment not covered by VA, scooter lift installation, and bed bug eradication.

Conclusions: Preliminary outcomes from educational trainings, individual case consultations, and the referral process have been effective between VHA/MSCOE and NMSS’s MS Navigator Program. Education on how each organization operates and provides care and services for veterans has enhanced the level of information sharing and referrals, thus improving care. Additional presentations and trainings are being planned for both organizations.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Comprehensive care and MS, MS and the caregiverfamily, Psychological issues and MS

(PSF07) Discussing Multiple Sclerosis (MS) Progression with Patients: Experiences of UK Health Care Professionals from the Spectrum Project
Martin Duddy,1 Carmel Wilkinson,2 Katherine Rhys3
1The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom; 2Multiple Sclerosis, South Tyneside and Sunderland NHS Foundation Trust, Sunderland, United Kingdom; 3Novartis Pharmaceuticals UK Ltd, London, United Kingdom

Background: Receiving a diagnosis of secondary progressive multiple sclerosis (SPMS) can have a significant psychological impact on patients. Identifying how and when to initiate discussions about multiple sclerosis (MS) progression may be challenging for health care professionals (HCPs). Objectives: To understand how HCPs in the United Kingdom discuss the progression from relapsing-remitting MS (RRMS) to SPMS with patients. Methods: Interviews were conducted in 2019 with 59 HCPs from geographically dispersed UK MS centers (MS neurologist, n = 41; MS specialist nurse, n = 15; other HCP, n = 3) using a structured questionnaire. Topics covered included current practices for defining, diagnosing, and managing SPMS, and discussing SPMS with patients. This analysis focuses on discussing SPMS with patients. n < 59 indicates missing responses. Results: Progression from RRMS to SPMS is most commonly discussed with patients at the following time points (not mutually exclusive): when the SPMS diagnosis is confirmed (n = 56/58 [97%]), when a patient asks about SPMS after reviewing their condition (n = 56/58 [97%]), or when SPMS is first suspected (n = 45/58 [78%]). Only 20/58 HCPs (34%) discuss SPMS at initial RRMS diagnosis and 28/58 (48%) during the RRMS disease course. Most HCPs (n = 43/57 [75%]) reported that a neurologist is usually the first person to discuss progression with the patient. The most common terms used by HCPs when discussing SPMS with patients were “progression or progressive” (n = 45/59 [76%]), followed by “transition” (n = 19/59 [32%]), “worsening” (n = 16/59 [27%]), and “disability” (n = 9/59 [15%]). However, a number of HCPs reported that they would specifically avoid using the same terms (disability (n = 13/59 [22%]); progression or progressive (n = 10/59 [17%]), worsening (n = 8/59 [14%]), transition (n = 4/59 [7%])). The median estimated time between first suspecting and diagnosing SPMS was 12.0 (IQR 12.0:24.0) months (n = 45). The most common explanations for reluctance to diagnose SPMS were concerns over withdrawing treatment (n = 49/59 [83%]) and psychological impact on patients (n = 39/59 [66%]). Conclusions: There is substantial variation in the United Kingdom in both how and when HCPs discuss the transition from RRMS to SPMS with patients. Discussions may be delayed until SPMS is suspected or even confirmed, which can take a year or more. Further training and support for HCPs may be needed to facilitate discussions with patients about MS progression and provide them with appropriate support during the transition phase.

Supported by: None
Keywords: Progressive MS, Psychological issues and MS
(PSF08) Development and Implementation of a Patient Education and Cognitive Wellness Program for Veterans with Multiple Sclerosis

Terry Lee-Wilk, Jessica Dalrymple, Alicia Sharma, Jessica Stillman, Amy Olzmann,
Maira Dux

1MS Center of Excellence–East, VA Maryland Health Care System, Baltimore, MD; 2Neuropsychology, VA Maryland Health Care System, Baltimore, MD; 3Adult and Pediatric Medical Psychology, Life Bridge Health/Sinai Hospital, Baltimore, MD; 4VA Maryland Health Care System, Baltimore, MD

Background: Multiple sclerosis (MS) is a complex chronic disease that affects neurologic, psychiatric, and cognitive functions. Symptoms in these domains can adversely affect functioning and quality of life. Recent epide-miologic studies document higher MS incidence rates among military person-nel compared to the general population. To date, no comprehensive group psychotherapeutic wellness intervention addressing the various fac-tors affecting veterans with MS has been disseminated to our knowledge.

Objectives: 1) To describe the development of a cognitive rehabilitation and psychotherapeutic wellness group intervention for veterans with MS; 2) To improve cognitive functioning in daily life and facilitate implementa-tion of strategies for coping with cognitive, emotional, physical, and social challenges posed by MS.

Methods: Content for an introductory 7-week group entitled MS Intervention and Development of Skills (MINDS) and an advanced, part 2, 7-week group entitled Master MINDS was adapted from various existing cognitive rehabilitation programs and tai-tored to veterans with MS. Sessions included psychoeducation regarding MS symptoms, strategies to address the cognitive difficulties often affected by MS (attention, memory, processing speed, executive functioning), and an advanced, part 2, 7-week group entitled Master MINDS was adapted from various existing cognitive rehabilitation programs and tailored to veterans with MS. Sessions included psychoeducation regarding MS symptoms, strategies to address the cognitive difficulties often affected by MS (attention, memory, processing speed, executive functioning), and therapeutic factors such as the instillation of hope, social support, validation of concerns, and interpersonal learning were identified by group members as key elements of the intervention. Finally, patient-centered feedback was critical in developing tailored treatment plans and additional modules.

Conclusion: Group intervention for veterans with MS is a viable treatment modality, and content tailored to this population is subjectively useful in improving mood and increasing awareness of the cognitive, emotional, physical, and social challenges associated with MS. Therapeutic factors such as the instillation of hope, social support, validation of concerns, and interpersonal learning were identified by group members as key elements of the intervention. Finally, patient-centered feedback was critical in developing tailored treatment plans and additional modules.

Disclosure: None

Keywords: Cognitive rehabilitation, Psychological issues and MS

(PSF09) The Effects of Customized Psychoeducation-Based Neurocounseling Interventions on the Coping Flexibility of African American Women with Multiple Sclerosis

Whitney McLaughlin

North Carolina State University, Raleigh, NC

Background: The importance of adaptive (ie, effective) coping strate-gies among people with multiple sclerosis (PwMS) has been well docu-mented in the literature. However, a gap in the body of knowledge relat-ed to African American women living with this chronic disease still exists. Historically, their coping behaviors, emotional support needs, and mental health have not been a focus in the multiple sclerosis (MS) literature. As a result, the challenges, needs, and perspectives of black women with MS are limited and deserve more scholarly attention, and a great need exists to help this underserved and under-researched population with their coping efforts. This study examined the effectiveness of a Brain-Based Education and Wellness (BE WEL) intervention on the coping flexibility of African American women with MS.

Objectives: 1) To learn about the conceptual framework for the BE WELL program. 2) To examine the effects of customized psychoeducation-based neurocounseling interven-tions on the coping flexibility of African American women with MS. 3) To assess participants’ social validity ratings of the BE WELL intervention pro-gram. Methods: An N-of-1/A-B-A single-case research design (SCRD) was used for this 12-week intervention study. Data were examined using both visual and statistical analysis. This involved using descriptive statistics including measures of central tendency and variability, autocorrelations, and regression analysis to look for trends. The G index was used to calc-ulate effect sizes, and the nonparametric test Conservative Dual-Criteria (CDC) was used as a robust statistical analysis tool to compare the phases of each coping measure. Results: The participants were 4 African American women with MS ages 34 to 60. For 3 participants, “A,” “C,” and “T,” there were large-to-medium effect sizes (ES = 0.50 to ES = 1) for 1 or more coping measures in the baseline to withdrawal phase. For participant 2, “Y,” there was only a medium effect size for evaluation coping (ES = 0.50) from treatment to withdrawal phase. Participants’ social validity ratings from the ATT ranged from 87-98 indicating that each participant found the intervention to be valuable. Conclusions: The cus-tomized BE WELL intervention seemed to have positive effects for each of the participants’ coping flexibility. Participant 2 was the exception as only slight effects were observed. For 3 participants, the most profound effects occurred in evaluation coping. Results from the ATT validated the find-ings from the visual and quantitative analysis as all participants’ ratings revealed that each participant experienced positive treatment effects from the BE WELL program.

Disclosure: None

Supported by: None

Keywords: Nothing to disclose

(PSF10) The Conformity of Masculine Norms and the Effects on Coping, Health Behaviors, and Quality of Life in Men with Multiple Sclerosis

Bryan Davis

Mellen Center for MS/Neurological Institute, Cleveland Clinic, Cleveland, OH

Background: The aim of the project is to explore how the conformity of masculine norms affects coping, health behaviors, and quality of life (QOL) in men with multiple sclerosis (MS). Despite some documented concerns of men with MS (eg, prognosis, QOL, targeted interventions) (Upton and Taylor, 2012), the specific conformity of socialized masculine norms and its effect on men with MS has received less attention in the academic literature. According to Lewand and Wimer (2014), masculinity conformity is complex in nature due to finding some gender performance to be protective and others to be detrimental when it comes to men’s health. It is unknown how masculinity conformity affects men with MS, specifically in terms of its association with coping, health behaviors, and QOL. This study aims to explore these factors to evaluate the experi-ences of men with MS. Such information will fill a void in the literature and inform future interventions to better serve men with MS.

Objectives: Examine and describe the association between masculinity conformity, coping, health behaviors, and QOL in a representative sample of men with MS. 1. Hypothesis: Higher scores on the masculinity inventory will produce lower/worse scores on health-related QOL. Subaim: Investigate the differential effect of coping and masculinity conformity on health behaviors. Methods: Participants in this study will include adult (18+ years) men with MS who are established patients at the Mellen Center (Cleveland Clinic). Demographic information (age, race, marital status, household income, education status) and clinical characteristics (years since MS diagnosis, Patient-Determined Disease Steps), and 5 patient-reported outcomes will be collected: The Conformity of Masculinity Inventory-46 which is a short version of the CMNI (Mahalik et al, 2003) will be used to assess the conformity to 9 masculine norms. Health-related quality of life will be assessed with the PROMIS Global Health (May 2009). 1) The Ways of Coping Questionnaire (Lazarus and Folkman, 1985) will be used to measure coping. 2) Health behaviors will be measured using the Health Behaviors Inventory. 3) Health impact will be measured using MS Performance Scales. Results: Research initiated January 2020. Results expected in spring of 2020. Conclusions: Research initiated January 2020. Results expected in spring of 2020.

Disclosure: None

Keywords: Cognitive education, Psychological issues and MS

International Journal of MS Care

Poster: Psychosocial Factors
(QOL01) Alemtuzumab Effects on Urogenital Function: Results Pooled from the CARE-MS 9-Year Functional Assessment of Multiple Sclerosis Quality-of-Life Survey
Aaron Boster,1 Rafael Arroyo,2 Antonio Bertolotto,3 Samuel F. Hunter,4 Carolina Ionete,5 Aaron Boster,1 Rafael Arroyo,2 Antonio Bertolotto,3 Samuel F. Hunter,4 Carolina Ionete,5

Methods: A preliminary survey of the findings of health through the context of social well-being, such as barriers or factors that promote the overall health and well-being for women affected by MS, will be presented. Further exploration is needed to further extrapolate these preliminary findings of the study.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Comprehensive care and MS, Nursing management in MS, Self-care and MS

QUALITY OF LIFE AND OUTCOMES

(QOL02) The Impact of Relapses on Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder: Data from the Phase 3 PREVENT Study
Achim Berthele,1 Michael Levy,2,3 Karissa Johnston,4 Meagan Harwood,4 Adrian Kielhorn,5 Achim Berthele,1 Michael Levy,2,3 Karissa Johnston,4 Meagan Harwood,4 Adrian Kielhorn,5

Background: Data are lacking on the impact of relapses on patients with neuromyelitis optica spectrum disorder (NMOSD). PREVENT (trial registration: NCT01892345) was a randomized, double-blind study of eculizumab in patients with aquaporin-4 immunoglobulin-G-positive NMOSD, which showed a 94% reduction in the risk of adjudicated relapse vs placebo; it also included survey assessments of health-related quality of life (QOL).

Objectives: To evaluate the effect of relapse on QOL in patients with NMOSD, using data from the phase 3 PREVENT study.

Methods: Patients’ health-related QOL was assessed using the EuroQol 5-Dimensions questionnaire (EQ-5D) and the Medical Outcomes Study Short-Form (36-item) Health Survey (SF-36), with higher values in both indicating better health-related QOL. In the current post hoc analysis, data from the eculizumab and placebo groups were pooled and the last observation carried forward was used to determine an adjudicated relapse, and patients were compared (at relapse level) with postrelapse scores (recorded ≥30 days after relapse) using a paired t test.

Results: In the absence of relapse, EQ-5D and SF-36 scores were stable over time, as expected. Mean scores before (n = 24) and after (n = 22) relapse were EQ-5D index (possible range 0-1): 0.656 and 0.595, respectively (pre-relapse difference, P < 0.012); EQ-5D visual analog scale score (possible range 0-100): 60.458 and 56.500, respectively (pre-relapse difference, −4.227;
are associated with a significant reduction in certain aspects of QOL beyond the immediate relapse period.

Supported by: None

Disclosure: Achim Berthel: Alexion Pharmaceuticals (consulting fee, contracted research, fees for non-CME/CE services received directly from commercial interest or its agents, speakers’ bureau). Michael Levy: Alexion Pharmaceuticals (consulting fee, contracted research, fees for non-CME/CE services received directly from commercial interest or its agent); Genentech, Quest Diagnostics, Viela Bio (consulting fee, fees for non-CME/CE services received directly from commercial interest or its agent). Karissa Johnson, Meagan Harwood: Nothing to disclose. Adrian Kielhorn, Mirinyo Royson: Alexion Pharmaceuticals (salary). Guido Sabella: Alexion Pharmaceuticals (ownership interest, salary). Jacqueline Palace: Biogen, Chugai (contracted research); LEK, Viela Bio, Guidepoint (consulting fee); Merck Serono (meeting/lecture/workshop participation); Novartis, Roche, Argexus (speakers’ bureau); UCB, Viela Bio, Roche (conference/exhibition participation).

Keywords: Quality of life in NMOSD

(QOL04) Understand Common Multiple Sclerosis Symptoms Experienced Among MS Patients Participating in an Online MS Community

Beth Schneider
MyHealthTeams, San Francisco, CA

Background: People with multiple sclerosis (MS) often seek perspectives and support from each other by connecting on patient social networks. These organic interactions provide unfiltered, rich insight into the day-to-day challenges and needs of patients, including both the emotional and physical issues they face. Directly understanding the holistic impact of MS on patients is crucial to treating patients, including improving doctor-patient interactions and enabling patients to better manage their multiple sclerosis (MS). Objectives: Leverage the largest MS patient social network in the world to understand the most prevalent symptoms of patients with MS as they reach out to one another for information and support. Methods: Research conducted on de-identified organic discussions within MyMSTeam.com, a social network of >127,000 people with MS in the United States. Using natural language processing, 178,884 verbatim discussions from April–September 2019 were analyzed. Key themes were identified and used to determine common symptoms and sentiment. Results: 40% of the discussions were about symptoms, which were highly negative (60%). Most prevalent discussion was pain (35% of symptom discussions), especially leg pain. While members turned to medicines such as gabapentin, they also sought out less traditional approaches like CBD in search of pain relief. Other common symptoms discussed included mobility issues and fatigue, but also the emotional impact of MS (depression and anxiety). While slowing MS progression is being addressed by their health care provider, MS symptoms were often not being treated, especially depression and anxiety. Conclusions: Understanding the physical and emotional symptoms that accompany MS but that are not always shared between patients and their doctors can help health care providers provide a more holistic approach to treating patients with MS. This includes helping patients with MS understand what symptoms they are likely to encounter and how they can mitigate them.

Supported by: None

Disclosure: Beth Schneider: MyHealthTeams (contracted research).

Keywords: Comprehensive care and MS, Management of activities of daily living in MS, Psychological issues and MS

(QOL06) System-Level Variation in All-Cause Hospitalizations in Multiple Sclerosis: Year-1 Results of the Multiple Sclerosis Continuous Quality Improvement (MS-CQI) Research Collaborative

Brant J. Oliver1,2,3,4 Fal S. Mehta5
1 Geisel School of Medicine at Dartmouth, Lebanon, NH; 2 Dartmouth Hitchcock Medical Center, Lebanon, NH; 3 The Dartmouth Institute, Hanover, NH; 4 Geisel School of Medicine, Hanover, NH; 5 Community & Family Medicine, Dartmouth, Lebanon, NH

Background: Multiple Sclerosis Continuous Quality Improvement (MS-CQI) is the first randomized, multicenter, prospective, longitudinal, systems-level, improvement science research study for multiple sclerosis (MS). MS-CQI is a 3-year study of system-level variation in performance outcomes, and leverages benchmarking to inform improvement using an informatics-enabled learning health system approach. MS-CQI collects 11 clinical electronic health record (EHR) outcome measures longitudinally, including MS treatment, all-cause emergency department utilization, and all-cause hospitalizations. We also collect demographic information and comorbidities. Objectives: To describe year-1 (baseline/preintervention) all-cause hospitalizations on a patient-level variation in selected clinical outcomes for individual sites, between sites, and for MS-CQI collectively. Methods: Four US MS centers are participating in MS-CQI: an urban academic center, a rural academic center, a rural community hospital, and a large urban private practice (total N = 3000 persons with MS). We collected approximately 7500 clinical measures abstracted from EHR data in year 1 from nearly 3000 clinical encounters. Demographic characteristics and longitudinal variation in measures did not vary significantly between sites. Encounter volume between centers was similar. We used analysis of variance, multiple regression, and maximum likelihood estimation methods to conduct inferential analyses. Results: Univariate analyses found significant differences (P < 0.05) between sites for multiple clinical outcomes including exacerbations, disease-modifying treatment, magnetic resonance imaging utilization, emergency department utilization, and hospitalizations. Controlling for individual level factors, including comorbidities, significant site (system-level) effects (with high-performing center specified as the referent group) were found for all-cause hospitalizations, with comparator sites demonstrating odds ratios ranging as high as 2.4 (95% CI: 1.34, 4.4). Conclusions: We found that significant geographic system-level variation in MS outcomes exists for all-cause hospitalizations for people with MS. Findings suggest that a focus on system-level variation and improvement may be needed to reduce all-cause hospitalizations for people with MS.
(QOL07) Relapse Rate Is Influenced by System-Level Variation: Year-2 Results of the Multiple Sclerosis Continuous Quality Improvement (MS-CQI) Research Collaborative

Brant J. Oliver,1 Karen Walch,2 for the MS-CQI Investigators
1Geisel School of Medicine, Hanover, NH; 2College of Population Health, Thomas Jefferson University, Philadelphia, PA

Background: Multiple Sclerosis Continuous Quality Improvement (MS-CQI) is the first multicenter improvement science research collaborative for multiple sclerosis (MS), and includes a systems-level study of variation in MS outcomes. MS-CQI is a 3-year study that leverages benchmarking results to inform system-level improvement efforts targeting clinical outcomes using an informatics-enabled learning health system approach.

Objectives: Here we present relapse rate results for year 1 (baseline/preintervention) compared to year 2 (first year of intervention). We also describe system-level variation in relapse rate for individual sites, between sites, and for MS-CQI collectively.

Methods: We collect administrative data from 41 centers to create an electronic health record (EHR) outcome measures longitudinally across 4 clinical MS care centers in the United States. We conduct statistical process control analyses for benchmarking. Logistic regression and maximum likelihood estimation methods are used for inferential analyses. Results: Four US MS centers are participating: an urban academic center (n = 1000), a rural academic center (n = 1000), with the community hospital (n = 1500), and an urban private practice (1500), following a total N = 5000 persons with MS. We have collected approximately 7200 clinical encounter measures from EHR data in year 1 and 10,000 in year 2. Demographic characteristics and longitudinal variation in measures did not vary significantly between sites. For year 1, center-specific proportions of persons with MS with at least 1 relapse ranged from 5%-16.9%. Mean relapse rate varied significantly (P < .01) across all centers. SPC analyses demonstrate a MS-CQI reduction of relapse rate from 11.5% (year 1) to 4.3% (year 2). Two sites were below the MS-CQI average of 7% (3.3%, 6.3%), and 2 were above the average (8.5%, 10.3%). Contrasting for individual factors and covariates, logistic regression identified significant factors affecting the relapse rate in year 1, with comparator sites demonstrating odds ratios as high as 2.61 (95% CI: 1.8, 3.8).

Conclusions: MS-CQI has observed a significant reduction in population-level relapse rate by 7.2% during the first year of quality improvement intervention. We also found significant geographic system-level variation in MS relapse, suggesting that a focus on system-level variation and improvement may be needed to optimize outcomes.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Comprehensive care and MS, Improvement science in MS

(QOL09) Living with Secondary Progressive Multiple Sclerosis: Results from an MS Coalition Survey

Hollie Schmidt,1 Bari Talente,2 Amanda Montague,3 Emily Willingham4
1Accelerated Cure Project for MS, Waltham, MA; 2National MS Society, Washington, DC; 3Multiple Sclerosis Association of America, Cherry Hill, NJ; 4San Francisco, CA

Background: Many people diagnosed with relapsing multiple sclerosis (MS) will eventually transition to secondary progressive MS (SPMS). Until recently, only mitoxantrone had been approved by the US Food and Drug Administration as a disease-modifying therapy (DMT) for this MS subtype. In 2018, however, the agency accepted an application for siponimod for treatment of SPMS. In anticipation of this drug’s approval, the MS Coalition, a network of 9 independent MS organizations, surveyed people with SPMS to understand how the disease affects their lives and their experiences with and attitudes about DMTs. The survey was developed by the Institute for Clinical and Economic Review (ICER), which at the time was conducting a review of siponimod for use in SPMS. Objectives: 1) To understand the challenges that people with SPMS face, including impacts on quality of life. 2) To learn about current use of DMTs among people with SPMS and their perspectives on future DMTs that could be developed for SPMS. Methods: Representative of MS Coalition members, ICER developed and administered the survey online, which was then disseminated by MS Coalition members whose constituents include people with MS. Results: A total of 2263 respondents completed the full survey, and 2966 answered at least 1 question. Of those who participated in the survey, 51% reported being unable to work because of disability, 69% needed help with activities of daily living, and 86% used a mobility aid. About three-fourths chose “fewer available treatment options” (78%) and “living a full line of quality of life” (72%) as impacts associated with their form of MS. Regarding use of DMTs, 37% reported no current use, and 22% indicated that they were taking Ocrevus. The other DMTs included in the survey were each used by fewer than 10% of respondents. When asked to consider a hypothetical new drug for SPMS, respondents expressed broad interest in possible benefits the drug could provide, including prevention of brain atrophy and improvement in SPMS symptoms. Side effects and long-term risks topped the list of reasons respondents gave for why they might not stay on a new drug. In responses to open-ended questions about impacts on daily life and family, common themes related to isolation, burden on family members, stress, and loss of mobility. Conclusions: Our respondents with SPMS described experiencing profound challenges, and their information provides insights into target areas of unmet need warranting continued therapeutic development.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Disease-modifying treatments in MS, Management of activities of daily living in MS, and the caregiver/family


Ivone R. Fernandes, Ana C. Sena, Maria A. Paschoal, Adakson M. Franco
Santa Casa of Misericordia, São Paulo, Brazil

Background: Pulse therapy is the preferred therapy for treatment of multiple sclerosis (MS) outbreaks, which is a neurologic, demyelinating, and inflammatory condition, with intermittent periods of outbreak-remission. The recommendation is corticosteroid doses (500 mg to 1 g), every 3-5 days, administered at the hospital, as an inpatient, or as outpatient at an infusion clinic. The treatment reduces the inflammation during the outbreak phase of the MS and seeks to stabilize the crisis. Despite their adverse effects, the glucocorticoids are potent anti-inflammatory agents in the treatment of autoimmune pathologies. The glucocorticoids block the entrance of glucose in the tissues and increase the proteolysis, decreasing their synthesis in muscles, skin, bones, connective tissue, fat cells, and lymphoid tissue. Before the pulse therapy, it is important to eliminate the possibility of an active infection and to always administer the antiperistatic to control possible infestations. Checking the blood pressure, body weight and capillary glucose are very important during the infusion. Daily checks pre- and post-infusion are required as hyperglycemia may occur as an adverse effect of the therapy. The capillary blood glucose check is a blood test that gives immediate results about glucose concentration in the capillaries and the digital pulp. Objectives: to describe a protocol for puncture site rotation for the capillary blood glucose test performed during pulse therapy. Methods: A rotation protocol was established for the digital pulp punctures. The patient is directed to properly wash the hands and dry well. The nurse professional punctures the selected site on the right or left side of the distal phalanx of the finger chosen for the test, by alternating the puncture sites, and records the date, time, location and biological sample value. Results: Not applicable. Conclusions: The introduction of a protocol for puncture site rotation, based on a simple code, assists in the communication between nursing professionals and promotes patient safety. The protocol allowed the participation and cooperation of the client thus establishing self-care.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Comprehensive care and MS, Hyperglycemia, Nursing management in MS

(QOL11) Natalizumab Is Associated with Improvement in Cognitive Processing Speed and Health-Related Quality of Life: STRIVE 4-Year Results

Joi Perumal,1 Roumen Babanov,2 Laura Balazs,3 Steven Galetta,4 Paula Read,5 Kuangnan Xiong,5 Denise Campagnolo,5 Christophe Heteromans,6 Lily Lee,7 Danette Rufledge,8 Robert J. Fox7
1Weill Cornell Medical College, Cornell University, New York, NY; 2Northwestern University, Chicago, IL; 3New York University School of Medicine, New York, NY; 4Biogen, Maidenhead, UK, United Kingdom; 5Biogen, Cambridge, MA; 6Biogen (at time of this analysis), Cambridge, MA; 7Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH

Background: Multiple sclerosis (MS) negatively affects cognitive function and quality of life (QoL), interfering with a patient’s ability to work, pursue leisure activities, and perform activities of daily living. Natalizumab is a highly effective treatment for patients with relapsing-remitting MS (RRMS) and has been associated with improved cognitive function...
(QOL12) Multiple Sclerosis Patient Perspectives: Disease Education and Communication Needs

Jessica O’Neill,1 Mavis G. Ayer,2 Samantha R. Colhoun,3 Nicola Daykin,4 Brenda Hamill,5 Maria Fei,6 Jordanne Florio,7 Serena Pulcini,8 Alison Thomson9

1Roche Products Ltd, Welwyn Garden City, United Kingdom; 2Multiple Sclerosis, University Hospital Southampton Trust, Southampton, United Kingdom; 3Neuro, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom; 4NHS North East, Newcastle upon Tyne, United Kingdom; 5Roche Products Ltd, Welwyn Garden City, United Kingdom; 6Roche Products Ltd, Welwyn Garden City, United Kingdom; 7Ipsos MORI UK Ltd, London, United Kingdom; 8Ipsos MORI, London, United Kingdom; 9Blizard Institute, Queen Mary University, London, United Kingdom

Background: Multiple sclerosis (MS) is a progressive neurologic disease that can significantly affect quality of life (QoL). In recent years there has been a shift towards increased patient engagement to inform patient-centered care. It is therefore important that people with MS (PwMS) are equipped with the knowledge needed for informed, shared decision making and maintaining independence outside of a formal care setting. This study aimed to identify unmet disease education and communication needs in PwMS to empower informed decisions, enable self-management, and to maintain independence for as long as possible.

Methods: In October 2018 a roundtable meeting of patient representatives, PwMS, carers, and MS nurses agreed on key themes associated with maintaining independence. In 2019, official project steering group formed, and 2 studies for PwMS were co-developed: a qualitative online patient community activity and a quantitative online survey. The qualitative activity used Ipsos’ Syndicated MS Online Patient Community (a consistent panel of PwMS), and the quantitative survey was recruited through the MS Trust monthly newsletter and Facebook group. Results were discussed and prioritized by the steering group. Results: Data were analyzed from 25 and 117 respondents with relapsing-remitting MS, from the Ipsos Syndicated MS Online Patient Community and quantitative survey, respectively. Data from the quantitative survey revealed the following: 66% of respondents “strongly/ somewhat” agreed their MS had prevented them from reaching their full potential, and had an impact on QoL, with 73% of participants reporting that their MS had a “very/slightly negative impact” on work life. Overall, 69% were in full- or part-time employment, with only 26% remaining in employment for the long term, and 21% said they set short-term/long-term goals for managing their MS. Overall, 66% “strongly somewhat” agreed MS had prevented them from reaching their full potential and had a “very/slightly negative” impact on QoL in the long term and/or short term, and 64% of PwMS caring for family (57%). Data from this study will explore the relationship between perceived MS knowledge, planning for the future, and impact on QoL. Conclusions: There is evidence of a negative impact of MS on QoL among participants of our study. This highlights the importance of understanding unmet needs in education, linking disease progression and impact on future QoL in the wider MS population.

Acknowledgments: This project was sponsored by Roche Products Ltd. Ipsos MORI UK Ltd provided support in developing and conducting the surveys and performing data analysis, which was funded by Roche Products Ltd.

Disclosure: Jessica O’Neill, Roche Products Ltd (works for). Mavis G. Ayer, Biogen, Roche (sponsored delegate); Celgene, Merck, Novartis, Sanofi (consulting fee); Teva (sponsored education). Samantha R. Colhoun, Alison Thomson, Biogen, Novartis, Roche Products Ltd (consulting fee). Nicola Daykin: Roche Products Ltd (consulting fee). Brenda Hamill: Biogen, Novartis (sponsored delegate); Roche (consulting fee). Maria Fei: Roche Products Ltd (works for Ipsos MORI, which was funded by Roche to undertake this research). Jordanne Florio: Roche Products Ltd (works for). Serena Pulcini: Roche Products Ltd (works for).

Keywords: Disease education, Employment in MS, Management of activities of daily living in MS, Patient education
Determining the Relationship of Demographic and Clinical Variables with Fatigue in Multiple Sclerosis, Using the 5-Item Modified Fatigue Impact Scale (MFIS-S)

Natalie Hamed, Jennifer A. Ruiz, Heather M. DelMastro, Mary Bailey

Background: Fatigue is reported by one of the most prevalent and disabling symptoms in patients with multiple sclerosis (MS). The Modified Fatigue Impact Scale (MFIS) is a self-reported tool that captures the degree of fatigue in relation to its impact on physical, cognitive, and psychosocial functioning. A recent article by Rooney et al. has provided a comprehensive understanding of the relationship of a wide range of demographic and clinical variables with the impact of fatigue on MS using the MFIS. To our knowledge, such a robust comparison has not been published using the short version, the MFIS-5.

Objectives: To determine the association between the impact of fatigue and demographics and clinical characteristics among persons with MS (PwMS).

Methods: This was a secondary analysis of a cross-sectional study of 253 PwMS. Demographic variables included age, gender, race (white/nonwhite), smoking status (smoker/nonsmoker), and employment status (employed/unemployed). Clinical characteristics included disease duration (DD), body mass index (BMI), level of disability (Patient-Determined Disease Steps [PDDS]), depression (Center for Epidemiologic Studies–Depression Scale [CES-D]), cognitive processing speed (Symbol Digit Modalities Test [SDMT]), and use of disease-modifying therapy (DMT [on a DMT/not on DMT]). All measures, including fatigue impact (MFIS-5), were collected at a single visit. Spearman correlation coefficient was used to determine the strength of the associations and Mann-Whitney U for comparison.

Results: The sample had a mean age of 48.6 ± 11.6 (range: 20-73) years, DD of 12.3 ± 8.7 (1-47) years, PDDS score of 2.7 ± 2.1 (range: 0-7), BMI of 28.9 ± 7.2 (range: 17.5-39.8), and MFIS-5 score of 9.6 ± 5.3 (range: 0-20). This sample was mostly female (75.9%), with relapsing-remitting MS (94.5%), unemployed (51.1%), white (84.5%), nonsmokers (84.9%), and on a DMT (83.8%). Fatigue impact was moderately correlated with disability (r = 0.571, P < .000) and depression (r = -0.552, P < .000) and weakly associated with age (r = 0.173, P = .006) and SDMT (r = -0.297, P = .000). No relationship was observed with DD or BMI. No difference was observed among dichotomized variables of gender, race, smoking status, or use of a DMT. However, the impact of fatigue was found to be different (P < .000) between those employed (median MFIS-5 score: 8) and unemployed (median MFIS-5 score: 12). Conclusions: Our study demonstrated that fatigue is, as expected, related to the MFIS-5, is associated with higher disability, depression, age, and decreased cognition and is greater among unemployed PwMS. Given its ease of administration, the MFIS-5 serves as a practical measure for assessing the impact of MS fatigue in clinical settings. The current study provides increased understanding of its relationship with various clinical and demographic variables.

Supported by: None

Disclosure: Natalie Hamed, Jennifer A. Ruiz, Heather M. DelMastro: Nothing to disclose. Mary Bailey: Alexion, Biogen, Genentech, Genzyme, Novartis (speakers’ bureau); Celgene (consulting fee).

Keywords: Comprehensive care and MS, Equipment in MS, Natural history of MS, Outcome measures of disease impact to improve treatment selection and monitoring for progression.
to QI in year 2 [private for profit] of the study, and 2 centers were randomized; 1 urban academic) in year 3. Site teams have identified QI foci including patient access, patient orientation, previsit planning, social work and behavioral health, and emergency room utilization. The teams are showing progress in their QI culture and development; IHI Improvement Progress Scale scores have changed from initial score of 1.5 (planning for the project has begun) to 3.5 (some improvements in measurements and outcomes and continuing to improve). Multiple Sclerosis Self-Efficacy Scale-10 item (MSSE), Godin Leisure-Time Programs, including the Multiple Sclerosis Impact Scale-29 (MSIS-29), Positive Affect (per MSSE & Neuro-QoL). Additionally, increased MSIS-29 scores directly correlate with anxiety while inversely correlating with 2-year comparison data of PROs, from MSAC members, have indicated members participating in the 6-week mindfulness course demonstrate improvement in mood and overall emotional wellness. Members of the MSAC program, members have the opportunity to participate in a 6-week mindfulness course to address physical, cognitive, and social well-being. Program activities include exercise, brain training, education, socialization, and community outings. As part of the MSAC program, members will be asked to complete 4 paper/pencil outcome measures in January 2020 as part of their annual participation in the MSAC’s program. The Multiple Sclerosis Self-Efficacy Scale-10 item (MSSE), Multiple Sclerosis Self-Efficacy Scale-10 item (MSSE), Godin Leisure-Time Exercise Questionnaire (GTLEG), and Neuro-QoL (Anxiety, Depression, Emotion & Behavior, Positive Affect, Cognition, Ability to Participate, and Social Roles sections are used). Members will be offered the opportunity to participate in a professionally facilitated 6-week mindfulness course, starting in January 2020, to provide education, strategies, resources, and emotional support to achieve what they need and/or want for the present moment. Participants of the mindfulness course will be asked to complete PRO measures upon completion of the course. Results: One-year and 2-year comparison data of PROs, from MSAC members, have indicated correlation between MSSE, Anxiety, Ability to Participate, and Positive Affect (per MSSE & Neuro-QoL). Additionally, increased MSIS-29 scores directly correlate with anxiety while inversely correlating with self-efficacy and GTLEG. Mean scores of depression, reported from the Neuro-QoL, remained the same (x = 48) over a 2-year reporting period. These comparisons did not specifically measure a member’s participation in the mindfulness course. Conclusions: Data collection and analysis will be completed for those members participating in the 6-week mindfulness course. Analysis will include pre and post measures, as well as comparison with those not participating in the mindfulness course.

**Disclosure:** Nothing to disclose. **Keywords:** Comprehensive care and MS, Nursing management in MS, Quality improvement

(QOL18) Does Participation in a 6-Week Mindfulness Course Improve Mood and Overall Emotional Wellness for People Living with Multiple Sclerosis? 
Tiffany Malone,1 Lacey Sayre,1 Brian Hutchinson2

1Multiple Sclerosis Achievement Center, Dignity Health, Citrus Heights, CA; 2Multiple Sclerosis Achievement Center, Dignity Health, Sacramento, CA

**Background:** People with multiple sclerosis (MS) often experience emotional distress about the life they had prior to the diagnosis of MS and what their diagnosis means for their future. The Multiple Sclerosis Achievement Center (MSAC) conducts day well-being programs to address physical, cognitive, and social well-being. Program activities include exercise, brain training, education, socialization, and community outings. As part of the MSAC program, members have the opportunity to participate in a 6-week mindfulness course to address quality of life, emotional wellness. **Objectives:** To determine, through the use of patient-reported outcomes (PROs), if members participating in the mindfulness course demonstrate improvement in mood and overall emotional wellness. **Methods:** Members of the MSAC will be asked to complete 4 paper/pencil outcome measures in January 2020 as part of their annual participation in the MSAC’s program. **Results:** The Multiple Sclerosis Self-Efficacy Scale-10 item (MSSE), Godin Leisure-Time Exercise Questionnaire (GTLEG), and Neuro-QoL (Anxiety, Depression, Emotion & Behavior, Positive Affect, Cognition, Ability to Participate, and Social Roles sections are used). Members will be offered the opportunity to participate in a professionally facilitated 6-week mindfulness course, starting in January 2020, to provide education, strategies, resources, and emotional support to achieve what they need and/or want for the present moment. Participants of the mindfulness course will be asked to complete PRO measures upon completion of the course. Results: One-year and 2-year comparison data of PROs, from MSAC members, have indicated correlation between MSSE, Anxiety, Ability to Participate, and Positive Affect (per MSSE & Neuro-QoL). Additionally, increased MSIS-29 scores directly correlate with anxiety while inversely correlating with self-efficacy and GTLEG. Mean scores of depression, reported from the Neuro-QoL, remained the same (x = 48) over a 2-year reporting period. These comparisons did not specifically measure a member’s participation in the mindfulness course. Conclusions: Data collection and analysis will be completed for those members participating in the 6-week mindfulness course. Analysis will include pre and post measures, as well as comparison with those not participating in the mindfulness course.

**Disclosure:** Nothing to disclose. **Keywords:** Mindfulness

(QOL19) The Mediterranean Diet and Fatigue, Depression, and Emotional Well-being in Multiple Sclerosis: A Study in Patient-Reported Outcomes 
Jaime J. Solling,1 Allison Kraus,1 Melissa Foster,1 Nicole Herndon,1 Aaron Carlson1

1Neurology, University of Florida, Gainesville, FL; 2Food Science and Human Nutrition, University of Florida, Gainesville, FL; 3Rehabilitation, UF Health, Gainesville, FL

**Background:** Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system and a leading cause of disability among young adults. It presents with a variety of neurologic symptoms, which can significantly affect the quality of life of affected individuals. Although no specific diet exists for MS, dietary factors show potential for beneficial effects on inflammation, neuroprotection, and repair. The increased dietary quality has been associated with lower disability and symptom burden in MS. Various diets, including ketogenic, fasting, Mediterranean, and plant-based diets produced mixed results in studies. The Mediterranean diet (MD) is high in antioxidants, fiber, and mono- and polyunsaturated fatty acids as it emphasizes higher intake of fish, olive oil, fruits, and vegetables. Previous studies have shown the MD may be beneficial in risk cardiovascular and metabolic conditions, such as type 2 diabetes, obesity, cognitive impairment, and brain atrophy. Limited studies have researched the relationship between MS outcomes and MD adherence. Preliminary evidence suggests that a MD may be beneficial in the MS population as it may be associated with reduced fatigue, impact of MS symptoms, and disability. Early findings warrant further investigation on the impact of an MD on MS outcomes to provide more evidence on the relationship of this diet on fatigue, cognitive function, and emotional well-being in MS. **Objectives:** To examine the relationship between adherence to the MD and fatigue, cognitive function, and emotional well-being, as captured by validated patient-reported outcomes in MS. **Methods:** Subjects will be recruited, consented, and enrolled from the University of Florida MS clinic. Adherence to the MD will be determined by using the validated 14-item Mediterranean Diet Assessment Tool. Neuro-QoL questionnaires will score cognitive function and emotional well-being, while the validated Modified Fatigue Impact Scale will score fatigue. Data collection is ongoing. **Conclusions:** Diet is an important factor to consider in comprehensive MS care and may have significant impact on quality of life. We hypothesize that MD will be associated with improved fatigue, cognitive function, and emotional well-being scores, although further research will better characterize its impact.

**Disclosure:** Tiffany Malone, Lacey Sayre; Nothing to disclose. **Keywords:** Mindfulness, Depression, Emotional Well-being in Multiple Sclerosis, Mediterranean Diet, Neuro-QoL

(REH01) Assistive Technology for Progressive Deficits in Communication and Access in People with Advanced Multiple Sclerosis: Case Studies in Iterative Design 
Alexander Burnham

Rehabilitation Services, The Boston Home, Boston, MA

**Background:** People with advanced multiple sclerosis (PwAMS) may face progressive motor disability. Faced with advanced neurodegenerative disorders, who have benefited from customized AT to meet unique access challenges in the MS population. This case series will describe the experiences of 3 PwAMS at the Boston Home, a specialized residence for individuals with advanced neurodegenerative disorders, who have benefited from using AT to meet unique access challenges in the MS population. Participants will have a better understanding of how nursing and allied health/rehabilitation disciplines can collaboratively support PwAMS to complete electronic activities of daily living even in the presence of severe motor disability. **Methods:** This case series will describe the experiences of 3 PwAMS at the Boston Home, a specialized residence for individuals with advanced neurodegenerative disorders, who have benefited from using AT to meet unique access challenges in the MS population. Participants will have a better understanding of how nursing and allied health/rehabilitation disciplines can collaboratively support PwAMS to complete electronic activities of daily living even in the presence of severe motor disability. **Objectives:** Participants will have the opportunity to understand how PwAMS can maximize functional independence with appropriate and supported access to AT. Participants will recognize how increasingly mainstream and ubiquitous technology can be modified and interfaced with more customized AT to meet unique access challenges in the MS population. Participants will have a better understanding of how nursing and allied health/rehabilitation disciplines can collaboratively support PwAMS to complete electronic activities of daily living even in the presence of severe motor disability. **Methods:** This case series will describe the experiences of 3 PwAMS at the Boston Home, a specialized residence for individuals with advanced neurodegenerative disorders, who have benefited from using AT to meet unique access challenges in the MS population. Participants will have a better understanding of how nursing and allied health/rehabilitation disciplines can collaboratively support PwAMS to complete electronic activities of daily living even in the presence of severe motor disability. **Objectives:** Participants will have the opportunity to understand how PwAMS can maximize functional independence with appropriate and supported access to AT. Participants will recognize how increasingly mainstream and ubiquitous technology can be modified and interfaced with more customized AT to meet unique access challenges in the MS population. Participants will have a better understanding of how nursing and allied health/rehabilitation disciplines can collaboratively support PwAMS to complete electronic activities of daily living even in the presence of severe motor disability. **Methods:** This case series will describe the experiences of 3 PwAMS at the Boston Home, a specialized residence for individuals with advanced neurodegenerative disorders, who have benefited from using AT to meet unique access challenges in the MS population. Participants will have a better understanding of how nursing and allied health/rehabilitation disciplines can collaboratively support PwAMS to complete electronic activities of daily living even in the presence of severe motor disability. **Objectives:** Participants will have the opportunity to understand how PwAMS can maximize functional independence with appropriate and supported access to AT. Participants will recognize how increasingly mainstream and ubiquitous technology can be modified and interfaced with more customized AT to meet unique access challenges in the MS population. Participants will have a better understanding of how nursing and allied health/rehabilitation disciplines can collaboratively support PwAMS to complete electronic activities of daily living even in the presence of severe motor disability. **Methods:** This case series will describe the experiences of 3 PwAMS at the Boston Home, a specialized residence for individuals with advanced neurodegenerative disorders, who have benefited from using AT to meet unique access challenges in the MS population. Participants will have a better understanding of how nursing and allied health/rehabilitation disciplines can collaboratively support PwAMS to complete electronic activities of daily living even in the presence of severe motor disability.
illustrate how postural limitations and desire for wheeled mobility guided the decision-making process for selecting and modifying systems to meet the needs of the users. The roles of rehabilitation, nursing, and adaptive technology specialists in developing, modifying, and implementing appropriate iterations of communication AT in this particular care setting will be described as part of the interdisciplinary team caring for this cohort of pwAMS. Results: Recommendations for providing caregiver education and assisting families with the considerations for designing, implementing, and adapting communication AT for pwAMS in other residential environments will be discussed. Outcomes in terms of satisfaction with AT access, services, and devices from pwAMS and caregivers will also be described using formal and informal assessment options. Conclusions: NA.

Supported by: None


Keywords: Comprehensive care and MS, Equipment in MS, Management of activities of daily living in MS

(REH02) Predictors of Improvement in Respiratory Function Following Resistive Inspiratory Muscle Training in Advanced Multiple Sclerosis

Alexander Burnham,1 Lisa Doyle,2 Min H. Huang,3 Donna Fry2

1Rehabilitation Services, The Boston Home, Boston, MA; 2Physical Therapy, Franklin Pierce University, Manchester, NH; 3University of Michigan-Flint, Flint, MI

Background: Respiratory compromise in people with advanced multiple sclerosis (pwAMS = Expanded Disability Status Scale [EDSS] score ≥ 6.5) worsens as the disease progresses and is a major cause of morbidity and mortality. There is evidence that exercise can improve respiratory muscle function in pwAMS even in later stages of the disease. Objectives: It is not known if certain characteristics of pwAMS contribute to their ability to benefit from a respiratory exercise program. This study identified some possible predictive factors. Methods: Thirty-eight subjects were recruited at a SNF specializing in care for pwAMS. Inclusion criteria were receiving resistive inspiratory muscle exercises daily for 10 weeks using the Threshold Inspiratory Muscle Trainer (IMT). Demographics, number of comorbidities, body mass index (BMI), EDSS score, and years post-MS diagnosis were obtained at time of enrollment. Maximum inspiratory pressure (MIP) and maximum expiratory pressure were obtained as measurements of respiratory muscle strength at several intervals over the 28-week duration of the study, including 10-week baseline phase, 10-week intervention phase, and 8-week retention period postintervention. Progression of IMT resistance was adjusted weekly by the research team based on symptoms, rate of perceived exertion, and baseline MIP. Secondary outcomes assessed included fatigue (evaluated with MFIS-5) and cognitive processing speed (measured with oral version of Symbol Digit Modalities Test [SDMT]). Results: Correlation analysis of baseline characteristics with MIP change scores (MIP-CS) was performed to identify potential predictors of improvements in MIP for the regression analysis. The current study used repeated measures linear regression models with MIP-CS and predicted values (MIP\%CS) as dependent variables were constructed. The regression model with BMI, fatigue (MFIS-5), and cognition (SDMT) as independent variables and MIP-CS as the dependent variable was significant (F[3,25] = 3.19, P = 0.041, R² = 0.53). SDMT was a significant independent predictor in the model (P = 0.035) (higher SDMT scores significantly associated with better outcomes of IMT training). BMI as predictor approached significance (P = 0.056). The regression model with BMI, MFIS-5, and SDMT as independent variables and MIP\%CS as the dependent variable was significant (F[3,25] = 3.19, P = 0.027, R² = 0.55). BMI was a significant independent predictor in the model (P = 0.029), with higher BMI associated with worse outcomes with IMT training; SDMT as predictor approached significance (P = 0.053) (SDMT scores significantly lower in those with MIP\%CS < 60). Conclusions: Participant scores in BMI, MFIS-5, SDMT, and age/gender-adjusted MIP at baseline significantly predicted MIP-CS (F[3,25] = 6.34, P = 0.001, R² = 0.44, R² adjusted = 0.37). Factors such as age, gender, duration of disease, EDSS score, and number of comorbidities were not significant predictors of MIP-CS.

Supported by: None

Disclosure: Nothing to disclose

Keywords: SLP intervention, Dysarthria

(REH04) Daily Occupational Performance in Multiple Sclerosis

Alice Estevo Dias,1 Gino Corsi2

1Scientific Research and 2Rehabilitation, Brazilian Association of Multiple Sclerosis, São Paulo, Brazil

Background: Multiple sclerosis (MS) is a chronic, inflammatory, and degenerative disease that affects the central nervous system. Occupational performance is often compromised and negatively impacts daily activities and activities. Objectives: To understand the perception of people affected by MS on occupational performance and identify the main difficulties in routine activities. Methods: 55 people with MS participated, being 40 (73%) women and 15 (27%) men, aged between 27 and 60 years. The 5 major impairments in occupational performance were observed, according to the degree of importance, according to the Canadian Occupational Therapy Model (COTM), then the participants self-assessed their performances and satisfactions by means of a scale of 1 to 10 points. Results: The analyses revealed that participants considered their ability to perform routines and perform roles and tasks related to moderate to poor personal care, leisure, and productivity. Conclusions: Signs and symptoms of muscle weakness, fatigue, cognitive and visual changes, and sensitivity were determinant to impair occupational performance appropriate to the needs and interests of the participants. The evaluation of occupational therapy and the rehabilitation of disabilities facilitated and facilitated the daily lives of people with MS.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Occupational therapy

(REH05) Assessing the Benefits of Using Telehealth in Conjunction with a Fitbit to Improve Walking in Veterans with Multiple Sclerosis

Kelley Volpenhein,1 Amy Banks,1 Lindsay J. Riegler,2 Sarah Kiefer Lühring1

1Cincinnati VA Medical Center, Cincinnati, OH; 2Rehab Care Line, Cincinnati VA Medical Center, Cincinnati, OH

Background: Patients with multiple sclerosis (MS) often have limitations with mobility due to fatigue, weakness, and impairments with balance and coordination. Many of these patients decrease their activity and walk a lot to these limitations, which can lead to further deconditioning. Objectives: The objective of this study was to examine improvements in walking distance and perceived impact of walking ability in patients with MS using a Fitbit in conjunction with telehabilitation. Methods: Currently 2 patients are enrolled in pilot with ongoing recruitment. Patients are asked for a self-perception of daily step count at evaluation. The 2-minute walk test and 10-meter walk test are administered at initial evalu-
Objective: The current systematic review provided a critical evaluation of exercise among persons with MS based on changes in functional outcomes, walking mobility, balance, and possibly cognition in persons with progressive neurologic disease such as MS and ALS can be effective and feasible and can improve fitness and quality of life for individuals with progressive neurologic disease. Clinical video telehealth (CVT) provides these veterans with access to specialists for their condition and significantly reduces the energy and financial costs of traveling to specific appointments. Barriers exist whether an individual lives in a rural community or within a few miles of a health center. Utilizing CVT can eliminate these barriers and greatly improve adherence to a physical therapy rehabilitation program. Finally, the ability to view an individual in their home environment gives providers the ability to solve physical challenges and safely assesses that may be present in a person’s home.

Objectives: 1) Extend specialty care from Neurology into Physical Medicine and Rehabilitation for Veterans with MS. 2) Determine the feasibility of the CVT devices in a variety of settings. 3) Decrease travel hours and costs.

Results: To be determined. Conclusions: To be determined.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Equipment in MS, Management of activities of daily living in MS, Telehealth

(REH06) Feasibility of Telehealth Rehabilitation for Veterans with Progressive Neuromuscular Disease

Benjamin Dons

Physical Medicine and Rehabilitation, Veterans Health Administration, Saint Louis, MO

Background: Individuals who live in rural communities have difficulty accessing specialized medical services such as physical therapy. Individuals with progressive neurologic diseases who do have access to physical therapy are limited to what is available in their community. Exercise is feasible and can improve fitness and quality of life for individuals with progressive neurologic disease. Clinical video telehealth (CVT) provides these veterans with access to specialists for their condition and significantly reduces the energy and financial costs of traveling to specific appointments. Barriers exist whether an individual lives in a rural community or within a few miles of a health center. Utilizing CVT can eliminate these barriers and greatly improve adherence to a physical therapy rehabilitation program. Finally, the ability to view an individual in their home environment gives providers the ability to solve physical challenges and safely assesses that may be present in a person’s home.

Objectives: 1) Extend specialty care from Neurology into Physical Medicine and Rehabilitation for Veterans with MS. 2) Determine the feasibility of the CVT devices in a variety of settings. 3) Decrease travel hours and costs.

Methods: There were 19 veterans evaluated during the study period, 18 of whom were diagnosed with multiple sclerosis (MS) and 1 with amyotrophic lateral sclerosis (ALS). Veterans were referred to PM&R physical therapy and evaluated by neurologic clinical specialist. They were evaluated before and after the intervention period using standardized functional outcome measures.

Results: Follow-up visits were scheduled at least once every week for 30-minute sessions and were re-evaluated every 30 days for up to 90 days. Veterans had the opportunity to extend their rehabilitation session for another 90 days if they were making improvements. Sessions took place with the clinical specialist in a private office with necessary rehabilitation equipment available for demonstration of exercises. Exercising for a total of 62 miles in 677 miles. Travel distance was 3724 miles.

Conclusions: Telehealth visits for patients with progressive neuromuscular disease such as MS and ALS can be effective and feasible in an outpatient setting. There were no adverse effects, and this program resulted in a significant reduction in miles traveled and cost savings for veterans and the Veteran Health Administration. Barriers to adopting new technology were an issue for some veterans, and greater improvements were seen with those who incorporated new technology easily.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Complementary/alternative therapies in MS, MS, and the caregiver family

(REH07) Systematic Review on Exercise Training as a Neuroplasticity-Inducing Behavior in Multiple Sclerosis

Catherine D. Jones, Jessica F. Boird, Robert W. Moff, Brian M. Sandroff

Physical Therapy, University of Alabama at Birmingham, Birmingham, AL

Background: Exercise training is associated with improvements in physical fitness, walking mobility, balance, and possibly cognition in persons with multiple sclerosis (MS), perhaps based on neuroplasticity. However, it is difficult to characterize exercise training as a neuroplasticity-inducing behavior among persons with MS based on changes in functional outcomes alone, as neuroplasticity reflects true brain-behavior relationships.

Objectives: The current systematic review provided a critical evaluation of exercise training as a neuroplasticity-inducing behavior in persons with MS based on a well-established conceptual model. This involved prioritizing exercise training studies in persons with MS that included both functional and neuroimaging outcomes and further examined associations among these outcomes.

Methods: We performed an open-data search of online scholarly databases in July 2019 using a targeted and comprehensive search strategy. To be eligible for full-review, papers had to be published in English and include the following components: a) exercise training, b) neuroimaging outcomes, and c) functional outcomes (i.e., measures of physical fitness, walking mobility, balance, and/or cognition) in persons with MS. Acceptable study designs included randomized controlled trials, single-group pre/post designs, and quasi-experimental designs. Four independent reviewers extracted relevant data from each eligible paper, including information on participant characteristics, exercise intervention characteristics, neuroimaging outcome characteristics, functional outcome characteristics, and pattern of study results.

Results: The literature search returned only 9 papers (involving 7 original interventions) that met eligibility criteria wherein inferences regarding neuroplasticity could be drawn, based on the inclusion of both neuroimaging and functional endpoints. Within those 9 papers, there is mixed evidence for exercise training as a neuroplasticity-inducing behavior in persons with MS. There is insufficient data necessary to draw definitive conclusions on exercise as a neuroplasticity-inducing behavior in MS.

Conclusions: To be determined.

Supported by: None

Disclosure: Nothing to disclose

Keywords: CNS repair, Exercise, Imaging and MS

(REH08) Aerobic Reserve in People with Multiple Sclerosis: Measurement and Correlates

Corey D. Feasel, Brian M. Sandroff, Robert W. Moff

Physical Therapy, University of Alabama at Birmingham, Birmingham, AL

Background: The concept of aerobic reserve reflects the available potential energy to perform essential tasks to maintain independent living and is calculated by subtracting the energetic demand for activities of daily living from peak aerobic power. To date, the concept of aerobic reserve has not been applied in multiple sclerosis (MS), and there are limited data on its measurement and correlates in this patient population.

Objectives: This study described the measurement and correlates of aerobic reserve in MS. The sample included 23 people with MS who were fully ambulatory (median [range] Expanded Disability Status Scale [EDSS] score = 3.0 [2.0]). Participants completed a single session that included obtaining informed consent, EDSS examination, demographic questionnaire, and assessment of the Symbol Digit Modalities Test (SDMT), Timed 25-Foot Walk Test (T25FW), 6-minute walk distance (6MWD), and a cardiopulmonary exercise test (CPET) performed on a treadmill (modified Balke protocol). Aerobic reserve was calculated by subtracting the patient’s steady-state VO2 from the peak VO2 obtained from the CPET. Results: Twenty-one of 23 participants met criteria for providing a maximal effort during the CPET. The mean (SD) aerobic reserve was 9.5 (± 3.7) mL/kg/min. Aerobic reserve strongly correlated with peak VO2 (mean [SD], 22.4 [±5.4] mL/kg/min), r = 0.77, P < .01. Aerobic reserve was positively correlated with SDMT raw score (mean [SD], 49.3 [±7.2]), r = 0.45, P = .03 and time to exhaustion in seconds on the CPET (mean [SD], 592.8 [±205.5]), r = 0.63, P < .01. Aerobic reserve was negatively correlated with resting heart rate (mean [SD], 79.4 [±11.5] bpm), r = −0.50, P < .01 and BMI (mean [SD], 29.6 [±5.8] kg/m2), r = −0.56, P < .01. Aerobic reserve did not correlate with age, sex, EDSS score, or T25FW or 6MWD results.

Conclusions: Aerobic reserve can be measured during CPET in people with MS, and there may have implications for understanding symptomatic and functional outcomes in people with MS.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Aerobic exercise training, Complementary/alternative therapies in MS, Management of activities of daily living in MS

(REH09) The Impact of Vascular Comorbidities on Perceived Functional Impact in Persons with Multiple Sclerosis

Elizabeth S. Grimich,a,1,2 Heather M. DeMastro,a,1 Lindsay O. Neto,1,4 Gabrielle C. DeLuco,1,2,4 Jennifer A. Ruiz,1,3 Aaron P. Turner,1,3,6 Thomas P. Agresta,1,3,6 Albert C. Lo1

1Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT; 2Department of Neurology, University of Connecticut School of Medicine, Farmington, CT; 3Department of Rehabilitation Medicine and
Background: Persons with multiple sclerosis (PwMS) can have a number of comorbidities and secondary conditions, which can complicate care and negatively affect health-related quality of life. In particular, chronic vascular conditions, such as diabetes, hypertension, hyperlipidemia, and heart disease, have been associated with more rapid accumulation of irreversible disability in PwMS. However, little is known about the impact of co-occurring chronic vascular conditions on perceived functional impact in PwMS. Objectives: To examine differences between PwMS with and without vascular comorbidity with regards to their self-reported functional impairment.

Methods: Participants: Twenty-five (n = 257) were randomly selected PwMS who participated in the MS Characterization of Upper Extremity Functioning (MS-CUE) study. The MS Impact Scale (MSIS-29) was used to measure perceived physical and psychological impact on daily life, while the Functional Status Index (FSI) was used to assess functional performance in 5 domains: gross mobility, hand activities, personal care, social/role, and psychological impact. Due to non-normally distributed data, Mann-Whitney U analyses were conducted to examine differences between PwMS with and without a vascular comorbidity, with effect size reported as r. Results: On average, PwMS were 48.72 ± 11.56 (0.73) years old and had MS for 12.40 ± 9.78 (1.47) years, with a median Patient-Determined Disease Steps (PDDS) score of 3 (0-7). A total of 112 of 257 (43%) PwMS had at least 1 co-occurring vascular condition, with hyperlipidemia (n = 72, 64.3%) and hypertension (n = 66, 58.9%) being the most common. PwMS with at least 1 vascular comorbidity reported higher levels of physical (r = −0.29, P < .001) and psychological impact (r = −0.16, P = .009), as well as more issues with gross mobility (r = −0.28, P < .001), hand activities (r = −0.17, P = .007), personal care (r = −0.19, P = .002), home chores (r = −0.40, P < .001), and social/role activities (r = −0.24, P < .001). Conclusions: PwMS with vascular comorbidity have worse perceived functional performance and physical and psychological well-being compared to PwMS without vascular comorbidity. These findings suggest that the presence of chronic vascular conditions in PwMS negatively affects perceived functioning, which has important implications for provision of care and quality of life for PwMS. Care unraveling the mechanism by which vascular comorbidity influences functional outcomes warrants further evaluation.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Management of activities of daily living in MS, Psychological issues and MS, Vascular comorbidity

(REH11) Is Treadmill Walking Analogous to Overground Walking in Persons with Multiple Sclerosis?

Evan T. Cohen,1 Herbert Karpätik,2 Lourdes Rodriguez,3 Rosangalis Rodriguez,3 Rachel Rhodes,1 Anna Rubo1

1Rehabilitation and Movement Sciences, Rutgers, The State University of New Jersey, Blackwood, NJ; 2Physical Therapy, Hunter College, New York, NY

Background: Gait and walking impairment is a common finding in persons with multiple sclerosis (PwMS) and is often studied using a treadmill. However, studies in other neuromotoric conditions have questioned whether treadmill walking accurately represents overground walking. If it does not, it may be questionable whether gait research performed on a treadmill can be generalized to overground walking. Similarly, it may suggest that the use of a treadmill for clinical gait evaluation and intervention for PwMS may not be supported.

Objectives: The purpose of this study is to examine whether treadmill walking speed is similar to overground walking speed in PwMS. If our hypothesis is correct, it will suggest that clinicians can be confident that use of a treadmill for the examination and treatment of gait and walking dysfunction is representative of overground walking. If our hypothesis is not supported, however, it would suggest that clinicians who use a treadmill for gait and walking impairment should reconsider the use of a treadmill as a tool for evaluation and treatment.

Methods: Nineteen people with MS [11 women and 8 men; median [IQR; range] Expanded Disability Status Scale score 4.5 [2.5; 2.0-6.5]] performed an overground 2-Minute Walk Test (2MWT) to determine their average walking speed, then were asked to walk at the same speed on a treadmill. Participants were allowed up to 10 attempts to familiarize themselves with the treadmill before trying to achieve their overground walking speed. Results: Pearson correlations were used to examine the relationship between predicted walking speed (PWS) [based on the mean walking speed during the 2MWT] and the actual walking speed (AWS) attained while on the treadmill.

There was a positive correlation between PWS and AWS (r = 0.841 [P = 0.707], n = 19, P = .000). 70.7% of the variance in PWS could be predicted by the AWS. This, however, leaves 29.3% of the variance unexplained. Conclusions: Although overground walking and treadmill walking may seem very similar, there are contextual differences in these activities that may limit generalizability between the two. Researchers should be cautious when generalizing outcomes in physical performance in PwMS measured during treadmill walking to expected performance in overground walking. Clinicians should also be cautious in expecting generalized training effects of treadmill walking overground walking in PwMS. The walking techniques used on a treadmill may not be the same ones used for overground walking, and therefore treadmill walking may not generalize to overground walking.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Complementary/alternative therapies in MS, Gait, Management of activities of daily living in MS

(REH11) Telerehabilitation Compared to Outpatient Rehabilitation for Patients with Multiple Sclerosis and Mobility Disorders

Heather Markel,1 Brittney McHugh,2 Wayne Hodges,3 Jessica Peter,3 Paul M. Hoffman2

1Rehabilitation, UF Health Jacksonville, Jacksonville, FL; 2UF Health Jacksonville, Jacksonville, FL; 3Neuroscience Institute, UF Health Jacksonville, Jacksonville, FL

Background: Multiple sclerosis (MS) is a multifocal disease of the central nervous system, often producing variable and longstanding symptoms that may lead to loss of function and disability. Access to specialized rehabilitation specialists may be limited by loss of mobility and distance from rural areas to outpatient rehabilitation centers. This pilot study was undertaken to determine the feasibility of conducting a physical therapy-guided telerehabilitation (TR) program for individuals with mobility deficits resulting from MS. Data on mobility, quality of life (QOL), fatigue, and travel cost were examined. The TR group was then compared retrospectively to an outpatient-based therapy (OP) group to review effect on mobility scores.

Objectives: 1) Determine if a TR program prescribed and monitored by an MS-certified physical therapist (PT) delivered on a home, web-based platform is a feasible delivery technique for individuals with MS. 2) Identify if a TR program can improve access to a comprehensive MS care while reducing travel cost. 3) Examine changes to mobility scores for a TR program compared with an OP group to determine the feasibility of the 2 delivery options for individuals with MS.

Methods: Subjects with confirmed MS and mobility deficits were recruited from the MS Center of Excellence at UF Health Jacksonville for the TR group. Initial and final face-to-face examinations were performed by a board-certified neurologist and an MS specialist PT. Subjects under went 8 weeks of physical therapy-guided TR using the Jintorix software platform and a kinetic tracking system. Subjects seen in OP by the same PTs performing the TR were selected by a chart review process from January 2018 through September 2019 with a diagnosis of MS identified by a board-certified neurologist. 30 TR participants were randomized to compare the effects of the 2 delivery options for individuals with MS.

Conclusions: Subjects were selected for comparison based on duration of treatment and matching outcome measures completed. Data were then reviewed for effect on mobility and travel between the 2 groups. Results: Eighty-eight percent of the TR group completed the program. All TR subjects demonstrated improvement in either fatigue, QOL, or mobility measures. No adverse events were noted during or following completion of the program. The 8 subjects saved a combined $8487.23 in projected travel costs. Results of measures between groups showed equivalence in terms of meeting minimal detectable change for the outcome measures examined.

Conclusions: A telerehabilitation program was feasible and safe for subjects with MS and mobility impairments. Compared to the OP group, the TH group demonstrated the same number of subjects meeting the minimal detectable change for the functional measures. Savings were superior in the TR group for travel cost and time. Further studies are needed to guide the design and establish the efficacy of TR compared with OP rehabilitation programs.
(REH12) Management of Low Back Pain for Individuals with Multiple Sclerosis: A Case Series
Heather Barkdolal, Joseph Supple
Rehabilitation, UF Health Jacksonville, Jacksonville, FL
Background: Individuals with multiple sclerosis (MS) are often referred to a physical therapist (PT) for evaluation of immobility, pain, and functional impairment. These individuals may be referred during the diagnosis process, a relapse, or while clinically stable. Self-reported pain symptoms for individuals with MS can also be multifactorial and originate from several areas including symptoms of central, peripheral, orthopedic, or a combination of these origins. There are no underlying diagnostic criteria for MS that complicate the evaluation, treatment plan, and progression for individuals with MS presenting with orthopedic complaints, including low back pain (LBP). This retrospective case series presents 4 cases of individuals with MS who were referred to physical therapy who also reported symptoms of LBP. Objectives: 1) Identify special considerations for evaluation techniques, treatment modifications, and progression modifications specific to individuals with MS and LBP. 2) Initiate guidelines that should be considered when establishing a plan of care for similar individuals with MS to establish the most effective approach for functional improvement or stability. Methods: All charts reviewed included subjects who attended clinic at Jacksonville, Florida outpatient rehabilitation center location and were seen by the participating PTs from January 2018 through August 2019. Of the charts reviewed, 4 satisfied inclusion-exclusion criteria and are reviewed here. Charts were reviewed for PT plan of care, pain reports, and functional measures. Results: In each case, subjects reported improvement or resolution in pain measures and also demonstrated improvement in functional measures examined. Specific interventions and functional measures were tailored for each patient and were found to vary due to individual differences in clinical presentation and differences in response to a given intervention. Conclusions: The variability between subject presentation and complexity for individuals with LBP and underlying MS diagnosis was found to result in noted variance in treatment duration and approach between subjects. This points to the importance of thorough initial evaluation to include both neurologic and orthopedic standard of care. The evaluation ensures an appropriate plan of care for individualized treatment as well as identification of potential barriers to progression of treatment. As MS is a progressive condition, it is important to educate and train patients in ways to self-manage their musculoskeletal pain and functional deficits once an appropriate treatment plan has been established. Further research is needed to establish specific outcome measures and screening tools to identify individuals who will benefit from outpatient physical therapy directed toward the improvement of LBP. The types of assessments and treatments reviewed in these cases may facilitate improved identification and standardization for these individuals.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Comprehensive care and MS, Tele-rehabilitation

(REH13) Predicting Fall Risk in Persons with Multiple Sclerosis Utilizing the 12-Item Multiple Sclerosis Walking Scale (MSWS-12)
Heather M. DelMastro,1,3 Elizabeth S. Grimmisch, Helen Dawes,4,6 Anton Pick,7 Jennifer A. Ruiz1
1Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT; 2Department of Rehabilitation Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT; 3Centre for Movement, Occupation and Rehabilitation Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, United Kingdom; 4Department of Clinical Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; 5Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom; 6Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; 7Nuffield Department of Clinical Neurology, Oxford University, Oxford, United Kingdom; 8Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom; 9Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom; 10Oxford Centre for Enablement, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Background: Individuals with multiple sclerosis (PwMS) report weakness and walking difficulty as some of their most disabling symptoms. Lower limb (LL) weakness is prevalent in PwMS and is associated with more significant disability, impaired balance, and increased difficulty walking. However, limited research exists describing the relationship between strength of specific LL muscle groups and walking in the same cohort. Objectives: To determine the impact of dominant (D) and nondominant (ND) LL strength on patient-reported outcomes (PROs) and objective walking outcome measures in PwMS. Methods: A cross-sectional sample of PwMS (n = 137) derived from a larger, ongoing study was used. The following walking measures were collected at a single visit: 12-item MS Walking Scale (MSWS-12), Timed 25-Foot Walk (T25FW), and D and ND stride length (StrL), step length (SL), and double support time (DStime). Isometric peak torque of hip extension and flexion (HExt; Flex), knee extension and flexion (KEext; Flex), ankle plantar and dorsiflexion (APF; DF), and hip abduction (HAbd) were also collected. Descriptive statistics were performed (age, gender, disease duration, and disability level: Patient-Determined Disease Steps [PDSS] score) and a correlation analysis was used to determine the strength of the association of walking measures with muscle groups in PwMS. Results: The MS cohort had a mean age of 51.4 (range: 21.75-75) years, disease duration of 14.5 (range: 0.3-40.0) years, and median PDSS score of 2.5 (range: 0-7), with 74.1% being female. All muscle groups were correlated with SL and StrL, and inversely correlated with T25FW, MSWS-12, and DStime. Strong associations were observed between hip strength (KEext; Flex) and SL (r = 0.63, P < .001), DStime (r = 0.63, P < .001), and ND SL (r = 0.60, P < .001).

Results:

Conclusions: The MSWS-12 score may help clinicians identify PwMS at greatest fall risk so that appropriate fall prevention interventions may be implemented.

Supported by: None
Disclosure: Heather M. DelMastro, Elizabeth S. Grimmisch, Helen Dawes, Anton Pick, Jennifer A. Ruiz
Keywords: Comprehensive care and MS, Fall

(REH14) The Impact of Lower Limb Strength on Walking in Persons with Multiple Sclerosis: A Preliminary Analysis
Heather M. DelMastro,1,3 Elizabeth S. Grimmisch,4,6 Anton Pick,7 Jennifer A. Ruiz1
1Mandell Center for Multiple Sclerosis, Mount Sinai Rehabilitation Hospital, Trinity Health Of New England, Hartford, CT; 2Department of Rehabilitation Medicine, Frank H. Netter MD School of Medicine at Quinnipiac University, North Haven, CT; 3Centre for Movement, Occupation and Rehabilitation Sciences, Faculty of Health and Life Sciences, Oxford Brookes University, Oxford, United Kingdom; 4Department of Clinical Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; 5Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom; 6Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; 7Nuffield Department of Clinical Neurology, Oxford University, Oxford, United Kingdom; 8Department of Clinical Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom; 9Department of Clinical Neurosciences, University of Oxford, Oxford, United Kingdom; 10Oxford Centre for Enablement, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Background: Individuals with multiple sclerosis (PwMS) report weakness and walking difficulty as some of their most disabling symptoms. Lower limb (LL) weakness is prevalent in PwMS and is associated with more significant disability, impaired balance, and increased difficulty walking. However, limited research exists describing the relationship between strength of specific LL muscle groups and walking in the same cohort. Objectives: To determine the impact of dominant (D) and nondominant (ND) LL strength on patient-reported outcomes (PROs) and objective walking outcome measures in PwMS. Methods: A cross-sectional sample of PwMS (n = 137) derived from a larger, ongoing study was used. The following walking measures were collected at a single visit: 12-item MS Walking Scale (MSWS-12), Timed 25-Foot Walk (T25FW), and D and ND stride length (StrL), step length (SL), and double support time (DStime). Isometric peak torque of hip extension and flexion (HExt; Flex), knee extension and flexion (KEext; Flex), ankle plantar and dorsiflexion (APF; DF), and hip abduction (HAbd) were also collected. Descriptive statistics were performed (age, gender, disease duration, and disability level: Patient-Determined Disease Steps [PDSS] score) and a correlation analysis was used to determine the strength of the association of walking measures with muscle groups in PwMS. Results: The MS cohort had a mean age of 51.4 (range: 21.75-75) years, disease duration of 14.5 (range: 0.3-40.0) years, and median PDSS score of 2.5 (range: 0-7), with 74.1% being female. All muscle groups were correlated with SL and StrL, and inversely correlated with T25FW, MSWS-12, and DStime. Strong associations were observed between hip strength (KEext; Flex) and SL (r = 0.63, P < .001), DStime (r = 0.63, P < .001), and ND SL (r = 0.60, P < .001).
ND KFlex and Stl (r = 0.610, P < .001); and ND: r = 0.622, P < .001), ND HAbd and ND Stl (r = 0.640, P < .001), and ND HAbd and Stl (r = 0.605, P < .001). Weak to moderate correlations (r = 0.190 to 0.599, P < .05) were found for all remaining strength and walking measures assessed. **Conclusions:** All LL muscle groups (HExt, HFlex, KExt, KFlex, APT, ADF, and HAbd) were associated with the PRO (MSWS-12) and objective walking variables (125FW, gaits; Stl, St, and ADF were collected). These findings suggest that strength training interventions of these muscles may improve walking in PwMS. Importantly, this study improves understanding of the relationship between different major LL muscle groups with both walking performance and perceived difficulty walking in PwMS.

**Supported by:** None

**Disclosure:** Heather M. DelMastro, Helen Dawes, Anton Pick, Jennifer A. Raub, Nothing to disclose. Gabrielle C. DeLuca: contracted research; Noura Farrokh: research; Sandor Gerzsemey: travel; Robert Keune: contracted research.

**Keywords:** Comprehensive care and MS. Walking

### (REH15) The Effects of Intermittent Versus Continuous Walking on Distance to Fatigue in Persons with Multiple Sclerosis

Herb Karpatkin, Rachel Rhodes, Lourdes Rodriguez, Rosangeli Rodriguez, Anna Rubeo

1Physical Therapy, Hunter College, New York, NY

**Background:** Diminished walking endurance is common in persons with multiple sclerosis (PwMS). Previous studies have shown that PwMS walk farther in 6 minutes when using intermittent walking (IW) (ie, with interspersed rest breaks) than with continuous walking (CW), but it is unknown whether PwMS can walk greater distances or longer duration when using IW for periods of longer than 6 minutes. **Objectives:** The purpose of this study is to compare distance and time walked on a treadmill at a fixed velocity utilizing IW or CW. We hypothesized that PwMS would be able to walk greater distances and for longer duration when walking intermittently than when walking continuously. **Methods:** A randomized crossover design was used. Participants were randomized into 2 order groups: IW then CW, or CW then IW. The IW condition included alternating 30 seconds of walking and 30 seconds of seated resting. The CW condition consisted of continuous walking. Participants wore an overhead harness for safety. Baseline walking speed was determined with a 2-minute walk test (2MWT). Participants walked at the fast pace up to the 2MWT speed until they either lost their balance or decided to stop walking. Time and distance walked were recorded. After 1 week, participants returned and performed the crossover condition. **Results:** 19 subjects (Expanded Disability Status Scale score 4.7±1.4, 10 female) completed the study. Participants had significantly longer walking distance in the intermittent condition than in the continuous condition (1575.4 ft SD ± 498.4 vs 1035.9 ft SD ± 356.2, P = .028). IW enabled participants to walk at best pace for greater distances than CW. **Conclusions:** These findings further support the use of IW training to improve walking endurance in PwMS. Adding rest breaks during endurance training enabled participants in this study to walk farther and longer, increasing the “dose” of the walking activity. Comparative effectiveness studies should be conducted to determine whether IW training is superior to the traditional model of CW training to improve walking endurance. In PwMS, greater walking endurance gains can be achieved with IW than with CW, suggesting that greater walking endurance gains can be made in these patients using this approach.

**Supported by:** None

**Disclosure:** Nothing to disclose

**Keywords:** Complementary/alternative therapies in MS, Gait, Management of activities of daily living in MS

### (REH17) A Combination of Core Exercise and Balance-Based Torso Weighting for Women with Multiple Sclerosis

Jeannie B. Stephenson,1 Douglas E. Haladay,1 Stephanie L. Carey,2 Jason W. Beckstead,3 Derrick Robertson4

1School of Physical Therapy & Rehabilitation Sciences, University of South Florida, Tampa, FL; 2Department of Mechanical Engineering, University of South Florida, Tampa, FL; 3College of Public Health, University of South Florida, Tampa, FL; 4College of Medicine, Neurology, University of South Florida, Tampa, FL

**Background:** Multiple sclerosis (MS) is a neurodegenerative disease that often results in fatigue and balance and walking impairment. Core exercise has been shown to reduce fatigue and improve balance and walking in people with MS. However, no studies have investigated the effects of a combination of core exercise and balance-based torso weighting (BBTW). **Objectives:** The purpose of this study was to investigate whether the combination of BBTW plus core exercise leads to greater improvement in self-reports of fatigue, balance confidence, and walking ability compared to core exercise alone in women with MS.

**Methods:** Eighteen women with MS (Expanded Disability Status Scale score 3.0±0.8) were randomly assigned to 1 of 2 groups: core exercise (CE) or BBTW plus core exercise (BBTW + CE). Subjects completed 3 questionnaires at baseline and after a 6-week intervention period: Modified Fatigue Impact Scale (MFIS), Activities-Specific Balance Confidence Scale (ABC Scale), and the MS Walking Scale (MSWS-12). All subjects participated in a Pilates-based CE program once a week with a physical therapist along with a daily home exercise program. In addition to the CE, 1 group also participated in the BBTW protocol. This involved fitting subjects with a vest worn on the torso and application of small weights to the vest at baseline followed by biweekly sessions to adjust weights and gradually increase wearing time up to 6 hours daily.

**Results:** Following the 6-week intervention period, both groups demonstrated positive change indicating improvements in self-reported fatigue, balance confidence, and walking ability. The percent change for each measure was as follows: MFIS: CE group = 14.1% decrease, BBTW + CE group = 19.9% decrease; ABC Scale: CE group = 9.7% increase, BBTW + CE group = 15.0% increase; and MSWS-12: CE group = 11.9% decrease, BBTW + CE group = 19.3% decrease. Despite these improvements, none of the decreased conduction through myelinated nerves. Prolonged exercise due to PwMS walking can lead to increased core temperature in PwMS, and therefore lead to progressive worsening of gait over the course of the walk. An intervention to prevent core temperature rise could limit OF during gait in PwMS. **Objectives:** The purpose of this study was to investigate whether the use of a commercially available cooling vest would result in decreased OF of gait in PwMS. We hypothesized that wearing the cooled vest for 30 minutes prior to a 6-minute walk (6MW) would result in less evidence of gait fatigability in PwMS when compared to performing the 6MW without prior cooling. If our hypothesis is correct, it will suggest that PwMS who experience gait fatigability can mitigate this by the use of cooling garments. **Methods:** A randomized crossover design is being used. Ambulatory patients with a diagnosis of MS were randomized into a cooled and uncooled condition. Cooling is accomplished by the wearing of a commercially available cooling vest for 30 minutes while seated. The uncooled condition is sitting for 30 minutes without wearing the vest. Immediately after the 30 minutes, subjects perform a 6MW test. Objective fatigability is measured by comparing the speed of the walk in the first minute to the speed of the walk in the sixth minute. Subjective fatigue is measured using the Visual Analog Scale of Fatigue (VASF). Data collection began fall of 2019 and will conclude winter of 2020.

**Results:** To date, 5 subjects (Expanded Disability Status Scale score 4.4) have completed the study. Due to the small sample size, only descriptive statistics are reported. Mean 6MW test distance was higher in the cooled condition (1137.3 in) than in the uncooled condition (1087.9). Mean differences between the distance walked in first minute and sixth minute was less in the cooled condition (−1.6) than in the uncooled (−12.4). Subjects experienced less subjective fatigue as measured by the VASF in the cooled condition (7.4 mm) than in the uncooled (13.8 mm).

**Conclusions:** These findings, although preliminary, support our hypothesis that cooling may diminish OF of gait in PwMS and thereby improve gait endurance. Once we have achieved an adequate sample size, a more in-depth analysis will be performed. If our hypothesis is then reaffirmed, it will suggest that the use of a commercially available cooling vest may decrease the impact of fatigue on gait in PwMS.

**Supported by:** None

**Disclosure:** Nothing to disclose

**Keywords:** Equipment in MS, Gait fatigue. Management of activities of daily living in MS

### (REH16) The Effects of Cooling Vests on Gait Fatigability in Persons with Multiple Sclerosis

Herbert Karpatkin, Sean Riva, Kaîîn Russo, Sandon Stevens, Winnie Yu

Physical Therapy, Hunter College, New York, NY

**Background:** Gait dysfunction is a ubiquitous and multifactorial finding in persons with multiple sclerosis (PwMS). A major reason for gait dysfunction in PwMS is objective fatigability (OF), characterized by progressive worsening of gait parameters over the course of a walk. Although OF is also multifactorial, it is presumed to be due in large part to multiple sclerosis (MS) thermosensitivity, where increased core temperature can be achieved with IW than with CW, suggesting that training interventions of these muscles may improve walking in PwMS. Importantly, this study improves understanding of the relationship between different major LL muscle groups with both walking performance and perceived difficulty walking in PwMS.

**Supported by:** None

**Disclosure:** Nothing to disclose

**Keywords:** Complementary/alternative therapies in MS, Gait, Management of activities of daily living in MS
change in scores exceeded the MDC95 estimates for each measure (MFIS = 8.6 points; S12 = 5.8 points; SF-36V-WSS12 = 53%). Conclusions: Core exercise with or without BBTW led to decreased self-perceived fatigue and improved balance confidence and walking ability, however, the percent change for both groups did not exceed MDC95 estimates. The percent change in perceived fatigue, balance, and walking was greater in the BBTW + CE group. The balance wear vest may provide individuals with added truncal proprioceptive input and recruitment of core stabilizers; however, the mechanism of improvement needs to be further investigated.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Complementary/alternative therapies in MS, Core exercise

(REH21) Impact of Restless Legs Syndrome Severity on Cognitive Function in Adults with Multiple Sclerosis and Restless Legs Syndrome Syndrome

Katie J.J. Cederberg,1 Morgan L. Schuetz,2 Brianna Mathison,2 Tiffany J. Braley,2 Arthur S. Walters,2 Robert W. Marks,2 1Physical Therapy, University of Alabama at Birmingham, Birmingham, AL; 2Neurology, University of Michigan, Ann Arbor, MI; 3Neurology, Vanderbilt University, Nashville, TN

Background: Restless legs syndrome (RLS) is a sleep disorder present in as many as 26% of persons with multiple sclerosis (PwMS) and may exacerbate many of the symptoms and consequences of multiple sclerosis (MS), including cognitive function. Additionally, RLS symptoms often impact patients’ quality of life, which could further exacerbate the neuropsychological symptoms associated with MS. Objectives: The present study examined the relationship between RLS severity and cognitive impairment in adults with MS and RLS. Methods: Participants with MS were screened for RLS using the Cambridge-Hopkins Restless Legs Syndrome Short Form Diagnostic Questionnaire (RLSDQ-SF) and were included in the analysis if they had a score of at least 19. Participants with MS were recruited with a rate of 80% to perform an examination for scoring the Expanded Disability Status Scale (EDSS) and participants completed the International Restless Legs Syndrome Study Group Scale (IRLS), the Pittsburgh Sleep Quality Index (PSQI), and the Epworth Sleepiness Scale (ESS) followed by the Brief International Cognitive Assessment for Multiple Sclerosis battery consisting of the Symbol Digit Modalities Test (SDMT), California Verbal Learning Test-II (CVLT-II), and Brief Visuospatial Memory Test–Revised (BVMT-R). Results: All participants (N = 22) had RLS (mean IRLS = 20.4; SD = 6.1). Non-parametric bivariate correlations indicated strong, negative associations between scores from the IRLS and CVLT-II (p = -0.627; P < .01); BVMT-R (p = -0.608; P < .01), and years of education (p = -0.632; P < .01). There were no significant associations among scores from the IRLS and the SDMT, PSQI, or ESS. We performed 2 multivariate linear regressions with forward stepwise selection wherein we regressed scores from 1) CVLT-II on IRLS scores and 2) BVMT on IRLS scores in step 1, and included variables that were significantly correlated with cognitive scores and IRLS scores in bivariate correlation analyses in step 2 (ie, years of education). IRLS scores significantly predicted CVLT-II (R² = 0.398) and BVMT-R performance (R² = 0.371), however, the relationship with BVMT-R performance was attenuated by including years of education (ΔR² = 0.144). Conclusions: Our findings suggest that worse RLS severity could contribute to worse immediate verbal recall and memory and worse immediate visual recall and visuospatial memory in PwMS. Additional research is necessary to determine why and how patients with MS may use different RLS severity pathways exists, diagnosis and treatment of RLS symptoms may offer new opportunities to reduce cognitive impairment in adults with MS.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Psychological issues and MS, Sleep and MS

(REH22) Utilization of Therapy Services Among Patients with Multiple Sclerosis

Laura K. Miller
Exercise Science, Bellarmine University, Louisville, KY

Background: Multiple sclerosis (MS) is a chronic, progressive neurological autoimmune disease affecting nearly 1 million individuals in the United States. Common symptoms of MS include pain, impaired mobility or activities of daily living, and fatigue, among many others. The use of rehabilitation in all settings has been shown to improve symptoms and function while helping to minimize disability. Objectives: The purpose of this study was to examine the utilization of various rehabilitation services in the Kentucky area and understand barriers to rehabilitation among patients with MS. A secondary objective was to identify areas in which patients require additional education related to managing their disease. Methods: Eighty-nine participants completed a voluntary online survey that included questions about their disease and experiences with being referred to various types of rehabilitation. Additional questions were asked about their knowledge and beliefs and any barriers related to therapy usage. Survey respondents were weighted to reflect the Survey Monkey demographic of MS participants. Results: Over half of participants are not participating in regular exercise, despite current literature that shows the benefits of exercise. Approximately one third of individuals surveyed are unaware of the benefits of various types of rehabilitation. Half of the participants have paths to make changes to either their diet or exercise programs over the next year. Around 30% of participants expressed interest in learning more about nutrition, supplements, exercise, stress management, and stretching. These results highlight the need for continued patient education regarding management of MS symptoms. Conclusions: Participants expressed interest in learning more about nutrition, supplements, exercise, stress management, and stretching. These results highlight the need for continued patient education regarding management of MS symptoms. Conclusions: Despite significant research that indicates the benefits of therapy for patients with MS, there continue to be many patients who have not been referred to skilled therapy services. Furthermore, most patients are interested in obtaining additional information related to managing their disease, which could be addressed by a comprehensive rehabilitation team.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Complementary/alternative therapies in MS, Comprehensive care and MS, Management of activities of daily living in MS

(REH23) Proximal Movement Compensations Are Related to Muscle Function and Walking Capacity in People with Multiple Sclerosis

Mark M. Manago,1,3 Enrique Alvarez,2 Paul Kline,1,3 Cory Christianson1,3 1Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine, Aurora, CO; 2Department of Neurology, University of Colorado School of Medicine, Aurora, CO; 3Geriatric, Research, Education, and Clinical Center, VA Eastern Colorado Healthcare System, Aurora, CO

Background: Distal lower extremity movement compensations are associated with muscle weakness and mobility limitations in people with multiple sclerosis (MS), however less is known about pelvis and trunk compensations during walking. Objectives: To 1) compare differences in pelvis and trunk kinematics during walking between participants with MS and a control group, and 2) determine associations of trunk and pelvis kinematics with muscle function, spatiotemporal parameters, and walking capacity in the participants with MS. Methods: In this cross-sectional study, 20 people with MS (Expanded Disability Status Scale 1.5-5.5) and 10 people with comparable age and sex (CTL) underwent 3-dimensional gait analysis. The primary kinematic variables of interest were frontal and sagittal plane pelvis and trunk angular displacement during the stance phase of walking. All participants also underwent muscle function assessments (hip and trunk strength and endurance), and walking capacity measures (Timed 25-Foot Walk [T25FW], 2-Minute Walk Test [2MWT]). Results: Compared to the CTL group, the MS group had significantly greater sagittal plane trunk and pelvic angular displacement during stance phase (P < .031) and weaker (P = .042) sides, less frontal plane trunk and pelvic angular displacement for both the stronger (P = .008) and weaker (P = .024) sides, and more sagittal plane trunk angular displacement for the stronger side (P = .047) during stance phase. There were low-to-moderate correlations in the MS group for sagittal plane pelvic angular displacement with trunk flexion endurance (r = -0.369, P = .019), and frontal plane pelvic angular displacement with lateral trunk flexion strength (r = 0.353, P = .030), step length (r = 0.529, P < .001), stance time (r = 0.433, P = .005), T25FW (r = 0.496, P < .001), and 2MWT (r = 0.582, P < .001). Conclusions: In people with MS, movement compensation at the pelvis during walking, particularly decreased frontal plane motion, was associated with worse walking capacity, muscle function, and spatiotemporal parameters. Future studies may consider targeting proximal muscular function to improve walking outcomes in people with MS. Rehabilitation clinicians may consider evaluation of proximal muscle function and gait compensations when planning rehabilitation interventions to improve walking capacity in people with MS.

Supported by: None

Disclosure: Mark M. Manago, Paul Kline, Cory Christianson: Nothing to disclose.

Keywords: Rehabilitation in MS

(REH24) Effects of a Weight-Based Training Program on Bone Density, Cognition, and Quality of Life of Multiple Sclerosis Patients

Mary Ann Picone
Holy Name Medical Center, Teaneck, NJ

International Journal of MS Care
Background: Multiple sclerosis (MS) is a chronic neurodegenerative disease caused by the lesion forming demyelination of the central nervous system. Some of the issues associated with MS include cognitive impairment, increased mental and physical fatigue, and decreased bone mineral density. Using different variations of exercise is a common practice in the care for patients diagnosed with MS. It has been supported that there is a positive impact associated with exercise and the long-term training related to increased quality of life in patients with MS. Objectives: Patients with MS have lower bone mineral density and a higher prevalence of osteoporosis. Physical activity has had a positive effect in bone health of patients with MS. The primary purpose of this study is to investigate if there is a correlation between weekly body weight exercise and bone density in patients with MS. Cognitive functioning and psychological well-being have also been shown to improve through the intervention of regular exercise. Additionally, cognitive and quality-of-life measures will also be investigated as part of this study. Methods: This study will enroll a total of 25 patients. Patients eligible for the study are between the ages of 40-55, diagnosed with MS, and having an Expanded Disability Status Scale score below 5.5. Each patient will receive a baseline dual energy X-ray absorptiometry (DEXA) scan, a verbal Symbol Digit Modalities Test (SDMT), and a Multiple Sclerosis Impact Scale (MSIS-29). Following the baseline visit, patients begin a 6-week body weight exercise program. The program consists of one 30-minute group session, under trained physical therapist supervision, and 1 video-guided at-home session for a total of 2 sessions per week. Upon completion of the training program, each patient completes a midpoint SDMT and MSIS-29. An endpoint DEXA scan, SDMT, and MSIS-29 are conducted 8 weeks after the completion of the training program. Data gathering will be conducted for potential changes in bone density values, SDMT scores, and MSIS-29 physical and psychological scores. Results: To date, 4 patients completed, 5 patients dropped, and 4 patient enrolled/awaiting enrollment. Data are being collected and further analysis is required. Conclusions: Thus far patients have reported positive experiences, but until analysis no conclusions can be made or supported with regard to bone density and cognitive effects.

Supported by: None

Disclosure: Mary Ann Picone: Biogen Inc (speakers' bureau).

Keywords: Body weight exercise for MS, Complementary/alternative therapies in MS, Management of activities of daily living in MS

(REH25) Orchestrating a New Path for Both Physical and Music Therapies

Megan Weigel,1 Renee Fleming,2 Brian Hutchinson,3 Wendy L. Magee,4 Wendy Su2

1First Coast Integrative Medicine, Jacksonville Beach, FL; 2John F. Kennedy Center for the Performing Arts, Washington, DC; 3Multiple Sclerosis Achievement Center, Dignity Health, Sermannet, CA; 4Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background: Although disease-modifying therapies (DMTs) are available for multiple sclerosis (MS) to delay disability progression and reduce relapses, as MS progresses additional support and management of symptoms play an increasingly important role. A significant role of nonpharmacologic therapies, focusing on physiotherapy (PT) and music therapy (MT) that can lead to improvements in both the physical and psychosocial domains that are negatively affected in patients with MS. Methods: MEDLINE was searched without date restriction to identify studies on the efficacy of PT and MT in MS. A panel of PT and MT experts was convened to identify important themes and research studies. Results: PT can lead to improvements in mobility and balance. A review of 16 randomized controlled trials showed that treadmill training 3 times per week for 8 weeks improved walking endurance by 26.5 m from baseline in patients with MS. PT can also lead to significant improvements in fatigue, health-related quality of life (HRQoL), mood, and cognition. In a group of 20 patients with MS who performed high-intensity resistance training twice a week for 12 weeks, patients achieved statistically significant reductions in anxiety ($P = .002$), depression ($P = .019$), and fatigue ($P = .001$). Likewise, MT can improve physical symptoms and HRQoL in MS. In a trial comparing rhythmic-elicited movement imagery, metronome-cued motor imagery, and no intervention, patients in the 2 intervention groups could, respectively, walk a mean of 62.1 m and 60.9 m further after 4 weeks vs baseline; the mean change in the no-intervention group was −17.1 m. Significant improvements in HRQoL and fatigue, as well as physical symptoms and burden, were also seen in both intervention groups vs the no-intervention groups for physical function, general health perception, vitality, social function, and mental health ($P < .05$). Conclusions: While DMTs aim to reduce disability progression and inflammatory activities in MS, additional nonpharmacologic therapies are an important adjunct for managing daily life with MS, particularly in impairing or maintaining mobility, cognition, and other functional systems. Current studies regarding the use of MT in MS are relatively new, but show promise in improving the loss of both fine and gross motor skills, improving overall well-being and psychosocial health factors, and, ultimately, preserving HRQoL. Further research on combined PT and MT interventions may further improve outcomes in MS.

Supported by: None


Keywords: Complementary/alternative therapies in MS, Comprehensive care and MS, Management of activities of daily living in MS

(REH26) Improving Quality of Life Using an End-Effector Robotic Rehabilitation Approach in Progressive Multiple Sclerosis

Sohvan Deepak Rajendra

Neurorehabilitation and Robotics, IU Health, Indianapolis, IN

Background: Progressive multiple sclerosis (MS) is characterized clinically by gradual disease progression and accumulation of neurologic disability, independent of relapses. Rehabilitation has been recommended as a means to reduce disability and restore function. High-quality evidence supporting progressive MS rehabilitation is limited. An end-effector robotic assisted gait training (RAGT) addresses many of the limitations of therapist-assisted gait training while providing an environment for regaining mobility and independence. Objectives: The objective of this study was to establish the safety and feasibility of RAGT and determine its impact on movement capacity, fatigue, and quality of life in patients with progressive MS. Methods: Single-blinded, randomized clinical trial using RAGT. Subjects trained 2 times per week for 10 weeks for a total of 20 training sessions. Five subjects with progressive MS have completed the RAGT protocol: 4 women and 1 man ranging in age from 33 to 63. The group has a range of Expanded Disability Status Scale scores from 4.5 to 6.5. Physical therapists individualized training intensity and RAGT characteristics to maximize benefits for each subject. Motor capacity outcomes (walking speed and endurance [2MW]), and quality of life measures (Modified Fatigue Impact Scale [MFIS] and the Multiple Sclerosis Impact Scale 29 [MSIS-29]) were assessed at baseline and after the final training session (20th session). Subjects were monitored at each visit for adverse events. Results: There was no reported adverse event for any subject. Three of the 5 subjects had a 10% or greater increase in walking speed with an average improvement of 0.062 m/s. The group averaged 13% improvement in fast walking speed. Subjects had an average improvement of 10% on the MFIS and 15% on the MSIS-29. MFIS subscales using the greatest amount of mental effort were in the physical domain (44%). The MSIS-29 subscales indicated that individuals had a significant decrease in physical disability (18%). Conclusions: These 5 subjects with progressive MS tolerated the treatment dosage of 2 times per week for 20 weeks and did not experience any adverse event throughout the trial. Focused gait training using RAGT resulted in improve ment in walking speed. Subjects reported that training reduced their disability and fatigue, enhancing their overall quality of life.

Supported by: None

Disclosure: Nothing to disclose

Keywords: Complementary/alternative therapies in MS, Equipment in MS

(REH27) Strategies to Foster Buy-in for Physical and Occupational Therapists: Engagement Across Multiple Sites and States for a Study on Tele-Exercise and Multiple Sclerosis (TEAMS)

Trey Fleming Tracy,1 Hui-Ju Young,1 Tapan Mehta,2 Mohanraj Thirumalai,3 Dorothy Poydashe,4 Emily Rose,1 Janet Jordan5

1Rehabilitation, Tanner Center for MS, Birmingham, AL; 2School of Health Professions, University of Alabama at Birmingham (UAB)/Lakeshore Foundation Collaborative, Birmingham, AL; 3School of Health Professions, UAB, Birmingham, AL; 4School of Public Health, UAB, Birmingham, AL; 5Tanner Center and Foundation for Multiple Sclerosis, Birmingham, AL

Background: Tele-Exercise and Multiple Sclerosis (TEAMS) is a research project funded by the Patient-Centered Outcomes Research Institute (PCORI) that aims to deliver a 12-week exercise-based rehabilitation intervention to 820 people with multiple sclerosis (MS) who live in Alabama, Mississippi, and Tennessee. Participants are randomized into 2 study arms: teleCAM and directCAM. The teleCAM consists of
testing visits with the intervention delivered via videos accessible through a direct link (CAAM). The 4 testing visits were held at 20 clinic visits where the intervention is delivered. Physical and occupational therapists at 43 outpatient clinics across the 3 states are trained to deliver the intervention to enrolled participants. This researcher-provider model is an integral part of the study design and is critical to the sustainability and success of the study. The aim of this presentation is to describe a multifaceted approach used to facilitate therapist engagement and form partnerships between the therapists, researchers, and study participants.

Methods: A Therapist Manual of Operating Procedures (TMOP) was developed for each clinic to ensure consistency of intervention delivery. The Clinical Research Coordinator used the TMOP along with a rehabilitation guideline established by the Consortium of Multiple Sclerosis Centers (CMSC) to train clinicians at each clinic. Continuing Education Units (CEUs) were approved allowing each clinician to claim 4-6 hours for on-site training. Videos were created to provide an instructional guide on how to administer each outcome measure. GoToMeeting was used as a platform to deliver ongoing study updates. Information pertaining to participants is communicated through a HIPPA-compliant portal (Box).

Results: 43 clinics across the 3 states and 86 therapists were trained for the study. Each clinic has a copy of the comprehensive (81 pp) TMOP available in print form with access to a digital copy on Box. 18 GoToMeetings have been held and recorded for training and study updates, and each of the 86 trained therapists has used the outcome-measure videos. 43 therapists have access to Box and have uploaded approximately 1900 documents within 26 months. There are 823 participants enrolled in the study, and 731 have been baseline evaluated. Conclusions: Our implementation science researcher-provider model has established partnerships with therapists, research staff, and participants and has resulted in seamless communications in intervention delivery and data management across the participating clinics in 3 states. Investments in education, resources, and technology have provided the foundation for successful recruitment, enrollment, retention, and dissemination in research. The model can be adapted for other similar projects that require strong emphasis on researchers engaging clinicians in implementation science.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Comprehensive care and MS, Engagement, MS and the caregiver/family

(REH28) Correlates of Change in First Trial Exposures Across 2 Days of Protective Steps Among Those with Multiple Sclerosis

Charles Van Liew,1 Leland E. Dibble,2 Bo Foreman,3 Daniel S. Peterson1,3
1College of Health Solutions, Arizona State University, Phoenix, AZ; 2Physical Therapy and Athletic Training, University of Utah, Salt Lake City, UT; 3Research, Phoenix Veterans Affairs Medical Center, Phoenix, AZ

Background: Multiple sclerosis (MS) is a common, debilitating, neurodegenerative disorder that causes myriad symptoms. Gait and balance dysfunction in MS are common and manifest early in the disease process, increasing fall risk. In particular, the ability to quickly and effectively react to a loss of balance is worse in people with MS. Therefore, improving reactive balance among those with MS is desirable. However, for maximum ecological validity, improvements in reactive balance through training would be demonstrable upon first loss-of-balance exposure. Objectives: The aim of this study is to evaluate first trial changes in people with MS before and after 1 day of protective stepping practice. The study also seeks to identify clinical correlates of first trial changes to begin evaluating for whom such training may provide benefit. Methods: Fourteen people with MS underwent 2 consecutive days of support-surface perturbations using an instrumented treadmill. Protective stepping outcomes were step length, step latency, and margin of stability. The backward step performance on the first trials on days 1 and 2 were compared, and difference scores were evaluated for relationships with correlates based on theoretical considerations. Results: There were no significant changes in first trial performance after training. However, some clinical and cognitive characteristics, such as mini-BESTest performance, improvement from day 1 to day 2 on the Symbol-Digits Modality test, type of MS diagnosis, and falls history were related with the amount of change individuals experienced. Conclusions: Although preliminary, these findings provide evidence that those with more favorable disease states may see more robust fristral improvements after perturbation training. Greater doses, larger and more homogeneous samples, or longer delay between training and reassessment may be needed to understand the existence and relevance of first trial changes.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Rehabilitation

(REH29) Lifestyle Redesign for Multiple Sclerosis: A Case Series of Female Hispanic Patients

Vanessa Miller, Rebecca Cunningham

Mrs. T.H. Chan Division of Occupational Science and Occupational Therapy, University of Southern California, Los Angeles, CA

Background: Research indicates that the incidence rate and clinical presentation of multiple sclerosis (MS) varies between patients of different ethnic backgrounds. On average, the incidence rate of Hispanic patients with MS tends to be lower than that of non-Hispanic whites, while the average age of first reported MS symptom is earlier in the Hispanic population. Hispanic patients have higher incidence of cervical spinal lesions, mobility impairments, and optic neuritis at first MS-related event. Patients with MS of Hispanic descent may be at a higher risk of disability earlier in the disease process. Due to the identified clinical presentation and disability risk, it is important to realize how this cohort will support symptom and disease management. Evidence in the MS literature supports behavior and lifestyle interventions as critical components for symptom and disease management, as well as improved quality of life. Lifestyle Redesign is an occupational therapy (OT) approach that focuses on helping patients acquire health-promoting habits and routines to improve overall function, health, and quality of life, as well as to improve self-management of chronic conditions. This methodology involves education, occupational self-analysis, personal exploration, and goal setting interventions, to facilitate reflection and increase motivation for and the execution of health-promoting behavior changes. Objectives: Describe the delivery of Lifestyle Redesign to address chronic disease and symptom management in patients with MS within an OT plan of care and provide a descriptive case series with clinical outcomes to demonstrate how this intervention can be applied clinically with Hispanic females with MS. Methods: The subjects included in this case series participated in an average of 11 OT sessions. All subjects are female, of Hispanic descent, and between the ages of 20 and 45. The Canadian Occupational Performance Measure (COPM), Multiple Sclerosis Quality of Life Inventory (MSQOLI), and Health Related Quality of Life Short Form-36 (SF-36) were used at pre- and postintervention. Results: Clinically significant improvements occurred in the COPM overall performance and satisfaction scores, with patients demonstrating an average 5.3-point increase on performance and an average 7.2-point increase on satisfaction. On average, SF-36 scores improved in 7 subscales including emotional well-being, social functioning, and bodily pain, and MSQOLI scores improved in 3 subscales including the MFIS. Conclusions: This case series supports the use of Lifestyle Redesign to address symptom and chronic disease management in Hispanic females with MS because of the demonstrated benefits in the areas of functional performance and symptom presentation. Additionally, this case series contributes to the broader evidence for the feasibility of Lifestyle Redesign services for neurologic populations.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Comprehensive care and MS, Lifestyle interventions, Management of activities of daily living in MS

(REH30) Cognitive Processing Speed as a Predictor of Motor Skill Learning in Healthy Adults and Persons with Multiple Sclerosis

Erin M. Edwards, Nora E. Fritz

Physical Therapy, Wayne State University, Detroit, MI

Background: Motor and cognitive deficits are frequently reported in individuals with multiple sclerosis (MS), resulting in a high incidence of rehabilitation enrollment. Presently, there is no way to predict whether a given patient will benefit from a specific rehabilitation program and factors mediating exercise responsiveness in MS remain unknown. Objectives: This study aims to determine baseline cognitive and pathological predictors of an individual’s ability to benefit from a balance-training program. We hypothesized that faster processing speed and increased myelin content (MWF) in brain regions related to balance at baseline would result in greater automaticity at the trained task, as measured by the change in dual-task cost (DTC) following training. Methods: Four healthy participants and 1 participant with MS (1 male, 4 female; age 40 ± 14.3 years) underwent a magnetic resonance imaging examination and 3-week period of balance training in the Neurocom Basic Balance Master. Each day involved a single session of twenty 2-minute blocks; participants performed weight shifts on a force platform in response to targets on a screen. Participants were evaluated pre- and post-training on their ability to perform a dual-task (Limit of Stability Test + 4-back Test). Results: Following training, all participants demonstrated improvements in reaction time (14%), velocity (34%), directional control (5%), and target...
**RELAPSE THERAPY**

**(RTH01) Safety of Satralizumab Based on Pooled Data from Phase 3 Studies in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)**

Benjamin M. Greenberg,1 Jerome de Seze,2 Edward Fox,3 Albert Saiz,4 takoshi Yamamura,5 Carole Marcillat,6 Xiujing Kou,7 Kristina Weber,8 Brian G. Weinshenker1

1University of Texas Southwestern Medical Center, Dallas, TX; 2Hopital de Hautepierre, Strasbourg, France; 3Central Texas Neurology Consultants, Round Rock, TX; 4Department of Neurology, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain; 5National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; 6Hoffmann-La Roche Ltd, Basel, Switzerland; 7Mayo Clinic, Rochester, MN

**Background:** Interleukin-6 (IL-6) is implicated in the immunopathology of neuromyelitis optica spectrum disorder (NMOSD). Satralizumab, a humanized recycling monoclonal antibody that binds to the IL-6 receptor, demonstrated a reduction in NMOSD relapse risk in two phase 3 studies: SAKuraSky (satralizumab in combination with baseline immunosuppressants) and SAKuraStar (satralizumab monotherapy; NCT02073279). Objectives: To evaluate the safety of satralizumab vs placebo in a pooled population of patients with NMOSD from the SAKura studies, using the latest data from their open-label extension (OLE) periods. Methods: SAKuraStar and SAKuraSky are randomized studies comprising a double-blind (DB) period (satralizumab 120 mg every 4 weeks vs placebo) followed by an OLE period (satralizumab only). The combined DB and extension period was defined as the overall satralizumab treatment period (OSTP) (cutoff June 7, 2019). Safety was evaluated in the DB and OSTP periods and reported as adverse event (AE) rate (events/100 patient-years [PYs]). Results: The pooled OLE population included 178 patients (satralizumab, n = 104; placebo, n = 74), and a total of 166 patients received satralizumab in the OLE. Mean and median satralizumab exposures in the OST period were 133.3 and 128.6 weeks. Rates of AEs and serious AEs were comparable between satralizumab and placebo groups in the DB period (AEs: 478.49 vs 506.51 events/100 PYs, respectively; serious AEs: 14.97 vs 17.98 events/100 PYs, respectively), and were consistent in the OST period. In the DB period, 4 patients (3.8%) in the satralizumab group and 6 (8.1%) in the placebo group withdrew from study due to an AE. Infection rates were lower with satralizumab vs placebo in the DB period (113.04 vs 154.85 events/100 PYs), with no increased risk of opportunistic infections. Infection rates with satralizumab were similar between the DB and OST periods. The injection-related reaction rate was higher with satralizumab vs placebo in the DB period (17.03 vs 8.99 events/100 PYs); injection-related reactions were mostly mild-to-moderate and did not lead to treatment discontinuation. No deaths or anaphylactic reactions were reported.

**Conclusions:** In patients with NMOSD, satralizumab was well tolerated and showed a favorable safety profile. Results from the overall satralizumab treatment period (DB and OST periods expanded on the DB periods by adding data from the ongoing OLE periods, were consistent with the DB period results.

**Supported by:** None

**Disclosure:** Benjamin M. Greenberg, Alcacin, Alcacin, EMD Serono, Genentech, Novartis (consulting fee); Chugai, CLENE Nanomedicine, Gaith-Jackson Charitable Foundation for NM, MedImmune, National MS Society, PCORI, Transverse Myelitis Association (contracted research); Jerome de Seze; Chugai, Roche (consulting fee); Edward Fox, AbVhi, Biogen, Celsagen, EMD Serono, Sanofi Genzyme (personal fees and grants); Chugai (consulted research, personal fees and grants, personal fees and non-financial support – recruiting site for the SAKuraStar study); Genentech, MedDay, Novartis, Roche, TG Therapeutics (consulting fee, contracted research, speakers’ bureau); Biogen, Novartis, Teijin Pharma (consulting fee, speakers’ bureau); Chiome Bioscience, Mirataz Holdings (consulted research); Chugai (consulting fee, contracted research, grant, speakers’ bureau); CSL Behring, Mitsubishi Tanabe, Takeda, Teijin Home Healthcare (speakers’ bureau); Carole Marcillat, Xiujing Kou, Kristina Weber; F. Hoffmann-La Roche (RTH01) Adolescents with Neuromyelitis Optica Spectrum Disorder; AstraZeneca, Biogen, Celsagen, Wexler, Chugai, Mitsubushi Tanabe, Roche, Vida Bio (consulting fee); Hospices Civil de Lyon, MVZ Lakor PD De Volkmann und Kollegen GbR, Oxford University, RSR Ltd (royalties).

**Keywords:** Neuromyelitis optica spectrum disorder

**(RTH02) Adolescents with Neuromyelitis Optica Spectrum Disorder Achieved Similar Exposures and Favorable Safety Profile When Treated with the Adult Satralizumab Dosing Regimen**

Cheryl Hemingway,1 Hanna Silber Baumann,2 Xiujing Kou,3 Daniela Stoikmaier,4 Patricia Sonvold Ducray,5 Veronica G. Anania,5 Hajime Ita,6 H.-Christian von Buecking,7 San Lennon-Chrimes8

1Great Ormond Street Children’s Hospital, London, United Kingdom; 2Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland; 3F. Hoffmann-La Roche Ltd, Basel, Switzerland; 4Genentech, San Francisco, CA; 5Chugai Pharmaceuticals Co Ltd, Tokyo, Japan; 6Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland; 7Mayo Clinic, Rochester, MN

**Background:** Interleukin-6 (IL-6) is implicated in the immunopathology of neuromyelitis optica spectrum disorder (NMOSD). Satralizumab, a humanized recycling monoclonal antibody that binds to the IL-6 receptor (IL-6R), demonstrated a reduction in NMOSD relapse risk in two phase 3 studies: SAKuraSky (satralizumab in combination with baseline immunosuppressants; trial registration: NCT01748846) and SAKuraStar (satralizumab monotherapy; NCT02073279). Objectives: To describe satralizumab exposure in adolescents with NMOSD to support dose selection. Methods: Patients in both studies (N = 178) received placebo or satralizumab 120 mg at weeks 0, 2, and 4, and every 4 weeks thereafter. Data on clinical and protocol-defined relapses (PDRs), aquaporin-4 autoantibodies (AQP4-IgG) serostatus, safety profile and pharmacokinetic (PK) and pharmacodynamic markers were evaluated in adolescent patients. A popPK model, developed using data from a phase 1 satralizumab trial (healthy volunteers) and both phase 3 studies, was used to analyze PK data. Results: Eight adolescent patients were enrolled in SAKuraSky (adolescents were not permitted in SAKuraStar). Seven were evaluated for efficacy (1 patient had PK data only). The mean age was 15.4 (range 13-17) years; mean weight (79.3 [range 47.5-140.4] kg) was similar to the adult population. Six patients were female; 3 patients were AQP4-IgG seropositive. The range of model-predicted exposures was similar to those in adults, correlating inversely with body weight, and not age. Treatment effects on soluble IL-6R levels, a marker of target engagement, were similar between adults and adolescents, with similar predicted median IL-6R occupancy (>95% maintained over the dose interval). One of 4 patients receiving satralizumab had a relapse (PDR, n = 1); all patients receiving placebo had a relapse (PDR, n = 1; clinical relapse, n = 2). The safety profile of satralizumab in adolescents was consistent with the adult patient population; no new safety signals were identified. Conclusions: These findings support the recommendation that adolescent patients with NMOSD receive the adult 120 mg loading and every 4 weeks maintenance regimen of satralizumab.

**Supported by:** None

**Disclosure:** Cheryl Hemingway, Biogen, Roche (consulting fee); Novartis (consulting fee, speakers’ bureau); Hanna Silber Baumann; F. Hoffmann-La Roche, Innovation Center (salary). Xiujing Kou, Patricia Sonvold Ducray, H.-Christian von Buecking; F. Hoffmann-La Roche (salary). Daniela Stoikmaier, Roche (salary); Veronica G. Anania, Genentech (salary). Hajime Ita, Chugai (salary). San Lennon-Chrms, Roche Products Ltd (salary).

**Keywords:** Neuromyelitis optica spectrum disorder

**(RTH03) Efficacy and Safety Outcomes from a Prospective Observational Registry of Repository Corticotropin Injection for Relapse of Multiple Sclerosis**

Jeffrey Kaplan,1 Tamara Miller,2 Matthew Baker,3 Brynn Dwe,4 Enyu Zhao1

1Kansas City Multiple Sclerosis Center, College Park Specialty Center, Overland Park, KS; 2Advanced Neurology of Colorado, Fort Collins, CO; 3Collier Neurologic Specialists, LLC, Naples, FL; 4Mallinckrodt Pharmaceuticals, Bedminster, NJ

**Background:** Effective relapse treatment is critical for minimizing disability in patients with multiple sclerosis (MS). Repository corticotropin injection (RCI) is approved by the US Food and Drug Administration for the treatment of MS exacerbations. Objectives: This multicenter, observational, \( \text{ POSTER } \text{ poster } \)
prospective, observational registry study aimed to characterize treat-
ment, relapse, and safety outcomes of RCI in the treatment of ac-
ute MS relapse. **Methods:** The following data were obtained upon
initiation of RCI therapy (baseline) and again at various time points after.
Clinical outcomes were assessed using the MS Impact Scale (MIS-29v1),
Expanded Disability Status Scale (EDSS), and Clinical Global Impression
of Improvement (CGI) scale. Patient-reported outcomes were collected via
Work Productivity and Activity Impairment Questionnaire: MS (WPAI:MS)
and Healthy Resource Utilization (HRU) questionnaire. Mean
changes from baseline were evaluated at 2 and 6 months via 2-sided
paired t-tests. Serious and nonserious adverse events (SAEs/ARES) were
reported throughout the study. **Results:** After treatment with RCI (N = 125),
mean MIS-29v1 physical subscale scores (primary end point) decreased from baseline (55.69) at 2 months (7.99, P = .0002)
and 6 months (−9.64, P < .0001). Post hoc analyses showed larger improve-
ments in patients who received >5 doses of RCI (n = 23) vs ≤5 doses
(n = 71) at 2 months (−10.74, P = .0018 vs −6.48, P = .0177) and
6 months (−14.62, P = .014 vs −7.90, P = .0011). Mean EDSS scores
decreased from baseline (3.92) at 2 months (−0.37, < .0001) and
6 months (−0.45, P < .0001), with greater improvement in patients who
received >5 doses vs ≤5 doses at 2 months (−0.50, P = .0068 vs −0.24,
P = .0059) and 6 months (−0.64, P = .0430 vs −0.36, P = .0111). CGI-
I scores improved 3.38% of patients (P < .0001) at 2 months and
61.40% of patients (P < .0001) at 6 months postbaseline. Eighty-three
AREs were reported by 35 patients (28%), and 16 SAEs were reported by
11 patients (8.8%). The most common AEs/SAEs were MS relapse (4%
AE, 4% SAE) and urticarial tract infection (3.2% AE, 1.6% SAE). WPAI:MS
and HRU responses showed improvements from baseline for most end
points at 2 and 6 months. **Conclusions:** Improvements in clinical
scales and patient-reported measures of MS impact, along with the low
incidence of AEs/SAEs, support the efficacy and safety of RCI as a treat-
ment option for MS relapse. Treatment response showed greater improve-
ments with >5 doses.

Supported by: None


Keywords: Comprehensive care and MS, Disease-modifying treatments in MS, Immunology and MS

(RTH05) Characterization of the Pharmacokinetics and Pharmacodynamics of Sotralizumab, a Recycling Antibody, to Support Once-Every-4-Weeks Dosing in Patients with Neuromyelitis Optica Spectrum Disorder

Stian Lennon-Chrimes,1 Hanna Silber Baumann,2 Gaele Klingleichschmidt,3 Kiyung Koo,4 Patricia Sonwald Ducray,5 Veronica G. Ananis,6 Hajime Ito,7 H-Christian van Buerdingen8
1Roche Innovation Center, Welwyn Garden City, United Kingdom; 2Roche Innovation Center, Hoffmann-La Roche Ltd, Basel, Switzerland; 3Hoffmann-La Roche Ltd, Basel, Switzerland; 4Genentech, San Francisco, CA; 5Chugai Pharmaceuticals Co Ltd, Tokyo, Japan

Background: Interleukin-6 (IL-6) has been implicated in the immuno-
pathology of neuromyelitis optica spectrum disorder (NMOSD). Sotrali-
zumab is a subcutaneously administered monoclonal antibody that binds
to and blocks the IL-6 receptor (IL-6R). Sotralizumab was engineered to be
recycled back into circulation via the neonatal Fc receptor (FcRn), increas-
ing its serum half-life and effecting prolonged inhibition of IL-6R signaling.

Objectives: To define an effective, convenient, long-term dosing regimen
for sotralizumab in patients with NMOSD. **Methods:** The pharma-
co logic characteristics (pharmacokinetics [PK] and pharmacodynamics)
of sotralizumab were assessed in 72 Japanese healthy volunteers (HV); single
dose, range 30-240 mg); 33 patients with rheumatoid arthritis (RA) (multiple
doses, range 30-120 mg), and 104 patients with NMOSD in two phase 3 stud-
ies in NMOSD (SAkuraSky [trial registration: NCT02028884] and SAkuraStar [NCT02073279]: 120 mg loading, once every 4 weeks). A popPK model, based on HV and NMOSD data,
was used to derive predictions for individual PK parameters. **Results:**
Sotralizumab provided significant inhibition of IL-6R signaling for 4
weeks; target engagement resulted in sustained increases in soluble IL-6R
levels in HVs and patients with RA and NMOSD. In the NMOSD popu-
lation, the PK of sotralizumab was shown to be nonlinear, with an effective
half-life of approximately 30 days at a dose of 120 mg; the median pre-
dicted IL-6R occupancy was maintained at >95% throughout the 4-week
dose interval. Meaningful and comparable efficacy vs placebo was demonstrated in patients with NMOSD in both phase 3 studies: hazard
ratio (95% CI) for reduction in protocol-defined relapse risk was 0.38
(0.16-0.88), P = .0184 in SAkuraSky; and 0.45 (0.23-0.89), P = .0184
in SAkuraStar. Sotralizumab showed a favorable safety profile in patients
with NMOSD, with the most frequent AEs being headache when administered as monotherapy or in combination with
baseline immunosuppressants. **Conclusions:** The recommended 120-mg
loading and every-4-weeks maintenance regimen of sotralizumab repre-
sents an effective, safe, and convenient treatment in NMOSD.

Supported by: None

Disclosure: Sian Lennon-Chrimes: Roche Products Ltd (salary). Hanna Silber Baumann: P. Hoffmann-La Roche, Innovation Center (salary). Gaele Klingleich-
Ito: Chugai (salary).

Keywords: Neuromyelitis optica spectrum disorder

SELF-CARE

(SEL01) Understanding Gaps in Knowledge Surrounding Flu Shots and Immunizations as They Relate to Multiple Sclerosis

Alexia Crispino
Multiple Sclerosis Association of America, Austin, TX

Background: Over the past 5 years the influx of US Food and Drug
Administration-approved treatment therapies, and advances in symptom
management for, multiple sclerosis (MS) has been astounding. Emphasis
has been placed on a healthier lifestyle to maximize quality of life, and

International Journal of MS Care
many experts including the American Academy of Neurology and the Centers for Disease Control and Prevention argue that receiving vaccinations and flu shots are a part of staying healthy, including for most individuals with MS. However, this evolving landscape in care and treatment options has also highlighted questions, misconceptions, and confusion surrounding the influence of flu shots and immunizations on MS. Objectives: Seeking to better understand gaps in knowledge and what patients with MS know/believe about flu shots and immunizations that they believe need to be addressed, we sought to analyze: 1) key areas of concern for receiving flu shots or immunizations; 2) how flu shots and immunizations are discussed with health care providers; and 3) understand current beliefs surrounding flu shots and immunizations. Methods: The Multiple Sclerosis Association of America (MSAA) developed and disseminated a 27-question survey on the topics of flu and immunizations as they relate to patients with MS that was emailed out to the MSAA client database. Results: 1926 patients with MS participated in the survey, with 32% of respondents reporting that they do not receive an annual flu shot and do not anticipate getting one this year. When asked why respondents do not receive flu shots, 36% opted out of this, concerns that flu shots are not good for people with MS, 36% are worried about side effects, and 28% do not trust or believe them to be safe. 68.26% reported an MS neurologist as their leading source of information, but still 37.74% said that they do not feel well informed about flu shots and 36.28% do not feel well informed enough about immunizations. 42% of respondents felt worried that if they receive an immunization or flu shot, they will have an adverse effect and 38% believe that if they receive an immunization or flu shot it will interfere with their disease-modifying therapy or worsen their MS. Overall, 62.19% of individuals feel well informed about flu shots and immunizations while 37.81% feel that they need more information. Conclusions: These findings suggest that although experts agree that flu shots and immunizations are recommended to people with MS, there is still significant confusion among the MS patient community. “I believe that there are links between flu shots / immunizations and multiple sclerosis” reflected “not sure” responses of 38.81% and 42.51%, respectively. Finally, when asked how they would prefer to receive information about flu shots and immunizations in the future, leading responses were from their MS neurologist, general care practitioner, and through printed materials.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Healthy lifestyle while living with MS

(SELO2) Experimental Project Fashion Design and Social Inclusion: Multiple Women
Alice Estevo Dias,1 Barbara Silva,2 Barbara Gimenes Oliveira,1 Carolline F. Mittermayer,2 Giovana L. Pereira,1 Graziele M. Freitas,1 Marcela A.M. Nogueira,1 Rafaela S. Santos,1 Rafaela E.F. N. Pereira,2 Victoria V. Alvarez,3 Cristiane F. Mesquita4
1Scientific Research, Brazilian Association of Multiple Sclerosis, Sao Paulo, Brazil; 2Design de produtos para wearability, Universidade de São Paulo, São Paulo, Brazil; 3School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada; 4University of Cambridge, United Kingdom

Background: Multiple Women is an experimental project composed of an inclusive clothing collection for social occasions. Through social design guidelines, the work embraces textile mechanisms that aim to answer the physiological limitations of women with multiple sclerosis (MS). Objectives: To articulate fashion design and social inclusion in MS, with the purpose to develop garments with ergonomic adaptations. Methods: A group of 95 women with several types of MS, aged 20 to 42, and expanded disability status scale of 2.0 and 3.0, took part in structured interviews containing 12 questions about their daily routines and clothing demands. A graphic and an infographic were elaborated as design visual tools to identify their current needs, the definition of the project parameters, and the planning of possible alternatives, along with a design proposal. Results: There is still significant confusion among the MS community about how textile and fashion is able to modify therapy or worsen their MS. Overall, 62.19% of individuals feel well informed about flu shots and immunizations while 37.81% feel that they need more information. Conclusions: These findings suggest that although experts agree that flu shots and immunizations are recommended to people with MS, there is still significant confusion among the MS patient community. “I believe that there are links between flu shots / immunizations and multiple sclerosis” reflected “not sure” responses of 38.81% and 42.51%, respectively. Finally, when asked how they would prefer to receive information about flu shots and immunizations in the future, leading responses were from their MS neurologist, general care practitioner, and through printed materials.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Experimental project, MS, social inclusion, fashion design

(SXMO1) Effect of Nabiximols on Spasticity and Muscle Strength in Patients with Multiple Sclerosis Across 3 Randomized Controlled Trials
Francois Bethoux,1 Kathryn Nichol,1 Joanne Wagner,2 Joris Berwaerts,2 Daniel Chackett,3 Elizabeth Gardener,4 Karen Cartwright4
1The Mellen Center for Multiple Sclerosis Treatment and Research, The Cleveland Clinic Foundation, Cleveland, OH; 2Greenwich Biosciences, Inc, Carlsbad, CA; 3GW Research Ltd, Cambridge, United Kingdom

Background: Spasticity is a common feature of multiple sclerosis (MS), especially in patients with longstanding illness. Medications that reduce spasticity may also reduce muscle strength, potentially impairing the ability to walk. Patients who do not respond adequately to conventional antispasticity medications need additional treatment options that improve spasticity without causing weakness. Objectives: Assess the relationship between changes in spasticity and muscle strength in lower extremities or mobility, using data from 3 randomized controlled trials (GWMS0106, GWSP0604, SAVANT) of nabiximols vs placebo in patients with spasticity due to MS inadequately controlled by antispasticity medications. Methods: Spasticity was evaluated using the Numerical Rating Scale (NRS) in all 3 trials, muscle strength using Motoricity Index (MI) in GWMS0106 and GWSP0604, and mobility using timed 10-Meter Walk Test (10MWT) in GWSP0604 and SAVANT. Adjusted mean differences for change from baseline in outcome measures between nabiximols and placebo are summarized. Pearson correlation analysis was conducted to assess the association between change from baseline in spasticity and muscle strength, controlling for relevant covariates.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Complementary/alternative therapies in MS

SYMPTOM MANAGEMENT

An Assessment of the Feasibility of a Dyadic Physical Activity Intervention for Persons with Advanced Multiple Sclerosis and Their Family Caregivers: Work in Progress
Odessa J. McKennon,1 Lara A. Plutti,1 Aloafasee Fakakolade,2 Marcia Finlayson,1 Amy Latiner-Cheung,1 Mark S. Freedman,1 CMSC UOttawa Authors’ Group
1Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada; 2School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada; 3School of Kinesiology and Health Studies, Queen’s University, Kingston, ON, Canada; 4University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada

Background: Many people with MS (PwMS) and their caregivers (CGs) do not engage in sufficient physical activity to achieve important health benefits. Emerging evidence in other disease contexts (ie, Parkinson disease, Alzheimer disease) suggests that dyadic (ie, partnered) physical activity interventions may improve health and well-being for both care recipients and CGs. In multiple sclerosis (MS), physical activity interventions rarely focus on people with advanced disability or target PwMS-CG dyads. To address this important gap, we have developed a theory-based, dyadic, intervention that incorporates evidence-based strategies for improving physical activity: Physical Activity Together for PwMS and Their CGs (PAT-MiS). PAT-MiS is a 12-week, teleconference-delivered intervention that includes education, guidance, and support from a trained activity coach, as well as behavior change techniques (eg, goal setting, problem solving). The primary purpose of this study was to analyze: 1) key areas of concern for receiving flu shots or immunizations; 2) how flu shots and immunizations are discussed with health care providers; and 3) understand current beliefs surrounding flu shots and immunizations. Methods: A single-site, assessor-blinded, randomized controlled pilot feasibility trial, with 1:1 allocation into an immediate intervention or a delayed control condition. A target of 20 PwMS-CG dyads will be included. PwMS-CG dyads will receive 6 group teleconferencing sessions (~60 minutes) every other week for a period of 12 weeks. The group sessions will be interspersed with brief (~15 minutes) 1-on-1 support telephone calls in the weeks that the group sessions do not occur. Feasibility metrics will include process (eg, recruitment and retention rates), resource (eg, monetary costs and communication time), management (eg, time and accuracy of data collection/reporting), and scientific assessment (eg, safety and participant experience).

Results: Data collection is ongoing. Anticipated completion is March 2020. The main findings regarding intervention feasibility will be presented. Conclusions: PAT-MiS is the first physical activity intervention to target PwMS-CG dyads who have advanced disability or target their CGs as active participants. The intervention presents a unique opportunity to increase physical activity behavior and improve the health outcomes of both PwMS and their CGs. The findings of this study will provide critical information on feasibility metrics that will inform and refine the design and delivery of subsequent stages of this research.

Supported by: None
Disclosure: Nothing to disclose

Keywords: MS and the caregiver/family, Physical activity

Posters: Symptom Management
change in strength or mobility for naxibimols and placebo groups separately. This analysis included 184 patients from GWMS0106, 241 from GWSP0604, and 106 from SAVANT. The baseline mean (SD) Expanded Disability Status Scale score was 6.0 (1.42) in GWSP0604 and 5.9 (1.1) in SAVANT. In GWMS0106, naxibimols significantly improved mean NRS spasticity score (−0.52 points [95% CI: −1.029, −0.004]; P = 0.048), without significantly affecting the MI for legs (3.56 (95% CI: 0.02, 0.54)). In GWSP0604, naxibimols significantly improved mean NRS spasticity score from baseline vs placebo (−0.84 [−1.29, −0.40]; P = 0.0002), without significantly affecting the MI for legs (0.97 [−1.49, 3.42]; P = 0.43) or the 10MWT results (−3.34 [−6.95, 0.26]; P = 0.069). In SAVANT, naxibimols significantly improved spasticity vs placebo (−1.42 [−2.73, −0.10]; P < 0.001), without significantly affecting the MI for legs (2.17 [3.84, 0.44]; P = 0.11). Pearson correlation coefficients were all under ±0.30 (indicating negligible correlation) for the association between change in NRS and MI and for the positive low correlation between change in NRS and 10MWT in the naxibimols group in SAVANT (0.326).

Conclusions: The improvement in spasticity with naxibimols was not accompanied by the increased weakness often observed with antispastic medication or by a notable change in improved walking speed.

Supported by: None

Disclosure: François Berthiaume: Adamas Pharmaceuticals (contracted research); Biogen (speakers’ bureau); GW Pharma Consulting fee; Springer Publishing (royalty). Kathryn Nicholson: Greenbich Biosciences, Inc. (salary); Joanne Wagner-Greenwich Biosciences/GW Pharmaceuticals (salary); Joanne Wagner: GW Pharmaceuticals (consulting fee); Karen Carriquiry: GW Pharmaceuticals (ownership interest); Jari Berens, Elizabeth Gardener: GW Pharmaceuticals (salary); Daniel Cheek, et al: GW Pharmaceuticals (salary); Karen Carriquiry: GW Pharmaceuticals (ownership interest; stockholder; salary).

Keywords: Complementary/alternative therapies in MS, Comprehensive care and MS, MS symptom management

(SXM02) MS Action Plan May Be Effective Tool Helping Patients with Acute Change in Multiple Sclerosis Symptoms


1Neurology, University of Washington, Seattle, WA; 2Nursing, Virginia Mason MS Center, Seattle, WA; 3Primary Care, UW Neighborhood Factory Clinic, Bellevue, WA; 4Neurology, Advanced Neurology Specialists, Falls, MT; 5Kaiser Permanente, Seattle, WA; 6Evergreen Health MS Center, Kirkland, WA; 7Providence Multiple Sclerosis Center and Atara Biotherapeutics, Portland, OR; 8Neurology, St Vincent Neuroscience Center, Billings, MT; 9University of Washington, Seattle, WA; 10Svenson Healthcare, Tacoma, WA; 11National Multiple Sclerosis Society, New York, NY

Background: The Greater Northwest Healthcare Provider Council of the National Multiple Sclerosis Society [NMSS] identified a need for patients with multiple sclerosis (MS) to be educated on what to do when they experience any new or worsening neurologic symptoms. Council members found that many of their patients with MS would flock themselves into the emergency room [ER] or urgent care for symptoms that may have been better treated in the outpatient setting. Objectives: The objectives of the MS Action Plan are to 1) foster clear communication between patient and provider, 2) help patients avoid any undue trips to urgent care or ER, and 3) educate patients on what to look out for and when they need to contact their MS provider team. Methods: The Healthcare Provider Council started with a document in use at the Virginia Mason MS Center in Seattle and adapted it for all MS providers to use and share with their patients with MS to help them better understand their MS symptoms. The Virginia Mason document was adapted from the Asthma Action Plan that had been widely used throughout the country. The MS Action Plan was first distributed at the Greater Northwest Regional MS Summit and professional education program to an audience of 80 MS care providers in March of 2019. Six months later, the Healthcare Provider Council created an online survey and distributed it to the Summit attendees to assess how the MS Action Plan is being used by providers and if they were finding it useful and effective. Results: Twenty providers responded to the survey. Of the responders, 60% answered that they have used the MS Action Plan in their practice and 87% found it useful. When asked who provides the MS Action Plan to patients, 80% selected “provider” with “RN” being the second most commonly selected answer. The most common way the clinics are using the action plan is in hardcopy handed to patients, followed by placing the MS Action Plan in examination rooms for patients to take. Conclusions: The MS Action Plan could be an effective tool in helping patients with MS better understand their MS symptoms, provide them with clear information in their decision making around when to be seen and when to wait. It has the potential for reducing the number of unnecessary ER visits and provides the patient with a clear plan of action should their symptoms change or worsen.

Supported by: None

Disclosure: Gloria von Geldern, Piper Paul, Janet Piehl, Jan Shilling, Nicole Lauwers, Kendra Yale, Piper Reynolds; Nothing to disclose. Dennis Dietrich: Adamant (contracted research); Biogen, Novartis (contracted research, speakers bureau); Sanofi (speakers bureau); Ted Brown: EMD Serono, Greenwich Pharmaceuticals (consulting fee). Joanne Wagner: Neuraxpharm (consulting fee). Karen Kresa-Reahl: Atara Biotherapeutics (salary from June 3, 2019, to present: they have a phase 1 MS trial but no medication on market); Biogen, Celgene, Genzyme, Novartis (speakers’ bureau). Annette Wunder; AbbVie, Alkermes (contracted research); Biogen (consulting fee, contracted research); Gary Stobbe; Roche (contracted research).

Keywords: Comprehensive care and MS, MS and the caregiver/family, MS symptom management

(SXM03) Intrathecal Baclofen Therapy in Ambulatory and Nonambulatory Multiple Sclerosis Patients: A Single-Center Experience

Justin Abbatangelo, Austin C. Griffin, Noble Jones, Jennifer Hartman, Keith McKeel, Zhini Wang, Sean Nagel, Andre Machado, Francois Bethoux.

1Neurological Institute, Cleveland Clinic, Cleveland, OH; 2Internal Medicine, The Cleveland Clinic Foundation, Cleveland, OH; 3Physical Medicine and Rehabilitation, Kessler Institute for Rehabilitation/Rutgers New Jersey Medical School, West Orange, NJ; 4Internal Medicine, Duke University, Durham, NC; 5Neurological Institute, Cleveland Clinic Mellen Center, Cleveland, OH; 6Neurological Institute, Cleveland Clinic Foundation, Cleveland, OH; 7Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, OH

Background: Spasticity is a common cause of disability and diminished quality of life in patients with multiple sclerosis (MS). Intrathecal baclofen therapy (ITB) is an effective treatment option for patients with MS who have severe spasticity that is refractory to oral drug administration, but there is limited evidence of its long-term efficacy and safety in ambulatory patients with MS. Objectives: This single-center, retrospective case series investigates the outcomes of ITB in ambulatory and nonambulatory patients with MS with medically intractable spasticity over a 5-year follow-up period. Methods: Data from the Mellen Center Intrathecal Baclofen Registry were analyzed retrospectively. All patients were diagnosed with MS and underwent an ITB test injection. Baseline demographics were collected along with outcome measures including Spasm Frequency Scale, Modified Ashworth scale (MAS), hip flexor strength, and walking speed on the Timed 25 Foot Walk. Group comparisons were done using 2-sample t-test or Wilcoxon rank sum test, and logistic regression was used to assess the occurrence of complications. Results: 170 patients with MS underwent ITB infusion system implantation. The aggregate MAS score for the ambulatory cohort (n = 87) was significantly reduced from 13.5 ± 6.96 to 5.6 ± 5.94 (P < 0.001) at 5 years. In SAVANT, nabiximols significantly improved spasticity vs placebo (−0.84 [−1.31, −0.38] at 5 years, P < 0.001). Longer disease duration (hazard ratio [HR] 1.01; 95% CI 1.005–1.014; P < 0.001) was a predictor for transition to nonambulatory status after ITB implantation. Complications were more common in the ambulatory ITB group (n = 29, 22.1%) compared to the nonambulatory cohort except at the 5-year follow-up visit. Among ambulatory patients at baseline, 56 (77.8%) were ambulatory at 1 year with no significant change in walking speed (baseline 0.45 m/s ± 0.30 vs 1 year 0.38 m/s ± 0.39 at 1 year, P = .80). At the 5-year follow-up point, 20 (41.7%) patients remained ambulatory with a walking speed of 0.26 m/s ± 0.37 P < 0.001). Longer disease duration (hazard ratio [HR] 1.04; 95% CI 1.01–1.07; P = .018), and lower hip flexor strength at baseline (HR 0.40; 95% CI 0.27–0.57; P = .001) were predictors of transition to nonambulatory status after ITB implantation. Complications were more common in the ambulatory ITB group (n = 29, 22.1%) compared to the nonambulatory group (n = 10, 8.0%) with an odds ratio of 3.30 (95% CI 2.17–5.02; P = .017). Conclusions: ITB is an effective therapy for reducing spasticity in ambulatory patients with MS without compromising walking speed in the short term, although we did observe a higher complication rate in this cohort. This study supports the use of ITB in carefully selected ambulatory patients with MS. Randomized, prospective studies are needed to provide more information on this important subject.

Supported by: None

Disclosure: Justin Abbatangelo, Austin C. Griffin, Noble Jones, Jennifer Hartman, Keith McKeel, Zhini Wang, Sean Nagel; Nothing to disclose. Andre Machado; Abbott (consulting fee); Medtronic (fellowship support); Francois Bethoux; Greenwich Biosciences (consulting fee); GW Pharmaceuticals (speakers’ bureau). Joanne Wagner, Karen Kresa-Reahl: Atara Biotherapeutics (salary). Ted Brown: EMD Serono, Greenwich Pharmaceuticals (consulting fee). Joanne Wagner: Neuraxpharm (consulting fee).
Background: Stress and fatigue in individuals with multiple sclerosis (MS) have been linked to a more severe course of the disease and weakened immune system. Mindfulness-based interventions (MBIs) have been found to reduce stress and fatigue and improve quality of life (QOL) in adults with MS. MBIs provided in an online format and led by a multidisciplinary team (nurse and art therapist) might strengthen overall effectiveness of MBIs. Objectives: The purpose of this pilot study was to compare the effect of virtually delivered meditation and mindfulness-based art therapy (MBAT) on the level of symptoms in a sample of adults with MS. We first beta-tested the protocol in 2 case subjects and collected feedback to identify areas needing improvement. We then plan to pilot the modified intervention to test feasibility, acceptability, and preliminary efficacy among a different sample of adults with MS. Methods: Art therapy and psychoeducation interventions were conducted by an MS nurse and an art therapist. Subjects engaged in mindfulness expressive arts interventions following a MBAT protocol on TEAMS, a video conferencing platform. Two facilitators led the interventions, as well as provided psychoeducational resources and feedback. We then interviewed the subjects to gather perceptions and feedback regarding the effectiveness of MBAT interventions in relieving stress and other symptoms. We also collected saliva cytokines, body temperature, and self-reported data on symptoms, physical function (standing balance, gait speed, minutes of daytime activity), and QOL. Results: At present, data analysis is ongoing. However, preliminary anecdotal feedback indicates that patients accept the MBAT interventions as accessible, easy to use, and helpful in reducing stress and fatigue. For example, 1 participant reported that creation of a particular art image enabled her to more effectively communicate the need for change with her spouse in a particular area of her life so that she could better manage her stress levels. Participants have also been responsive to psychoeducational resources given during sessions. Conclusions: Preliminary findings suggest that an MBAT intervention led by a nurse and art therapist in a virtual format may be an effective method for relieving stress and fatigue in adults with MS. A future larger study is warranted for this important intervention.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Management of activities of daily living in MS, Nursing management in MS

(SXM05) Virtual Delivery of Mindfulness-Based Art Therapy (MBAT) to Improve Symptoms Among Adults with Multiple Sclerosis (MS)
Pamela K. Newland, Rebecca D. Miller, Eva Buch, Rebecca Lorentz
1Goldfarb School of Nursing at Barnes Jewish College, St Louis, MO; 2Art Therapy, St Mary of the Woods College, Terre Haute, IN; 3Goldfarb School of Nursing, St Louis, MO; 4University of Buffalo, Buffalo, NY

Background: Urinary symptoms, including overactive bladder (OAB), are seen in up to 80% of patients with multiple sclerosis (MS). Most anti-spasmodics for OAB are anticholinergic, which may worsen cognition and constipation in MS. Mirabegron, approved for OAB in the general population, is a B3 adrenergic agonist, so it may be better tolerated in patients with MS. Objectives: To assess safety, tolerability, and efficacy of mirabegron in patients with MS. Methods: Twenty-eight patients with MS and OAB were randomized 1:1 into placebo and treatment arms of this double-blind, placebo-controlled 10-week study. All patients received pelvic floor exercise training and watched a video about behavioral management of OAB. Patients in the control arm received placebo and patients in the treatment arm received mirabegron (25 mg) with optional up-titration to 50 mg. Seventy-two–hour voiding diaries were used. The primary outcome measure was the change in OAB Symptom Composite Score (OAB-SCS), which assesses voiding frequency and urgency; higher scores mean worse symptoms. Secondary measures included number and volume of micrurition, incontinence episodes, and patient assessments of OAB severity. Results: While both groups' scores were significantly lower than at baseline, the final daily average OAB-SCS for the mirabegron group was 0.47 higher than that of the placebo group (95% CI = 0.047, 0.893, P = .031). Thus, the mirabegron group had a worse primary outcome. On the other hand, for Subject Global Impression, the mirabegron group rated their overall symptom control as significantly better relative to the placebo group (95% CI = 0.375, 2.381, P = .009). Trends suggesting treatment-related improvement in other secondary measures favored mirabegron on number of micrurition and incontinence episodes per day, but these were not statistically significant. Adverse events were limited and similar between groups, and there were no serious adverse events. Drug adherence was about 95%. Conclusions: Mirabegron was safe and well-tolerated in this MS population. Our mixed results do not demonstrate benefit from adding mirabegron to a program of behavior modification for OAB. Patients with MS may have neurologic differences from a general OAB population that reduce the responsiveness to beta-3 adrenergic agonists. A larger study population may elucidate the extent of the treatment effect on bladder function in patients with MS.

Supported by: None
Disclosure: Theodore R. Brown: AbbVie, Adamas, Astellas, Merck (contracted research); EMD Serono, Greenwich Pharma (consulting fee); Novartis (speakers’ bureau), Virginia I. Simnad: Actelion, Biogen, Celgene, Novartis (contracted research).
Keywords: Bladder management, Comprehensive care and MS, Nursing management in MS

(SXM06) A Pilot Study of Mirabegron (Myrbetriq) and Behavioral Modification Including Pelvic Floor Exercise for Overactive Bladder in Multiple Sclerosis
Theodore S. Brown, Virginia I. Simnad
EvergreenHealth Multiple Sclerosis Center, EvergreenHealth, Kirkland WA, WA

Background: While both groups' scores were significantly lower than at baseline, the final daily average OAB-SCS for the mirabegron group was 0.47 higher than that of the placebo group (95% CI = 0.047, 0.893, P = .031). Thus, the mirabegron group had a worse primary outcome. On the other hand, for Subject Global Impression, the mirabegron group rated their overall symptom control as significantly better relative to the placebo group (95% CI = 0.375, 2.381, P = .009). Trends suggesting treatment-related improvement in other secondary measures favored mirabegron on number of micrurition and incontinence episodes per day, but these were not statistically significant. Adverse events were limited and similar between groups, and there were no serious adverse events. Drug adherence was about 95%. Conclusions: Mirabegron was safe and well-tolerated in this MS population. Our mixed results do not demonstrate benefit from adding mirabegron to a program of behavior modification for OAB. Patients with MS may have neurologic differences from a general OAB population that reduce the responsiveness to beta-3 adrenergic agonists. A larger study population may elucidate the extent of the treatment effect on bladder function in patients with MS.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Management of activities of daily living in MS, Nursing management in MS

(SXM07) The Clinical Spectrum of Myelin Oligodendrocyte Glycoprotein (MOG) Antibody–Associated Demyelinating Disorders: Three Case Reports
Ameneh Zare, Aram Zabeti
Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, OH

Background: Myelin oligodendrocyte glycoprotein (MOG) antibody–associated disorders are distinct from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD) with positive aquaporin-4-IgG (AQP4-Ab). The full clinical spectrum of this newly described condition is unknown. In this report we sought to describe clinical and imaging presentations of 3 MOG antibody–seropositive patients. Objectives: To present 3 cases of autoimmune MOG antibody–associated demyelination. Methods: Case 1: A 45-year-old woman presented with spasms and pain in lower back with radiation to both legs. Also, she had complaints about muscle spasm, fatigue, and tremor in right hand. Five years after the onset of first symptoms, she developed left retrobulbar optic neuritis (ON) which was diagnosed as myoclonus epilepsy-familial. Case 2: A 57-year-old man who was previously diagnosed with relapsing MS presented with ON. He was treated with interferon beta-1a, glatiramer acetate, teriflunomide, and fingolimod. After 8 years from the onset of MS, the patient developed dysarthria, vertigo, and dysphagia initially treated with IV steroids but did not have a good recovery, and repeat MRI showed progression of multiple areas of enhancement in the posterior fossa. So, he was admitted to the hospital and received PLEX, which significantly improved his symptoms. Cell-based immunassay was positive for anti-MOG antibody with a titer 1:100 and negativity for AQP4-Ab. Case 3: A 73-year-old woman started with headache, vomiting, and diplopia initially treated with IV steroids, then she had a complete recovery. Six months later, she was readmitted with left extremities weakness, ataxia, and nystagmus. MRI revealed positivity for anti-MOG antibody with a titer of 1:100 and negativity for AQP4-Ab. So, she was hospitalized on mycophenolate mofetil. Conclusion: MOG antibody–associated disorders seem to be a distinct entity. Cell-based immunassay was positive for anti-MOG antibody with a titer 1:1000. Subsequently his treatment was switched to rituximab, and his symptoms remained stable ever since. Case 3: A 45-year-old woman with first presentation as asesthasia and progressive cognitive decline was diagnosed with relapsing-remitting MS based on MRI and presence of oligoclonal band in cerebrospinal fluid. She had 2 major attacks that presented as weakness and numbness in lower extremities and face, which was treated with IV steroids. Her last attack presented as ON that partially improved with IV steroids. MRI indicated severe enhancing lesions in brain as well as cervical and thoracic spine. Cell-based immunassay revealed positivity for anti-MOG antibody with a titer 1:100 and negativity for AQP4-Ab. Treatment with ocrelizumab started afterward. Results: Three cases are presented. Conclusions: MOG-associated demyelinating disorders seem to represent a new disease entity. Reporting MOG seropositive cases helps us to extend our knowledge about its clinical and imaging presentations and disease course and the best available treatment options.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Myelin oligodendrocyte glycoprotein antibody, MOG antibody associated demyelinating disorder, Cell-based immunassay, Natural history of MS
WHITAKER RESEARCH TRACK

The late Dr. John N. Whitaker was a world-famous researcher in multiple sclerosis (MS). His work inspired many scientists to enter the field of MS and develop their skills and talents. Each year, the Consortium of Multiple Sclerosis Centers (CMSC) honors Dr. Whitaker’s memory by presenting one award for innovative research by a young investigator. The CMSC and the Foundation of the CMSC will present a prize to a scholar whose work exemplifies the mission of this visionary leader in MS.

(WHI01) Characterizing the Acute Exercise Response in Nonambulatory People with Progressive Multiple Sclerosis

Thomas Edwards,
Dilpreet Bajwa,
Lisa A. Walker,
Larry A. Pilutti

School of Human Kinetics, University of Ottawa, Ottawa, ON, Canada; Interdisciplinary Health Sciences, University of Ottawa, Ottawa, ON, Canada; Psychology, Carleton University, Ottawa, ON, Canada; Psychology, University of Ottawa Brain and Mind Research Institute, Ottawa, ON, Canada; Neuroscience, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Interdisciplinary School of Health Sciences, University of Ottawa, Ottawa, ON, Canada

Background: While the benefits of exercise training among people with multiple sclerosis (MS) who have mild-to-moderate disability (Expanded Disability Status Scale [EDSS] score = 1.0-6.5) have been established, the extent of exercise for persons with MS who are nonambulatory (EDSS ≥ 7.0) is largely unknown. This evidence is limited, in part, due to the need for specialized exercise modalities to deliver exercise for persons who are nonambulatory. An investigation of the physiological and symptomatic response associated with adapted exercise is needed as a first step toward understanding the potential benefits of exercise training for this population. Objectives: To characterize and compare the acute physiological and symptomatic response associated with adapted exercise modalities in persons with MS who are nonambulatory. Methods: Ten participants (mean age, 62.5 ± 10.3; all progressive MS) with EDSS score of 1.25 (interquartile range 0.5), disease duration of 1.7 (SD 2.0) years, and total relapses of 3.0, and higher BMI than controls (T = -5.8, P < .001). VO2max and 2-minute walk test differed in MS vs controls (t = 4.6, P < .001, Cohen d = 1.5) and (t = 2.6, P = .02, Cohen d = 0.9), respectively. Controls demonstrated higher VO2max (P < .001), VO2peak (P < .001), and heart rate (P < .001). Participants completed 2 submaximal exercise sessions on adapted exercise modalities (arm ergometer, recumbent stepper, and functional electrical stimulation [FES] cycle). Physical activity and %VO2peak as well as %heart rate were measured at 3 time points: before exercise, immediately postexercise, and 30 minutes postexercise. Results: All participants completed the FES cycling and recumbent stepper submaximal exercise sessions. Two participants could not complete the arm ergometer exercise, citing pain as the reason for cessation. Participants elicited a VO2max exceeding 70% of %VO2peak, a heart rate response exceeding 70% of %heart rate. This exercise intensity corresponded with moderate-vigorous physical activity, an intensity associated with cardiorespiratory fitness benefits. There was a significant increase in pain immediately after arm ergometer exercise compared to FES cycling (P < .05) and recumbent stepper exercise (P < .05). All adapted exercise modalities tested appeared to be viable approaches for improving cardiorespiratory fitness in nonambulatory people with MS. However, symptomatic response should be considered when prescribing and developing exercise interventions. These findings will help to inform and optimize exercise prescription for people with MS who are nonambulatory.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Exercise training, Management of activities of daily living in MS

(WHI04) Dietary Patterns and Health-Related Quality of Life of Individuals with Multiple Sclerosis

Babita Birt,
Laurel K. Mischley,
Tyler J. Titcomb,
Joshua Farahnik,
Linda G. Sneteslaar,
Terry L. Watts

Department of Internal Medicine, University of Iowa, Iowa City, IA; Basyr University Research Institute, Basyr University, Kenmore, WA; Department of Epidemiology, University of Iowa, Iowa City, IA

Background: Individuals with multiple sclerosis (MS) look for dietary changes to improve their disease outcome. Information regarding what specific dietary changes are being implemented by individuals with MS and if these changes affect quality of life (QOL) can be useful in shaping future research. Objectives: 1) To assess prevalence of MS-specific diets (eg, Wahls diet, Swank diet, vegan diet) and dietary patterns of individuals with MS. 2) To investigate effects of intake of certain food groups on relapses and self-reported QOL measure. Methods: Individuals with MS participated in an online survey and completed questions regarding intake of specific diets, frequency of intake of specific foods, relapses, and Patient-Reported Outcome Measurement Information System (PRO-MIS) based on past 6 months. PRO-MIS Global scores (range, 10-50) were used to measure QOL where higher scores reflect higher QOL. Estimated daily servings of foods from food frequency questions. In this cross-sectional analysis, we included 977 participants who provided complete data. Results: Individuals with MS with mean age 47.7 (SD 11) years and average 10 (SD 8.9) years since diagnosis participated in this study. Specific diets for MS were followed by 72% of participants, suggesting that most individuals with MS are implementing dietary changes. Most prevalent MS diets were Wahls (26%), paleolithic (16%), anti-inflammatory (13%) diets. Some participants (11%) reported following multiple diets as well. Only 12% reported having a relapse in past 6 months. Mann-Whitney U tests showed that individuals who did not have any relapse had higher median daily intake of alcohol (0.08 vs 0.05 ounce equivalent, P < .016) than individuals who had relapses in prior 6 months. PROMIS Global average scores were 33.4 (SD 6.1).

Supported by: None
Disclosure: Nothing to disclose
Keywords: Management of activities of daily living in MS, Physical fitness

(WHI03) Youth with Multiple Sclerosis Have Low Fitness Levels

Samantha Stephens,
Jane E. Schneiderman,
Tara Benenbaum,
Marcia Finlayson,
Robert W. Maat,
Ann Yeh

Department of Neurosciences and Mental Health, The Hospital for Sick Children, Toronto, ON, Canada; Clinical Research Services, Research Institute, Hospital for Sick Children, Toronto, ON, Canada; School of Rehabilitation Therapy, Queen’s University, Kingston, ON, Canada; Physical Therapy, University of Alabama at Birmingham, Birmingham, AL; Department of Paediatrics, Division of Neurology, The Hospital for Sick Children, Toronto, ON, Canada

Background: We have demonstrated an association between higher levels of physical activity and lower levels of disease activity, depression, and fatigue in youth with multiple sclerosis (MS). Fitness is a separate construct which may be dependent on a multitude of factors, including genetics and physical activity. The relationship between fitness, physical activity, depression, fatigue, and disease in youth with MS is unknown. Objectives: 1) To determine if measures of cardiovascular fitness and strength differ between youth with MS and healthy controls. 2) To explore the relationship between fitness, physical activity, fatigue, and depression in youth with MS. Methods: Youth (age <18 years) with MS (n = 19) and controls (n = 21) completed a battery of tests that included a cycle ergometer test to determine peak aerobic capacity (VO2peak), and NIH Toolbox protocols for a 2-minute walk test and grip strength, to determine endurance and muscular strength, respectively. We administered questionnaires and clinical and physiological assessments including PedsQL (fatigue), CES-D (depression), Godin Leisure Time Exercise Questionnaire, height/weight/body mass index (BMI), and physical activity (accelerometry and PROMIS Global scores). Differences between MS and control groups were determined using student t tests. Pearson R and Spearman Rho were used to examine the relationship between fitness, physical activity, fatigue, and depression in MS (JASP version 0.10.2). Results: MS and control groups did not differ in sex or age (MS 16 years, control 16.5 years, P = .99; MS EDSS 3.1, HC 2.1, P = .585). Youth with MS had a median Expanded Disability Status Scale (EDSS) score of 1.25 (interquartile range 0.5), disease duration of 1.7 (SD 2.0) years, and total relapses of 3.0, and higher BMI than controls (T = -5.8, P < .001). VO2max and 2-minute walk test differed in MS vs controls (t = 4.6, P < .001, Cohen d = 1.5) and (t = 2.6, P = .02, Cohen d = 0.9), respectively. Controls demonstrated higher VO2max (P < .001), VO2peak (P < .001), and heart rate (P < .001). Participants then completed 3 submaximal exercise sessions on adapted exercise modalities (arm ergometer, recumbent stepper, and functional electrical stimulation [FES] cycle). Physical activity and %VO2peak as well as %heart rate were measured at 3 time points: before exercise, immediately postexercise, and 30 minutes postexercise. Results: All participants completed the FES cycling and recumbent stepper submaximal exercise sessions. Two participants could not complete the arm ergometer exercise, citing pain as the reason for cessation. Participants elicited a VO2max exceeding 70% of %VO2peak, a heart rate response exceeding 70% of %heart rate. This exercise intensity corresponded with moderate-vigorous physical activity, an intensity associated with cardiorespiratory fitness benefits. There was a significant increase in pain immediately after arm ergometer exercise compared to FES cycling (P < .05) and recumbent stepper exercise (P < .05). All adapted exercise modalities tested appeared to be viable approaches for improving cardiorespiratory fitness in nonambulatory people with MS. However, symptomatic response should be considered when prescribing and developing exercise interventions. These findings will help to inform and optimize exercise prescription for people with MS who are nonambulatory.

Supported by: None
Disclosure: Nothing to disclose
Keywords: Exercise training, Management of activities of daily living in MS

Downloaded from http://meridian.allenpress.com/ijmsc/article-pdf/22/s2/1/2539865/i1537-2073-22-s2-1.pdf by guest on 18 September 2020
Dairy and alcohol may affect relapse rate and QOL of these individuals. Future studies should assess role of dietary changes as complimentary treatment for MS.

Supported by: None


Keywords: Complementary/alternative therapies in MS, Diet

Conclusions: Most individuals with MS report making dietary changes to improve disease outcome. Dairy and alcohol may affect relapse rate and QOL of these individuals. Future studies should assess role of dietary changes as complimentary treatment for MS.

Median (interquartile range) daily servings intake of different foods were as follows: total fruits and vegetables, 2.2 (1.2-3.4); total dairy, 0.1 (0.0-0.5); total grains, 0.4 (0.1-1.4); total meat and fish, 3.7 (1.9-5.1); total alcohol, 0.1 (0.0-0.4); and total eggs, 0.1 (0.0-0.4). These results show low intake of dairy, grains, eggs, and alcohol among individuals with MS. Spearman correlation did not show any significant relationship between PROMIS Global scores and dosage of different food intake. However, Mann-Whitney U test showed that individuals who were not taking dairy had higher PROMIS scores than those who were (median 36 vs 33, P < .001). Additionally, individuals taking alcohol had higher PROMIS scores than those who were not taking any (median 34 vs 32, P = .001). These results suggest potential beneficial effects of avoiding dairy and consuming alcohol on QOL of individuals with MS.
LATE BREAKING
The Consortium of Multiple Sclerosis Centers and its educational partner, the Delaware Media Group, the publisher of the International Journal of MS Care, are pleased to provide you with a selection of late-breaking abstracts. As you know, at the live meeting, this work is usually displayed in a separate section during the Poster Session. This year, due to circumstances beyond our control, these abstracts will be presented to you in a printed and digital format without prior review. Our leadership has opted to do this to provide you with the broadest selection of material to enhance your knowledge about multiple sclerosis and related problems with the broadest possible perspective.

Real-World Evidence Assessment of Betaseron (interferon beta-1b) Adherence Following the Introduction of the BETACONNECT Autoinjector
Osina Butler,1 Simone Werner, Katriaina Holl,2 Ann-Kathrin Frenz,3 Eva-Maria Wicklein,3 Sandy Yeo,1 Mark Rametta1
1Real World Evidence, Medical Affairs, Bayer AG, Berlin, Germany; 2Medical Affairs Statistics, Bayer AG, Berlin, Germany; 3Bayer Pharma AG, Berlin, Germany; Bayer (Sea) Pte Ltd, Singapore, Singapore; 4Medical Affairs, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ

Background: Maintaining adherence to disease-modifying therapies (DMTs) is challenging for chronic conditions such as multiple sclerosis (MS), and poor adherence in MS has been associated with increased risk of disease activity and higher resource utilization. For DMTs requiring parenteral self-administration such as interferon beta, adherence to autoinjectors or needles may help patients overcome injection-related factors interfering with treatment adherence. The BETACONNECT device is an electronic autoinjector for the injection of interferon beta-1b (Betaseron), a DMT used in relapsing-remitting MS (RRMS). Objectives: This retrospective analysis of a US claims database evaluated adherence, as indexed by medication possession ratio (MPR) and persistence, to 2 subcutaneous DMTs, Rebif (interferon beta-1a) and Betaseron (interferon beta-1b), during the period prior to and following the introduction of the BETACONNECT autoinjector for Betaseron in patients with MS. Methods: Data from MarketScan, a US claims database, for patients with a medical claim for Rebif or Betaseron either prior to or after the introduction of BETACONNECT (October 2013–September 2015) or post approval and uptake of BETACONNECT (October 2016–September 2018), were evaluated. Patients aged ≥18 years with ≥1 confirmed MS diagnosis in the 12-month period prior to the first relevant DMT prescription within the defined time frames were included in this analysis. Four cohorts were defined: incident Rebif or Betaseron users over the 24-month period prior to the introduction of BETACONNECT; >80% MPR was higher for Rebif (90%, 95% CI 87%-93%) than Betaseron (83%, 95% CI 76%-88%), while in the post-BETACONNECT period, the proportion of users with ≥80% MPR was higher for Betaseron (92%, 95% CI 85%-95%) than Rebif (86%, 95% CI 81%-91%). Persistence: In the pre-BETACONNECT period, median persistence in days was higher for Rebif (199, 95% CI 167-235) than for Betaseron (152, 95% CI 105-231), while in the post-BETACONNECT period, persistence was higher for Betaseron (327, 95% CI 244-440) than for Rebif (229, 95% CI 184-304). Conclusions: Following the introduction of BETACONNECT, Betaseron users were more adherent, with improved persistence and with >90% of users meeting 80% MPR, a threshold commonly used to define good adherence.

Supported by: None
Disclosure: Osina Butler, Simone Werner, Katriaina Holl, Ann-Kathrin Frenz, Eva-Maria Wicklein, Bayer AG (salary); Sandy Yeo, Bayer (South East Asia) Pte Ltd (salary); Mark Rametta, Bayer HealthCare Pharmaceuticals Inc (salary).

Keywords: Disease-modifying treatments in MS, Equipment in MS, Patient empowerment in MS treatment

A Unique Case of a Patient with Tuberous Sclerosis and Recent Diagnosis of Neuromyelitis Optica
Maziar Eslami Farsani,1 Jacob Rubie,2 Shiltz K. Srivastava,2 Evanthia Bernitsas2
1Neurology, Wayne State School of Medicine, Detroit, MI; 2Neurology, Wayne State University, Detroit, MI; 3Neurology, West Virginia University, Morgantown, WV; 4Neurology, Wayne State University School of Medicine, Detroit, MI

Background: Tuberous sclerosis complex (TSC) is an inherited neurocutaneous disorder that is characterized by pleomorphic features that involve many organ systems, including multiple benign hamartomas of the brain, eyes, heart, lung, liver, kidney, and skin. Neuromyelitis optica (NMO, previously known as Devic disease) and NMO spectrum disorders (NMOsD) are inflammatory disorders of the central nervous system characterized by severe, immune-mediated demyelination and axonal loss predominantly in the spinal cord and optic nerve. Traditionally considered a variant of multiple sclerosis, NMO is now recognized as a distinct clinical entity based on unique immunologic features. Objectives: To report a unique case of TSC and NMO.

Methods: Case report.

Results: A 30-year-old woman who carries the diagnosis of TSC suddenly started to have tingling in the legs and vomiting. The vomiting was severe, intolerable, and continued for a week. Her tingling progressed up to her waist and into her abdomen. She also started having episodic spasms in her arms and legs. A month later she started having difficulty walking and tingling in her hands. She underwent magnetic resonance imaging (MRI) of spine that showed longitudinally extensive spinal cord lesions in her upper cervical and lower thoracic cord. Differential diagnosis at that time included NMO, transverse myelitis, and astrocystoma in the setting of tuberous sclerosis, but then NMO IgG antibody was found to be positive both in serum and cerebrospinal fluid (CSF). The patient received 5 days of steroids, and, as she still had symptoms, she was given plasma exchange for 5 sessions and then continue treatment plan with rituximab. Conclusions: This is a unique case of a patient who was diagnosed with TSC with clinical (seizures) and brain MRI features (cortical tubers) of TSC in her childhood and now diagnosed with NMO at the age of 30 with clinical features: longitudinally extensive spinal cord lesions and positive NMO IgG antibody in serum and CSF. Further studies are needed to find more information regarding the co-occurrence of a genetic disorder such as TSC and an immune-mediated disease like NMO.

Supported by: None
Disclosure: Nothing to disclose

Keywords: Genetics and MS, NMO, TS

Shorter Infusion Time of Ocrelizumab: Primary Results from the ENSEMBLE PLUS Study in Patients with Relapsing-Remitting Multiple Sclerosis
Amy Perrin Ross,1 Thomas Berger,2 Robert Bermel,3 Mark S. Freedman,4 Trygve Holmøy,5,6 Joep Killestein,7 Regina Buffels,1 Monika Garas,1 Karen Kadner,1 Marianna Manfrini,1 John McNamara,7 Hans-Peter Hartung2
1Loyola University Chicago, Chicago, IL; 2Department of Neurology, Medical University of Vienna, Vienna, Austria; 3Mellen Center for Multiple Sclerosis, Cleveland Clinic, Cleveland, OH; 4University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada; 5Department of Neurology, Akerhus University Hospital, Lareneskog, Norway; 6Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 7Department of Neurology, VU University Medical Center, Amsterdam, Netherlands; 8F. Hoffmann-La Roche Ltd, Basel, Switzerland; 9John F Kennedy Center for Southeastern Legal Co, United Kingdom; 2Department of Neurology, UKD, Center of Neurology and Neuropsychiatry and LVR-Klinikum, Heinrich-Heine Universität Düsseldorf, Düsseldorf, Germany

Background: Ocrelizumab is an intravenously administered anti-CD20 antibody approved for relapsing and primary progressive multiple sclerosis (MS). Shortening the infusion to 2 hours may reduce the total site stay from 3-4 hours (approved infusion duration including mandatory premedication/observation) to 4 hours, which may reduce patient and site staff burden. Objectives: To investigate the safety profile of ocrelizumab when administered over a shorter infusion period, using primary results from ENSEMBLE PLUS. Methods: ENSEMBLE PLUS is a randomized, double-blind substudy to the single-arm ENSEMBLE study (trial registration: NCT03085810). In ENSEMBLE, patients with early-stage relapsing-remitting MS (18-55 years; treatment-naive; disease duration ≤3 years; Expanded Disability Status Scale score 0-3.5) receive ocrelizumab 600 mg every 24 weeks for 192 weeks. In ENSEMBLE PLUS, patients, with early-stage relapsing-remitting MS (18-55 years; treatment-naive; disease duration ≤3 years; Expanded Disability Status Scale score 0-3.5) receive ocrelizumab 600 mg infusions every 24 weeks for 192 weeks. In ENSEMBLE PLUS, ocrelizumab (600 mg) administered over the approved infusion time (3.5 hours; conventional duration) is compared with a 2-hour infusion (shorter duration): the initial infusion (2 × 300 mg) duration remains unaffected. The ENSEMBLE PLUS primary end point is the proportion of patients with infusion-related reactions (IRRs) following the first randomized infusion (frequency/severity assessed during and 24 hours postinfusion). Results: As of September 2019, 291 and 289 patients were randomized to the conventional and shorter infusion groups, respectively. Following the first randomized infusion, 67 patients (23.1%) in the conventional and 71 patients (24.6%) in the shorter infusion group had IRRs, from which 17.9% vs 31.0% were throat irritation and 25.4% vs 23.9% were fatigue, respectively. Most IRRs were mild or moderate; ≥98% of all IRRs resolved without sequelae in both groups. No IRRs were life threatening, serious, or fatal; 1 severe IRR occurred in both the conventional...
LLN, and association between low IgG/IgM levels and incidence of infections. A total of 1204 patients reached IgM levels $<50$% with ofatumumab (median IgG [g/L]: ASCLEPIOS I and II, 10.57 and 9.57, respectively) or teriflunomide (10.01 and 9.65). The proportion of patients who reached IgM levels $<50$% LLN was 2.1% ($n = 20/944$) with ofatumumab (median IgG [g/L]: 0.91 and 0.59) and 0.6% ($n = 6/933$) with teriflunomide (0.84 and 0.92) at week 120. Of these patients, 5 had infections with ofatumumab, mostly nonserious (grade 1/2 in severity), except one grade 3 recurrent urinary tract infection, but all infections were resolved. One patient on teriflunomide who had nasopharyngitis had not recovered at the time of last follow-up. Conclusions: A reduction in serum IgG levels $<50$% LLN was not observed with either treatment. IgM levels showed reductions with both ofatumumab and teriflunomide treatments; there was no apparent association with increased rate of serious/nonserious infections in patients with RMS.

Supported by: None

Disclosure: Jérôme de Seze: Alexion, Allergan, Almirall, Bayer, Biogen, Chongqi, CSL Behring, F. Hoffmann-La Roche Ltd, Genzyme, LFB, Merck, Novartis, Teva (consulting fee). Amit Bar-Or: Astra Biotherapeutics, Biogen, Celgene, ReceptoRx, Genentech/Roche, GlaxoSmithKline, Mapi, MedImmune, Merck, EMD Serono, Novartis, Sanofi Genzyme (consulting fee, grant support, speakers bureau). Jorge Carreño: Merck-Serono, Biogen, Novartis, Roche, Genentech (board member, contracted research). Anne H. Cross: Academic CME (CE provider) (participation in clinical trials in MS sponsored by); Almirall, Biologix, Bionorica, Sanofigen, Biotix (scientific advisory board member); Alector, Annexon, Biogen, Chugai, EMD Canada, Genzyme, LFB, Merck, Novartis, Roche (honoraria/consultation fees). Joep Killestein: F. Hoffmann-La Roche Ltd, Genentech Inc, Genzyme, Novartis (consulting fee). Mark S. Freedman: Actelion, Bayer HealthCare, Biogen, Cline Nanomedicine, F. Hoffmann-La Roche Ltd, Merck, Novartis, Sanofi-Aventis (honoraria/consultation fees, membership of a company advisory board, board of directors or other similar group); Celgene, Chongqi, EMD Canada, Genzyme, Pendopharm, Tena Canada Innovation (honoraria/consultation fees); Genzyme Canada (research grant); MedDay (member of a company advisory board, board of directors, or other similar group); Sanofi Genzyme (speakers’ bureau). Trygve Holmøy: Biogen, Merck, Roche, Sanofi Genzyme (honoraria/consultation fee). Josef Killestein: Biogen, F. Hoffmann-La Roche Ltd, Merck, Novartis, Sanofi Genzyme, Tena (contracted research). Virginie Buffère: F. Hoffmann-La Roche (salary). Karen Kallmeyer: F. Hoffmann-La Roche Ltd (salary). Mounia Gharbi, Marionna Marfis: F. Hoffmann-La Roche (ownership interest, salary). John McNamara: AstraZeneca, F. Hoffmann-La Roche Ltd (consulting fee); John McNamara Consulting (ownership interest, salary). Hans-Peter Hartung: Bayer, Biogen, GenNeuro, Merck, Novartis, Roche, Sanofi Genzyme (honorary for serving on steering and data monitoring committees).

Keywords: Disease-modifying treatments in MS, Ocrelizumab

Effect of Ofatumumab on Serum Immunoglobulin Levels and Infection Risk in Relapsing Multiple Sclerosis Patients from the Phase 3 ASCLEPIOS I and II Trials

Jérôme de Seze,1 Amit Bar-Or,2 Patrick K. Coyle,3 Anne H. Cross,4 Ludwig Kappos,5 Michael H. Ludwig Kappos,6 Krysztof Selmaj,7 Heinz Wieden,8 Cecile Kerloeguen,9 Alexandra Goodyear,9 Ratnakar Pingili,9 Roseanne Sullivan,9 Ayan Das Gupta,10 Valentine Jehl,10 Dieter A. Hirling,10 Martin Merschhemke,10 Stephen L. Hauser11

1University Hospital of Strasbourg, Strasbourg, France; 2Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA; 3Institute for Neurological Research Dr. Raul Carrea, Buenos Aires, Argentina; 4Washington University School of Medicine, St. Louis, MO; 5Neurologic Clinic and Polyclinic, Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital and University of Basel, Basel, Switzerland; 6Center for Neurology, Lodz, Poland; 7University of Münster, Münster, Germany; 8Novartis Pharma AG, Basel, Switzerland; 9Novartis Pharmaceuticals Corporation, East Hanover, NJ; 10Novartis Healthcare Pvt. Ltd., Hyderabad, India; 11Department of Neurology, UCSF Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA

Background: Ocrelizumab, the first fully human anti-CD20 monoclonal antibody, demonstrated superior efficacy vs teriflunomide in patients with relapsing-remitting multiple sclerosis (RRMS) in the phase 3 ASCLEPIOS I/II trials. A decline in serum immunoglobulin (lg) levels was observed with other anti-CD20 therapies. Objectives: To determine serum IgG and IgM levels and investigate associations between IgG/IgM levels and risk of infections in ofatumumab-treated patients. Methods: In the ASCLEPIOS trials, patients with relapsing-remitting multiple sclerosis were randomized to receive ofatumumab 20 mg 0, 1, 7, and 14, week 4, and every 4 weeks thereafter or once-daily oral teriflunomide 14 mg for up to 30 months (average follow-up duration: 18 months). Serum IgG/IgM levels were monitored at baseline, weeks 4 and 12, and every 4 weeks thereafter (ofatumumab, n = 946; teriflunomide, n = 936). A notable decline in IgG/IgM levels was defined as 50% of the lower limit of normal (LLN) at any time (IgG, 3.5 g/L; IgM, 0.2 g/L). Outcomes included the proportion of patients with IgG/IgM levels $<50$%
The odds of achieving NEDA-3 with ofatumumab vs teriflunomide were >3-fold higher at month (M) 0-12 (47.0% vs 24.5%; p < .001) and >8-fold higher at M12-24 (8.0% vs 0.9%; p < .001). Ofatumumab significantly reduced the mean number of gadolinium-enhanced (Gd+) T1 lesion activities in the FAS (negative binomial model for both) were also analyzed. **Results:** The odds of achieving NEDA-3 with ofatumumab vs teriflunomide were >3-fold higher at month (M) 0-12 (47.0% vs 24.5%; p < .001) and >8-fold higher at M12-24 (8.0% vs 0.9%; p < .001). Ofatumumab significantly reduced the mean number of Gd+ T1 lesions per scan by 95.9% compared with teriflunomide [mean (95% CI): 0.02 (0.01; 0.03) vs 0.50 (0.42; 0.59); p < .001]. **Conclusions:** Ofatumumab increased the probability of achieving NEDA-3 and demonstrated superior efficacy vs teriflunomide in patients with RMS.

**Supported by:**

**Disclosure:**

Stephen L. Hauser, Alector, Annexon, Biogen, Molecular Systasis; Symbio (scientific advisory board member, stock options received); Pfizer, Hoffman-La Roche (travel support/reimbursement and writing support for anti-CD20 meetings and presentations); Novartis (board of trustees member, stock options previously received); Novartis (travel support/reimbursement for anti-CD20 meetings and presentations). Amit Bar-Or: Astra Biotherapeutics, Biogen, Celgene, EMD Serono, Genentech/Roche, Genzyme/Sanofi, MedImmune, Merck, Novartis, Recepta, Sanofi Genzyme (consulting fee, grant support, speakers' bureau). Jeffrey A. Cohen: Multiple Sclerosis Journal (co-editor); Adamas, Convolo, Mylan, Population Council (consulting fee). Giancarlo Cami: Almirall SPA, Biogen, Biogen Italia Srl, Celgene Group, EXCEMED, F. Hoffmann-La Roche (Travel support/reimbursement). 09:09 (9-9 years), a higher proportion of ofatumumab-treated patients were free from 6mCDW (91.9% vs 88.9%), relapses (82.3% vs 69.2%), and lesion activities (54.1% vs 27.5%) compared with teriflunomide. Ofatumumab significantly reduced ARR compared with teriflunomide at all cumulative time intervals: M0-3 (P < .011), and all subsequent time intervals from M0-27 (P < .001). Ofatumumab significantly reduced the mean number of Gd+ T1 lesions per scan by 95.9% compared with teriflunomide [mean (95% CI): 0.02 (0.01; 0.03) vs 0.50 (0.42; 0.59); p < .001].

**Conclusions:** Ofatumumab increased the probability of achieving NEDA-3 and demonstrated superior efficacy vs teriflunomide in patients with RMS.
Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor (BTKI) Evobrutinib in Relapsing Multiple Sclerosis over 108 Weeks: Open-Label Extension to a Phase 2 Study

Xavier Montalban,1,2 Douglas L Arnold,3,4 Martin S. Weber,5 Ivan Staikov,6 Karolina Ptaszecka-Stryczewska,7 Emily C. Martin,7 Matthew Mandel,7 Victor Ona,7 Fernando Dangond,7 Jerry S. Wolinsky10

1University of Toronto, St. Michael’s Hospital, Toronto, ON, Canada; 2Vall d’Hebron University Hospital, Barcelona, Spain; 3NeuroRx Research, Montreal, QC, Canada; 4Institute of Neuropathology and Department of Neurology, University Medical Center, Göttingen, Germany; 5Department of Neurology and Acute Neurological Diseases, Poznan University of Medical Sciences, Poznan, Poland; 6EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA; 7Global Clinical Development Center, EMD Serono, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA; 8McGovern Medical School, UTHouston, Houston, TX

Background: In a phase 2 randomized controlled trial (RCT; trial registration: NCT02975349) in patients with relapsing multiple sclerosis (MS), evobrutinib 75 mg twice daily reduced total T1 gadolinium-enhancing lesions (primary end point) andannualized relapse rate (ARR) over 24 weeks vs placebo, with efficacy maintained through week 48. Objectives: To assess long-term efficacy and safety in the open-label extension (OLE). Methods: In the original double-blind period, patients received evobrutinib 25 mg or 75 mg once daily, evobrutinib 75 mg twice daily, open-label dimethyl fumarate (240 mg twice daily), or placebo for the first 24 weeks; all arms continued with the original treatment assignment until 48 weeks, except placebo patients who were switched to evobrutinib 25 mg once daily. At week 48, all patients could enter the OLE, where treatment was initially evobrutinib 75 mg once daily (for approximately 48 weeks, median) before switching to 75 mg twice daily. The OLE assessed long-term efficacy (0-108 weeks) and safety (60-week OLE) of evobrutinib. Results: Of 267 randomized patients, 213 (79.8%) completed 108 weeks of treatment (48-week main study, 60-week OLE). For patients who received evobrutinib 75 mg twice daily in the double-blind period, the ARR [95% CI] was 0.11 (0.040-0.25) at week 48 and 0.12 (0.060-0.22) for the 108-week period. Evobrutinib was generally well tolerated, with the safety profile maintained during the 60-week OLE. Transient elevated liver aminotransferases, reported in the 48-week double-blind period, were not observed in the OLE. Conclusions: Efficacy and safety were maintained long-term. Two phase 3 RCTs evaluating the efficacy and safety of evobrutinib in patients with relapsing MS commence in 2020.

Sponsored by: EMD Serono, Inc, Rockland, MA, USA, a business of Merck KGaA, Darmstadt, Germany

Disclosure: Xavier Montalban: Actelion, Alexion, Bayer, Biogen, Celgene, EMD Serono, EXCEMED, Genzyme, Innvata, MedDay, Merck, MS International Federation, Mylan, Nervigen, National MS Society, Novartis, Roche, Sanofi Genzyme, Teva Pharmaceutical, TG Therapeutics (consulting fee). Douglas L. Arnold: Acorda, Adelphi, Alkermes, Biogen, Celgene, Frequency Therapeutics, Genentech, Genzyme, F. Hoffmann-La Roche, Immune Tolerance Network, Innvata, MedDay Pharmaceuticals, Merck Serono, Novartis, Pfizer, Receptos, Sanofi-Aventis (consulting fee); NeuroRx Research (ownership interest); Martin S. Weber: Bayer, Biogen, F. Hoffmann-La Roche, Genzyme, Merck Serono, Novartis, Teva (consulting fee). Ivan Staikov: Adapt, Bayer, Boehringer Ingelheim, Eiwupharma-Biogen, F. Hoffmann-La Roche, Gedeon Richter, Merck Serono, Mylan, Penumbra, Pfizer, Polpharma, Sanofi Genzyme, Shire, Teva (consulting fee). Emily C. Martin: Mannkind, Novartis, Sanofi Genzyme, Teva (consulting fee). Kevin A. Hom: EMD Serono, Inc (a business of Merck KGaA, Darmstadt, Germany) (salary). Jerry S. Wolinsky: Acorda Therapeutics, Actelion, Alkermes, Brainstorm Cell Therapeutics, Genzyme, EMD Serono, GeNeuro, GW Pharma Ltd, MedDay Pharmaceuticals, NerGen Pharma Corp, Novartis, Otsuka, PTC Therapeutics, Roche/Genentech, Sanofi Genzyme (consulting fee); Millipore Corporation (paid to UTHouston), University of Texas (royalty).

Keywords: Disease-modifying treatments in MS

Natalizumab-Treated Patients with Relapsing-Remitting Multiple Sclerosis Report Better “Feel-Good” Outcomes on Key Physical, Emotional, and Cognitive Domains Compared to Other Disease-Modifying Therapies

John Foley1; Regina Berkovich1,2; Mark Gudesblatt1; Carl de Moor1; Stephanie Licata3; Pei-Ran Ho1; Karthik Bodinathan4; Robin Avila1; Lily Lee5

1Rocky Mountain MS Clinic, Salt Lake City, UT; 2Neurology Program, Los Angeles County and University of Southern California Medical Center, Los Angeles, CA; 3South Shore Neurologic Associates, Patchogue, NY; Biogen, Cambridge, MA; Biogen (at time of this study), Cambridge, MA; Biogen (at time of this analysis), Cambridge, MA

Background: Natalizumab is an efficacious therapy for patients with relapsing-remitting multiple sclerosis (RRMS). Some patients have reported an increased experience of qualitatively positive or “feel-good” experiences while on natalizumab. Prior qualitative interviews of natalizumab-treated patients have suggested that the feel-good experience may be associated with increased energy and improved emotional and cognitive functioning. Objectives: To describe survey results assessing patients self-reporting a “feel-good” experience while receiving natalizumab or other disease-modifying therapies (DMTs). Methods: Surveys were administered to adult patients with RRMS through MyMSTeam (part of the MyHealthTeam application). Patients were asked about their current DMT use and its “feel-good” effect assessed by self-reported improvements in physical, emotional, or cognitive domains. Natalizumab vs other-DMT patient responses were compared for multiple measures and compared using t test and log-rank tests. Results: Patients receiving natalizumab (n = 95) or other-DMT (n = 252) were included. Time since RRMS diagnosis was <6 years in 29% (natalizumab) and 35% (other-DMT) and >15 years in 29% (natalizumab) and 27% (other-DMT). Significantly higher percentages of natalizumab than other-DMT patients reported that they “feel good” on their DMT (63% vs 45%; P = .001). Physical benefits were reported by 78% of natalizumab and 67% of other-DMT patients (P = .017), with significantly higher rates of improved energy (23% vs 12%; P = .011) and coordination (22% vs 12%; P = .017) for natalizumab vs other-DMT. Comparison of patients on natalizumab vs other-DMT indicated significantly higher scores on emotional components of quality-of-life measures; improvement in emotional, and happiness (24% vs 11%; P = .004); and improvement on cognitive component involving organizing one’s thoughts (24% vs 14%; P = .021). Among natalizumab patients, 59 out of 95 (61%) scored high [either 4 or 5 for “agree”/“strongly agree”) on feel-good effect, and also reported significantly increased energy, balance, coordination, motivation, happiness, and cognitive benefits (each P < .001). Conclusions: These real-world patient-centric survey results suggest that natalizumab is associated with a significantly improved experience compared with other DMTs, consistent with qualitative, emotional, and cognitive functioning were more common in patients receiving natalizumab than in patients receiving other DMTs, consistent with qualitative interviews. These results are limited by the subjective nature of the survey responses.

Supported by: Biogen

Disclosure: John Foley: Biogen, EMD Serono, Genzyme, Genentech-Roche (consulting fee); Biogen, Genentech-Roche, Natanz, Genzyme, Mallinckrodt, Adamas (research support); Regina Berkovich: Alexion, Bayer, Biogen, Celgene, Genentech, Novartis, Sanofi (consulting fee). Carl de Moor: Stephanie Licata, Karthik Bodinathan, Robin Avila. Biogen (employee of and own stock and/or stock options in). Pei-Ran Ho: Lily Lee. Biogen (former employee of and may own stock and/or stock options in).

Keywords: Disease-modifying treatments in MS, Patient-reported outcomes
## Author Index

**A**
- Aael, Greg ................................................. 1
- Abasianik, Zuhal ........................................... 44
- Abate, Mario .................................................. 80
- Abu-Al-Hawa, Maha ....................................... 55
-Abrash, Rany A ............................................... 39
- Achiron, Anat ................................................. 41
- Adeyemi, Ayo .................................................. 18
- Afsar, Salam ................................................... 43
- Agresta, Thomas P ........................................... 70
- Akta, Orhan .................................................... 2, 21
- Alarieh, Rola F ................................................. 38
- Aldridge, Julie ................................. 5, 18, 23, 25, 33
- Alexi, Nektaria ............................................... 50
- Allen, Kerstin .................................................. 8
- Almens, Ruth .................................................. 8
- Alroughani, Raed ............................................ 43
- Altincal, Arman .............................................. 18, 41
- Alvarenga, Victoria V .................................... 79
- Alvarez, Enrique ............................................. 17, 74, 86
- Amezcuea, Lilibya ......................................... 31
- Anadani, Nidhi .............................................. 11
- Anania, Veronica G ......................................... 77, 78
- Antonovich, Natasha M ................................... 53
- Aquillano, Lisa .............................................. 32
- Ararat, Kerime ................................................ 56
- Armstrong, Rosin ......................................... 20, 26, 30, 40
- Arndt, Nancy .................................................. 17
- Arnold, Douglas L ......................................... 87
- Arroyo, Rafael .................................................. 63
- Aslan, Taha ..................................................... 40
- Atkins, Harold ............................................... 55
- Augustyn, Joan .............................................. 60
- Aungst, Angela ............................................... 23
- Avila, Mirla ..................................................... 50
- Avila, Roblin L ................................................ 17, 20, 87
- Aydemir, Aida ................................................. 30
- Ayer, Mavis G .................................................. 59, 66

**B**
- Baba, Cavid .................................................. 40
- Babenko-Moud, Yolanda .................................. 63
- Baber, Morten ................................................ 63
- Bahmanyar, Shahram ...................................... 34
- Bailey, Mary .................................................... 61
- Baird, Jessica F ................................................. 69
- Bajwa, Dilpreet ............................................... 82
- Baker, Darren P ................................................. 39
- Baker, Matthew ................................................ 77
- Balaban, Roumen .......................................... 65
- Balcer, Laura .................................................... 65
- Bammann, Marcs ............................................ 9
- Bando, Mauricio O .......................................... 56
- Banks, Amy ...................................................... 63
- Banwell, Brenda .............................................. 43
- Bardley, Belinda .............................................. 13
- Barkh, Frederik ................................................ 3
- Barkdale, Heather .......................................... 71, 72
- Barlow, Laura ................................................... 4
- Bar-Or, Amit ................................. 14, 16, 17, 19, 31, 37, 38, 44, 45
- Barr, Gerard .................................................... 21
- Barstow, Elizabeth .......................................... 11
- Bass, Ann D ..................................................... 42
- Bautista, Jonathan ........................................... 48

**Beauvais, John................................. 51
Beckstead, Jason W .......................................... 73
Belboure, Reina .............................................. 56
Benedict, Ralph H.B ......................................... 24, 37
Bennett, Jeffrey L ............................................ 21
Benson, Leslie .................................................. 1
Berard, Jason A ............................................... 55
Ben, Ian A ....................................................... 19
Benedenbaum, Tara ....................................... 3, 47, 82
Berger, Thomas ............................................... 84
Berkovich, Regina .......................................... 4, 87
Bermel, Robert ............................................... 84
Bernatias, Evanthia ......................................... 84
Berthele, Achim .............................................. 20, 26, 30, 34, 40, 63
Bertolatto, Antonio ......................................... 63
Beuvaerts, Joris ............................................. 7, 79
Bethoux, Francois .......................................... 79, 80
Bet-Slimmon, Saron ....................................... 15
Bhan, Virender ............................................... 86
Bish, Babita ..................................................... 82
Bleich Kimelman, Nadav ................................ 23
Block, Allinson N ........................................... 11
Bolling, Jamie ............................................... 28, 51, 68
Bomprezzi, Roberto .......................................... 56
Bonafele, Machaon ......................................... 38
Borgert, Brooke .............................................. 57
Borowski, Jenna .............................................. 22
Boschert, Ursula ............................................. 22
Bosc, Jenna ..................................................... 22
Boster, Aaron L ............................................... 4, 63
Bowman, Mary H ........................................... 7
Bowman, Sean .................................................. 8
Boyd, A. Suzanne ............................................ 74
Boyle, Alexey ................................................... 30
Bray, Tiffany J .................................................. 74
Bransdatter, Rachel ......................................... 58
Brandt, Alexander ........................................... 47
Bridges, Gail .................................................... 24
Broadley, Simon ............................................... 43
Brook, Richard A .............................................. 19
Brown, Brandon .............................................. 17
Brown, Cynthia ............................................... 9
Brown, Ted/Thedore R ...................................... 80, 81
Brun, Denise R ............................................... 1
Byes, Arne ...................................................... 47
Buch, Eva ........................................................ 81
Bueno, Ericka M ............................................. 63
Buffsels, Regine ............................................... 84
Buhse, Marijoe ................................................. 7, 48, 59, 67
Bunstead, Barbara .......................................... 7, 48, 67
Burkill, Sarah .................................................... 34
Burnham, Alexander ........................................ 68, 69
Burton, Jason .................................................... 86
Butler, Oisin ..................................................... 84

**C**
- Calabrese, Peter A .......................................... 54
- Callwood, Jonathan ......................................... 29
- Campagno, Denise ......................................... 65
- Canzonieri, Ana ............................................. 48
- Canzonieri, Ana Maria ..................................... 56
- Carera, Karen ................................................ 10
- Carey, Stephanie ............................................ 73
- Carlile, Nicola ............................................... 14, 36
- Carlson, Aaron .............................................. 28, 51, 68
- Cartwright, Karen .......................................... 79
- Casper, T. Charles .......................................... 6
- Caserly, Courtney S ........................................ 6
- Cedergren, Katie L .......................................... 74
- Chahin, Salim .................................................. 14
- Chapman, Katherine ...................................... 58
- Chapman, Sandra .......................................... 10
- Checkettos, Daniel .......................................... 79
- Chen, Hailu .................................................... 17, 34
- Chen, Kun ..................................................... 1
- Chester, Jennifer ............................................. 13
- Chinchilla, Dennis .......................................... 32
- China, Angel .................................................... 12, 45
- Chinitis, Tania .................................................. 1
- Chong, Suyin ..................................................... 50
- Choudhry, Zia ................................................... 43
- Chisiant, Sarah .................................................. 45
- Christians, Cori ................................................. 74
- Chung, Luke ...................................................... 39
- Cifrici, Beyza .................................................... 3
- Cimbra, Daniel ................................................ 2, 21
- Cinc, Edith ....................................................... 19
- Ciotti, John R ..................................................... 14
- Cisfio, Stacey .................................................... 8
- Cohen, Stanley I ............................................... 16, 22, 24, 41
- Cohen, Eran T ................................................... 71
- Cohen, Jeffrey A ............................................... 4, 23, 29, 38, 44, 85
- Coleman, Lynette .......................................... 59, 61
- Colquhoun, Samantha R .................................. 66
- Colic, Marija ..................................................... 55
- Comi, Giancarlo ................................................. 4, 25, 29, 33, 42, 43, 85
- Conway, Devon ............................................... 3
- Cook, Stuart ..................................................... 36, 42
- Correale, Jorge ............................................... 4, 38, 85
- Corsi, Gina ...................................................... 69
- Costello, Fiona .................................................. 3
- Costello, Kathleen ............................................ 3, 57, 59
- Courtman, David ............................................. 55
- Coyle, Patricia K ............................................... 4, 16, 25, 32, 38, 85
- Cree, Bruce A .................................................. 2, 16, 17, 19, 21, 24,
- 29, 31, 37, 44
- Crispino, Alexis ............................................... 78
- Cross, Anne H ................................................... 4, 14, 38, 85
- Cunningham, Rebecca ..................................... 76
- Curko, Nina A ................................................... 55
- Cutter, Gary ..................................................... 2, 8, 15, 21, 24

**D**
- Dahlke, Frank .................................................. 19
- Dazadeh, Nadia .............................................. 4, 43, 63
- Dalrymple, Jessica ......................................... 62
- Damian, Dori .................................................... 37, 42
- Damir, Peter ..................................................... 3
- Danes, Fernando ............................................... 5, 23, 25, 87
- Danon, Uri ....................................................... 23
- Da Silva, Talita D ............................................. 56
- Darsh, Neda ..................................................... 55
- Davis, Bryan ..................................................... 62
- Dawes, Helen ................................................... 72
- Daykin, Nicola .................................................. 66
- DelMastro, Heather M ...................................... 67, 70, 72
- DeLuca, Gabriele C .......................................... 70, 72
- DeLuca, John ................................................... 7, 29

---

*International Journal of MS Care*
Author Index

Frenz, Ann-Kathrin ........................................ 84
Friedman, Coleen ......................................... 59
Fritz, Nora E. .................................................. 76
Fry, Donna ...................................................... 69
Fujihara, Kazuo .............................................. 20, 21, 26, 30, 34, 40
Fujina, Kenji .................................................... 20, 26
Fuller, Ryan ...................................................... 39, 45
Gabriele, Simone ............................................. 66
Galazka, Andrew ............................................ 18, 23, 25, 33, 42
Galetta, Steven ............................................... 65
Garas, Monika .................................................. 54
Garcia-Alonso, Belen ........................................ 30
Gardener, Elizabeth ........................................... 79
Garmon, Eric .................................................... 57
Gavrylyuk, Jodie R ............................................ 60
Gaythorpe, Jackie ........................................... 52
Geis, Hannah M .............................................. 26, 27
Geissbuehler, Yvonne ........................................ 34
Gerefasikis, Caroline ......................................... 17, 20
Gilbertson, Peter .............................................. 46
Giovannini, George ........................................... 5, 18, 19, 23, 25, 27, 30, 33, 36, 42, 67, 86
Giri, Shivraman ................................................. 60
Glanz, Bonnie Ilene ........................................... 60
Golan, Daniel .................................................... 7, 48, 53, 67
Gold, Ralf .......................................................... 19
Goldenberg, Anna ............................................... 3
Goodman, Andrew ............................................. 31
Goodyear, Alexandra .......................................... 4, 16, 23, 85
Gorman, Mark .................................................. 1
Grader-Beck, Thomas ......................................... 54
Graves, Jennifer S............................................... 1, 55
Green, Ari .......................................................... 21
Greenberg, Benjamin M ....................................... 58, 77
Grenningloh, Roland ........................................... 28
Grillo, Andrea .................................................... 35
Grillo, Austin C ................................................... 80
Gromisch, Elizabeth S ......................................... 36, 51, 70, 72
Gudesblatt, Mark ............................................... 7, 48, 53, 67, 87
Guikema, Benjamin ........................................... 40
Gupta, Ayan Das ............................................... 38, 85
Gygi, Tirisham V .................................................. 28, 51, 57, 68
Hach, Thomas ................................................... 86
Haering, Dieter A ............................................... 4, 16, 38
Hakkarainen, Kaija ............................................ 19
Haladag, Douglas E ............................................ 73
Halper, June ....................................................... 3, 45, 46, 59
Hameed, Nasiba ................................................ 67
Hamill, Brenda ................................................... 59, 66
Han, May H ....................................................... 44
Hanssen, Andrea ............................................... 35
Harder, Lena ...................................................... 58
Hardigan, Patrick ............................................... 54
Haring, Dieter A .................................................. 85
Harris, Colleen ................................................... 52
Harris, Kenneth .................................................. 3
Harris, Yolanda ................................................... 1
Hartigan, Clai T ................................................... 12, 49
Hartmann, Jennifer ............................................ 80
Harrison, Hans-Peter .......................................... 2, 21, 43, 84
Harty, Gerard ..................................................... 37
Harwood, Meagan ............................................. 63
Haselkorn, Jodie K ............................................. 40, 51, 58
Hauser, Stephen L ............................................... 4, 38, 85
Haynes, John ..................................................... 19
Hellwig, Kerstin ............................................... 77
Hemmingway, Cheryl ......................................... 77
Henderson, Rochelle .......................................... 24
Henke, Christian ............................................... 19
Henry, Jaimie ..................................................... 79
Herriot, Elise ..................................................... 19
Herron, Nicole ................................................... 68
Hersh, Carrie M ................................................ 19, 86
Hilbert, Jan ......................................................... 34
Hillman, Lynda R ............................................... 58
Hillner, Jennifer R ............................................. 52
Ho, Pei-Ran ....................................................... 82
Hodges, Wayne ................................................. 71
Hoffman, Leah ................................................... 36
Hoffman, Paul M ............................................... 71
Hoffmann, Olaf .................................................. 86
Holl, Katriyna .................................................... 84
Holmoy, Trygve .................................................. 84
Hooshmand, Sam I ............................................. 14, 36
Hopkins, Sarah ............................................... 13
Hotermans, Christophe ...................................... 65
Houtchens, Maria K ............................................ 1, 60
Howard, Jennifer L ............................................. 63
Hua, Le H ......................................................... 3, 8, 17, 31
Huang, Deren .................................................... 22
Huang, Min H .................................................... 69
Hunter, Samuel F ................................................. 39, 63
Hutchinson, Brian .............................................. 6, 11, 68, 75
Hyvert, Yann .................................................... 18, 33
I
Ilhar, Lee S ....................................................... 55
Ingram, Michele F ............................................. 35
Inshasi, Jihad Said ............................................. 28
Iones, Carolina .................................................. 63
Issard, Delphine ................................................ 33
Ita, Hajime ....................................................... 77, 78
J
Jack, Dominic ................................................. 5, 25, 37, 42
Jackson, Kimberly ............................................. 63
Jacobs, Alan ..................................................... 71
Jacobs, Dina ..................................................... 71
Jacques, Francois ............................................... 40
Jaenicke, Kaitlyn ............................................... 57
Jainy, Nina ....................................................... 44
Jainska, Elabeta .................................................. 34
Jehl, Valentine .................................................. 38, 85
Johnson, Elizabeth ........................................... 57
Johnston, Karissa ............................................. 63
Jones, Angela ................................................... 46
Jones, Catherine D ............................................ 70
Jones, Cynthia C ............................................... 70
Jones, Daniel .................................................... 23, 25
Jones, Noble ..................................................... 80
Kaczmarek, Olivia ............................................. 7, 48, 53, 67
Kadas, Ella M ..................................................... 47
Kadner, Karen ................................................... 84
Kakareka, Algirdas ............................................ 46
Kalotay, Irena .................................................... 27
Kantor, Daniel ................................................... 7
Kapadia, Shivani ............................................... 17, 34
Kaplan, Jeffrey ................................................... 77
Kaplan, Tyler ..................................................... 13
Kappos, Ludwig ................................................ 19, 4, 19, 29, 33, 37, 38, 85
Author Index

Stefoski, Dusan .................................................30
Stephens, Samantha ...........................................82
Stephenson, Jeannie B. .......................................73
Stevens, Sondra ..................................................73
Stillman, Jessica ..................................................62
Stobbe, Gary ......................................................80
Stokmaier, Daniela .............................................77
Stoneman, Dea ....................................................23
Stirling, India C. ................................................26, 27
Stuve, Olaf ..........................................................29
Su, Ray .............................................................17, 20, 22
Su, Wendy .........................................................16, 17, 24, 31, 37, 75
Sugden, Joseph ..................................................72
Suh, Hyojin .........................................................35
Sullivan, Cynthia ..................................................7, 48, 67
Sullivan, Roseanne .............................................85
Suzuzi-Woischnik, Kiliana .....................................34
Syed, Sara ..........................................................25, 28, 33, 42
Sylvester, Elke ....................................................42
Szafrań, Eric .......................................................57

T
Talente, Bari .......................................................65
Tanvir, Imran ........................................................30
Taub, Edward ....................................................17, 20, 22
Tchalibon, Susanna .............................................23
Terzi, Murat .........................................................20, 26, 30, 34, 40
Testor, Nicole ....................................................68
Thakolwiboon, Smalthorn ......................................50
Thirumalai, Mohanraj ...........................................75
Thomas, Florian P ...............................................24, 45, 55
Thompson, Heidi ..................................................50
Thomson, Allison ..................................................66
Thrower, Ben .......................................................10
Tiel-Wilk, Klaus ....................................................41
Tilibary, Charles F. ................................................49
Tintoret, Mar .........................................................4
Titcomb, Tyler J. ...................................................45, 82
Tomice, Davorka ....................................................4
Totoyvan, Natala ...................................................20, 26, 30, 34, 40
Touil Alloua, Imsahane .......................................55
Trabousee, Anthony ..............................................3, 4
Tracy, Tracy Flemming ..........................................75
Travis, Lori H. .......................................................32
Trojano, Maria .....................................................86
Tsang, William A. ................................................55
Tiao, Nicole .........................................................18
Turner, Aaron P. ...................................................51, 70

U
Uswatte, Gitendra ...............................................7

V
Vale, Vanessa D. ..................................................49
van de Ven, Kim ...................................................3, 4
Vanечкі, Wim ......................................................3, 48
Van Liew, Charles ...............................................76
Van Vliet-Berghe, Elie ..........................................47, 48
Van Wijmersch, Bart ............................................63
Vargas, Diana .....................................................32
Vercruysen, Sophie .............................................47
Verdon di Cantogno, Elisabetta ..............................30
Verheijen, Melissa ...............................................47
Veri, Shelby .........................................................56
Verkoniemi-Ahol, Auli .........................................34
Vermersch, Patrick .............................................4, 19, 25, 32, 36, 37, 39, 43, 86
Vernon, Karen .....................................................59
Verrinder, Amy ....................................................13
Vicente, Ivanne ....................................................10
Vieira, Teresa Cristina .........................................10
Vignos, Meg O ....................................................17, 20, 41
Viswanathan, Shanthi ..........................................20, 26, 30, 34, 40
Volpenhein, Kelvor .............................................69
von Buidingen, H.-Christian ................................77, 78
von Gelderen, J. ...................................................14, 15, 80
Vording, Nancy ....................................................6
Vucic, Steve ..........................................................41
Vukusic, Sandra ...................................................41

W
Wade, Peter ..........................................................36
Wagner, Joanne ...................................................7, 79
Wahls, Terry L. ....................................................45, 82
Walker, Bryan ......................................................5, 25
Walker, Lisa A.S ....................................................55, 82
Walker, Tracy .......................................................49
Wallace, Trent .....................................................45, 80
Wallin, Mitchell T ................................................3, 10, 53
Walsh, Karen .......................................................65
Walters, Arthur S. .................................................74
Waltz, Michael .....................................................1
Wan, Michael J. ...................................................47
Wang, Kai-Chen ..................................................20, 26, 30, 34, 40
Wang, Liangwei ...................................................2
Wang, Yujie ..........................................................54
Wang, Zhini ..........................................................80
Ward, Jordan ......................................................6
Waso, Carin S. .....................................................10
Waubant, Emmanuelle .........................................1
Weber, Kristina ....................................................77
Weber, Martin S. ..................................................28, 87
Weckbecker, Gisbert ...........................................55
Wei, Olivia ............................................................36
Weigel, Megan ....................................................75
Weisnhenker, Brian G. ..........................................2, 21, 77
Weinstock-Gutman, Bianca ................................1
Weiss, Jamie L. ....................................................24
Weiss, Michael S. ................................................22
Wells, Christopher ..............................................12
Werner, Kristine ...................................................10
Werner, Simone ...................................................84
West, Kathryn ....................................................48
West, Timothy .....................................................20
Wickelin, Eva-Maria .............................................84
Wiedl, Heinz ......................................................4, 16, 39, 85
Wilen, Jeffrey .....................................................7, 48, 53, 67
Wilkinson, Carmel .............................................59, 61
Will, Roman .......................................................4, 85
Williams, Justin D. ..............................................61
Williams, Mitzi J ...................................................31
Williamson, Eric ...................................................35
Willingham, Emily ..............................................65
Wilson, Kathleen .................................................38
Wilson, Whitney ....................................................57
Wingerchuk, Dean ..............................................2, 20, 21, 26, 30, 34, 40
Wingerden, Janneke ..........................................41
Wisdom, Peggy J ...................................................13
Wittek, Stephanie ...............................................39
Wolinsky, Jerry S ..................................................3, 87
Wombke, Brent M. ..............................................47
Wong, Schiffon L ..................................................3
Wray, Sibyl .........................................................18, 22, 34, 40, 41, 43
Wu, Naomi ...........................................................35
Wuerfel, Jens .......................................................28
Wundes, Annette .................................................14, 15, 17, 80

X
Xiong, Kuangnan ...............................................65

Y
Yadav, Sunil K. .....................................................47
Yale, Kendra .......................................................80
Yamamura, Takashi .............................................77
Yamout, Bassem ..................................................30
Yang, Ling ...........................................................29
Ye, E. Ann ...........................................................3, 47, 82
Yeo, Sandy ...........................................................84
Yigit, Pinar ..........................................................40, 44
Young, Angela ....................................................59
Young, Hui-Ju .....................................................75
Yountz, Marcus ...................................................20, 26, 30, 34, 40
Yu, Winnie ..........................................................73

Z
Zabeti, Aram .......................................................81
Zachariah, Jilkku ..................................................43
Zaffaroni, Mauro ................................................41
Zalesak, Martin ....................................................45
Zare, Ameneh .....................................................81
Zarif, Myassar .....................................................7, 48, 67
Zhao, Enxu ...........................................................77
Zheng, Chao ........................................................45
Zhou, Jia ..............................................................31
Zichn, Marina .....................................................23, 44
Ziemssen, Tjalf ....................................................4, 86
Zimmerman, Vanessa ..........................................57
Zivadinov, Robert ...............................................29
Zuppichini, Mark D. ..........................................48

International Journal of MS Care
An educational series for people with multiple sclerosis (MS) developed in conjunction with the International Organization of MS Nurses (IOMSN). Provided through educational grants from Biogen, Celgene, and Sanofi Genzyme.

Download at:
http://iomsn.org/publications

Provided through educational grants from Biogen, Celgene, and Sanofi Genzyme.